

GenCore version 5.1.6
Copyright (c) 1993 - 2004 Compugen Ltd.

OM protein - protein search, using sw model

Run on: July 23, 2004, 12:41:46 ; Search time 52 Seconds
(without alignments)
48.902 Million cell updates/sec

Title: US-09-458-298b-711

Perfect score: 44

Sequence: 1 KVAELVHFL 9

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 1586107 seqs, 282547505 residues

Total number of hits satisfying chosen parameters: 1586107

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : A_Geneseq_29Jan04:*

- 1: Geneseqp1980s:*
- 2: Geneseqp1990s:*
- 3: Geneseqp2000s:*
- 4: Geneseqp2001s:*
- 5: Geneseqp2002s:*
- 6: Geneseqp2003as:*
- 7: Geneseqp2003bs:*
- 8: Geneseqp2004s:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	44	100.0	9	2 AAR73095	Aar73095 Antigen f
2	44	100.0	9	2 AAR73849	Aar73849 Antigen f
3	44	100.0	9	2 AAW70041	Aaw70041 MAGE 3 an
4	44	100.0	9	2 AAY47403	Aay47403 Immunogen
5	44	100.0	9	4 AAG84845	Asg84845 MAGE3 HLA
6	44	100.0	9	4 AAG84677	Asg84677 MAGE3 cro
7	44	100.0	9	4 AAG84835	Asg84835 MAGE3 A2
8	44	100.0	9	4 AAB99697	Aab99697 HLA A2 bi
9	44	100.0	9	4 AAG62400	Asg62400 Immunogen
10	44	100.0	9	4 AAB31314	Aab31314 Exemplary
11	44	100.0	9	4 AAB82008	Aab82008 HLA-A2 bi
12	44	100.0	9	5 AAE31199	Aae31199 Human mag
13	44	100.0	9	5 AAE31251	Aae31251 Human mag
14	44	100.0	9	6 ABU04441	Abu04441 Human exp
15	44	100.0	9	6 ABU04429	Abu04429 Human exp
16	44	100.0	9	6 ABU04444	Abu04444 Human exp
17	44	100.0	9	6 ABU04428	Abu04428 Human exp
18	44	100.0	9	6 ABU04451	Abu04451 Human exp
19	44	100.0	9	6 ABU04437	Abu04437 Human exp
20	44	100.0	9	6 ABU04439	Abu04439 Human exp
21	44	100.0	9	6 ABU04440	Abu04440 Human exp
22	44	100.0	9	6 ABU03321	Abu03321 Human exp
23	44	100.0	9	6 ABU04427	Abu04427 Human exp
24	44	100.0	9	6 ABU04435	Abu04435 Human exp
25	44	100.0	10	2 AAR73850	Aar73850 Antigen f

26	44	100.0	10	2 AAW70038	Aaw70038 MAGE 3 an
27	44	100.0	10	2 AAY47162	Aay47162 Immunogen
28	44	100.0	10	4 AAG84678	Asg84678 MAGE3 cro
29	44	100.0	10	4 AAG84836	Asg84836 MAGE3 A2
30	44	100.0	10	6 ABU04436	Abu04436 Human exp
31	44	100.0	10	6 ABU04442	Abu04442 Human exp
32	44	100.0	10	6 ABU04450	Abu04450 Human exp
33	44	100.0	10	6 ABU04438	Abu04438 Human exp
34	44	100.0	10	6 ABU04443	Abu04443 Human exp
35	44	100.0	15	3 AAB08828	Aab08828 Amino aci
36	44	100.0	15	4 AAG84626	Asg84626 MAGE3 DR
37	44	100.0	15	6 ABU04426	Abu04426 Human exp
38	44	100.0	15	6 ABU04434	Abu04434 Human exp
39	44	100.0	16	2 AAY01721	Aay01721 Peptide d
40	44	100.0	16	3 AAY92313	Aay92313 MAGE-A3 a
41	44	100.0	16	3 AAB02566	Aab02566 MAGE-A3 H
42	44	100.0	16	6 ABU04446	Abu04446 Human exp
43	44	100.0	16	6 ABU04424	Abu04424 Human exp
44	44	100.0	16	6 ABU04452	Abu04452 Human exp
45	44	100.0	30	5 AAU85051	Aau85051 Human MAG

ALIGNMENTS

RESULT 1

AAR73095
ID AAR73095 standard; peptide; 9 AA.

XX AAR73095;

DT 25-MAR-2003 (revised)

DT 16-JUN-1995 (first entry)

XX

DE Antigen fragment 1 from MAGE3 has binding affinity for HLA-2.1.

XX antigen; epitope; immunogenic target protein; PSA; HBVc; HBVs; EBV; HIV1;
XX plasma specific antigen; hepatitis B virus; Epstein Barr;
XX human immunodeficiency virus; human papilloma virus; p53; c-ERB2; MAGE-1;
XX melanoma antigen-1; core antigen; surface antigen;
XX pharmaceutical composition; in vivo; ex vivo; therapeutic; diagnostic;
XX MHC class I molecule; major histocompatibility complex; HLA-A2.1; 9mer;
XX 10mer; anchor; human leukocyte antigen; PLP; 8mer; algorithm prediction;
XX MBP; CMV; cytomegalovirus; HSV; herpes simplex virus; influenza A; M1.
XX Homo sapiens.

OS Homo sapiens.

XX WO9420127-A1.

XX PD 15-SEP-1994.

XX PF 04-MAR-1994; 94WO-US002353.

XX PR 05-MAR-1993; 93US-00027146.

XX PR 04-JUN-1993; 93US-00073205.

XX PR 29-NOV-1993; 93US-00159184.

XX (CYTE-) CYTEL CORP.

XX PI Grey HM, Sette A, Sidney J, Kast W;

XX WPI; 1994-302678/37.

XX DR Immunogenic peptide(s) having an HLA-A2.1 binding motif - used for

XX treatment or prophylaxis of cancer, virus infection or autoimmune

XX diseases.

XX PT Disclosure; Page 90; 138pp; English.

XX PS AAR73058-121 are potential peptide binders of HLA-A2.1 motif. Using

XX CC motifs disclosed in the invention, these peptides were screened for

XX CC further motifs. Only peptides with binding affinity of at least 1%

XX CC (binding affinity is expressed as an IC50 value) as compared to the

CC standard peptide (AAR71293) in assays. This peptide from the human
 CC melanoma antigen has a binding value of 0.2200. The peptides of the
 CC invention can induce cytotoxic T lymphocytes which can react with target
 CC cells. They can be used for the treatment or prophylaxis of cancer, eg.
 CC prostate cancer or lymphoma, etc. (Updated on 25-MAR-2003 to correct PN
 CC field.)
 XX
 SQ Sequence 9 AA;
 Query Match 100.0%; Score 44; DB 2; Length 9;
 Best Local Similarity 100.0%; Pred. No. 1.4e+06;
 Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 KVAELVHFL 9
 DB 1 KVAELVHFL 9
 RESULT 2
 ID AAR73849 standard; peptide; 9 AA.
 XX AAR73849;
 AC AAR73849;
 XX
 DT 25-MAR-2003 (revised)
 DT 22-JUN-1995 (first entry)
 XX
 DE Antigen fragment 165, from MAGE3 has binding affinity for HLA-2.1.
 XX
 KW antigen; epitope; immunogenic target protein; PSA; HBVc; HBVs; EBV; HIV1;
 KW plasma specific antigen; hepatitis B virus; Epstein Barr;
 KW human immunodeficiency virus; human papilloma virus; p53; c-ERB2; MAGE-1;
 KW melanoma antigen-1; core antigen; surface antigen;
 KW pharmaceutical composition; in vivo; ex vivo; therapeutic; diagnostic;
 KW MHC class I molecule; major histocompatibility complex; HLA-A2.1; 9mer;
 KW 10mer; anchor; human leukocyte antigen; PLP; 8mer; algorithm prediction;
 KW MBP; CMV; cytomegalovirus; HSV; herpes simplex virus; influenza A; M1;
 KW LCMV.
 XX
 OS Homo sapiens.
 XX
 PN WO9420127-A1.
 XX
 PD 15-SEP-1994.
 XX
 PF 04-MAR-1994; 94WO-US002353.
 XX
 PR 05-MAR-1993; 93US-00027146.
 PR 04-JUN-1993; 93US-00073205.
 PR 29-NOV-1993; 93US-00159184.
 XX
 PA (CYTE-) CYTEL CORP.
 XX
 PI Grey HM, Sette A, Sidney J, Kast W;
 XX
 DR WPI; 1994-302678/37.
 XX
 PT Immunogenic peptide(s) having an HLA-A2.1 binding motif - used for
 PT treatment or prophylaxis of cancer, virus infection or autoimmune
 PT diseases.
 XX
 XX Disclosure; Page 86; 138pp; English.
 XX
 PS AAR73685-876 are potential peptide binders of HLA-A2.1 motif. Using
 CC motifs disclosed in the invention, these peptides were screened for
 CC further motifs. Only peptides with binding affinity of at least 1%
 CC (binding affinity is expressed as an IC50 value) as compared to the
 CC standard peptide (AAR71293) in assays. This peptide from MAGE3 has a
 CC binding value of 0.0550. The peptides of the invention can induce
 CC cytotoxic T lymphocytes which can react with target cells. They can be
 CC used for the treatment or prophylaxis of cancer, eg. prostate cancer or
 CC lymphoma, etc. (Updated on 25-MAR-2003 to correct PN field.)
 XX

SQ Sequence 9 AA;
 Query Match 100.0%; Score 44; DB 2; Length 9;
 Best Local Similarity 100.0%; Pred. No. 1.4e+06;
 Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 KVAELVHFL 9
 DB 1 KVAELVHFL 9
 RESULT 3
 ID AAW70041 standard; peptide; 9 AA.
 XX AAW70041;
 AC AAW70041;
 XX
 DT 22-OCT-1998 (first entry)
 XX
 DE MAGE 3 antigen derived HLA-A2.1 binding peptide 7 (residues 112-120).
 XX
 KW Cytotoxic T lymphocyte; CTL; major histocompatibility complex; MHC;
 KW human leukocyte antigen; HLA; tumour associated antigen; cancer;
 KW antigen presenting cell; APC; immunogenic peptide; immune disorder;
 KW viral infection; AIDS; hepatitis; bacterial infection; malaria;
 KW fungal infection; tuberculosis; melanoma; MAGE antigen.
 XX
 OS Synthetic.
 OS Homo sapiens.
 XX
 PN WO9833889-A1.
 XX
 PD 06-AUG-1998.
 XX
 PF 30-JAN-1998; 98WO-US001959.
 XX
 PR 31-JAN-1997; 97US-0036696P.
 XX
 PA (EPIM-) EPIMMUNE INC.
 XX
 PI Teai V, Southwood S, Sidney J, Sette A, Celis E;
 XX
 DR WPI; 1998-437445/37.
 XX
 PT Production of antigen-specific cytotoxic T cells - by incubating
 PT immunogenic peptide(s) from antigen that binds class I major
 PT histocompatibility complex molecules with pre-treated antigen presenting
 PT cells.
 XX
 PS Example 5; Page 72; 104pp; English.
 XX
 CC Sequences shown in AAW70027 to AAW70043 represent peptides derived from
 CC MAGE2 and MAGE3 antigens. The peptides can bind to a human leukocyte
 CC antigen (HLA), HLA-A2.1 and are used to exemplify the method of invention
 CC of producing antigen-specific cytotoxic T cells (CTLs) in vitro. The
 CC method comprises contacting immunogenic peptides from an antigen that
 CC binds class I major histocompatibility complex (MHC) molecules with
 CC antigen presenting cells (APCs) pretreated with pretreatment growth
 CC factors, and incubating the APCs with purified CD8 cells in the presence
 CC of at least 2 incubation growth factors, thereby producing antigen-
 CC specific CTLs. A method for specifically killing target cells in a human
 CC patient is also provided which comprises obtaining a fluid sample
 CC containing CTLs from a patient, contacting the cytotoxic T cells with
 CC APCs pretreated with pre-treatment growth factors, where the APCs
 CC comprise class I MHC molecules. The pretreated APCs are incubated with
 CC the cytotoxic growth factors, thereby producing activated CTLs which are
 CC contacted with a carrier to form a composition. The composition can then
 CC be administered to the patient. The activated CTLs can be used for
 CC treating cancers, immune disorders, viral infections, AIDS, hepatitis,
 CC bacterial infection, fungal infection, malaria or tuberculosis
 XX
 SQ Sequence 9 AA;

Query Match 100.0%; Score 44; DB 2; Length 9;
 Best Local Similarity 100.0%; Pred. No. 1.4e+06;
 Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 KVAELVHFL 9
 |||||
 DB 1 KVAELVHFL 9

RESULT 5
 AAG84845
 ID AAG84845 standard; peptide; 9 AA.
 XX
 AC AAG84845;
 XX
 DT 10-SEP-2001 (first entry)
 XX
 DE MAGE3 HLA-A2 supermotif-bearing peptide #1.
 XX
 KW Human; human leukocyte antigen; HLA epitope; cytotoxic T lymphocyte; CTL;
 KW MAGE2; MAGE3; melanoma antigen gene; immune response; vaccine; cancer;
 KW cytostatic; immunostimulant.
 XX
 OS Homo sapiens.
 OS Synthetic.
 XX
 PN W0200142267-A1.
 XX
 PD 14-JUN-2001.
 XX
 PF 11-DEC-2000; 2000WO-US033545.
 XX
 PR 10-DEC-1999; 99US-00458298.
 XX
 PA (EPIM-) EPIMMUNE INC.
 XX
 PI Fikes J, Sette A, Sidney J, Southwood S, Chesnut R, Celis E;
 PI Keogh E;
 XX
 DR WPI; 2001-375002/39.
 XX
 PT An isolated prepared MAGE2/3 epitope (I) for use in pharmaceuticals for
 PT the treatment and prevention of cancer.
 XX
 PS Claim 1; Page 161; 171pp; English.
 XX
 CC The present invention describes MAGE2/3 epitopes (I). Also described are:
 CC (1) a clonal cytotoxic T lymphocyte (CTL) that is cultured in vivo and
 CC binds to a complex of (I); (2) a peptide (II) comprising (I) and a second
 CC epitope and has less than 50 contiguous amino acids; (3) a vaccine
 CC composition comprising (II), a unit dose of a peptide with at least 50
 CC contiguous amino acids with 100% identity to the native peptide sequence
 CC of MAGE2/3, and a pharmaceutical excipient; (4) an isolated nucleic acid
 CC encoding (I); and (5) an isolated nucleic acid encoding (II). (I) has
 CC cytostatic activity, and can be used in vaccines and as an
 CC immunostimulant. A vaccine of (3) is useful for the treatment and
 CC prevention of cancer. (I) is useful for monitoring or evaluating an
 CC immune response by incubating a T-lymphocyte sample from a patient with
 CC (I) that binds to an human leukocyte antigen (HLA) allele present in the
 CC patient and detecting the presence of the T-lymphocyte that binds to the
 CC peptide. The vaccine allows the opportunity to combine epitopes derived
 CC from multiple tumour-associated molecules reducing the likelihood of
 CC tumour escape due to antigen loss. AAG84515 to AAG84909 and AAG99725
 CC represent amino acid sequences used in the exemplification of the present
 CC invention

Query Match 100.0%; Score 44; DB 4; Length 9;
 Best Local Similarity 100.0%; Pred. No. 1.4e+06;
 Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 KVAELVHFL 9
 |||||
 DB 1 KVAELVHFL 9

RESULT 4
 AAY47403
 ID AAY47403 standard; peptide; 9 AA.
 XX
 AC AAY47403;
 XX
 DT 01-DEC-1999 (first entry)
 XX
 DE Immunogenic peptide having a human leukocyte antigen binding motif #2014.
 XX
 KW Human leukocyte antigen; binding; immunogenic; glycoprotein; MHC; HLA;
 KW immune response; T cell activation; major histocompatibility complex;
 KW cytotoxic T lymphocyte; CTL; tumour rejection; viral infection; cancer;
 KW prostate cancer; hepatitis B; hepatitis C; AIDS; renal carcinoma;
 KW vaccine; immunisation.
 XX
 OS Synthetic.
 OS Homo sapiens.
 XX
 PN W09945954-A1.
 XX
 PD 16-SEP-1999.
 XX
 PF 13-MAR-1998; 98WO-US005039.
 XX
 PR 13-MAR-1998; 98WO-US005039.
 XX
 PA (EPIM-) EPIMMUNE INC.
 XX
 PI Sette A, Kubo RT, Sidney J, Celis E, Grey HM, Southwood S;
 PI WPI; 1999-551214/46.
 XX
 DR New immunogenic peptides with HLA binding motif, useful in treatment and
 DR diagnosis of cancers and viral diseases.
 PT
 PS Claim 1; Page 107; 150pp; English.
 XX
 CC AAY45390 to AAY48214 represent specifically claimed immunogenic peptides
 CC having a human major histocompatibility complex (MHC) Class I (also known
 CC as human leukocyte antigen (HLA)) binding motif. The immunogenic peptides
 CC can bind to a specific HLA allele (i.e. HLA-A subtypes HLA-A2.1, A1, A3.2
 CC or A24.1 or HLA-B or C) and induce a cytotoxic T cell response against
 CC the antigen from which the peptide is derived. Cytotoxic T lymphocytes
 CC (CTLs) which destroy antigen-bearing cells are normally induced by an
 CC antigen in the form of a peptide fragment bound to a HLA molecule, rather
 CC than the intact foreign antigen itself, and are particularly important in
 CC tumour rejection and in fighting viral infections. The peptides are
 CC therefore useful therapeutically to treat or prevent viral infections and
 CC cancers in mammals (especially humans) e.g. prostate cancer, hepatitis B
 CC and C, AIDS, and renal carcinoma. They can be administered as vaccines to
 CC elicit an immune response in individuals susceptible or otherwise at risk
 CC of viral infection or cancer, or used to treat chronic or acute
 CC conditions. They are also useful diagnostically, and can be used to
 CC induce a cytotoxic T cell response, by contacting a cytotoxic T cell with
 CC the peptide e.g. to produce CTLs ex vivo for infusion back into a
 CC patient. The polynucleotides encoding the immunogenic peptides are also
 CC useful therapeutically and for immunisation as above

Query Match 100.0%; Score 44; DB 2; Length 9;
 Best Local Similarity 100.0%; Pred. No. 1.4e+06;
 Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 KVAELVHFL 9
 |||||
 DB 1 KVAELVHFL 9

```

RESULT 6
AAG84677
ID AAG84677 standard; peptide; 9 AA.
XX
XX
AC AAG84677;
XX
XX
DT 10-SEP-2001 (first entry)
XX
XX
DE MAGE3 crossbinding data A2 supermotif peptide #1.
XX
XX
KW Human; human leukocyte antigen; HLA epitope; cytotoxic T lymphocyte; CTL;
KW MAGE2; MAGE3; melanoma antigen gene; immune response; vaccine; cancer;
KW cytostatic; immunostimulant.
XX
XX
OS Homo sapiens.
OS Synthetic.
XX
XX
PN WO200142267-A1.
XX
XX
PD 14-JUN-2001.
XX
XX
PF 11-DEC-2000; 2000WO-US033545.
XX
XX
PR 10-DEC-1999; 99US-00458298.
XX
XX
PA (EPIM-) EPIMMUNE INC.
XX
XX
PI Fikes J, Sette A, Sidney J, Southwood S, Chesnut R, Celis E;
PI Keogh E;
XX
XX
DR WPI; 2001-375002/39.
XX
XX
PT An isolated prepared MAGE2/3 epitope (I) for use in pharmaceuticals for
PT the treatment and prevention of cancer.
XX
XX
PS Example 2; Page 151; 171pp; English.
XX
XX
CC The present invention describes MAGE2/3 epitopes (I). Also described are:
CC (1) a clonal cytotoxic T lymphocyte (CTL) that is cultured in vivo and
CC binds to a complex of (I); (2) a peptide (II) comprising (I) and a second
CC epitope and has less than 50 contiguous amino acids; (3) a vaccine
CC composition comprising (II), a unit dose of a peptide with at least 50
CC contiguous amino acids with 100% identity to the native peptide sequence
CC of MAGE2/3, and a pharmaceutical excipient; (4) an isolated nucleic acid
CC encoding (I); and (5) an isolated nucleic acid encoding (II). (I) has
CC cytostatic activity, and can be used in vaccines and as an
CC immunostimulant. A vaccine of (3) is useful for the treatment and
CC prevention of cancer. (I) is useful for monitoring or evaluating an
CC immune response by incubating a T-lymphocyte sample from a patient with
CC (I) that binds to an human leukocyte antigen (HLA) allele present in the
CC patient and detecting the presence of the T-lymphocyte that binds to the
CC peptide. The vaccine allows the opportunity to combine epitopes derived
CC from multiple tumour-associated molecules reducing the likelihood of
CC tumour escape due to antigen loss. AAG84515 to AAG84909 and AAB99725
CC represent amino acid sequences used in the exemplification of the present
CC invention
XX
SQ Sequence 9 AA;
Query Match 100.0%; Score 44; DB 4; Length 9;
Best Local Similarity 100.0%; Pred. No. 1.4e+06;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 KVAELVHFL 9
DB 1 KVAELVHFL 9
RESULT 7
AAG84835
ID AAG84835 standard; peptide; 9 AA.
XX

```

```

AC AAG84835;
XX
XX
DT 10-SEP-2001 (first entry)
XX
XX
DE MAGE3 A2 supermotif peptide #1.
XX
XX
KW Human; human leukocyte antigen; HLA epitope; cytotoxic T lymphocyte; CTL;
KW MAGE2; MAGE3; melanoma antigen gene; immune response; vaccine; cancer;
KW cytostatic; immunostimulant.
XX
XX
OS Homo sapiens.
OS Synthetic.
XX
XX
PN WO200142267-A1.
XX
XX
PD 14-JUN-2001.
XX
XX
PF 11-DEC-2000; 2000WO-US033545.
XX
XX
PR 10-DEC-1999; 99US-00458298.
XX
XX
PA (EPIM-) EPIMMUNE INC.
XX
XX
PI Fikes J, Sette A, Sidney J, Southwood S, Chesnut R, Celis E;
PI Keogh E;
XX
XX
DR WPI; 2001-375002/39.
XX
XX
PT An isolated prepared MAGE2/3 epitope (I) for use in pharmaceuticals for
PT the treatment and prevention of cancer.
XX
XX
PS Claim 1; Page 160; 171pp; English.
XX
XX
CC The present invention describes MAGE2/3 epitopes (I). Also described are:
CC (1) a clonal cytotoxic T lymphocyte (CTL) that is cultured in vivo and
CC binds to a complex of (I); (2) a peptide (II) comprising (I) and a second
CC epitope and has less than 50 contiguous amino acids; (3) a vaccine
CC composition comprising (II), a unit dose of a peptide with at least 50
CC contiguous amino acids with 100% identity to the native peptide sequence
CC of MAGE2/3, and a pharmaceutical excipient; (4) an isolated nucleic acid
CC encoding (I); and (5) an isolated nucleic acid encoding (II). (I) has
CC cytostatic activity, and can be used in vaccines and as an
CC immunostimulant. A vaccine of (3) is useful for the treatment and
CC prevention of cancer. (I) is useful for monitoring or evaluating an
CC immune response by incubating a T-lymphocyte sample from a patient with
CC (I) that binds to an human leukocyte antigen (HLA) allele present in the
CC patient and detecting the presence of the T-lymphocyte that binds to the
CC peptide. The vaccine allows the opportunity to combine epitopes derived
CC from multiple tumour-associated molecules reducing the likelihood of
CC tumour escape due to antigen loss. AAG84515 to AAG84909 and AAB99725
CC represent amino acid sequences used in the exemplification of the present
CC invention
XX
SQ Sequence 9 AA;
Query Match 100.0%; Score 44; DB 4; Length 9;
Best Local Similarity 100.0%; Pred. No. 1.4e+06;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 KVAELVHFL 9
DB 1 KVAELVHFL 9
RESULT 8
AAB99697
ID AAB99697 standard; peptide; 9 AA.
XX
XX
XX
XX
XX
XX
DT 06-SEP-2001 (first entry)
DE HLA A2 binding CTL epitope peptide from MAGE3 SEQ ID NO:18.

```

KW Human leukocyte antigen A2 binding peptide; HLA class I A2; CTL;
 KW cytotoxic T-cell lymphocyte; tumour associated antigen; CEA; HER2/neu;
 KW MAGE3; p53; vaccine; cancer; cytostatic; immunomodulator;
 KW immunotherapy; immune response.
 XX
 OS Homo sapiens.
 XX
 FN WO200141741-A1.
 XX
 PD 14-JUN-2001.
 XX
 XX 13-DEC-2000; 2000WO-US034318.
 PF
 XX 13-DEC-1999; 99US-0170448P.
 PR
 PR 05-APR-2000; 2000US-00543608.
 PR 30-MAY-2000; 2000US-00583200.
 XX
 XX (EPIM-) EPIMMUNE INC.
 PA
 XX Fikes J, Sette A, Sidney J, Southwood S, Celis E, Keogh E;
 PI Chesnut R;
 XX
 XX WPI; 2001-381489/40.
 DR
 XX
 XX Compositions for use in a vaccine for treating, e.g., breast, lung and
 PT colon cancer comprises at least one peptide that comprises an isolated
 PT epitope of a tumor-associated antigen.
 XX
 XX Claim 1; Page 76; 86pp; English.
 PS
 XX The present invention describes a composition (I) comprising at least one
 CC peptide that comprises an isolated, prepared epitope consisting of a
 CC sequence selected from 25 short amino acid sequences given in AAB99680 to
 CC AAB99704. Also described are: (1) a composition (II) comprising one or
 CC more peptides, and further comprising at least two epitopes selected from
 CC the 25 short amino acid sequences (as above), where each of the one or
 CC more peptides comprise less than 50 contiguous amino acids that have 100%
 CC identity with a native peptide sequence; and (2) a vaccine composition
 CC (III) comprising an epitope selected from the 25 short amino acid
 CC sequences (as above) and a pharmaceutical excipient. (I) has cytostatic
 CC and immunomodulatory activities and can be used in vaccine production and
 CC immunotherapy. The peptide epitope compositions (I)-(III) are useful for
 CC monitoring an immune response to a tumour associated antigen or when one
 CC or more peptides are combined to create a vaccine (III) that stimulates
 CC the cellular arm of the immune system. In particular, the vaccine
 CC mediates immune responses against tumours in individuals who bear an
 CC allele of the human leukocyte antigen (HLA)-A2 supertype and improve the
 CC standard of care for patients being treated for breast, colon, or lung
 CC cancer
 XX
 SQ Sequence 9 AA;
 Query Match 100.0%; Score 44; DB 4; Length 9;
 Best Local Similarity 100.0%; Pred. No. 1.4e+06;
 Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 Qy 1 KVAELVHFL 9
 Db 1 KVAELVHFL 9
 |||||
 RESULT 9
 AAG62400
 ID AAG62400 standard; peptide; 9 AA.
 XX
 AC AAG62400;
 XX
 XX 03-SEP-2001 (first entry)
 DT
 XX Immunogenic peptide MAGE3.112 SEQ ID 4.
 DE
 XX Class I epitope; immunogenic; heteroclitic analogue; immune response;
 KW

KW antigen display; viral disease; cancer.
 XX
 OS Synthetic.
 XX
 PN WO200136452-A2.
 XX
 XX 25-MAY-2001.
 PD
 XX 20-NOV-2000; 2000WO-US031856.
 PF
 XX 18-NOV-1999; 99US-0166529P.
 PR
 PR 06-OCT-2000; 2000US-0239008P.
 XX
 XX (EPIM-) EPIMMUNE INC.
 PA
 XX Tangri S, Sette A, Ishioka G;
 PI WPI; 2001-355609/37.
 XX
 XX Enhancing immunogenicity of peptide containing class I epitope, useful
 PT for treating cancer, comprises providing (semi-)conservative amino acid
 PT substitutions at specified positions of these epitopes.
 XX
 PS Disclosure; Fig 1A; 96pp; English.
 XX
 XX This invention relates to a method of enhancing the immunogenicity of a
 CC peptide, where the peptide contains a class I epitope. The invention
 CC includes methods for preparing peptides containing epitopes which have
 CC enhanced ability to effect an immune response (compared to wild-type
 CC epitopes). The peptides are referred to as heteroclitic analogues. The
 CC method is useful for eliciting an immune response by contacting CTLs with
 CC the immunogenically enhanced peptide in vitro in the presence of an
 CC antigen presenting cell, or by administering to a subject a nucleic acid
 CC molecule comprising a nucleotide sequence encoding the peptide. The
 CC peptides are useful as reagents to evaluate an immune response and the
 CC efficacy of the vaccine, and for making antibodies. The heteroclitic
 CC analogues are useful in immunological compositions for the treatment of
 CC viral diseases, cancer, and other conditions which are characterised by
 CC displayed antigens on target cells. The present sequence represents a
 CC class I epitope which may be used in the method of the invention
 XX
 SQ Sequence 9 AA;
 Query Match 100.0%; Score 44; DB 4; Length 9;
 Best Local Similarity 100.0%; Pred. No. 1.4e+06;
 Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 Qy 1 KVAELVHFL 9
 Db 1 KVAELVHFL 9
 |||||
 RESULT 10
 AAB31314
 ID AAB31314 standard; peptide; 9 AA.
 XX
 AC AAB31314;
 XX
 XX 20-APR-2001 (first entry)
 DT
 XX Exemplary antigen characteristic of tumours and derived from MAGE-A3.
 DE
 XX MAGE-A1; HLA; human leukocyte antigen; CD4+ T lymphocyte; cancer;
 KW MAGE-A1 HLA class II-binding protein; vaccine.
 KW
 OS Homo sapiens.
 XX
 PN WO200078806-A1.
 XX
 PD 28-DEC-2000.
 XX
 PF 14-JUN-2000; 2000WO-US016287.
 XX

```
PR 18-JUN-1999; 99US-00336091.
XX (LUDW-) LUDWIG INST CANCER RES.
XX Van Snick J, Lethe B, Chau P, Boon-Palleur T, Van Der Bruggen P;
XX WPI; 2001-102698/11.
XX
XX Novel MAGE-A1 human leukocyte antigen class II peptides which bind to and
XX are presented to the class II molecules, useful for inducing immune
XX response and treating cancers characterized by expression of MAGE-A1.
XX
XX Disclosure; Page 32; 78pp; English.
XX
XX AAB31302-59 represent exemplary antigens which are characteristic of
XX tumours. They can be used to enhance the immune response of vaccines
XX comprising peptides derived from human MAGE-A1 HLA (human leukocyte
XX antigen) class II-binding protein. Peptides derived from the MAGE-A1 HLA
XX binding protein stimulate the activity and proliferation of CD4+ T
XX lymphocytes. The MAGE-A1 HLA binding protein is useful as a diagnostic
XX agent for diagnosing a disorder characterized by expression of MAGE-A1.
XX The protein is used for treating a disorder characterized by expression
XX of MAGE-A1 such as cancers e.g. melanoma, squamous cell carcinomas,
XX colorectal carcinomas, osteosarcomas, and lymphocytic leukemias. Peptides
XX derived from the MAGE-A1 HLA binding protein are useful in the production
XX of anti-tumour vaccines
XX
XX Sequence 9 AA;
XX
XX Query Match 100.0%; Score 44; DB 4; Length 9;
XX Best Local Similarity 100.0%; Pred. NO. 1.4e+06;
XX Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX QY 1 KVAELVHFL 9
XX Db |||||
XX 1 KVAELVHFL 9
XX
XX RESULT 11
XX AAB82008
XX ID AAB82008 standard; peptide; 9 AA.
XX AC AAB82008;
XX
XX 12-JUN-2001 (first entry)
XX
XX HLA-A2 binding peptide derived from MAGE-A3.
XX
XX Multiple myeloma; tumour rejection antigen precursor; MAGE; BAGE; GAGE;
XX LAGE; NY-ESO-1; PRAME; DAGE; human; HLA.
XX
XX Homo sapiens.
XX
XX US6210886-B1.
XX
XX 03-APR-2001.
XX
XX 30-OCT-1998; 98US-00183931.
XX
XX 04-FEB-1998; 98US-00018422.
XX
XX (LUDW-) LUDWIG INST CANCER RES.
XX
XX Van Baren N, Brasseur F, Boon-Palleur T;
XX WPI; 2001-289628/30.
XX
XX Detecting multiple myeloma in a patient, comprises contacting a nucleic
XX acid containing sample taken from bone marrow or blood with a
XX hybridization probe specific for a tumor rejection antigen precursor.
XX
XX Example 3; Col 11; 16pp; English.
XX

CC The present invention relates to a method for detecting multiple myeloma.
CC The method comprises contacting a nucleic acid containing a sample taken
CC from a bone marrow or blood of a patient, with a hybridisation probe
CC specific for a tumour rejection antigen precursor. Tumour rejection
CC antigen precursors used in the present invention are the MAGE family,
CC BAGE, GAGE, LAGE, NY-ESO-1 and PRAME (previously referred to as DAGE).
CC Expression of the tumour rejection antigen precursor indicates possible
CC multiple myeloma in the patient. The method can also be used for
CC monitoring the disease progress and course of therapeutic regime. The
CC present sequence is a peptide derived from a tumour rejection antigen
CC precursor, which was used in the method of the present invention
XX
XX Sequence 9 AA;
XX
XX Query Match 100.0%; Score 44; DB 4; Length 9;
XX Best Local Similarity 100.0%; Pred. NO. 1.4e+06;
XX Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX QY 1 KVAELVHFL 9
XX Db |||||
XX 1 KVAELVHFL 9
XX
XX RESULT 12
XX AAE31199
XX ID AAE31199 standard; peptide; 9 AA.
XX AC AAE31199;
XX
XX 24-FEB-2003 (first entry)
XX
XX Human mage3 peptide #4.
XX
XX Human; T-lymphocyte; vaccine; viral infection; gene therapy; cancer.
XX
XX Homo sapiens.
XX
XX WO200272627-A2.
XX
XX 19-SEP-2002.
XX
XX 11-MAR-2002; 2002WO-EP002666.
XX
XX 09-MAR-2001; 2001US-0274250P.
XX
XX 14-MAY-2001; 2001US-0290353P.
XX
XX 18-MAY-2001; 2001US-0291610P.
XX
XX (CALL-) CALLISTOGEN AG.
XX
XX Wrede P, Walden P, Eichler-Mertens M, Filter M;
XX WPI; 2002-759836/82.
XX
XX Providing, identifying or optimizing peptides for inducing cytotoxic T-
XX lymphocytes and for treating cancer, comprises selecting conserved
XX regions in antigenic proteins and identifying CD8+ T-cell epitopes in the
XX protein.
XX
XX Disclosure; Page 9; 32pp; English.
XX
XX The invention relates to a method for providing, identifying or/and
XX optimising peptides which induce cytotoxic T-lymphocytes and to the uses
XX of the obtained peptides for vaccination. The method is useful for
XX providing, identifying and/or optimising peptides that are useful in
XX manufacturing a pharmaceutical composition for the induction of cytotoxic
XX T-lymphocytes, and for the prevention, treatment or diagnosis of cancer
XX or viral infections. The invention is also used in gene therapy. The
XX present sequence is human mage3 peptide used to illustrate the method of
XX the invention
XX
XX Sequence 9 AA;
XX
XX Query Match 100.0%; Score 44; DB 5; Length 9;
```

```
Best Local Similarity 100.0%; Pred. No. 1.4e+06;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KVAELVHFL 9
Db 1 KVAELVHFL 9

RESULT 13
AAE31251
ID AAE31251 standard; peptide; 9 AA.
AC AAE31251;
DT 24-FEB-2003 (first entry)
XX Human mage9 peptide #4.
XX Human; T-lymphocyte; vaccine; viral infection; gene therapy; cancer.
XX Homo sapiens.
XX WO200272627-A2.
XX 19-SEP-2002.
XX 11-MAR-2002; 2002WO-EP002666.
XX 09-MAR-2001; 2001US-0274250P.
XX 14-MAY-2001; 2001US-0290353P.
XX 18-MAY-2001; 2001US-0291610P.
XX (CALL-) CALLISTOGEN AG.
XX Wrede P, Walden P, Eichler-Mertens M, Filter M;
XX WPI; 2002-759836/82.
XX Providing, identifying or optimizing peptides for inducing cytotoxic T-
XX lymphocytes and for treating cancer, comprises selecting conserved
XX regions in antigenic proteins and identifying CD8+ T-cell epitopes in the
XX protein.
XX Disclosure; Page 10; 32pp; English.
XX The invention relates to a method for providing, identifying or/and
XX optimising peptides which induce cytotoxic T-lymphocytes and to the uses
XX of the obtained peptides for vaccination. The method is useful for
XX providing, identifying and/or optimising peptides that are useful in
XX manufacturing a pharmaceutical composition for the induction of cytotoxic
XX T-lymphocytes, and for the prevention, treatment or diagnosis of cancer
XX or viral infections. The invention is also used in gene therapy. The
XX present sequence is human mage9 peptide used to illustrate the method of
XX the invention
XX Sequence 9 AA;
Query Match 100.0%; Score 44; DB 5; Length 9;
Best Local Similarity 100.0%; Pred. No. 1.4e+06;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KVAELVHFL 9
Db 1 KVAELVHFL 9

RESULT 14
ABU0441
ID ABU0441 standard; protein; 9 AA.
XX AC ABU0441;
XX 29-JAN-2003 (first entry)
DT 29-JAN-2003 (first entry)
```

```
XX Human expressed protein tag (EPT) #1107.
DE Translational profiling; expressed protein tag; EPT; kinase; phosphatase;
XX protease; protease inhibitor; transporter; cytoskeletal protein;
KW receptor; transcription factor; cancer; MHC;
KW major histocompatibility complex; myeloma; colon cancer; gastric cancer;
KW adenocarcinoma; sarcoma; melanoma; lymphoma; leukaemia.
XX Homo sapiens.
OS WO200278524-A2.
XX 10-OCT-2002.
XX 28-MAR-2002; 2002WO-US009671.
XX 28-MAR-2001; 2001US-0279495P.
XX 21-MAY-2001; 2001US-0292544P.
XX 08-AUG-2001; 2001US-0310801P.
XX 01-OCT-2001; 2001US-0326370P.
XX 04-DEC-2001; 2001US-0336780P.
XX 20-FEB-2002; 2002US-0358985P.
XX (ZYCO-) ZYCOS INC.
XX Chicx RM, Tomlinson AJ, Urban RG;
XX WPI; 2003-040607/03.
XX New polypeptides (e.g. kinases, phosphatases, proteases, transporters,
XX cytoskeletal proteins, receptors or transcription factors), useful for
XX treating cancer, e.g. colon cancer, gastric cancer, sarcoma, lymphoma or
XX leukemia.
XX Example 2; SEQ ID NO 1107; 134pp; English.
XX The invention describes a purified polypeptide, which comprises a
XX fragment of a kinase, phosphatase, protease, protease inhibitor,
XX transporter, cytoskeletal protein, receptor or transcription factor. The
XX polypeptide is useful as an immunogenic composition for eliciting in a
XX mammal an immunogenic response directed against any of the purified
XX polypeptide. The purified polypeptide, or the antibody that binds to this
XX polypeptide, is useful for treating cancer. The polypeptide is also
XX useful for identifying compounds that binds to a naturally processed
XX class I or class II MHC-binding polypeptide. The polypeptides and
XX polynucleotides are particularly useful for treating or preventing
XX myeloma, colon cancer, gastric cancer, adenocarcinoma, sarcoma, melanoma,
XX lymphoma or leukaemia. These are also useful for screening agents for
XX treating the above mentioned diseases. This sequence represents an
XX expressed protein tag (EPT) isolated from human tissue for translational
XX profiling. Note: This sequence does not appear in the printed
XX specification but was obtained in electronic format directly from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX Sequence 9 AA;
Query Match 100.0%; Score 44; DB 6; Length 9;
Best Local Similarity 100.0%; Pred. No. 1.4e+06;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KVAELVHFL 9
Db 1 KVAELVHFL 9

RESULT 15
ABU04429
ID ABU04429 standard; protein; 9 AA.
XX AC ABU04429;
XX 29-JAN-2003 (first entry)
DT 29-JAN-2003 (first entry)
```

```
XX DE Human expressed protein tag (EPT) #1095.
XX DE
XX DE
KW KW Translational profiling; expressed protein tag; EPT; kinase; phosphatase;
KW KW protease; protease inhibitor; transporter; cytoskeletal protein;
KW KW receptor; transcription factor; cancer; MHC;
KW KW major histocompatibility complex; myeloma; colon cancer; gastric cancer;
KW KW adenocarcinoma; sarcoma; melanoma; lymphoma; leukaemia.
XX OS
XX OS Homo sapiens.
XX PN WO200278524-A2.
XX PD 10-OCT-2002.
XX PF 28-MAR-2002; 2002WO-US009671.
XX PR 28-MAR-2001; 2001US-0279495P.
XX PR 21-MAY-2001; 2001US-0292544P.
XX PR 08-AUG-2001; 2001US-0310801P.
XX PR 01-OCT-2001; 2001US-0326370P.
XX PR 04-DEC-2001; 2001US-0336780P.
XX PR 20-FEB-2002; 2002US-0358985P.
XX PA (ZYCO-) ZYCOS INC.
XX PI Chicx RM, Tomlinson AJ, Urban RG;
XX PI WPI; 2003-040607/03.
XX DR
XX XX New polypeptides (e.g. kinases, phosphatases, proteases, transporters,
PT PT cytoskeletal proteins, receptors or transcription factors), useful for
PT PT treating cancer, e.g. colon cancer, gastric cancer, sarcoma, lymphoma or
PT PT leukemia.
XX PS Example 2; SEQ ID NO 1095; 134pp; English.
XX CC The invention describes a purified polypeptide, which comprises a
CC CC fragment of a kinase, phosphatase, protease, protease inhibitor,
CC CC transporter, cytoskeletal protein, receptor or transcription factor. The
CC CC polypeptide is useful as an immunogenic composition for eliciting in a
CC CC mammal an immunogenic response directed against any of the purified
CC CC polypeptide. The purified polypeptide, or the antibody that binds to this
CC CC polypeptide, is useful for treating cancer. The polypeptide is also
CC CC useful for identifying compounds that binds to a naturally processed
CC CC class I or class II MHC-binding polypeptide. The polypeptides and
CC CC polynucleotides are particularly useful for treating or preventing
CC CC myeloma, colon cancer, gastric cancer, adenocarcinoma, sarcoma, melanoma,
CC CC lymphoma or leukaemia. These are also useful for screening agents for
CC CC treating the above mentioned diseases. This sequence represents an
CC CC expressed protein tag (EPT) isolated from human tissue for translational
CC CC profiling. Note: This sequence does not appear in the printed
CC CC specification but was obtained in electronic format directly from WIPO at
CC CC ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 9 AA;
XX Query Match 100.0%; Score 44; DB 6; Length 9;
XX Best Local Similarity 100.0%; Pred. No. 1.4e+06;
XX Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 KVAELVHFL 9
DB 1 KVAELVHFL 9
RESULT 16
ABU04444
ID ABU04444 standard; protein; 9 AA.
XX AC ABU04444;
XX AC
XX DT 29-JAN-2003 (first entry)

XX DE Human expressed protein tag (EPT) #1110.
XX DE
XX DE
KW KW Translational profiling; expressed protein tag; EPT; kinase; phosphatase;
KW KW protease; protease inhibitor; transporter; cytoskeletal protein;
KW KW receptor; transcription factor; cancer; MHC;
KW KW major histocompatibility complex; myeloma; colon cancer; gastric cancer;
KW KW adenocarcinoma; sarcoma; melanoma; lymphoma; leukaemia.
XX OS
XX OS Homo sapiens.
XX PN WO200278524-A2.
XX PD 10-OCT-2002.
XX PF 28-MAR-2002; 2002WO-US009671.
XX PR 28-MAR-2001; 2001US-0279495P.
XX PR 21-MAY-2001; 2001US-0292544P.
XX PR 08-AUG-2001; 2001US-0310801P.
XX PR 01-OCT-2001; 2001US-0326370P.
XX PR 04-DEC-2001; 2001US-0336780P.
XX PR 20-FEB-2002; 2002US-0358985P.
XX PA (ZYCO-) ZYCOS INC.
XX PI Chicx RM, Tomlinson AJ, Urban RG;
XX PI WPI; 2003-040607/03.
XX DR
XX XX New polypeptides (e.g. kinases, phosphatases, proteases, transporters,
PT PT cytoskeletal proteins, receptors or transcription factors), useful for
PT PT treating cancer, e.g. colon cancer, gastric cancer, sarcoma, lymphoma or
PT PT leukemia.
XX PS Example 2; SEQ ID NO 1110; 134pp; English.
XX CC The invention describes a purified polypeptide, which comprises a
CC CC fragment of a kinase, phosphatase, protease, protease inhibitor,
CC CC transporter, cytoskeletal protein, receptor or transcription factor. The
CC CC polypeptide is useful as an immunogenic composition for eliciting in a
CC CC mammal an immunogenic response directed against any of the purified
CC CC polypeptide. The purified polypeptide, or the antibody that binds to this
CC CC polypeptide, is useful for treating cancer. The polypeptide is also
CC CC useful for identifying compounds that binds to a naturally processed
CC CC class I or class II MHC-binding polypeptide. The polypeptides and
CC CC polynucleotides are particularly useful for treating or preventing
CC CC myeloma, colon cancer, gastric cancer, adenocarcinoma, sarcoma, melanoma,
CC CC lymphoma or leukaemia. These are also useful for screening agents for
CC CC treating the above mentioned diseases. This sequence represents an
CC CC expressed protein tag (EPT) isolated from human tissue for translational
CC CC profiling. Note: This sequence does not appear in the printed
CC CC specification but was obtained in electronic format directly from WIPO at
CC CC ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 9 AA;
XX Query Match 100.0%; Score 44; DB 6; Length 9;
XX Best Local Similarity 100.0%; Pred. No. 1.4e+06;
XX Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 KVAELVHFL 9
DB 1 KVAELVHFL 9
RESULT 17
ABU04428
ID ABU04428 standard; protein; 9 AA.
XX AC ABU04428;
XX AC
XX DT 29-JAN-2003 (first entry)
```



```

XX DE Human expressed protein tag (EPT) #1094.
XX KW Translational profiling; expressed protein tag; EPT; kinase; phosphatase;
XX KW protease; protease inhibitor; transporter; cytoskeletal protein;
XX KW receptor; transcription factor; cancer; MHC;
XX KW major histocompatibility complex; myeloma; colon cancer; gastric cancer;
XX KW adenocarcinoma; sarcoma; melanoma; lymphoma; leukaemia.
XX OS Homo sapiens.
XX PN WO200278524-A2.
XX PD 10-OCT-2002.
XX PF 28-MAR-2002; 2002WO-US009671.
XX PR 28-MAR-2001; 2001US-0279495P.
XX PR 21-MAY-2001; 2001US-0292544P.
XX PR 08-AUG-2001; 2001US-0310801P.
XX PR 01-OCT-2001; 2001US-0326370P.
XX PR 04-DEC-2001; 2001US-0336780P.
XX PR 20-FEB-2002; 2002US-0358985P.
XX PA (ZYCO-) ZYCOS INC.
XX PI Chicx RM, Tomlinson AJ, Urban RG;
XX XX WPI; 2003-040607/03.
XX DR New polypeptides (e.g. kinases, phosphatases, proteases, transporters,
XX PT cytoskeletal proteins, receptors or transcription factors), useful for
XX PT treating cancer, e.g. colon cancer, gastric cancer, sarcoma, lymphoma or
XX PT leukemia.
XX PS Example 2; SEQ ID NO 1094; 134pp; English.
XX CC The invention describes a purified polypeptide, which comprises a
XX CC fragment of a kinase, phosphatase, protease, protease inhibitor,
XX CC transporter, cytoskeletal protein, receptor or transcription factor. The
XX CC polypeptide is useful as an immunogenic composition for eliciting in a
XX CC mammal an immunogenic response directed against any of the purified
XX CC polypeptide. The purified polypeptide, or the antibody that binds to this
XX CC polypeptide, is useful for treating cancer. The polypeptide is also
XX CC useful for identifying compounds that binds to a naturally processed
XX CC class I or class II MHC-binding polypeptide. The polypeptides and
XX CC polynucleotides are particularly useful for treating or preventing
XX CC myeloma, colon cancer, gastric cancer, adenocarcinoma, sarcoma, melanoma,
XX CC lymphoma or leukaemia. These are also useful for screening agents for
XX CC treating the above mentioned diseases. This sequence represents an
XX CC expressed protein tag (EPT) isolated from human tissue for translational
XX CC profiling. Note: This sequence does not appear in the printed
XX CC specification but was obtained in electronic format directly from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 9 AA;

Query Match 100.0%; Score 44; DB 6; Length 9;
Best Local Similarity 100.0%; Pred. No. 1.4e+06;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KVAELVHFL 9
Db 1 KVAELVHFL 9

RESULT 18
ABU04451
ID ABU04451 standard; protein; 9 AA.
XX AC ABU04451;
XX DT 29-JAN-2003 (first entry)

XX DE Human expressed protein tag (EPT) #1117.
XX KW Translational profiling; expressed protein tag; EPT; kinase; phosphatase;
XX KW protease; protease inhibitor; transporter; cytoskeletal protein;
XX KW receptor; transcription factor; cancer; MHC;
XX KW major histocompatibility complex; myeloma; colon cancer; gastric cancer;
XX KW adenocarcinoma; sarcoma; melanoma; lymphoma; leukaemia.
XX OS Homo sapiens.
XX PN WO200278524-A2.
XX PD 10-OCT-2002.
XX PF 28-MAR-2002; 2002WO-US009671.
XX PR 28-MAR-2001; 2001US-0279495P.
XX PR 21-MAY-2001; 2001US-0292544P.
XX PR 08-AUG-2001; 2001US-0310801P.
XX PR 01-OCT-2001; 2001US-0326370P.
XX PR 04-DEC-2001; 2001US-0336780P.
XX PR 20-FEB-2002; 2002US-0358985P.
XX PA (ZYCO-) ZYCOS INC.
XX PI Chicx RM, Tomlinson AJ, Urban RG;
XX XX WPI; 2003-040607/03.
XX DR New polypeptides (e.g. kinases, phosphatases, proteases, transporters,
XX PT cytoskeletal proteins, receptors or transcription factors), useful for
XX PT treating cancer, e.g. colon cancer, gastric cancer, sarcoma, lymphoma or
XX PT leukemia.
XX PS Example 2; SEQ ID NO 1117; 134pp; English.
XX CC The invention describes a purified polypeptide, which comprises a
XX CC fragment of a kinase, phosphatase, protease, protease inhibitor,
XX CC transporter, cytoskeletal protein, receptor or transcription factor. The
XX CC polypeptide is useful as an immunogenic composition for eliciting in a
XX CC mammal an immunogenic response directed against any of the purified
XX CC polypeptide. The purified polypeptide, or the antibody that binds to this
XX CC polypeptide, is useful for treating cancer. The polypeptide is also
XX CC useful for identifying compounds that binds to a naturally processed
XX CC class I or class II MHC-binding polypeptide. The polypeptides and
XX CC polynucleotides are particularly useful for treating or preventing
XX CC myeloma, colon cancer, gastric cancer, adenocarcinoma, sarcoma, melanoma,
XX CC lymphoma or leukaemia. These are also useful for screening agents for
XX CC treating the above mentioned diseases. This sequence represents an
XX CC expressed protein tag (EPT) isolated from human tissue for translational
XX CC profiling. Note: This sequence does not appear in the printed
XX CC specification but was obtained in electronic format directly from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 9 AA;

Query Match 100.0%; Score 44; DB 6; Length 9;
Best Local Similarity 100.0%; Pred. No. 1.4e+06;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KVAELVHFL 9
Db 1 KVAELVHFL 9

RESULT 19
ABU04437
ID ABU04437 standard; protein; 9 AA.
XX AC ABU04437;
XX DT 29-JAN-2003 (first entry)

```

```
XX DE Human expressed protein tag (EPT) #1103.
XX DE
XX KW Translational profiling; expressed protein tag; EPT; kinase; phosphatase;
XX KW protease; protease inhibitor; transporter; cytoskeletal protein;
XX KW receptor; transcription factor; cancer; MHC;
XX KW major histocompatibility complex; myeloma; colon cancer; gastric cancer;
XX KW adenocarcinoma; sarcoma; melanoma; lymphoma; leukaemia.
XX OS Homo sapiens.
XX PN WO200278524-A2.
XX PD 10-OCT-2002.
XX PF 28-MAR-2002; 2002WO-US009671.
XX PR 28-MAR-2001; 2001US-0279495P.
XX PR 21-MAY-2001; 2001US-0292544P.
XX PR 08-AUG-2001; 2001US-0310801P.
XX PR 01-OCT-2001; 2001US-0326370P.
XX PR 04-DEC-2001; 2001US-0336780P.
XX PR 20-FEB-2002; 2002US-0358985P.
XX PA (ZYCO-) ZYCOS INC.
XX PI Chicx RM, Tomlinson AJ, Urban RG;
XX PI WPI; 2003-040607/03.
XX DR
XX PT New polypeptides (e.g. kinases, phosphatases, proteases, transporters,
XX PT cytoskeletal proteins, receptors or transcription factors), useful for
XX PT treating cancer, e.g. colon cancer, gastric cancer, sarcoma, lymphoma or
XX PT leukemia.
XX PS Example 2; SEQ ID NO 1103; 134pp; English.
XX CC The invention describes a purified polypeptide, which comprises a
XX CC fragment of a kinase, phosphatase, protease, protease inhibitor,
XX CC transporter, cytoskeletal protein, receptor or transcription factor. The
XX CC polypeptide is useful as an immunogenic composition for eliciting in a
XX CC mammal an immunogenic response directed against any of the purified
XX CC polypeptide. The purified polypeptide, or the antibody that binds to this
XX CC polypeptide, is useful for treating cancer. The polypeptide is also
XX CC useful for identifying compounds that binds to a naturally processed
XX CC class I or class II MHC-binding polypeptide. The polypeptides and
XX CC polynucleotides are particularly useful for treating or preventing
XX CC myeloma, colon cancer, gastric cancer, adenocarcinoma, sarcoma, melanoma,
XX CC lymphoma or leukaemia. These are also useful for screening agents for
XX CC treating the above mentioned diseases. This sequence represents an
XX CC expressed protein tag (EPT) isolated from human tissue for translational
XX CC profiling. Note: This sequence does not appear in the printed
XX CC specification but was obtained in electronic format directly from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 9 AA;
XX Query Match 100.0%; Score 44; DB 6; Length 9;
XX Best Local Similarity 100.0%; Pred. No. 1.4e+06;
XX Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 KVAELVHFL 9
DB 1 KVAELVHFL 9
RESULT 20
ABU04439
ID ABU04439 standard; protein; 9 AA.
XX AC ABU04439;
XX DT 29-JAN-2003 (first entry)

XX DE Human expressed protein tag (EPT) #1105.
XX DE
XX KW Translational profiling; expressed protein tag; EPT; kinase; phosphatase;
XX KW protease; protease inhibitor; transporter; cytoskeletal protein;
XX KW receptor; transcription factor; cancer; MHC;
XX KW major histocompatibility complex; myeloma; colon cancer; gastric cancer;
XX KW adenocarcinoma; sarcoma; melanoma; lymphoma; leukaemia.
XX OS Homo sapiens.
XX PN WO200278524-A2.
XX PD 10-OCT-2002.
XX PF 28-MAR-2002; 2002WO-US009671.
XX PR 28-MAR-2001; 2001US-0279495P.
XX PR 21-MAY-2001; 2001US-0292544P.
XX PR 08-AUG-2001; 2001US-0310801P.
XX PR 01-OCT-2001; 2001US-0326370P.
XX PR 04-DEC-2001; 2001US-0336780P.
XX PR 20-FEB-2002; 2002US-0358985P.
XX PA (ZYCO-) ZYCOS INC.
XX PI Chicx RM, Tomlinson AJ, Urban RG;
XX PI WPI; 2003-040607/03.
XX DR
XX PT New polypeptides (e.g. kinases, phosphatases, proteases, transporters,
XX PT cytoskeletal proteins, receptors or transcription factors), useful for
XX PT treating cancer, e.g. colon cancer, gastric cancer, sarcoma, lymphoma or
XX PT leukemia.
XX PS Example 2; SEQ ID NO 1105; 134pp; English.
XX CC The invention describes a purified polypeptide, which comprises a
XX CC fragment of a kinase, phosphatase, protease, protease inhibitor,
XX CC transporter, cytoskeletal protein, receptor or transcription factor. The
XX CC polypeptide is useful as an immunogenic composition for eliciting in a
XX CC mammal an immunogenic response directed against any of the purified
XX CC polypeptide. The purified polypeptide, or the antibody that binds to this
XX CC polypeptide, is useful for treating cancer. The polypeptide is also
XX CC useful for identifying compounds that binds to a naturally processed
XX CC class I or class II MHC-binding polypeptide. The polypeptides and
XX CC polynucleotides are particularly useful for treating or preventing
XX CC myeloma, colon cancer, gastric cancer, adenocarcinoma, sarcoma, melanoma,
XX CC lymphoma or leukaemia. These are also useful for screening agents for
XX CC treating the above mentioned diseases. This sequence represents an
XX CC expressed protein tag (EPT) isolated from human tissue for translational
XX CC profiling. Note: This sequence does not appear in the printed
XX CC specification but was obtained in electronic format directly from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 9 AA;
XX Query Match 100.0%; Score 44; DB 6; Length 9;
XX Best Local Similarity 100.0%; Pred. No. 1.4e+06;
XX Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 KVAELVHFL 9
DB 1 KVAELVHFL 9
RESULT 21
ABU04440
ID ABU04440 standard; protein; 9 AA.
XX AC ABU04440;
XX DT 29-JAN-2003 (first entry)
```

```
XX DE Human expressed protein tag (EPT) #1106.
XX DE
XX DE Translational profiling; expressed protein tag; EPT; kinase; phosphatase;
KW protease; protease inhibitor; transporter; cytoskeletal protein;
KW receptor; transcription factor; cancer; MHC;
KW major histocompatibility complex; myeloma; colon cancer; gastric cancer;
KW adenocarcinoma; sarcoma; melanoma; lymphoma; leukaemia.
XX OS
XX OS Homo sapiens.
XX PN WO200278524-A2.
XX PD 10-OCT-2002.
XX PF 28-MAR-2002; 2002WO-US009671.
XX PR 28-MAR-2001; 2001US-0279495P.
XX PR 21-MAY-2001; 2001US-0292544P.
XX PR 08-AUG-2001; 2001US-0310801P.
XX PR 01-OCT-2001; 2001US-0326370P.
XX PR 04-DEC-2001; 2001US-0336780P.
XX PR 20-FEB-2002; 2002US-0358985P.
XX PA (ZYCO-) ZYCOS INC.
XX PI Chicx RM, Tomlinson AJ, Urban RG;
XX DR WPI; 2003-040607/03.
XX PT New polypeptides (e.g. kinases, phosphatases, proteases, transporters,
PT cytoskeletal proteins, receptors or transcription factors), useful for
PT treating cancer, e.g. colon cancer, gastric cancer, sarcoma, lymphoma or
PT leukemia.
XX PS Example 2; SEQ ID NO 1106; 134pp; English.
XX CC The invention describes a purified polypeptide, which comprises a
CC fragment of a kinase, phosphatase, protease, protease inhibitor,
CC transporter, cytoskeletal protein, receptor or transcription factor. The
CC polypeptide is useful as an immunogenic composition for eliciting in a
CC mammal an immunogenic response directed against any of the purified
CC polypeptide. The purified polypeptide, or the antibody that binds to this
CC polypeptide, is useful for treating cancer. The polypeptide is also
CC useful for identifying compounds that binds to a naturally processed
CC class I or class II MHC-binding polypeptide. The polypeptides and
CC polynucleotides are particularly useful for treating or preventing
CC myeloma, colon cancer, gastric cancer, adenocarcinoma, sarcoma, melanoma,
CC lymphoma or leukaemia. These are also useful for screening agents for
CC treating the above mentioned diseases. This sequence represents an
CC expressed protein tag (EPT) isolated from human tissue for translational
CC profiling. Note: This sequence does not appear in the printed
CC specification but was obtained in electronic format directly from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 9 AA;
XX Query Match 100.0%; Score 44; DB 6; Length 9;
XX Best Local Similarity 100.0%; Pred. No. 1.4e+06;
XX Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 KVAELVHFL 9
Db 1 KVAELVHFL 9
RESULT 22
ABU03321
ID ABU03321 standard; protein; 9 AA.
XX AC ABU03321;
XX DT 29-JAN-2003 (first entry)

XX DE Human expressed protein tag (EPT) #101.
XX DE
XX DE Translational profiling; expressed protein tag; EPT; kinase; phosphatase;
KW protease; protease inhibitor; transporter; cytoskeletal protein;
KW receptor; transcription factor; cancer; MHC;
KW major histocompatibility complex; myeloma; colon cancer; gastric cancer;
KW adenocarcinoma; sarcoma; melanoma; lymphoma; leukaemia.
XX OS
XX OS Homo sapiens.
XX PN WO200278524-A2.
XX PD 10-OCT-2002.
XX PF 28-MAR-2002; 2002WO-US009671.
XX PR 28-MAR-2001; 2001US-0279495P.
XX PR 21-MAY-2001; 2001US-0292544P.
XX PR 08-AUG-2001; 2001US-0310801P.
XX PR 01-OCT-2001; 2001US-0326370P.
XX PR 04-DEC-2001; 2001US-0336780P.
XX PR 20-FEB-2002; 2002US-0358985P.
XX PA (ZYCO-) ZYCOS INC.
XX PI Chicx RM, Tomlinson AJ, Urban RG;
XX DR WPI; 2003-040607/03.
XX PT New polypeptides (e.g. kinases, phosphatases, proteases, transporters,
PT cytoskeletal proteins, receptors or transcription factors), useful for
PT treating cancer, e.g. colon cancer, gastric cancer, sarcoma, lymphoma or
PT leukemia.
XX PS Claim 10; SEQ ID NO 101; 134pp; English.
XX CC The invention describes a purified polypeptide, which comprises a
CC fragment of a kinase, phosphatase, protease, protease inhibitor,
CC transporter, cytoskeletal protein, receptor or transcription factor. The
CC polypeptide is useful as an immunogenic composition for eliciting in a
CC mammal an immunogenic response directed against any of the purified
CC polypeptide. The purified polypeptide, or the antibody that binds to this
CC polypeptide, is useful for treating cancer. The polypeptide is also
CC useful for identifying compounds that binds to a naturally processed
CC class I or class II MHC-binding polypeptide. The polypeptides and
CC polynucleotides are particularly useful for treating or preventing
CC myeloma, colon cancer, gastric cancer, adenocarcinoma, sarcoma, melanoma,
CC lymphoma or leukaemia. These are also useful for screening agents for
CC treating the above mentioned diseases. This sequence represents an
CC expressed protein tag (EPT) isolated from human tissue for translational
CC profiling. Note: This sequence does not appear in the printed
CC specification but was obtained in electronic format directly from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 9 AA;
XX Query Match 100.0%; Score 44; DB 6; Length 9;
XX Best Local Similarity 100.0%; Pred. No. 1.4e+06;
XX Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 KVAELVHFL 9
Db 1 KVAELVHFL 9
RESULT 23
ABU04427
ID ABU04427 standard; protein; 9 AA.
XX AC ABU04427;
XX DT 29-JAN-2003 (first entry)
```

```
XX DE Human expressed protein tag (EPT) #1093.
XX KW Translational profiling; expressed protein tag; EPT; kinase; phosphatase;
XX KW protease; protease inhibitor; transporter; cytoskeletal protein;
XX KW receptor; transcription factor; cancer; MHC;
XX KW major histocompatibility complex; myeloma; colon cancer; gastric cancer;
XX KW adenocarcinoma; sarcoma; melanoma; lymphoma; leukaemia.
XX OS Homo sapiens.
XX PN WO200278524-A2.
XX PD 10-OCT-2002.
XX PF 28-MAR-2002; 2002WO-US009671.
XX PR 28-MAR-2001; 2001US-0279495P.
XX PR 21-MAY-2001; 2001US-0292544P.
XX PR 08-AUG-2001; 2001US-0310801P.
XX PR 01-OCT-2001; 2001US-0326370P.
XX PR 04-DEC-2001; 2001US-0336780P.
XX PR 20-FEB-2002; 2002US-0358985P.
XX PA (ZYCO-) ZYCOS INC.
XX PI Chicx RM, Tomlinson AJ, Urban RG;
XX DR WPI; 2003-040607/03.
XX PT New polypeptides (e.g. kinases, phosphatases, proteases, transporters,
XX PT cytoskeletal proteins, receptors or transcription factors), useful for
XX PT treating cancer, e.g. colon cancer, gastric cancer, sarcoma, lymphoma or
XX PT leukemia.
XX PS Example 2; SEQ ID NO 1093; 134pp; English.
XX CC The invention describes a purified polypeptide, which comprises a
XX CC fragment of a kinase, phosphatase, protease, protease inhibitor,
XX CC transporter, cytoskeletal protein, receptor or transcription factor. The
XX CC polypeptide is useful as an immunogenic composition for eliciting in a
XX CC mammal an immunogenic response directed against any of the purified
XX CC polypeptide. The purified polypeptide, or the antibody that binds to this
XX CC polypeptide, is useful for treating cancer. The polypeptide is also
XX CC useful for identifying compounds that binds to a naturally processed
XX CC class I or class II MHC-binding polypeptide. The polypeptides and
XX CC polynucleotides are particularly useful for treating or preventing
XX CC myeloma, colon cancer, gastric cancer, adenocarcinoma, sarcoma, melanoma,
XX CC lymphoma or leukaemia. These are also useful for screening agents for
XX CC treating the above mentioned diseases. This sequence represents an
XX CC expressed protein tag (EPT) isolated from human tissue for translational
XX CC profiling. Note: This sequence does not appear in the printed
XX CC specification but was obtained in electronic format directly from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 9 AA;
XX Query Match 100.0%; Score 44; DB 6; Length 9;
XX Best Local Similarity 100.0%; Pred. No. 1.4e+06;
XX Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX QY 1 KVAELVHFL 9
XX Db 1 KVAELVHFL 9
XX RESULT 24
XX ABU04435
XX ID ABU04435 standard; protein; 9 AA.
XX AC ABU04435;
XX XX
XX DT 29-JAN-2003 (first entry)

XX DE Human expressed protein tag (EPT) #1101.
XX KW Translational profiling; expressed protein tag; EPT; kinase; phosphatase;
XX KW protease; protease inhibitor; transporter; cytoskeletal protein;
XX KW receptor; transcription factor; cancer; MHC;
XX KW major histocompatibility complex; myeloma; colon cancer; gastric cancer;
XX KW adenocarcinoma; sarcoma; melanoma; lymphoma; leukaemia.
XX OS Homo sapiens.
XX PN WO200278524-A2.
XX PD 10-OCT-2002.
XX PF 28-MAR-2002; 2002WO-US009671.
XX PR 28-MAR-2001; 2001US-0279495P.
XX PR 21-MAY-2001; 2001US-0292544P.
XX PR 08-AUG-2001; 2001US-0310801P.
XX PR 01-OCT-2001; 2001US-0326370P.
XX PR 04-DEC-2001; 2001US-0336780P.
XX PR 20-FEB-2002; 2002US-0358985P.
XX PA (ZYCO-) ZYCOS INC.
XX PI Chicx RM, Tomlinson AJ, Urban RG;
XX DR WPI; 2003-040607/03.
XX PT New polypeptides (e.g. kinases, phosphatases, proteases, transporters,
XX PT cytoskeletal proteins, receptors or transcription factors), useful for
XX PT treating cancer, e.g. colon cancer, gastric cancer, sarcoma, lymphoma or
XX PT leukemia.
XX PS Example 2; SEQ ID NO 1101; 134pp; English.
XX CC The invention describes a purified polypeptide, which comprises a
XX CC fragment of a kinase, phosphatase, protease, protease inhibitor,
XX CC transporter, cytoskeletal protein, receptor or transcription factor. The
XX CC polypeptide is useful as an immunogenic composition for eliciting in a
XX CC mammal an immunogenic response directed against any of the purified
XX CC polypeptide. The purified polypeptide, or the antibody that binds to this
XX CC polypeptide, is useful for treating cancer. The polypeptide is also
XX CC useful for identifying compounds that binds to a naturally processed
XX CC class I or class II MHC-binding polypeptide. The polypeptides and
XX CC polynucleotides are particularly useful for treating or preventing
XX CC myeloma, colon cancer, gastric cancer, adenocarcinoma, sarcoma, melanoma,
XX CC lymphoma or leukaemia. These are also useful for screening agents for
XX CC treating the above mentioned diseases. This sequence represents an
XX CC expressed protein tag (EPT) isolated from human tissue for translational
XX CC profiling. Note: This sequence does not appear in the printed
XX CC specification but was obtained in electronic format directly from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 9 AA;
XX Query Match 100.0%; Score 44; DB 6; Length 9;
XX Best Local Similarity 100.0%; Pred. No. 1.4e+06;
XX Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX QY 1 KVAELVHFL 9
XX Db 1 KVAELVHFL 9
XX RESULT 25
XX AAR73850
XX ID AAR73850 standard; peptide; 10 AA.
XX XX
XX AC AAR73850;
XX XX
XX DT 25-MAR-2003 (revised)
```

DT 22-JUN-1995 (first entry)
 DE Antigen fragment 166, from MAGE3 has binding affinity for HLA-2.1.
 XX
 KW antigen; epitope; immunogenic target protein; PSA; HBVC; HBVs; EBV; HIV1;
 DE plasma specific antigen; hepatitis B virus; Epstein Barr;
 KW human immunodeficiency virus; human papilloma virus; p53; c-ERB2; MAGE-1;
 KW melanoma antigen-1; core antigen; surface antigen;
 KW pharmaceutical composition; in vivo; ex vivo; therapeutic; diagnostic;
 KW MHC class I molecule; major histocompatibility complex; HLA-A2.1; 9mer;
 KW 10mer; anchor; human leukocyte antigen; PLP; 8mer; algorithm prediction;
 KW MBP; CMV; cytomegalovirus; HSV; herpes simplex virus; influenza A; M1;
 KW LCWV.
 XX
 OS Homo sapiens.
 XX
 XX WO9420127-A1.
 XX
 XX 15-SEP-1994.
 XX
 XX 04-MAR-1994; 94WO-US002353.
 XX
 XX 05-MAR-1993; 93US-00027146.
 PR 04-JUN-1993; 93US-00073205.
 PR 29-NOV-1993; 93US-00159184.
 XX
 PA (CYTE-) CYTEL CORP.
 XX
 XX Grey HM, Sette A, Sidney J, Kast W;
 XX WPI; 1994-302678/37.
 XX
 XX Immunogenic peptide(s) having an HLA-A2.1 binding motif - used for
 PT treatment or prophylaxis of cancer, virus infection or autoimmune
 PT diseases.
 XX
 PS Disclosure; Page 86; 138pp; English.
 XX
 CC AAR73685-876 are potential peptide binders of HLA-A2.1 motif. Using
 CC motifs disclosed in the invention, these peptides were screened for
 CC further motifs. Only peptides with binding affinity of at least 1%
 CC (binding affinity is expressed as an IC50 value) as compared to the
 CC standard peptide (AAR71293) in assays. This peptide from MAGE3 has a
 CC binding value of 0.0120. The peptides of the invention can induce
 CC cytotoxic T lymphocytes which can react with target cells. They can be
 CC used for the treatment or prophylaxis of cancer, eg. prostate cancer or
 CC lymphoma, etc. (Updated on 25-MAR-2003 to correct PN field.)
 XX
 XX Sequence 10 AA;
 SQ
 Query Match 100.0%; Score 44; DB 2; Length 10;
 Best Local Similarity 100.0%; Pred. No. 0.028;
 Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 KVAELVHFL 9
 Db 1 KVAELVHFL 9
 |||||
 RESULT 26
 AAW70038
 ID AAW70038 standard; peptide; 10 AA.
 XX
 XX AAW70038;
 XX
 XX 22-OCT-1998 (first entry)
 XX
 DE MAGE 3 antigen derived HLA-A2.1 binding peptide 4 (residues 112-121).
 KW Cytotoxic T lymphocyte; CTL; major histocompatibility complex; MHC;
 KW human leukocyte antigen; HLA; tumour associated antigen; cancer;
 KW antigen presenting cell; APC; immunogenic peptide; immune disorder;
 KW viral infection; AIDS; hepatitis; bacterial infection; malaria;

KW fungal infection; tuberculosis; melanoma; MAGE antigen.
 XX
 OS Synthetic.
 OS Homo sapiens.
 XX
 XX WO9833888-A1.
 XX
 PD 06-AUG-1998.
 XX
 XX 30-JAN-1998; 98WO-US001959.
 XX
 XX 31-JAN-1997; 97US-0036696P.
 XX
 XX (EPIM-) EPIMMUNE INC.
 XX
 XX Tsai V, Southwood S, Sidney J, Sette A, Celis E;
 PI WPI; 1998-437445/37.
 XX
 XX Production of antigen-specific cytotoxic T cells - by incubating
 PT immunogenic peptide(s) from antigen that binds class I major
 PT histocompatibility complex molecules with pre-treated antigen presenting
 PT cells.
 XX
 PS Example 5; Page 72; 104pp; English.
 XX
 CC Sequences shown in AAW70027 to AAW70043 represent peptides derived from
 CC MAGE2 and MAGE3 antigens. The peptides can bind to a human leukocyte
 CC antigen (HLA), HLA-A2.1 and are used to exemplify the method of invention
 CC of producing antigen-specific cytotoxic T cells (CTLs) in vitro. The
 CC method comprises contacting immunogenic peptides from an antigen that
 CC binds class I major histocompatibility complex (MHC) molecules with
 CC antigen presenting cells (APCs) pretreated with pretreatment growth
 CC factors, and incubating the APCs with purified CD8 cells in the presence
 CC of at least 2 incubation growth factors, thereby producing antigen-
 CC specific CTLs. A method for specifically killing target cells in a human
 CC patient is also provided which comprises obtaining a fluid sample
 CC containing CTLs from a patient, contacting the cytotoxic T cells with
 CC APCs pretreated with pre-treatment growth factors, where the APCs
 CC comprise class I MHC molecules. The pretreated APCs are incubated with
 CC the cytotoxic growth factors, thereby producing activated CTLs which are
 CC contacted with a carrier to form a composition. The composition can then
 CC be administered to the patient. The activated CTLs can be used for
 CC treating cancers, immune disorders, viral infections, AIDS, hepatitis,
 CC bacterial infection, fungal infection, malaria or tuberculosis
 XX
 XX Sequence 10 AA;
 SQ
 Query Match 100.0%; Score 44; DB 2; Length 10;
 Best Local Similarity 100.0%; Pred. No. 0.028;
 Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 KVAELVHFL 9
 Db 1 KVAELVHFL 9
 |||||
 RESULT 27
 AAY47162
 ID AAY47162 standard; peptide; 10 AA.
 XX
 XX AAY47162;
 AC
 XX 01-DEC-1999 (first entry)
 DT
 XX Immunogenic peptide having a human leukocyte antigen binding motif #1773.
 DE Human leukocyte antigen; binding; immunogenic; glycoprotein; MHC; HLA;
 KW immune response; T cell activation; major histocompatibility complex;
 KW cytotoxic T lymphocyte; CTL; tumour rejection; viral infection; cancer;
 KW prostate cancer; hepatitis B; hepatitis C; AIDS; renal carcinoma;
 KW vaccine; immunisation.
 KW

```
OS Synthetic.
OS Homo sapiens.
XX WO9945954-A1.
XX PN
XX 16-SEP-1999.
XX PD
XX 13-MAR-1998; 98WO-US005039.
XX PF
XX 13-MAR-1998; 98WO-US005039.
XX PR
XX (EPIM-) EPIMMUNE INC.
XX PA
XX Sette A, Kubo RT, Sidney J, Celis E, Grey HM, Southwood S;
XX PI WPI; 1999-551214/46.
XX DR
XX New immunogenic peptides with HLA binding motif, useful in treatment and
XX PT diagnosis of cancers and viral diseases.
XX PS Claim 1; Page 96; 150pp; English.
XX CC
XX AAY45390 to AAY48214 represent specifically claimed immunogenic peptides
XX CC having a human major histocompatibility complex (MHC) Class I (also known
XX CC as human leukocyte antigen (HLA)) binding motif. The immunogenic peptides
XX CC can bind to a specific HLA allele (i.e. HLA-A subtypes HLA-A2.1, A1, A3.2
XX CC or A24.1 or HLA-B or C) and induce a cytotoxic T cell response against
XX CC the antigen from which the peptide is derived. Cytotoxic T lymphocytes
XX CC (CTLs) which destroy antigen-bearing cells are normally induced by an
XX CC antigen in the form of a peptide fragment bound to a HLA molecule, rather
XX CC than the intact foreign antigen itself, and are particularly important in
XX CC tumour rejection and in fighting viral infections. The peptides are
XX CC therefore useful therapeutically to treat or prevent viral infections and
XX CC cancers in mammals (especially humans) e.g. prostate cancer, hepatitis B
XX CC and C, AIDS, and renal carcinoma. They can be administered as vaccines to
XX CC elicit an immune response in individuals susceptible or otherwise at risk
XX CC of viral infection or cancer, or used to treat chronic or acute
XX CC conditions. They are also useful diagnostically, and can be used to
XX CC induce a cytotoxic T cell response, by contacting a cytotoxic T cell with
XX CC the peptide e.g. to produce CTLs ex vivo for infusion back into a
XX CC patient. The polynucleotides encoding the immunogenic peptides are also
XX CC useful therapeutically and for immunisation as above
XX SQ Sequence 10 AA;

Query Match 100.0%; Score 44; DB 2; Length 10;
Best Local Similarity 100.0%; Pred. No. 0.028;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KVAELVHFL 9
Db 1 KVAELVHFL 9
|||||

RESULT 28
AAG84678
ID AAG84678 standard; peptide; 10 AA.
XX AC
XX AAG84678;
XX DT
XX 10-SEP-2001 (first entry)
XX DE
XX MAGE3 crossbinding data A2 supermotif peptide #2.
XX KW Human; human leukocyte antigen; HLA epitope; cytotoxic T lymphocyte; CTL;
XX KW MAGE2; MAGE3; melanoma antigen gene; immune response; vaccine; cancer;
XX KW cytostatic; immunostimulant.
XX OS Homo sapiens.
XX OS Synthetic.
XX PN WO200142267-A1.
XX PD
XX 11-DEC-2000; 2000WO-US033545.
XX PR 10-DEC-1999; 99US-00458298.

PD 14-JUN-2001.
XX PF
XX 11-DEC-2000; 2000WO-US033545.
XX PR
XX 10-DEC-1999; 99US-00458298.
XX PA (EPIM-) EPIMMUNE INC.
XX XX
XX Fikes J, Sette A, Sidney J, Southwood S, Chesnut R, Celis E;
XX PI Keogh E;
XX XX
XX WPI; 2001-375002/39.
XX XX
XX An isolated prepared MAGE2/3 epitope (I) for use in pharmaceuticals for
XX PT the treatment and prevention of cancer.
XX PS Example 2; Page 151; 171pp; English.
XX CC
XX The present invention describes MAGE2/3 epitopes (I). Also described are:
XX CC (1) a clonal cytotoxic T lymphocyte (CTL) that is cultured in vivo and
XX CC binds to a complex of (I); (2) a peptide (II) comprising (I) and a second
XX CC epitope and has less than 50 contiguous amino acids; (3) a vaccine
XX CC composition comprising (II), a unit dose of a peptide with at least 50
XX CC contiguous amino acids with 100% identity to the native peptide sequence
XX CC of MAGE2/3, and a pharmaceutical excipient; (4) an isolated nucleic acid
XX CC encoding (I); and (5) an isolated nucleic acid encoding (II). (I) has
XX CC cytostatic activity, and can be used in vaccines and as an
XX CC immunostimulant. A vaccine of (3) is useful for the treatment and
XX CC prevention of cancer. (I) is useful for monitoring or evaluating an
XX CC immune response by incubating a T-lymphocyte sample from a patient with
XX CC (1) that binds to an human leukocyte antigen (HLA) allele present in the
XX CC patient and detecting the presence of the T-lymphocyte that binds to the
XX CC peptide. The vaccine allows the opportunity to combine epitopes derived
XX CC from multiple tumour-associated molecules reducing the likelihood of
XX CC tumour escape due to antigen loss. AAG84515 to AAG84909 and AAG89725
XX CC represent amino acid sequences used in the exemplification of the present
XX CC invention
XX SQ Sequence 10 AA;

Query Match 100.0%; Score 44; DB 4; Length 10;
Best Local Similarity 100.0%; Pred. No. 0.028;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KVAELVHFL 9
Db 1 KVAELVHFL 9
|||||

RESULT 29
AAG84836
ID AAG84836 standard; peptide; 10 AA.
XX AC
XX AAG84836;
XX DT
XX 10-SEP-2001 (first entry)
XX DE
XX MAGE3 A2 supermotif peptide #2.
XX KW Human; human leukocyte antigen; HLA epitope; cytotoxic T lymphocyte; CTL;
XX KW MAGE2; MAGE3; melanoma antigen gene; immune response; vaccine; cancer;
XX KW cytostatic; immunostimulant.
XX OS Homo sapiens.
XX OS Synthetic.
XX PN WO200142267-A1.
XX PD
XX 14-JUN-2001.
XX PF
XX 11-DEC-2000; 2000WO-US033545.
XX PR 10-DEC-1999; 99US-00458298.
```

XX PA (EPIM-) EPIMUNE INC.
XX PI Fikes J, Sette A, Sidney J, Southwood S, Chesnut R, Celis E;
XX PI Keogh E;
XX DR WPI; 2001-375002/39.
XX
XX PT An isolated prepared MAGE2/3 epitope (I) for use in pharmaceuticals for
XX PT the treatment and prevention of cancer.
XX PS Claim 1; Page 160; 171pp; English.
XX
XX CC The present invention describes MAGE2/3 epitopes (I). Also described are:
XX CC (1) a clonal cytotoxic T lymphocyte (CTL) that is cultured in vivo and
XX CC binds to a complex of (I); (2) a peptide (II) comprising (I) and a second
XX CC epitope and has less than 50 contiguous amino acids; (3) a vaccine
XX CC composition comprising (II), a unit dose of a peptide with at least 50
XX CC contiguous amino acids with 100% identity to the native peptide sequence
XX CC of MAGE2/3, and a pharmaceutical excipient; (4) an isolated nucleic acid
XX CC encoding (I); and (5) an isolated nucleic acid encoding (II). (I) has
XX CC cytosolic activity, and can be used in vaccines and as an
XX CC immunostimulant. A vaccine of (3) is useful for the treatment and
XX CC prevention of cancer. (I) is useful for monitoring or evaluating an
XX CC immune response by incubating a T-lymphocyte sample from a patient with
XX CC (I) that binds to an human leukocyte antigen (HLA) allele present in the
XX CC patient and detecting the presence of the T-lymphocyte that binds to the
XX CC peptide. The vaccine allows the opportunity to combine epitopes derived
XX CC from multiple tumour-associated molecules reducing the likelihood of
XX CC tumour escape due to antigen loss. AAG84515 to AAG84909 and AAB99725
XX CC represent amino acid sequences used in the exemplification of the present
XX CC invention
XX SQ Sequence 10 AA;

Query Match 100.0%; Score 44; DB 4; Length 10;
Best Local Similarity 100.0%; Pred. No. 0.028;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KVAELVHFL 9
| | | | |
Db 1 KVAELVHFL 9

RESULT 30
ABU04436
ID ABU04436 standard; protein; 10 AA.

XX AC ABU04436;

XX DT 29-JAN-2003 (first entry)

XX DE Human expressed protein tag (EPT) #1102.

XX KW Translational profiling; expressed protein tag; EPT; kinase; phosphatase;
XX KW protease; protease inhibitor; transporter; cytoskeletal protein;
XX KW receptor; transcription factor; cancer; MHC;
XX KW major histocompatibility complex; myeloma; colon cancer; gastric cancer;
XX KW adenocarcinoma; sarcoma; melanoma; lymphoma; leukaemia.

XX OS Homo sapiens.

XX PN WO200278524-A2.

XX PD 10-OCT-2002.

XX PF 28-MAR-2002; 2002WO-US009671.

XX PR 28-MAR-2001; 2001US-0279495P.

XX PR 21-MAY-2001; 2001US-0292544P.

XX PR 08-AUG-2001; 2001US-0310801P.

XX PR 01-OCT-2001; 2001US-0326370P.

XX PR 04-DEC-2001; 2001US-0336780P.

PR 20-FEB-2002; 2002US-0358985P.

XX PA (ZYCO-) ZYCOS INC.

XX PI Chic RM, Tomlinson AJ, Urban RG;

XX DR WPI; 2003-040607/03.

XX PT New polypeptides (e.g. kinases, phosphatases, proteases, transporters,
XX PT cytoskeletal proteins, receptors or transcription factors), useful for
XX PT treating cancer, e.g. colon cancer, gastric cancer, sarcoma, lymphoma or
XX PT leukemia.

XX PS Example 2; SEQ ID NO 1102; 134pp; English.

XX CC The invention describes a purified polypeptide, which comprises a
XX CC fragment of a kinase, phosphatase, protease, protease inhibitor,
XX CC transporter, cytoskeletal protein, receptor or transcription factor. The
XX CC polypeptide is useful as an immunogenic composition for eliciting in a
XX CC mammal an immunogenic response directed against any of the purified
XX CC polypeptide. The purified polypeptide, or the antibody that binds to this
XX CC polypeptide, is useful for treating cancer. The polypeptide is also
XX CC useful for identifying compounds that binds to a naturally processed
XX CC class I or class II MHC-binding polypeptide. The polypeptides and
XX CC polynucleotides are particularly useful for treating or preventing
XX CC myeloma, colon cancer, gastric cancer, adenocarcinoma, sarcoma, melanoma,
XX CC lymphoma or leukaemia. These are also useful for screening agents for
XX CC treating the above mentioned diseases. This sequence represents an
XX CC expressed protein tag (EPT) isolated from human tissue for translational
XX CC profiling. Note: This sequence does not appear in the printed
XX CC specification but was obtained in electronic format directly from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences

XX SQ Sequence 10 AA;

Query Match 100.0%; Score 44; DB 6; Length 10;
Best Local Similarity 100.0%; Pred. No. 0.028;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KVAELVHFL 9
| | | | |
Db 1 KVAELVHFL 9

RESULT 31
ABU04442
ID ABU04442 standard; protein; 10 AA.

XX AC ABU04442;

XX DT 29-JAN-2003 (first entry)

XX DE Human expressed protein tag (EPT) #1108.

XX KW Translational profiling; expressed protein tag; EPT; kinase; phosphatase;
XX KW protease; protease inhibitor; transporter; cytoskeletal protein;
XX KW receptor; transcription factor; cancer; MHC;
XX KW major histocompatibility complex; myeloma; colon cancer; gastric cancer;
XX KW adenocarcinoma; sarcoma; melanoma; lymphoma; leukaemia.

XX OS Homo sapiens.

XX PN WO200278524-A2.

XX PD 10-OCT-2002.

XX PF 28-MAR-2002; 2002WO-US009671.

XX PR 28-MAR-2001; 2001US-0279495P.

XX PR 21-MAY-2001; 2001US-0292544P.

XX PR 08-AUG-2001; 2001US-0310801P.

XX PR 01-OCT-2001; 2001US-0326370P.

XX PR 04-DEC-2001; 2001US-0336780P.

PR 20-FEB-2002; 2002US-0358985P.
XX (ZYCO-) ZYCOS INC.
XX
XX
XX Chicx RM, Tomlinson AJ, Urban RG;
XX
XX WPI; 2003-040607/03.
XX
XX New polypeptides (e.g. kinases, phosphatases, proteases, transporters,
PT cytoskeletal proteins, receptors or transcription factors), useful for
PT treating cancer, e.g. colon cancer, gastric cancer, sarcoma, lymphoma or
PT leukemia.
XX
XX
PS Example 2; SEQ ID NO 1108; 134pp; English.
XX
XX The invention describes a purified polypeptide, which comprises a
CC fragment of a kinase, phosphatase, protease, protease inhibitor,
CC transporter, cytoskeletal protein, receptor or transcription factor. The
CC polypeptide is useful as an immunogenic composition for eliciting in a
CC mammal an immunogenic response directed against any of the purified
CC polypeptide. The purified polypeptide, or the antibody that binds to this
CC polypeptide, is useful for treating cancer. The polypeptide is also
CC useful for identifying compounds that binds to a naturally processed
CC class I or class II MHC-binding polypeptide. The polypeptides and
CC polynucleotides are particularly useful for treating or preventing
CC myeloma, colon cancer, gastric cancer, adenocarcinoma, sarcoma, melanoma,
CC lymphoma or leukaemia. These are also useful for screening agents for
CC treating the above mentioned diseases. This sequence represents an
CC expressed protein tag (EPT) isolated from human tissue for translational
CC profiling. Note: This sequence does not appear in the printed
CC specification but was obtained in electronic format directly from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX SQ Sequence 10 AA;

Query Match 100.0%; Score 44; DB 6; Length 10;
Best Local Similarity 100.0%; Pred. No. 0.028;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 KVAELVHFL 9
|||
DB 1 KVAELVHFL 9

RESULT 32
ABU04450
ID ABU04450 standard; protein; 10 AA.

XX AC ABU04450;

XX DT 29-JAN-2003 (first entry)

XX DE Human expressed protein tag (EPT) #1116.

XX KW Translational profiling; expressed protein tag; EPT; kinase; phosphatase;
KW protease; protease inhibitor; transporter; cytoskeletal protein;
KW receptor; transcription factor; cancer; MHC;
KW major histocompatibility complex; myeloma; colon cancer; gastric cancer;
KW adenocarcinoma; sarcoma; melanoma; lymphoma; leukaemia.

XX OS Homo sapiens.

XX PN WO200278524-A2.

XX PD 10-OCT-2002.

XX PF 28-MAR-2002; 2002WO-US009671.

XX PR 28-MAR-2001; 2001US-0279495P.

XX PR 21-MAY-2001; 2001US-0292544P.

XX PR 08-AUG-2001; 2001US-0310801P.

XX PR 01-OCT-2001; 2001US-0326370P.

XX PR 04-DEC-2001; 2001US-0336780P.

PR 20-FEB-2002; 2002US-0358985P.
XX (ZYCO-) ZYCOS INC.
XX
XX Chicx RM, Tomlinson AJ, Urban RG;
XX
XX WPI; 2003-040607/03.
XX
XX New polypeptides (e.g. kinases, phosphatases, proteases, transporters,
PT cytoskeletal proteins, receptors or transcription factors), useful for
PT treating cancer, e.g. colon cancer, gastric cancer, sarcoma, lymphoma or
PT leukemia.
XX
XX
PS Example 2; SEQ ID NO 1116; 134pp; English.

XX The invention describes a purified polypeptide, which comprises a
CC fragment of a kinase, phosphatase, protease, protease inhibitor,
CC transporter, cytoskeletal protein, receptor or transcription factor. The
CC polypeptide is useful as an immunogenic composition for eliciting in a
CC mammal an immunogenic response directed against any of the purified
CC polypeptide. The purified polypeptide, or the antibody that binds to this
CC polypeptide, is useful for treating cancer. The polypeptide is also
CC useful for identifying compounds that binds to a naturally processed
CC class I or class II MHC-binding polypeptide. The polypeptides and
CC polynucleotides are particularly useful for treating or preventing
CC myeloma, colon cancer, gastric cancer, adenocarcinoma, sarcoma, melanoma,
CC lymphoma or leukaemia. These are also useful for screening agents for
CC treating the above mentioned diseases. This sequence represents an
CC expressed protein tag (EPT) isolated from human tissue for translational
CC profiling. Note: This sequence does not appear in the printed
CC specification but was obtained in electronic format directly from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX SQ Sequence 10 AA;

Query Match 100.0%; Score 44; DB 6; Length 10;
Best Local Similarity 100.0%; Pred. No. 0.028;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 KVAELVHFL 9
|||
DB 1 KVAELVHFL 9

RESULT 33
ABU04438
ID ABU04438 standard; protein; 10 AA.

XX AC ABU04438;

XX DT 29-JAN-2003 (first entry)

XX DE Human expressed protein tag (EPT) #1104.

XX KW Translational profiling; expressed protein tag; EPT; kinase; phosphatase;
KW protease; protease inhibitor; transporter; cytoskeletal protein;
KW receptor; transcription factor; cancer; MHC;
KW major histocompatibility complex; myeloma; colon cancer; gastric cancer;
KW adenocarcinoma; sarcoma; melanoma; lymphoma; leukaemia.

XX OS Homo sapiens.

XX PN WO200278524-A2.

XX PD 10-OCT-2002.

XX PF 28-MAR-2002; 2002WO-US009671.

XX PR 28-MAR-2001; 2001US-0279495P.

XX PR 21-MAY-2001; 2001US-0292544P.

XX PR 08-AUG-2001; 2001US-0310801P.

XX PR 01-OCT-2001; 2001US-0326370P.

XX PR 04-DEC-2001; 2001US-0336780P.


```
PR 20-FEB-2002; 2002US-0358985P.
XX (ZYCO-) ZYCOS INC.
XX Chicx RM, Tomlinson AJ, Urban RG;
XX WPI; 2003-040607/03.
XX New polypeptides (e.g. kinases, phosphatases, proteases, transporters,
PT cytoskeletal proteins, receptors or transcription factors), useful for
PT treating cancer, e.g. colon cancer, gastric cancer, sarcoma, lymphoma or
PT leukemia.
XX
XX Example 2; SEQ ID NO 1104; 134pp; English.
XX
CC The invention describes a purified polypeptide, which comprises a
CC fragment of a kinase, phosphatase, protease, protease inhibitor,
CC transporter, cytoskeletal protein, receptor or transcription factor. The
CC polypeptide is useful as an immunogenic composition for eliciting in a
CC mammal an immunogenic response directed against any of the purified
CC polypeptide. The purified polypeptide, or the antibody that binds to this
CC polypeptide, is useful for treating cancer. The polypeptide is also
CC useful for identifying compounds that binds to a naturally processed
CC class I or class II MHC-binding polypeptide. The polypeptides and
CC polynucleotides are particularly useful for treating or preventing
CC myeloma, colon cancer, gastric cancer, adenocarcinoma, sarcoma, melanoma,
CC lymphoma or leukaemia. These are also useful for screening agents for
CC treating the above mentioned diseases. This sequence represents an
CC expressed protein tag (EPT) isolated from human tissue for translational
CC profiling. Note: This sequence does not appear in the printed
CC specification but was obtained in electronic format directly from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 10 AA;
XX
Query Match 100.0%; Score 44; DB 6; Length 10;
Best Local Similarity 100.0%; Pred. No. 0.028;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 KVAELVHFL 9
DB 1 KVAELVHFL 9
| | | | |
| | | | |
RESULT 34
ABU04443
ID ABU04443 standard; protein; 10 AA.
XX
AC ABU04443;
XX
XX 29-JAN-2003 (first entry)
XX
XX Human expressed protein tag (EPT) #1109.
XX
XX Translational profiling; expressed protein tag; EPT; kinase; phosphatase;
KW protease; protease inhibitor; transporter; cytoskeletal protein;
KW receptor; transcription factor; cancer; MHC;
KW major histocompatibility complex; myeloma; colon cancer; gastric cancer;
KW adenocarcinoma; sarcoma; melanoma; lymphoma; leukaemia.
XX
OS Homo sapiens.
XX
XX WO200278524-A2.
XX
XX 10-OCT-2002.
XX
XX 28-MAR-2002; 2002WO-US009671.
XX
XX 28-MAR-2001; 2001US-0279495P.
PR 21-MAY-2001; 2001US-0292544P.
PR 08-AUG-2001; 2001US-0310801P.
PR 01-OCT-2001; 2001US-0326370P.
PR 04-DEC-2001; 2001US-0336780P.
PR
```

```
PR 20-FEB-2002; 2002US-0358985P.
XX (ZYCO-) ZYCOS INC.
XX Chicx RM, Tomlinson AJ, Urban RG;
XX WPI; 2003-040607/03.
XX New polypeptides (e.g. kinases, phosphatases, proteases, transporters,
PT cytoskeletal proteins, receptors or transcription factors), useful for
PT treating cancer, e.g. colon cancer, gastric cancer, sarcoma, lymphoma or
PT leukemia.
XX
XX Example 2; SEQ ID NO 1109; 134pp; English.
XX
CC The invention describes a purified polypeptide, which comprises a
CC fragment of a kinase, phosphatase, protease, protease inhibitor,
CC transporter, cytoskeletal protein, receptor or transcription factor. The
CC polypeptide is useful as an immunogenic composition for eliciting in a
CC mammal an immunogenic response directed against any of the purified
CC polypeptide. The purified polypeptide, or the antibody that binds to this
CC polypeptide, is useful for treating cancer. The polypeptide is also
CC useful for identifying compounds that binds to a naturally processed
CC class I or class II MHC-binding polypeptide. The polypeptides and
CC polynucleotides are particularly useful for treating or preventing
CC myeloma, colon cancer, gastric cancer, adenocarcinoma, sarcoma, melanoma,
CC lymphoma or leukaemia. These are also useful for screening agents for
CC treating the above mentioned diseases. This sequence represents an
CC expressed protein tag (EPT) isolated from human tissue for translational
CC profiling. Note: This sequence does not appear in the printed
CC specification but was obtained in electronic format directly from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 10 AA;
XX
Query Match 100.0%; Score 44; DB 6; Length 10;
Best Local Similarity 100.0%; Pred. No. 0.028;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 KVAELVHFL 9
DB 1 KVAELVHFL 9
| | | | |
| | | | |
RESULT 35
AAB08828
ID AAB08828 standard; peptide; 15 AA.
XX
AC AAB08828;
XX
XX 02-JAN-2001 (first entry)
XX
XX Amino acid sequence of a MAGE-3 derived immunogenic peptide.
XX
XX Melanoma associated antigen-3; MAGE-3; immunogenic peptide;
KW major histocompatibility complex; MHC; class II molecule; tumour;
KW CD4+ T cell proliferation; melanoma cell; immune response; vaccine.
XX
OS Homo sapiens.
XX
XX WO200052045-A2.
XX
XX 08-SEP-2000.
XX
XX 23-FEB-2000; 2000WO-EP001458.
XX
XX 26-FEB-1999; 99IT-MI000396.
XX
XX (SANR-) FOND CENT SAN RAFFAELE DEL MONTE TABOR.
PA Protti MP, Dellabona P;
XX WPI; 2000-601867/57.
XX
```

XX Novel melanoma associated antigen (MAGE)-3 derived immunogenic peptides
PT useful as vaccine for inducing immune response against tumor.
XX
PS Claim 1; Page 18; 27pp; English.
XX
CC AAB0827-37 represent melanoma associated antigen (MAGE)-3 derived
CC immunogenic peptides. The peptides are capable of binding to major
CC histocompatibility complex (MHC) class II molecules. Stimulation with the
CC peptides induces proliferation of CD4+ T cells, and of their cytolytic
CC activity. CD4+ T cells exposed to the peptides were able to cause lysis
CC of melanoma cells expressing MAGE-3 and HLA-DR molecules. The peptides
CC are useful for inducing an immune response against tumour cells
CC expressing a MAGE-3 antigen. They are also useful for the preparation of
CC anti-tumour medicament for use as a vaccine
XX
SQ Sequence 15 AA;

Query Match 100.0%; Score 44; DB 3; Length 15;
Best Local Similarity 100.0%; Pred. No. 0.043;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 KVAELVHFL 9
DB 2 KVAELVHFL 10

RESULT 36
AAG84626
ID AAG84626 standard; peptide; 15 AA.
XX
AC AAG84626;
XX
DT 10-SEP-2001 (first entry)
XX
DE MAGE3 DR supermotif binding peptide #37.
XX
KW Human; human leukocyte antigen; HLA epitope; cytotoxic T lymphocyte; CTL;
KW MAGE2; MAGE3; melanoma antigen gene; immune response; vaccine; cancer;
KW cytostatic; immunostimulant.
XX
OS Homo sapiens.
OS Synthetic.
XX
FN WO200142267-A1.
XX
PD 14-JUN-2001.
XX
PP 11-DEC-2000; 2000WO-US033545.
XX
PR 10-DEC-1999; 99US-00458298.
XX
PA (EPIM-) EPIMUNE INC.
XX
PI Fikes J, Sette A, Sidney J, Southwood S, Chesnut R, Celis E;
PI Keogh E;
XX
DR WPI; 2001-375002/39.
XX
PT An isolated prepared MAGE2/3 epitope (I) for use in pharmaceuticals for
PT the treatment and prevention of cancer.
XX
PS Disclosure; Page 138; 171pp; English.
XX
CC The present invention describes MAGE2/3 epitopes (I). Also described are:
CC (1) a clonal cytotoxic T lymphocyte (CTL) that is cultured in vivo and
CC binds to a complex of (I); (2) a peptide (II) comprising (I) and a second
CC epitope and has less than 50 contiguous amino acids; (3) a vaccine
CC composition comprising (II), a unit dose of a peptide with at least 50
CC contiguous amino acids with 100% identity to the native peptide sequence
CC of MAGE2/3, and a pharmaceutical excipient; (4) an isolated nucleic acid
CC encoding (I); and (5) an isolated nucleic acid encoding (II). (I) has
CC cytostatic activity, and can be used in vaccines and as an

CC immunostimulant. A vaccine of (3) is useful for the treatment and
CC prevention of cancer. (I) is useful for monitoring or evaluating an
CC immune response by incubating a T-lymphocyte sample from a patient with
CC (I) that binds to an human leukocyte antigen (HLA) allele present in the
CC patient and detecting the presence of the T-lymphocyte that binds to the
CC peptide. The vaccine allows the opportunity to combine epitopes derived
CC from multiple tumour-associated molecules reducing the likelihood of
CC tumour escape due to antigen loss. AAG84515 to AAG84909 and AAB99725
CC represent amino acid sequences used in the exemplification of the present
XX invention
SQ Sequence 15 AA;

Query Match 100.0%; Score 44; DB 4; Length 15;
Best Local Similarity 100.0%; Pred. No. 0.043;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 KVAELVHFL 9
DB 7 KVAELVHFL 15

RESULT 37
ABU04426
ID ABU04426 standard; protein; 15 AA.
XX
AC ABU04426;
XX
DT 29-JAN-2003 (first entry)
XX
DE Human expressed protein tag (EPT) #1092.
XX
KW Translational profiling; expressed protein tag; EPT; kinase; phosphatase;
KW protease; protease inhibitor; transporter; cytoskeletal protein;
KW receptor; transcription factor; cancer; MHC;
KW major histocompatibility complex; myeloma; colon cancer; gastric cancer;
KW adenocarcinoma; sarcoma; melanoma; lymphoma; leukaemia.
XX
OS Homo sapiens.
XX
PN WO200278524-A2.
XX
PD 10-OCT-2002.
XX
PF 28-MAR-2002; 2002WO-US009671.
XX
PR 28-MAR-2001; 2001US-0279495P.
PR 21-MAY-2001; 2001US-0292544P.
PR 08-AUG-2001; 2001US-0310801P.
PR 01-OCT-2001; 2001US-0326370P.
PR 04-DEC-2001; 2001US-0336780P.
PR 20-FEB-2002; 2002US-0358985P.
XX
PA (ZYCO-) ZYCOS INC.
XX
PI Chicx RM, Tomlinson AJ, Urban RG;
XX
DR WPI; 2003-040607/03.
XX
PT New polypeptides (e.g. kinases, phosphatases, proteases, transporters,
PT cytoskeletal proteins, receptors or transcription factors), useful for
PT treating cancer, e.g. colon cancer, gastric cancer, sarcoma, lymphoma or
PT leukemia.
XX
PS Example 2; SEQ ID NO 1092; 134pp; English.
XX
CC The invention describes a purified polypeptide, which comprises a
CC fragment of a kinase, phosphatase, protease, protease inhibitor,
CC transporter, cytoskeletal protein, receptor or transcription factor. The
CC polypeptide is useful as an immunogenic composition for eliciting in a
CC mammal an immunogenic response directed against any of the purified
CC polypeptide. The purified polypeptide, or the antibody that binds to this
CC polypeptide, is useful for treating cancer. The polypeptide is also

CC useful for identifying compounds that binds to a naturally processed
CC class I or class II MHC-binding polypeptide. The polypeptides and
CC polynucleotides are particularly useful for treating or preventing
CC myeloma, colon cancer, gastric cancer, adenocarcinoma, sarcoma, melanoma,
CC lymphoma or leukaemia. These are also useful for screening agents for
CC treating the above mentioned diseases. This sequence represents an
CC expressed protein tag (EPT) isolated from human tissue for translational
CC profiling. Note: This sequence does not appear in the printed
CC specification but was obtained in electronic format directly from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX SQ Sequence 15 AA;

Query Match 100.0%; Score 44; DB 6; Length 15;
Best Local Similarity 100.0%; Pred. No. 0.043;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 KVAELVHFL 9
| | | | |
DB 2 KVAELVHFL 10

RESULT 38
ABU0434
ID ABU0434 standard; protein; 15 AA.
XX
AC ABU0434;
XX
XX 29-JAN-2003 (first entry)
XX
XX Human expressed protein tag (EPT) #1100.

XX Translational profiling; expressed protein tag; EPT; kinase; phosphatase;
KW protease; protease inhibitor; transporter; cytoskeletal protein;
KW receptor; transcription factor; cancer; MHC;
KW major histocompatibility complex; myeloma; colon cancer; gastric cancer;
KW adenocarcinoma; sarcoma; melanoma; lymphoma; leukaemia.
XX
OS Homo sapiens.
XX
XX WO200278524-A2.
XX
XX 10-OCT-2002.
XX
XX 28-MAR-2002; 2002WO-US009671.
XX
XX 28-MAR-2001; 2001US-0279495P.
XX
XX 21-MAY-2001; 2001US-0292544P.
XX
XX 08-AUG-2001; 2001US-0310801P.
XX
XX 01-OCT-2001; 2001US-0326370P.
XX
XX 04-DEC-2001; 2001US-0336780P.
XX
XX 20-FEB-2002; 2002US-0358985P.
XX
XX (ZYCO-) ZYCO INC.
XX
XX Chicx RM, Tomlinson AJ, Urban RG;
XX
XX WPI; 2003-040607/03.
XX
XX New polypeptides (e.g. kinases, phosphatases, proteases, transporters,
PT cytoskeletal proteins, receptors or transcription factors), useful for
PT treating cancer, e.g. colon cancer, gastric cancer, sarcoma, lymphoma or
PT leukemia.
XX
XX Example 2; SEQ ID NO 1100; 134pp; English.

XX The invention describes a purified polypeptide, which comprises a
CC fragment of a kinase, phosphatase, protease, protease inhibitor,
CC transporter, cytoskeletal protein, receptor or transcription factor. The
CC polypeptide is useful as an immunogenic composition for eliciting in a
CC mammal an immunogenic response directed against any of the purified
CC polypeptide. The purified polypeptide, or the antibody that binds to this
CC polypeptide, is useful for treating cancer. The polypeptide is also

CC useful for identifying compounds that binds to a naturally processed
CC class I or class II MHC-binding polypeptide. The polypeptides and
CC polynucleotides are particularly useful for treating or preventing
CC myeloma, colon cancer, gastric cancer, adenocarcinoma, sarcoma, melanoma,
CC lymphoma or leukaemia. These are also useful for screening agents for
CC treating the above mentioned diseases. This sequence represents an
CC expressed protein tag (EPT) isolated from human tissue for translational
CC profiling. Note: This sequence does not appear in the printed
CC specification but was obtained in electronic format directly from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX SQ Sequence 15 AA;

Query Match 100.0%; Score 44; DB 6; Length 15;
Best Local Similarity 100.0%; Pred. No. 0.043;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 KVAELVHFL 9
| | | | |
DB 7 KVAELVHFL 15

RESULT 39
AAV01721
ID AAV01721 standard; peptide; 16 AA.
XX
AC AAV01721;
XX
XX 25-JUN-1999 (first entry)
XX
XX Peptide derived from MAGE-3 protein amino acids 111-126.

XX MAGE-3 tumour associated gene; human leucocyte antigen Class II;
KW autologous CD4+ cell; MAGE-3 related disease; cancer; melanoma;
KW osteosarcoma; leukemia; carcinoma.
XX
OS Synthetic.
OS Homo sapiens.
XX
XX WO9914326-A1.
XX
XX 25-MAR-1999.
XX
XX 04-SEP-1998; 98WO-US018601.
XX
XX 12-SEP-1997; 97US-00928615.
XX
XX (LUDW-) LUDWIG INST CANCER RES.
XX (UYVR-) UNIV VRIJE BRUSSEL.

XX Thielemans K, Heirman C, Corthals J, Chaux P, Stroobant V;
PI Boon-Falleur T, Van Der Bruggen P, Luiten R;
XX WPI; 1999-244031/20.
XX
XX Isolated peptides that bind to human leucocyte antigen class II
PT molecules.
XX
XX Claim 3; Page 36; 88pp; English.

XX The present sequence represents a peptide derived from the MAGE-3
CC protein. This protein is encoded by the MAGE-3 tumour associated gene.
CC Peptides (AAV01721-25) that bind human leucocyte antigen (HLA) Class II
CC molecules can be derived from the MAGE-3 protein. These peptides and
CC autologous CD4+ cells that bind to a complex of MAGE-3 peptide and HLA
CC Class II, are used to treat MAGE-3 related diseases, particularly cancers
CC (e.g. melanoma, osteosarcoma, leukemia and various forms of carcinoma).
CC The peptides are also used to produce specific antibodies. Detection of
CC of the peptides, e.g. in binding assays, particularly with antibodies, is
CC used for diagnosis of such diseases
XX
XX SQ Sequence 16 AA;

Query Match 100.0%; Score 44; DB 2; Length 16;
Best Local Similarity 100.0%; Pred. No. 0.046;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 KVAELVHFL 9
Db 2 KVAELVHFL 10

RESULT 40

AA92313
ID AA92313 standard; peptide; 16 AA.

XX AC AA92313;

XX DT 10-AUG-2000 (first entry)

XX DE MAGE-A3 antigenic peptide epitope.

XX KW MAGE-A3; antigen; epitope; cytotoxic T lymphocyte; CTL; complex; HLA;
human leukocyte antigen.

XX OS Homo sapiens.

XX FN WO200020445-A2.

XX PD 13-APR-2000.

XX PF 15-SEP-1999; 99WO-IB001664.

XX PR 02-OCT-1998; 98US-00165863.

XX PR 09-APR-1999; 99US-00289350.

XX PA (CHAU//) CHAUX P.

XX PA (LUIT//) LUITEN R.

XX PA (DEMO//) DEMOTTE N.

XX PA (DUFF//) DUFFOUR M.

XX PA (LURQ//) LURQUIN C.

XX PA (TRAV//) TRAVERSARI C.

XX PA (STRO//) STROOBANT V.

XX PA (CORN//) CORNELIS G R.

XX PA (BOON//) BOON-FALLEUR T.

XX PA (VERU//) VAN DER BRUGGEN P.

XX PA (SCHU//) SCHULTZ E.

XX PA (WARN//) WARNIER G.

PI Chaux P, Luiten R, Demotte N, Duffour M, Lurquin C, Traversari C;

PI Stroobant V, Cornelis GR, Boon-Falleur T, Van Der Bruggen P;

PI Schultz E, Warnier G;

XX WPI; 2000-303739/26.

XX Isolation of cytotoxic T-lymphocytes clones by successive steps of
stimulation and testing of lymphocytes with antigen presenting cells
which present antigens derived from different expression systems.

XX Example 12; Page 71; 99pp; English.

XX A novel method of isolation of cytotoxic T-lymphocytes (CTL) clones
comprises successive steps of stimulation and testing of lymphocytes with
antigen presenting cells (APCs) which present antigens derived from
different expression systems. The CTL clones isolated recognize specific
antigenic peptides of proteins, preferably of the MAGE family. The APC is
autologous and each expression system is different from at least one of
the other expression systems, therefore isolating a cytotoxic T cell
clone specific for the protein. The method can also be used to identify
an antigenic peptide epitope. Isolated CTL clones specific for a
peptide/human leukocyte antigen (HLA) complex are claimed. The CTL cells
specific for the complexes, peptides or cells which present the complexes
on the cell surface are useful for treating pathological conditions
characterized by abnormal expression of the complexes

XX Sequence 16 AA;

SQ

Query Match 100.0%; Score 44; DB 3; Length 16;
Best Local Similarity 100.0%; Pred. No. 0.046;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 KVAELVHFL 9
Db 6 KVAELVHFL 14

Search completed: July 23, 2004, 12:51:37
Job time : 53 secs

Result No.	Score	%		Length	DB	ID	Description
		Match	Query				
1	44	100.0	9	3	US-09-183-931-34	Sequence 34, Appl	
2	44	100.0	9	4	US-09-705-160-34	Sequence 34, Appl	
3	44	100.0	9	4	US-09-543-608A-5	Sequence 5, Appl	
4	44	100.0	16	2	US-08-328-615-3	Sequence 3, Appl	
5	44	100.0	16	3	US-09-166-448-3	Sequence 3, Appl	
6	44	100.0	16	4	US-09-348-933-3	Sequence 3, Appl	
7	44	100.0	16	4	US-09-697-884-3	Sequence 3, Appl	
8	44	100.0	314	2	US-08-928-615-2	Sequence 2, Appl	
9	44	100.0	314	3	US-09-166-448-2	Sequence 2, Appl	
10	44	100.0	314	4	US-09-348-933-2	Sequence 2, Appl	
11	44	100.0	314	4	US-09-697-884-2	Sequence 2, Appl	
12	44	100.0	314	4	US-09-392-714-30	Sequence 30, Appl	
13	40	90.9	9	4	US-08-197-484-86	Sequence 86, Appl	
14	40	90.9	9	4	US-08-197-484-145	Sequence 145, App	
15	40	90.9	9	5	PCT-US95-02131-86	Sequence 86, Appl	
16	40	90.9	9	5	PCT-US95-02121-145	Sequence 145, App	
17	40	90.9	129	4	US-09-634-238-358	Sequence 358, App	
18	39	88.6	14	3	US-09-166-448-26	Sequence 26, Appl	
19	39	88.6	14	4	US-09-697-884-26	Sequence 26, Appl	
20	39	88.6	15	3	US-09-166-448-25	Sequence 25, Appl	
21	39	88.6	15	4	US-09-697-884-25	Sequence 25, Appl	
22	39	88.6	16	3	US-09-166-448-24	Sequence 24, Appl	
23	39	88.6	16	4	US-09-697-884-24	Sequence 24, Appl	
24	37	84.1	9	1	US-08-217-188A-3	Sequence 3, Appl	
25	37	84.1	9	1	US-08-687-226-3	Sequence 3, Appl	
26	37	84.1	9	3	US-08-667-725B-3	Sequence 3, Appl	
27	37	84.1	9	3	US-09-007-748-3	Sequence 3, Appl	

```
; LENGTH: 9
; TYPE: PRT
; ORGANISM: Homo sapiens
; FEATURE:
; OTHER INFORMATION:
US-09-705-160-34

Query Match      100.0%; Score 44; DB 4; Length 9;
Best Local Similarity 100.0%; Pred. No. 3e+05;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KVAELVHFL 9
Db 1 KVAELVHFL 9

RESULT 3
US-09-543-608A-5
; Sequence 5, Application US/09543608A
; Patent No. 6602510
; GENERAL INFORMATION:
; APPLICANT: Fikes, John D.
; APPLICANT: Sette, Alessandro
; APPLICANT: Sidney, John
; APPLICANT: Southwood, Scott
; APPLICANT: Celis, Esteban
; APPLICANT: Keogh, Elissa A.
; APPLICANT: Chesnut, Robert
; APPLICANT: Epimmune Inc.
; TITLE OF INVENTION: HLA Class I A2 Tumor Associated Antigen
; FILE OF INVENTION: Peptides and Vaccine Compositions
; FILE REFERENCE: 018623-015710US
; CURRENT APPLICATION NUMBER: US/09/543,608A
; CURRENT FILING DATE: 2002-04-05
; NUMBER OF SEQ ID NOS: 52
; SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 5
; LENGTH: 9
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: MAGE3.112
US-09-543-608A-5

Query Match      100.0%; Score 44; DB 4; Length 9;
Best Local Similarity 100.0%; Pred. No. 3e+05;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KVAELVHFL 9
Db 1 KVAELVHFL 9

RESULT 4
US-08-928-615-3
; Sequence 3, Application US/08928615
; Patent No. 5965535
; GENERAL INFORMATION:
; APPLICANT: Chauv, Pascal
; APPLICANT: Stroobant, Vincent
; APPLICANT: Boon, Thierry
; APPLICANT: van der Bruggen, Pierre
; TITLE OF INVENTION: MAGE-3 PEPTIDES PRESENTED
; FILE OF INVENTION: BY HLA CLASS II MOLECULES
; NUMBER OF SEQUENCES: 13
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Wolf, Greenfield & Sacks, P.C.
; STREET: 600 Atlantic Avenue
; CITY: Boston
; STATE: MA
; COUNTRY: U.S.A.
; ZIP: 02210-2211
; COMPUTER READABLE FORM:

; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: DOS
; SOFTWARE: FastSEQ for Windows Version 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/928,615
; FILING DATE:
; CLASSIFICATION: 424
; ATTORNEY/AGENT INFORMATION:
; NAME: Van Amsterdam, John R.
; REGISTRATION NUMBER: 40,212
; REFERENCE/DOCKET NUMBER: L0461/7017
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 617-720-3500
; TELEFAX: 617-720-2441
; INFORMATION FOR SEQ ID NO: 3:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 16 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
US-08-928-615-3

Query Match      100.0%; Score 44; DB 2; Length 16;
Best Local Similarity 100.0%; Pred. No. 0.015;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KVAELVHFL 9
Db 2 KVAELVHFL 10

RESULT 5
US-09-166-448-3
; Sequence 3, Application US/09166448
; Patent No. 6291430
; GENERAL INFORMATION:
; APPLICANT: Chauv, Pascal
; APPLICANT: Vantomme, Valrie
; APPLICANT: Stroobant, Vincent
; APPLICANT: Boon-Falleur, Thierry
; APPLICANT: van der Bruggen, Pierre
; APPLICANT: Thielemans, Kris
; APPLICANT: Corthals, Jurgen
; TITLE OF INVENTION: MAGE-3 PEPTIDES PRESENTED BY HLA CLASS II MOLECULES
; FILE REFERENCE: L0461/7052
; CURRENT APPLICATION NUMBER: US/09/166,448
; CURRENT FILING DATE: 1998-10-05
; NUMBER OF SEQ ID NOS: 81
; SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 3
; LENGTH: 16
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-166-448-3

Query Match      100.0%; Score 44; DB 3; Length 16;
Best Local Similarity 100.0%; Pred. No. 0.015;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KVAELVHFL 9
Db 2 KVAELVHFL 10

RESULT 6
US-09-348-933-3
; Sequence 3, Application US/09348933
; Patent No. 6369211
; GENERAL INFORMATION:
; APPLICANT: Chauv, Pascal
; APPLICANT: Stroobant, Vincent
```

```
; APPLICANT: Boon-Falleur, Thierry
; APPLICANT: van der Bruggen, Pierre
; TITLE OF INVENTION: MAGE-3 PEPTIDES PRESENTED BY HLA CLASS II MOLECULES
; FILE REFERENCE: L0461/7065
; CURRENT APPLICATION NUMBER: US/09/348,933
; CURRENT FILING DATE: 1999-07-07
; EARLIER APPLICATION NUMBER: US 08/928,615
; EARLIER FILING DATE: 1997-09-12
; NUMBER OF SEQ ID NOS: 13
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 3
; LENGTH: 16
; TYPE: PRT
; ORGANISM: Homo sapiens
; US-09-348-933-3

Query Match      100.0%; Score 44; DB 4; Length 16;
Best Local Similarity 100.0%; Pred. No. 0.015;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 KVAELVHFL 9
        |||||
Db      2 KVAELVHFL 10

RESULT 7
US-09-697-884-3
; Sequence 3, Application US/09697884
; Patent No. 6426217
; GENERAL INFORMATION:
; APPLICANT: Chauv, Pascal
; APPLICANT: Vantomme, Valrie
; APPLICANT: Stroobant, Vincent
; APPLICANT: Boon-Falleur, Thierry
; APPLICANT: van der Bruggen, Pierre
; APPLICANT: Thielemans, Kris
; APPLICANT: Corthals, Jurgen
; TITLE OF INVENTION: MAGE-3 PEPTIDES PRESENTED BY HLA CLASS II MOLECULES
; FILE REFERENCE: L0461/7052
; CURRENT APPLICATION NUMBER: US/09/697,884
; CURRENT FILING DATE: 2000-10-27
; PRIOR APPLICATION NUMBER: 09/166,448
; PRIOR FILING DATE: 1998-10-05
; NUMBER OF SEQ ID NOS: 81
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 3
; LENGTH: 16
; TYPE: PRT
; ORGANISM: Homo sapiens
; US-09-697-884-3

Query Match      100.0%; Score 44; DB 4; Length 16;
Best Local Similarity 100.0%; Pred. No. 0.015;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 KVAELVHFL 9
        |||||
Db      2 KVAELVHFL 10

RESULT 8
US-08-928-615-2
; Sequence 2, Application US/08928615
; Patent No. 5965535
; GENERAL INFORMATION:
; APPLICANT: Chauv, Pascal
; APPLICANT: Stroobant, Vincent
; APPLICANT: Boon, Thierry
; APPLICANT: van der Bruggen, Pierre
; TITLE OF INVENTION: MAGE-3 PEPTIDES PRESENTED
; NUMBER OF SEQUENCES: 13
; CORRESPONDENCE ADDRESS:
```

```
; ADDRESSEE: Wolf, Greenfield & Sacks, P.C.
; STREET: 600 Atlantic Avenue
; CITY: Boston
; STATE: MA
; COUNTRY: U.S.A.
; ZIP: 02210-2211
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: DOS
; SOFTWARE: FastSeq for Windows Version 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/928,615
; FILING DATE:
; CLASSIFICATION: 424
; ATTORNEY/AGENT INFORMATION:
; NAME: Van Amsterdam, John R.
; REGISTRATION NUMBER: 40,212
; REFERENCE/DOCKET NUMBER: L0461/7017
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 617-720-3500
; TELEFAX: 617-720-2441
; INFORMATION FOR SEQ ID NO: 2:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 314 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; US-08-928-615-2

Query Match      100.0%; Score 44; DB 2; Length 314;
Best Local Similarity 100.0%; Pred. No. 0.31;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 KVAELVHFL 9
        |||||
Db      112 KVAELVHFL 120

RESULT 9
US-09-166-448-2
; Sequence 2, Application US/09166448
; Patent No. 6291430
; GENERAL INFORMATION:
; APPLICANT: Chauv, Pascal
; APPLICANT: Vantomme, Valrie
; APPLICANT: Stroobant, Vincent
; APPLICANT: Boon-Falleur, Thierry
; APPLICANT: van der Bruggen, Pierre
; APPLICANT: Thielemans, Kris
; APPLICANT: Corthals, Jurgen
; TITLE OF INVENTION: MAGE-3 PEPTIDES PRESENTED BY HLA CLASS II MOLECULES
; FILE REFERENCE: L0461/7052
; CURRENT APPLICATION NUMBER: US/09/166,448
; CURRENT FILING DATE: 1998-10-05
; NUMBER OF SEQ ID NOS: 81
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 2
; LENGTH: 314
; TYPE: PRT
; ORGANISM: Homo sapiens
; US-09-166-448-2

Query Match      100.0%; Score 44; DB 3; Length 314;
Best Local Similarity 100.0%; Pred. No. 0.31;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 KVAELVHFL 9
        |||||
Db      112 KVAELVHFL 120
```

```
RESULT 10
US-09-348-933-2
; Sequence 2, Application US/09348933
; Patent No. 6369211
; GENERAL INFORMATION:
; APPLICANT: Chaux, Pascal
; APPLICANT: Stroobant, Vincent
; APPLICANT: Boon-Falleur, Thierry
; APPLICANT: van der Bruggen, Pierre
; TITLE OF INVENTION: MAGE-3 PEPTIDES PRESENTED BY HLA CLASS II MOLECULES
; FILE REFERENCE: L0461/7065
; CURRENT APPLICATION NUMBER: US/09/348,933
; CURRENT FILING DATE: 1999-07-07
; EARLIER APPLICATION NUMBER: US 08/928,615
; EARLIER FILING DATE: 1997-09-12
; NUMBER OF SEQ ID NOS: 13
; SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 2
; LENGTH: 314
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-348-933-2

Query Match      100.0%; Score 44; DB 4; Length 314;
Best Local Similarity 100.0%; Pred. No. 0.31;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 KVAELVHFL 9
Db      112 KVAELVHFL 120

RESULT 11
US-09-697-884-2
; Sequence 2, Application US/09697884
; Patent No. 6426217
; GENERAL INFORMATION:
; APPLICANT: Chaux, Pascal
; APPLICANT: Vantomme, Val,rie
; APPLICANT: Stroobant, Vincent
; APPLICANT: Boon-Falleur, Thierry
; APPLICANT: van der Bruggen, Pierre
; APPLICANT: Thielemans, Kris
; TITLE OF INVENTION: MAGE-3 PEPTIDES PRESENTED BY HLA CLASS II MOLECULES
; FILE REFERENCE: L0461/7052
; CURRENT APPLICATION NUMBER: US/09/697,884
; CURRENT FILING DATE: 2000-10-27
; PRIOR APPLICATION NUMBER: 09/166,448
; PRIOR FILING DATE: 1998-10-05
; NUMBER OF SEQ ID NOS: 81
; SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 2
; LENGTH: 314
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-697-884-2

Query Match      100.0%; Score 44; DB 4; Length 314;
Best Local Similarity 100.0%; Pred. No. 0.31;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 KVAELVHFL 9
Db      112 KVAELVHFL 120

RESULT 12
US-09-392-714-30
; Sequence 30, Application US/09392714A
; Patent No. 6686147
; GENERAL INFORMATION:
; APPLICANT: Scanlan, Matthew J.
```

```
; APPLICANT: Gure, Ali O.
; APPLICANT: Williamson, Barbara
; APPLICANT: Chen, Yao-Tseng
; APPLICANT: Old, Lloyd J.
; TITLE OF INVENTION: Cancer Associated Antigens and Uses
; FILE REFERENCE: L0461/7062
; CURRENT APPLICATION NUMBER: US/09/392,714A
; CURRENT FILING DATE: 1999-09-09
; EARLIER APPLICATION NUMBER: PCT/US98/14679
; EARLIER FILING DATE: 1998-07-15
; NUMBER OF SEQ ID NOS: 30
; SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 30
; LENGTH: 314
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-392-714-30

Query Match      100.0%; Score 44; DB 4; Length 314;
Best Local Similarity 100.0%; Pred. No. 0.31;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 KVAELVHFL 9
Db      112 KVAELVHFL 120

RESULT 13
US-08-197-484-86
; Sequence 86, Application US/08197484
; Patent No. 641931
; GENERAL INFORMATION:
; APPLICANT: VITIELLO, Maria A.
; APPLICANT: CHESTNUT, Robert W.
; APPLICANT: SETTE, Alessandro D.
; APPLICANT: CELIS, Esteban
; APPLICANT: GRAY, Howard
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR ELICITING
; TITLE OF INVENTION: CTL IMMUNITY
; NUMBER OF SEQUENCES: 153
; CORRESPONDENCE ADDRESS:
; ADDRESS: Townsend and Townsend Kourie and Crew
; STREET: Steuart Street Tower, One Market Plaza
; CITY: San Francisco
; STATE: California
; COUNTRY: US
; ZIP: 94105-1493
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/197,484
; FILING DATE: 16-FEB-1994
; CLASSIFICATION: 424
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/935,811
; FILING DATE: 26-AUG-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/874,491
; FILING DATE: 27-APR-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/827,682
; FILING DATE: 29-JAN-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/749,568
; FILING DATE: 26-AUG-1991
; ATTORNEY/AGENT INFORMATION:
; NAME: Parmelee, Steven W.
; REGISTRATION NUMBER: 31,990
; REFERENCE/DOCKET NUMBER: 14137-26-4
```


TELECOMMUNICATION INFORMATION:
TELEPHONE: (206) 467-9600
TELEFAX: (206) 623-6793
INFORMATION FOR SEQ ID NO: 86:
SEQUENCE CHARACTERISTICS:
LENGTH: 9 amino acids
TYPE: amino acid
STRANDEDNESS: unknown
TOPOLOGY: unknown
MOLECULE TYPE: peptide
US-08-197-484-86

Query Match 90.9%; Score 40; DB 4; Length 9;
Best Local Similarity 88.9%; Pred. No. 3e+05;
Matches 8; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1 KVAELVHFL 9
Db 1 KVAEFVHFL 9

RESULT 14
US-08-197-484-145
Sequence 145, Application US/08197484
Patent No. 641931
GENERAL INFORMATION:
APPLICANT: VITIELLO, Maria A.
APPLICANT: CHESNUT, Robert W.
APPLICANT: SETTE, Alessandro D.
APPLICANT: CELIS, Esteban
APPLICANT: GRAY, Howard
TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR ELICITING
TITLE OF INVENTION: CTL IMMUNITY
NUMBER OF SEQUENCES: 153
CORRESPONDENCE ADDRESS:
ADDRESSEE: Townsend and Townsend Kourie and Crew
STREET: Stewart Street Tower, One Market Plaza
CITY: San Francisco
STATE: California
COUNTRY: US
ZIP: 94105-1493
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent in Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/197,484
FILING DATE: 16-FEB-1994
CLASSIFICATION: 424
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/935,811
FILING DATE: 26-AUG-1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/874,491
FILING DATE: 27-APR-1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/827,682
FILING DATE: 29-JAN-1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/749,568
FILING DATE: 26-AUG-1991
ATTORNEY/AGENT INFORMATION:
NAME: Parmelee, Steven W.
REGISTRATION NUMBER: 31,990
REFERENCE/DOCKET NUMBER: 14137-26-4
TELECOMMUNICATION INFORMATION:
TELEPHONE: (206) 467-9600
TELEFAX: (206) 623-6793
INFORMATION FOR SEQ ID NO: 145:
SEQUENCE CHARACTERISTICS:
LENGTH: 9 amino acids
TYPE: amino acid

STRANDEDNESS: unknown
TOPOLOGY: unknown
MOLECULE TYPE: peptide
US-08-197-484-145
Query Match 90.9%; Score 40; DB 4; Length 9;
Best Local Similarity 88.9%; Pred. No. 3e+05;
Matches 8; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Qy 1 KVAELVHFL 9
Db 1 KVAEFVHFL 9
RESULT 15
PCT-US95-02121-86
Sequence 86, Application PC/TUS9502121
GENERAL INFORMATION:
APPLICANT:
TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR ELICITING
TITLE OF INVENTION: CTL IMMUNITY
NUMBER OF SEQUENCES: 153
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent in Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: PCT/US95/02121
FILING DATE: 16-FEB-1995
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/197,484
FILING DATE: 16-FEB-1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/935,811
FILING DATE: 26-AUG-1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/874,491
FILING DATE: 27-APR-1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/827,682
FILING DATE: 29-JAN-1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/749,568
FILING DATE: 26-AUG-1991
ATTORNEY/AGENT INFORMATION:
NAME: Parmelee, Steven W.
REGISTRATION NUMBER: 31,990
REFERENCE/DOCKET NUMBER: 14137-26-4PC
TELECOMMUNICATION INFORMATION:
TELEPHONE: (206) 467-9600
TELEFAX: (415) 543-5043
INFORMATION FOR SEQ ID NO: 86:
SEQUENCE CHARACTERISTICS:
LENGTH: 9 amino acids
TYPE: amino acid
STRANDEDNESS: unknown
TOPOLOGY: unknown
MOLECULE TYPE: peptide
PCT-US95-02121-86

Query Match 90.9%; Score 40; DB 5; Length 9;
Best Local Similarity 88.9%; Pred. No. 3e+05;
Matches 8; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1 KVAELVHFL 9
Db 1 KVAEFVHFL 9

RESULT 16
PCT-US95-02121-145

; Sequence 145, Application PC/TUS9502121
; GENERAL INFORMATION:
; APPLICANT:
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR ELICITING
; TITLE OF INVENTION: CTL IMMUNITY
; NUMBER OF SEQUENCES: 153
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION NUMBER: US 08/197,484
; FILING DATE: 16-FEB-1995
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/197,484
; FILING DATE: 16-FEB-1994
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/935,811
; FILING DATE: 26-AUG-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/874,491
; FILING DATE: 27-APR-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/827,682
; FILING DATE: 29-JAN-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/749,568
; FILING DATE: 26-AUG-1991
; ATTORNEY/AGENT INFORMATION:
; NAME: Parmelee, Steven W.
; REGISTRATION NUMBER: 31,990
; REFERENCE/DOCKET NUMBER: 14137-26-4PC
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (206) 467-9600
; TELEFAX: (415) 543-5043
; INFORMATION FOR SEQ ID NO: 145:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 9 amino acids
; TYPE: amino acid
; STRANDEDNESS: unknown
; TOPOLOGY: unknown
; MOLECULE TYPE: peptide
PCT-US95-02121-145

Query Match 90.9%; Score 40; DB 5; Length 9;
Best Local Similarity 88.9%; Pred. No. 3e+05;
Matches 8; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1 KVAELVHFL 9
Db 1 KVAELVHFL 9
|||||

RESULT 17
US-09-634-238-358
; Sequence 358, Application US/09634238
; Patent No. 654472
; GENERAL INFORMATION:
; APPLICANT: Glenn, Matthew
; APPLICANT: Havukkala, Ilkka J.
; APPLICANT: Bloksberg, Leonard, N.
; APPLICANT: Lubbers, Mark W.
; APPLICANT: Dekker, James
; APPLICANT: Christenson, Anna C.
; APPLICANT: Holland, Ross
; APPLICANT: O'Toole, Paul W.
; APPLICANT: Reid, Julian R.
; APPLICANT: Coolbear, Timothy
; TITLE OF INVENTION: Polynucleotides, materials incorporating
; TITLE OF INVENTION: them and methods for using them.
; FILE REFERENCE: 11000.1043U1

; CURRENT APPLICATION NUMBER: US/09/634,238
; CURRENT FILING DATE: 2000-08-08
; NUMBER OF SEQ ID NOS: 422
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 358
; LENGTH: 129
; TYPE: PRT
; ORGANISM: Lactobacillus rhamnosus
US-09-634-238-358

Query Match 90.9%; Score 40; DB 4; Length 129;
Best Local Similarity 100.0%; Pred. No. 0.81;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KVAELVHF 8
Db 103 KVAELVHF 110
|||||

RESULT 18
US-09-166-448-26
; Sequence 26, Application US/09166448
; Patent No. 6291430
; GENERAL INFORMATION:
; APPLICANT: Chau, Pascal
; APPLICANT: Vantomme, Valrie
; APPLICANT: Stroobant, Vincent
; APPLICANT: Boon-Falleur, Thierry
; APPLICANT: van der Bruggen, Pierre
; APPLICANT: Thielemans, Kris
; APPLICANT: Corthals, Jurgen
; TITLE OF INVENTION: MAGE-3 PEPTIDES PRESENTED BY HLA CLASS II MOLECULES
; FILE REFERENCE: L0461/7052
; CURRENT APPLICATION NUMBER: US/09/166,448
; CURRENT FILING DATE: 1998-10-05
; NUMBER OF SEQ ID NOS: 81
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 26
; LENGTH: 14
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-166-448-26

Query Match 88.6%; Score 39; DB 3; Length 14;
Best Local Similarity 100.0%; Pred. No. 0.14;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2 VAEVHFL 9
Db 1 VAEVHFL 8
|||||

RESULT 19
US-09-697-884-26
; Sequence 26, Application US/09697884
; Patent No. 6426217
; GENERAL INFORMATION:
; APPLICANT: Chau, Pascal
; APPLICANT: Vantomme, Val,rie
; APPLICANT: Stroobant, Vincent
; APPLICANT: Boon-Falleur, Thierry
; APPLICANT: van der Bruggen, Fierre
; APPLICANT: Thielemans, Kris
; APPLICANT: Corthals, Jurgen
; TITLE OF INVENTION: MAGE-3 PEPTIDES PRESENTED BY HLA CLASS II MOLECULES
; FILE REFERENCE: L0461/7052
; CURRENT APPLICATION NUMBER: US/09/697,884
; CURRENT FILING DATE: 2000-10-27
; PRIOR APPLICATION NUMBER: 09/166,448
; PRIOR FILING DATE: 1998-10-05
; NUMBER OF SEQ ID NOS: 81
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 26

```
; LENGTH: 14
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-697-884-26

Query Match      88.6%; Score 39; DB 4; Length 14;
Best Local Similarity 100.0%; Pred. No. 0.14;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      2 VAEVHFL 9
Db      1 VAEVHFL 8

RESULT 20
US-09-166-448-25
; Sequence 25, Application US/09166448
; Patent No. 6291430
; GENERAL INFORMATION:
; APPLICANT: Chauv, Pascal
; APPLICANT: Vantomme, Valrie
; APPLICANT: Stroobant, Vincent
; APPLICANT: Boon-Falleur, Thierry
; APPLICANT: van der Bruggen, Pierre
; APPLICANT: Thielemans, Kris
; APPLICANT: Corthals, Jurgen
; TITLE OF INVENTION: MAGE-3 PEPTIDES PRESENTED BY HLA CLASS II MOLECULES
; FILE REFERENCE: L0461/7052
; CURRENT APPLICATION NUMBER: US/09/166,448
; CURRENT FILING DATE: 1998-10-05
; NUMBER OF SEQ ID NOS: 81
; SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 25
; LENGTH: 15
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-166-448-25

Query Match      88.6%; Score 39; DB 3; Length 15;
Best Local Similarity 100.0%; Pred. No. 0.15;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      2 VAEVHFL 9
Db      1 VAEVHFL 8

RESULT 21
US-09-697-884-25
; Sequence 25, Application US/09697884
; Patent No. 6426217
; GENERAL INFORMATION:
; APPLICANT: Chauv, Pascal
; APPLICANT: Vantomme, Valrie
; APPLICANT: Stroobant, Vincent
; APPLICANT: Boon-Falleur, Thierry
; APPLICANT: van der Bruggen, Pierre
; APPLICANT: Thielemans, Kris
; APPLICANT: Corthals, Jurgen
; TITLE OF INVENTION: MAGE-3 PEPTIDES PRESENTED BY HLA CLASS II MOLECULES
; FILE REFERENCE: L0461/7052
; CURRENT APPLICATION NUMBER: US/09/697,884
; CURRENT FILING DATE: 2000-10-27
; PRIOR APPLICATION NUMBER: 09/166,448
; PRIOR FILING DATE: 1998-10-05
; NUMBER OF SEQ ID NOS: 81
; SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 25
; LENGTH: 15
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-697-884-25

Query Match      88.6%; Score 39; DB 4; Length 15;
Best Local Similarity 100.0%; Pred. No. 0.15;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      2 VAEVHFL 9
Db      1 VAEVHFL 8

RESULT 22
US-09-166-448-24
; Sequence 24, Application US/09166448
; Patent No. 6291430
; GENERAL INFORMATION:
; APPLICANT: Chauv, Pascal
; APPLICANT: Vantomme, Valrie
; APPLICANT: Stroobant, Vincent
; APPLICANT: Boon-Falleur, Thierry
; APPLICANT: van der Bruggen, Pierre
; APPLICANT: Thielemans, Kris
; APPLICANT: Corthals, Jurgen
; TITLE OF INVENTION: MAGE-3 PEPTIDES PRESENTED BY HLA CLASS II MOLECULES
; FILE REFERENCE: L0461/7052
; CURRENT APPLICATION NUMBER: US/09/166,448
; CURRENT FILING DATE: 1998-10-05
; NUMBER OF SEQ ID NOS: 81
; SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 24
; LENGTH: 16
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-166-448-24

Query Match      88.6%; Score 39; DB 3; Length 16;
Best Local Similarity 100.0%; Pred. No. 0.16;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      2 VAEVHFL 9
Db      1 VAEVHFL 8

RESULT 23
US-09-697-884-24
; Sequence 24, Application US/09697884
; Patent No. 6426217
; GENERAL INFORMATION:
; APPLICANT: Chauv, Pascal
; APPLICANT: Vantomme, Valrie
; APPLICANT: Stroobant, Vincent
; APPLICANT: Boon-Falleur, Thierry
; APPLICANT: van der Bruggen, Pierre
; APPLICANT: Thielemans, Kris
; APPLICANT: Corthals, Jurgen
; TITLE OF INVENTION: MAGE-3 PEPTIDES PRESENTED BY HLA CLASS II MOLECULES
; FILE REFERENCE: L0461/7052
; CURRENT APPLICATION NUMBER: US/09/697,884
; CURRENT FILING DATE: 2000-10-27
; PRIOR APPLICATION NUMBER: 09/166,448
; PRIOR FILING DATE: 1998-10-05
; NUMBER OF SEQ ID NOS: 81
; SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 24
; LENGTH: 16
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-697-884-24

Query Match      88.6%; Score 39; DB 4; Length 16;
Best Local Similarity 100.0%; Pred. No. 0.16;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      2 VAEVHFL 9
```

Db 1 VAEVLVHFL 8
|||||
RESULT 24
US-08-217-188A-3
; Sequence 3, Application US/08217188A
; Patent No. 5554724
; GENERAL INFORMATION:
; APPLICANT: Melief, Cornelis J. M.
; APPLICANT: Visseren, M. J. W.
; APPLICANT: Kast, W. M.
; APPLICANT: van der Bruggen, Pierre
; APPLICANT: Boon-Falleur, Thierry
; TITLE OF INVENTION: Isolated Tumor Rejection Antigen
; TITLE OF INVENTION: Precursor MAGE-2 Derived Peptides, and Uses Thereof
; NUMBER OF SEQUENCES: 62
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Felfe & Lynch
; STREET: 805 Third Avenue
; CITY: New York City
; STATE: New York
; COUNTRY: USA
; ZIP: 10022
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette, 5.25 inch, 360 kb storage
; COMPUTER: IBM PS/2
; OPERATING SYSTEM: PC-DOS
; SOFTWARE: Wordperfect
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/217,188A
; FILING DATE: 24-MARCH-1994
; CLASSIFICATION: 530
; ATTORNEY/AGENT INFORMATION:
; NAME: Hanson, No. 5554724man D.
; REGISTRATION NUMBER: 30,946
; REFERENCE/DOCKET NUMBER: LUD 5340
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 688-9200
; TELEFAX: (212) 838-3884
; INFORMATION FOR SEQ ID NO: 3:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 9 amino acid residues
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: protein
US-08-217-188A-3
Query Match 84.1%; Score 37; DB 1; Length 9;
Best Local Similarity 77.8%; Pred. No. 3e+05;
Matches 7; Conservative 1; Mismatches 1; Indels 0; Gaps 0;
Qy 1 KVAELVHFL 9
|:|||||
Db 1 KMWELVHFL 9
|:|||||
RESULT 25
US-08-687-226-3
; Sequence 3, Application US/08687226
; Patent No. 5686068
; GENERAL INFORMATION:
; APPLICANT: Melief, Cornelis J. M.; Visseren, M. W.;
; APPLICANT: van der Burg, Sjoerd; van der Bruggen, Pierre;
; APPLICANT: Boon-Falleur, Thierry
; TITLE OF INVENTION: Isolated Peptides Derived From
; TITLE OF INVENTION: MAGE-2, Cytolytic T Cells Specific To Complexes Of
; TITLE OF INVENTION: Peptides And HLA-A2 Molecules, And Uses Thereof
; NUMBER OF SEQUENCES: 72
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Felfe & Lynch
; STREET: 805 Third Avenue
; CITY: New York City

; STATE: New York
; COUNTRY: USA
; ZIP: 10022
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette, 3.5 inch, 360 kb storage
; COMPUTER: IBM PS/2
; OPERATING SYSTEM: PC-DOS
; SOFTWARE: Wordperfect
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/687,226
; FILING DATE: 25-JULY-1996
; CLASSIFICATION: 530
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/217,188
; FILING DATE: 24-MARCH-1994
; ATTORNEY/AGENT INFORMATION:
; NAME: Hanson, No. 5686068man D.
; REGISTRATION NUMBER: 30,946
; REFERENCE/DOCKET NUMBER: LUD 5447
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 688-9200
; TELEFAX: (212) 838-3884
; INFORMATION FOR SEQ ID NO: 3:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 9 amino acid residues
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: protein
US-08-687-226-3
Query Match 84.1%; Score 37; DB 1; Length 9;
Best Local Similarity 77.8%; Pred. No. 3e+05;
Matches 7; Conservative 1; Mismatches 1; Indels 0; Gaps 0;
Qy 1 KVAELVHFL 9
|:|||||
Db 1 KMWELVHFL 9
|:|||||
RESULT 26
US-08-667-725B-3
; Sequence 3, Application US/08667725B
; Patent No. 6063900
; GENERAL INFORMATION:
; APPLICANT: Melief, Cornelis J. M.
; APPLICANT: Visseren, M. J. W.
; APPLICANT: Kast, W. M.
; APPLICANT: van der Bruggen, Pierre
; APPLICANT: Boon-Falleur, Thierry
; TITLE OF INVENTION: Isolated Tumor Rejection Antigen
; TITLE OF INVENTION: Precursor MAGE-2 Derived Peptides, and Uses Thereof
; NUMBER OF SEQUENCES: 64
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Fulbright & Jaworski LLP
; STREET: 666 Fifth Avenue
; CITY: New York City
; STATE: New York
; COUNTRY: USA
; ZIP: 10103
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette, 5.25 inch, 360 kb storage
; COMPUTER: IBM PS/2
; OPERATING SYSTEM: PC-DOS
; SOFTWARE: Wordperfect
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/667,725B
; FILING DATE: 21 June 1996
; CLASSIFICATION: 530
; ATTORNEY/AGENT INFORMATION:
; NAME: Hanson, No. 6063900man D.
; REGISTRATION NUMBER: 30,946
; REFERENCE/DOCKET NUMBER: LUD 5340.1 DIV (081585)
; TELECOMMUNICATION INFORMATION:

TELEPHONE: (212) 318-3000
TELEFAX: (212) 752-5958
INFORMATION FOR SEQ ID NO: 3:
SEQUENCE CHARACTERISTICS:
LENGTH: 9 amino acid residues
TYPE: amino acid
TOPOLOGY: linear
MOLECULE TYPE: protein
US-08-667-725B-3

Query Match 84.1%; Score 37; DB 3; Length 9;
Best Local Similarity 77.8%; Pred. No. 3e+05;
Matches 7; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

Qy 1 KVAELVHFL 9
|: |||||
Db 1 KMVELVHFL 9

RESULT 27

US-09-007-748-3
Sequence 3, Application US/09007748
Patent No. 6147187
GENERAL INFORMATION:
APPLICANT: Melief, Cornelis J. M.
APPLICANT: Visseren, M. J. W.
APPLICANT: Kast, W. M.
APPLICANT: Boon-Falleur, Pierre
TITLE OF INVENTION: Isolated Tumor Rejection Antigen
TITLE OF INVENTION: Precursor MAGE-2 Derived Peptides, and Uses Thereof
NUMBER OF SEQUENCES: 64
CORRESPONDENCE ADDRESS:
ADDRESSSEE: Fulbright & Jaworski LLP
STREET: 666 Fifth Avenue
CITY: New York City
STATE: New York
COUNTRY: USA
ZIP: 10103

COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette, 5.25 inch, 360 kb storage
COMPUTER: IBM PS/2
OPERATING SYSTEM: PC-DOS
SOFTWARE: Wordperfect
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/007.748
FILING DATE: 15 January 1998
CLASSIFICATION: 530
ATTORNEY/AGENT INFORMATION:
NAME: Hanson, No. 6147187man D.
REGISTRATION NUMBER: 30,946
REFERENCE/DOCKET NUMBER: LUD 5340.2 DIV (081572)
TELECOMMUNICATION INFORMATION:
TELEPHONE: (212) 318-3000
TELEFAX: (212) 752-5958
INFORMATION FOR SEQ ID NO: 3:
SEQUENCE CHARACTERISTICS:
LENGTH: 9 amino acid residues
TYPE: amino acid
TOPOLOGY: linear
MOLECULE TYPE: protein
US-09-007-748-3

Query Match 84.1%; Score 37; DB 3; Length 9;
Best Local Similarity 77.8%; Pred. No. 3e+05;
Matches 7; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

Qy 1 KVAELVHFL 9
|: |||||
Db 1 KMVELVHFL 9

RESULT 28

US-09-183-931-31
Sequence 31, Application US/09183931C
Patent No. 6210886
GENERAL INFORMATION:
APPLICANT: Van Baren, Nicolas
APPLICANT: Brasseur, Francis
APPLICANT: Boon-Falleur, Thierry
TITLE OF INVENTION: METHOD FOR DIAGNOSING LEUKEMIA BY DETERMINING
TITLE OF INVENTION: TUMOR REJECTION ANTIGEN PRECURSORS
FILE REFERENCE: LUD 5527.1-JEL/ES
CURRENT APPLICATION NUMBER: US/09/183,931C
CURRENT FILING DATE: 2000-02-28
EARLIER APPLICATION NUMBER: US 09/018,422
EARLIER FILING DATE: 1998 - 02 - 04
NUMBER OF SEQ ID NOS: 44
SEQ ID NO 31
LENGTH: 9
TYPE: PRT
ORGANISM: Homo sapiens
FEATURE:
OTHER INFORMATION:
US-09-183-931-31

Query Match 84.1%; Score 37; DB 3; Length 9;
Best Local Similarity 77.8%; Pred. No. 3e+05;
Matches 7; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

Qy 1 KVAELVHFL 9
|: |||||
Db 1 KMVELVHFL 9

RESULT 29

US-09-705-160-31
Sequence 31, Application US/09705160
Patent No. 6387630
GENERAL INFORMATION:
APPLICANT: Van Baren, Nicolas
APPLICANT: Brasseur, Francis
APPLICANT: Boon-Falleur, Thierry
TITLE OF INVENTION: METHOD FOR DIAGNOSING LEUKEMIA BY DETERMINING
TITLE OF INVENTION: TUMOR REJECTION ANTIGEN PRECURSORS
FILE REFERENCE: LUD 5527.3-JEL/MAS
CURRENT APPLICATION NUMBER: US/09/705,160
CURRENT FILING DATE: 2001-11-02
PRIOR APPLICATION NUMBER: US 09/183,931
PRIOR FILING DATE: 1998 - 10 - 30
NUMBER OF SEQ ID NOS: 44
SEQ ID NO 31
LENGTH: 9
TYPE: PRT
ORGANISM: Homo sapiens
FEATURE:
OTHER INFORMATION:
US-09-705-160-31

Query Match 84.1%; Score 37; DB 4; Length 9;
Best Local Similarity 77.8%; Pred. No. 3e+05;
Matches 7; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

Qy 1 KVAELVHFL 9
|: |||||
Db 1 KMVELVHFL 9

RESULT 30

US-08-197-484-81
Sequence 81, Application US/08197484
Patent No. 6419931
GENERAL INFORMATION:
APPLICANT: VITIELLO, Maria A.
APPLICANT: CHESTNUT, Robert W.
APPLICANT: SETTE, Alessandro D.

APPLICANT: CELIS, Esteban
APPLICANT: GRAY, Howard
TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR ELICITING
TITLE OF INVENTION: CTL IMMUNITY
NUMBER OF SEQUENCES: 153
CORRESPONDENCE ADDRESS:
ADDRESSEE: Townsend and Townsend Khourie and Crew
STREET: Steuart Street Tower, One Market Plaza
CITY: San Francisco
STATE: California
COUNTRY: US
ZIP: 94105-1493
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/197,484
FILING DATE: 16-FEB-1994
CLASSIFICATION: 424
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/935,811
FILING DATE: 26-AUG-1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/874,491
FILING DATE: 27-APR-1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/827,682
FILING DATE: 29-JAN-1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/749,568
FILING DATE: 26-AUG-1991
ATTORNEY/AGENT INFORMATION:
NAME: Parmelee, Steven W.
REGISTRATION NUMBER: 31,990
REFERENCE/DOCKET NUMBER: 14137-26-4
TELEPHONE: (206) 467-9600
TELEFAX: (206) 623-6793
INFORMATION FOR SEQ ID NO: 81:
SEQUENCE CHARACTERISTICS:
LENGTH: 9 amino acids
TYPE: amino acid
STRANDEDNESS: unknown
TOPOLOGY: unknown
MOLECULE TYPE: peptide
US-08-197-484-81

Query Match 84.1%; Score 37; DB 4; Length 9;
Best Local Similarity 77.8%; Pred. No. 3e+05;
Matches 7; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

Qy 1 KVAELVHFL 9
|: |||||
Db 1 KMVELVHFL 9

RESULT 31
US-08-197-484-140
Sequence 140, Application US/08197484
Patent No. 6419931
GENERAL INFORMATION:
APPLICANT: VITTELLO, Maria A.
APPLICANT: CHESTNUT, Robert W.
APPLICANT: SETTE, Alessandro D.
APPLICANT: CELIS, Esteban
APPLICANT: GRAY, Howard
TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR ELICITING
TITLE OF INVENTION: CTL IMMUNITY
NUMBER OF SEQUENCES: 153
CORRESPONDENCE ADDRESS:
ADDRESSEE: Townsend and Townsend Khourie and Crew

STREET: Steuart Street Tower, One Market Plaza
CITY: San Francisco
STATE: California
COUNTRY: US
ZIP: 94105-1493
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/197,484
FILING DATE: 16-FEB-1994
CLASSIFICATION: 424
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/935,811
FILING DATE: 26-AUG-1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/874,491
FILING DATE: 27-APR-1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/827,682
FILING DATE: 29-JAN-1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/749,568
FILING DATE: 26-AUG-1991
ATTORNEY/AGENT INFORMATION:
NAME: Parmelee, Steven W.
REGISTRATION NUMBER: 31,990
REFERENCE/DOCKET NUMBER: 14137-26-4
TELEPHONE: (206) 467-9600
TELEFAX: (206) 623-6793
INFORMATION FOR SEQ ID NO: 140:
SEQUENCE CHARACTERISTICS:
LENGTH: 9 amino acids
TYPE: amino acid
STRANDEDNESS: unknown
TOPOLOGY: unknown
MOLECULE TYPE: peptide
US-08-197-484-140

Query Match 84.1%; Score 37; DB 4; Length 9;
Best Local Similarity 77.8%; Pred. No. 3e+05;
Matches 7; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

Qy 1 KVAELVHFL 9
|: |||||
Db 1 KMVELVHFL 9

RESULT 32
PCT-US95-02121-81
Sequence 81, Application PC/TUS9502121
GENERAL INFORMATION:
APPLICANT:
TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR ELICITING
TITLE OF INVENTION: CTL IMMUNITY
NUMBER OF SEQUENCES: 153
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: PCT/US95/02121
FILING DATE: 16-FEB-1995
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/197,484
FILING DATE: 16-FEB-1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/935,811

```

; FILING DATE: 26-AUG-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/874,491
; FILING DATE: 27-APR-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/827,682
; FILING DATE: 29-JAN-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/749,568
; FILING DATE: 26-AUG-1991
; ATTORNEY/AGENT INFORMATION:
; NAME: Parmelee, Steven W.
; REGISTRATION NUMBER: 31,990
; REFERENCE/DOCKET NUMBER: 14137-26-4PC
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (206) 467-9600
; TELEFAX: (415) 543-5043
; INFORMATION FOR SEQ ID NO: 81:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 9 amino acids
; TYPE: amino acid
; STRANDEDNESS: unknown
; TOPOLOGY: unknown
; MOLECULE TYPE: peptide
PCT-US95-02121-81

Query Match 84.1%; Score 37; DB 5; Length 9;
Best Local Similarity 77.8%; Pred. No. 3e+05;
Matches 7; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

Qy 1 KVAELVHFL 9
Db 1 KMVELVHFL 9

RESULT 33
PCT-US95-02121-140
; Sequence 140, Application PC/TUS9502121
; GENERAL INFORMATION:
; APPLICANT:
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR ELICITING
; TITLE OF INVENTION: CTL IMMUNITY
; NUMBER OF SEQUENCES: 153
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: PCT/US95/02121
; FILING DATE: 16-FEB-1995
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/197,484
; FILING DATE: 16-FEB-1994
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/935,811
; FILING DATE: 26-AUG-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/874,491
; FILING DATE: 27-APR-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/827,682
; FILING DATE: 29-JAN-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/749,568
; FILING DATE: 26-AUG-1991
; ATTORNEY/AGENT INFORMATION:
; NAME: Parmelee, Steven W.
; REGISTRATION NUMBER: 31,990
; REFERENCE/DOCKET NUMBER: 14137-26-4PC
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (206) 467-9600

```

```

; TELEFAX: (415) 543-5043
; INFORMATION FOR SEQ ID NO: 140:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 9 amino acids
; TYPE: amino acid
; STRANDEDNESS: unknown
; TOPOLOGY: unknown
; MOLECULE TYPE: peptide
PCT-US95-02121-140

Query Match 84.1%; Score 37; DB 5; Length 9;
Best Local Similarity 77.8%; Pred. No. 3e+05;
Matches 7; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

Qy 1 KVAELVHFL 9
Db 1 KMVELVHFL 9

RESULT 34
US-08-217-188A-20
; Sequence 20, Application US/08217188A
; Patent No. 5554724
; GENERAL INFORMATION:
; APPLICANT: Melief, Cornelis J. M.
; APPLICANT: Visseren, M. J. W.
; APPLICANT: Kast, W. M.
; APPLICANT: van der Bruggen, Pierre
; APPLICANT: Boon-Faller, Thierry
; TITLE OF INVENTION: Isolated Tumor Rejection Antigen
; TITLE OF INVENTION: Precursor MAGE-2 Derived Peptides, and Uses Thereof
; NUMBER OF SEQUENCES: 62
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Felfe & Lynch
; STREET: 805 Third Avenue
; CITY: New York City
; STATE: New York
; COUNTRY: USA
; ZIP: 10022
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette, 5.25 inch, 360 kb storage
; COMPUTER: IBM PS/2
; OPERATING SYSTEM: PC-DOS
; SOFTWARE: Wordperfect
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/217,188A
; FILING DATE: 24-MARCH-1994
; CLASSIFICATION: 530
; ATTORNEY/AGENT INFORMATION:
; NAME: Hanson, No. 5554724man D.
; REGISTRATION NUMBER: 30,946
; REFERENCE/DOCKET NUMBER: LUD 5340
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 688-9200
; TELEFAX: (212) 838-3884
; INFORMATION FOR SEQ ID NO: 20:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 10 amino acid residues
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: protein
US-08-217-188A-20

Query Match 84.1%; Score 37; DB 1; Length 10;
Best Local Similarity 77.8%; Pred. No. 0.24;
Matches 7; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

Qy 1 KVAELVHFL 9
Db 1 KMVELVHFL 9

RESULT 35

```

US-08-687-226-20
; Sequence 20, Application US/08687226
; Patent No. 5686068
; GENERAL INFORMATION:
; APPLICANT: Melief, Cornelis J. M.; Visseren, M. W.;
; APPLICANT: van der Burg, Sjoerd; van der Bruggen, Pierre;
; APPLICANT: Boon-Falleur, Thierry
; TITLE OF INVENTION: Isolated Peptides Derived From
; TITLE OF INVENTION: Mage-2, Cytolytic T Cells Specific To Complexes Of
; TITLE OF INVENTION: Peptides And HLA-A2 Molecules, And Uses Thereof
; NUMBER OF SEQUENCES: 72
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Felfe & Lynch
; STREET: 805 Third Avenue
; CITY: New York City
; STATE: New York
; COUNTRY: USA
; ZIP: 10022
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette, 3.5 inch, 360 kb storage
; COMPUTER: IBM PS/2
; OPERATING SYSTEM: PC-DOS
; SOFTWARE: Wordperfect
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/687,226
; FILING DATE: 25-JULY-1996
; CLASSIFICATION: 530
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/217,188
; FILING DATE: 24-MARCH-1994
; ATTORNEY/AGENT INFORMATION:
; NAME: Hanson, No. 5686068man D.
; REGISTRATION NUMBER: 30,946
; REFERENCE/DOCKET NUMBER: LUD 5447
; TELEPHONE: (212) 688-9200
; TELEFAX: (212) 838-3884
; INFORMATION FOR SEQ ID NO: 20:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 10 amino acid residues
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: protein
US-08-687-226-20
Query Match 84.1%; Score 37; DB 1; Length 10;
Best Local Similarity 77.8%; Pred. No. 0.24;
Matches 7; Conservative 1; Mismatches 1; Indels 0; Gaps 0;
Qy 1 KVAELVHFL 9
|: |||||
Db 1 KMVELVHFL 9
RESULT 36
US-08-667-725B-20
; Sequence 20, Application US/0866725B
; Patent No. 6063900
; GENERAL INFORMATION:
; APPLICANT: Melief, Cornelis J. M.
; APPLICANT: Visseren, M. J. W.
; APPLICANT: Kast; W. M.
; APPLICANT: van der Bruggen, Pierre
; APPLICANT: Boon-Falleur, Thierry
; TITLE OF INVENTION: Isolated Tumor Rejection Antigen
; TITLE OF INVENTION: Precursor Mage-2 Derived Peptides, and Uses Thereof
; NUMBER OF SEQUENCES: 64
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Fulbright & Jaworski LLP
; STREET: 666 Fifth Avenue
; CITY: New York City
; STATE: New York
; COUNTRY: USA
; ZIP: 10010
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette, 5.25 inch, 360 kb storage
; COMPUTER: IBM PS/2
; OPERATING SYSTEM: PC-DOS
; SOFTWARE: Wordperfect
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/007,748
; FILING DATE: 15 January 1998
; CLASSIFICATION: 530
; ATTORNEY/AGENT INFORMATION:
; NAME: Hanson, No. 6147187man D.
; REGISTRATION NUMBER: 30,946
; REFERENCE/DOCKET NUMBER: LUD 5340.2 DIV (081572)
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 318-3000
; TELEFAX: (212) 752-5958
; INFORMATION FOR SEQ ID NO: 20:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 10 amino acid residues

US-08-667-725B-20
; ZIP: 10103
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette, 5.25 inch, 360 kb storage
; COMPUTER: IBM PS/2
; OPERATING SYSTEM: PC-DOS
; SOFTWARE: Wordperfect
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/667,725B
; FILING DATE: 21 June 1996
; CLASSIFICATION: 530
; ATTORNEY/AGENT INFORMATION:
; NAME: Hanson, No. 6063900man D.
; REGISTRATION NUMBER: 30,946
; REFERENCE/DOCKET NUMBER: LUD 5340.1 DIV (081585)
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 318-3000
; TELEFAX: (212) 752-5958
; INFORMATION FOR SEQ ID NO: 20:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 10 amino acid residues
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: protein
US-08-667-725B-20
Query Match 84.1%; Score 37; DB 3; Length 10;
Best Local Similarity 77.8%; Pred. No. 0.24;
Matches 7; Conservative 1; Mismatches 1; Indels 0; Gaps 0;
Qy 1 KVAELVHFL 9
|: |||||
Db 1 KMVELVHFL 9
RESULT 37
US-09-007-748-20
; Sequence 20, Application US/09007748
; Patent No. 6147187
; GENERAL INFORMATION:
; APPLICANT: Melief, Cornelis J. M.
; APPLICANT: Visseren, M. J. W.
; APPLICANT: Kast; W. M.
; APPLICANT: van der Bruggen, Pierre
; APPLICANT: Boon-Falleur, Thierry
; TITLE OF INVENTION: Isolated Tumor Rejection Antigen
; TITLE OF INVENTION: Precursor Mage-2 Derived Peptides, and Uses Thereof
; NUMBER OF SEQUENCES: 64
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Fulbright & Jaworski LLP
; STREET: 666 Fifth Avenue
; CITY: New York City
; STATE: New York
; COUNTRY: USA
; ZIP: 10103
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette, 5.25 inch, 360 kb storage
; COMPUTER: IBM PS/2
; OPERATING SYSTEM: PC-DOS
; SOFTWARE: Wordperfect
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/007,748
; FILING DATE: 15 January 1998
; CLASSIFICATION: 530
; ATTORNEY/AGENT INFORMATION:
; NAME: Hanson, No. 6147187man D.
; REGISTRATION NUMBER: 30,946
; REFERENCE/DOCKET NUMBER: LUD 5340.2 DIV (081572)
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 318-3000
; TELEFAX: (212) 752-5958
; INFORMATION FOR SEQ ID NO: 20:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 10 amino acid residues

;
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: protein
US-09-007-748-20

Query Match 84.1%; Score 37; DB 3; Length 10;
Best Local Similarity 77.8%; Pred. No. 0.24;
Matches 7; Conservative 1; Mismatches 1; Indels 1; Gaps 0;

Qy 1 KVAELVHFL 9
|: |||||
Db 1 KMVELVHFL 9

RESULT 38
US-08-197-484-82
; Sequence 82, Application US/08197484
; Patent No. 6419931
; GENERAL INFORMATION:
; APPLICANT: VITIELLO, Maria A.
; APPLICANT: CHESTNUT, Robert W.
; APPLICANT: SETTE, Alessandro D.
; APPLICANT: CELIS, Esteban
; APPLICANT: GRAY, Howard
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR ELICITING
; TITLE OF INVENTION: CTL IMMUNITY
; NUMBER OF SEQUENCES: 153
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Townsend and Townsend Kourie and Crew
; STREET: Steuart Street Tower, One Market Plaza
; CITY: San Francisco
; STATE: California
; COUNTRY: US
; ZIP: 94105-1493
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/197,484
; FILING DATE: 16-FEB-1994
; CLASSIFICATION: 424
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/935,811
; FILING DATE: 26-AUG-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/874,491
; FILING DATE: 27-APR-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/827,682
; FILING DATE: 29-JAN-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/749,568
; FILING DATE: 26-AUG-1991
; ATTORNEY/AGENT INFORMATION:
; NAME: Parmelee, Steven W.
; REGISTRATION NUMBER: 31,990
; REFERENCE/DOCKET NUMBER: 14137-26-4
; TELEPHONE: (206) 467-9600
; TELEFAX: (206) 623-6793
; INFORMATION FOR SEQ ID NO: 82:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 10 amino acids
; TYPE: amino acid
; STRANDEDNESS: unknown
; TOPOLOGY: unknown
; MOLECULE TYPE: peptide
US-08-197-484-82

Query Match 84.1%; Score 37; DB 4; Length 10;
Best Local Similarity 77.8%; Pred. No. 0.24;

Matches 7; Conservative 1; Mismatches 1; Indels 1; Gaps 0;
Qy 1 KVAELVHFL 9
|: |||||
Db 1 KMVELVHFL 9

RESULT 39
US-08-197-484-141
; Sequence 141, Application US/08197484
; Patent No. 6419931
; GENERAL INFORMATION:
; APPLICANT: VITIELLO, Maria A.
; APPLICANT: CHESTNUT, Robert W.
; APPLICANT: SETTE, Alessandro D.
; APPLICANT: CELIS, Esteban
; APPLICANT: GRAY, Howard
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR ELICITING
; TITLE OF INVENTION: CTL IMMUNITY
; NUMBER OF SEQUENCES: 153
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Townsend and Townsend Kourie and Crew
; STREET: Steuart Street Tower, One Market Plaza
; CITY: San Francisco
; STATE: California
; COUNTRY: US
; ZIP: 94105-1493
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/197,484
; FILING DATE: 16-FEB-1994
; CLASSIFICATION: 424
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/935,811
; FILING DATE: 26-AUG-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/874,491
; FILING DATE: 27-APR-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/827,682
; FILING DATE: 29-JAN-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/749,568
; FILING DATE: 26-AUG-1991
; ATTORNEY/AGENT INFORMATION:
; NAME: Parmelee, Steven W.
; REGISTRATION NUMBER: 31,990
; REFERENCE/DOCKET NUMBER: 14137-26-4
; TELEPHONE: (206) 467-9600
; TELEFAX: (206) 623-6793
; INFORMATION FOR SEQ ID NO: 141:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 10 amino acids
; TYPE: amino acid
; STRANDEDNESS: unknown
; TOPOLOGY: unknown
; MOLECULE TYPE: peptide
US-08-197-484-141

Query Match 84.1%; Score 37; DB 4; Length 10;
Best Local Similarity 77.8%; Pred. No. 0.24;
Matches 7; Conservative 1; Mismatches 1; Indels 1; Gaps 0;

Qy 1 KVAELVHFL 9
|: |||||
Db 1 KMVELVHFL 9

```

RESULT 40
PCT-US95-02121-82
; Sequence 82, Application PC/TUS9502121
; GENERAL INFORMATION:
; APPLICANT:
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR ELICITING
; TITLE OF INVENTION: CTL IMMUNITY
; NUMBER OF SEQUENCES: 153
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: PCT/US95/02121
; FILING DATE: 16-FEB-1995
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/197,484
; FILING DATE: 16-FEB-1994
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/935,811
; FILING DATE: 26-AUG-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/874,491
; FILING DATE: 27-APR-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/827,682
; FILING DATE: 29-JAN-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/749,568
; FILING DATE: 26-AUG-1991
; ATTORNEY/AGENT INFORMATION:
; NAME: Parmelee, Steven W.
; REGISTRATION NUMBER: 31,990
; REFERENCE/DOCKET NUMBER: 14137-26-4PC
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (206) 467-9600
; TELEFAX: (415) 543-5043
; INFORMATION FOR SEQ ID NO: 82:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 10 amino acids
; TYPE: amino acid
; STRANDEDNESS: unknown
; TOPOLOGY: unknown
; MOLECULE TYPE: peptide
PCT-US95-02121-82

```

```

Query Match      84.1%; Score 37; DB 5; Length 10;
Best Local Similarity 77.8%; Pred. No. 0.24;
Matches 7; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

Qy      1 KVAELVHFL 9
      |:|||||
Db      1 KMWELVHFL 9

```

Search completed: July 23, 2004, 12:53:44
Job time : 19 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2004 Compugen Ltd.

OM protein - protein search, using sw model

Run on: July 23, 2004, 12:52:52 ; Search time 42 Seconds
(without alignments)
67.104 Million cell updates/sec

Title: US-09-458-298b-711

Perfect score: 44

Sequence: 1 KVAELVHPL 9

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 1288442 seqs, 313154207 residues

Total number of hits satisfying chosen parameters: 1288442

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : Published Applications AA:*

- 1: /cgn2_6/ptodata/2/pubpaa/US07_PUBCOMB.pep.*
- 2: /cgn2_6/ptodata/2/pubpaa/PCT_NEW_PUB.pep.*
- 3: /cgn2_6/ptodata/2/pubpaa/US06_NEW_PUB.pep.*
- 4: /cgn2_6/ptodata/2/pubpaa/US06_PUBCOMB.pep.*
- 5: /cgn2_6/ptodata/2/pubpaa/US07_NEW_PUB.pep.*
- 6: /cgn2_6/ptodata/2/pubpaa/PCTUS_PUBCOMB.pep.*
- 7: /cgn2_6/ptodata/2/pubpaa/US08_NEW_PUB.pep.*
- 8: /cgn2_6/ptodata/2/pubpaa/US08_PUBCOMB.pep.*
- 9: /cgn2_6/ptodata/2/pubpaa/US09A_PUBCOMB.pep.*
- 10: /cgn2_6/ptodata/2/pubpaa/US09B_PUBCOMB.pep.*
- 11: /cgn2_6/ptodata/2/pubpaa/US09C_PUBCOMB.pep.*
- 12: /cgn2_6/ptodata/2/pubpaa/US09_NEW_PUB.pep.*
- 13: /cgn2_6/ptodata/2/pubpaa/US10A_PUBCOMB.pep.*
- 14: /cgn2_6/ptodata/2/pubpaa/US10B_PUBCOMB.pep.*
- 15: /cgn2_6/ptodata/2/pubpaa/US10C_PUBCOMB.pep.*
- 16: /cgn2_6/ptodata/2/pubpaa/US10_NEW_PUB.pep.*
- 17: /cgn2_6/ptodata/2/pubpaa/US60_NEW_PUB.pep.*
- 18: /cgn2_6/ptodata/2/pubpaa/US60_PUBCOMB.pep.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	44	100.0	9	12	US-10-149-135-367
2	44	100.0	9	12	US-10-149-135-711
3	44	100.0	9	12	US-10-149-135-2214
4	44	100.0	9	12	US-10-149-135-2282
5	44	100.0	9	12	US-10-149-135-2357
6	44	100.0	9	12	US-10-149-135-2372
7	44	100.0	9	14	US-10-116-118-4
8	44	100.0	9	14	US-10-116-118-46
9	44	100.0	10	12	US-10-149-135-368
10	44	100.0	10	12	US-10-149-135-712
11	44	100.0	10	12	US-10-149-135-900
12	44	100.0	10	12	US-10-149-135-2283
13	44	100.0	10	12	US-10-149-135-2358
14	44	100.0	10	12	US-10-149-135-2373
15	44	100.0	11	12	US-10-149-135-369

16	44	100.0	11	12	US-10-149-135-713	Sequence 713, App
17	44	100.0	11	12	US-10-149-135-901	Sequence 901, App
18	44	100.0	11	12	US-10-149-135-905	Sequence 905, App
19	44	100.0	15	12	US-10-149-135-2003	Sequence 2003, App
20	44	100.0	16	14	US-10-170-832-3	Sequence 3, Appli
21	44	100.0	30	12	US-10-296-734-1296	Sequence 1296, Ap
22	44	100.0	221	9	US-09-784-199-4	Sequence 4, Appli
23	44	100.0	314	9	US-09-766-889A-55	Sequence 55, Appli
24	44	100.0	314	9	US-09-784-199-2	Sequence 2, Appli
25	44	100.0	314	10	US-09-860-840-2	Sequence 2, Appli
26	44	100.0	314	10	US-09-849-602-29	Sequence 29, Appli
27	44	100.0	314	12	US-10-149-135-2440	Sequence 2440, Ap
28	44	100.0	314	12	US-10-296-734-829	Sequence 829, App
29	44	100.0	314	14	US-10-146-473-53	Sequence 53, Appli
30	44	100.0	314	14	US-10-177-390-20	Sequence 20, Appli
31	44	100.0	314	14	US-10-170-832-2	Sequence 2, Appli
32	44	100.0	314	15	US-10-117-937-73	Sequence 73, Appli
33	44	100.0	314	16	US-10-444-683-2	Sequence 2, Appli
34	44	100.0	315	14	US-10-093-766-40	Sequence 40, Appli
35	44	100.0	315	14	US-10-157-031-54	Sequence 54, Appli
36	44	100.0	315	15	US-10-295-027-366	Sequence 366, App
37	44	100.0	522	14	US-10-296-770-2	Sequence 2, Appli
38	44	100.0	3541	12	US-10-296-734-1454	Sequence 1454, Ap
39	42	95.5	9	9	US-09-894-018-321	Sequence 321, App
40	42	95.5	9	14	US-10-116-118-5	Sequence 5, Appli
41	42	95.5	144	9	US-09-894-018-129	Sequence 129, App
42	42	95.5	147	9	US-09-894-018-131	Sequence 131, App
43	42	95.5	148	9	US-09-894-018-127	Sequence 127, App
44	41	93.2	9	12	US-10-149-135-2215	Sequence 2215, Ap
45	41	93.2	9	12	US-10-149-135-2216	Sequence 2216, Ap

ALIGNMENTS

RESULT 1

US-10-149-135-367
; Sequence 367, Application US/10149135
; Publication No. US20040053822A1
; GENERAL INFORMATION:
; APPLICANT: Fixes, John
; APPLICANT: Sette, Alessandro
; APPLICANT: Sidney, John
; APPLICANT: Southwood, Scott
; APPLICANT: Chesnut, Robert
; APPLICANT: Celis, Esteban
; APPLICANT: Keogh, Elissa
; TITLE OF INVENTION: Inducing Cellular Immune Responses to
; TITLE OF INVENTION: MAGE2/3 Using Peptide and Nucleic Acid Compositions
; FILE REFERENCE: 2060.0130001
; CURRENT APPLICATION NUMBER: US/10/149,135
; CURRENT FILING DATE: 2000-12-11
; PRIOR APPLICATION NUMBER: PCT/US00/33545
; PRIOR FILING DATE: 2000-12-11
; PRIOR APPLICATION NUMBER: US 09/458,298
; PRIOR FILING DATE: 1999-12-10
; PRIOR APPLICATION NUMBER: US 09/189,702
; PRIOR FILING DATE: 1998-11-10
; PRIOR APPLICATION NUMBER: US 08/205,713
; PRIOR FILING DATE: 1994-03-04
; PRIOR APPLICATION NUMBER: US 08/159,184
; PRIOR FILING DATE: 1993-11-29
; PRIOR APPLICATION NUMBER: US 08/073,205
; PRIOR FILING DATE: 1993-06-04
; PRIOR APPLICATION NUMBER: US 08/027,146
; PRIOR FILING DATE: 1993-03-05
; NUMBER OF SEQ ID NOS: 2479
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 367
; LENGTH: 9
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:

[illegible]

; LENGTH: 9
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Artificial Peptide
US-10-149-135-2282

Query Match 100.0%; Score 44; DB 12; Length 9;
Best Local Similarity 100.0%; Pred. No. 1.2e+06;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KVAELVHFL 9
| | | | | | | |
Db 1 KVAELVHFL 9

RESULT 5

US-10-149-135-2357
; Sequence 2357, Application US/10149135
; Publication No. US20040053822A1
; GENERAL INFORMATION:
; APPLICANT: Fikes, John
; APPLICANT: Sette, Alessandro
; APPLICANT: Sidney, John
; APPLICANT: Southwood, Scott
; APPLICANT: Chesnut, Robert
; APPLICANT: Celis, Esteban
; APPLICANT: Keogh, Elissa
; TITLE OF INVENTION: Inducing Cellular Immune Responses to
; FILE REFERENCE: 2060.0130001
; CURRENT APPLICATION NUMBER: US/10/149,135
; CURRENT FILING DATE: 2000-12-11
; PRIOR APPLICATION NUMBER: PCT/US00/33545
; PRIOR FILING DATE: 2000-12-11
; PRIOR APPLICATION NUMBER: US 09/458,298
; PRIOR FILING DATE: 1999-12-10
; PRIOR APPLICATION NUMBER: US 09/189,702
; PRIOR FILING DATE: 1998-11-10
; PRIOR APPLICATION NUMBER: US 08/205,713
; PRIOR FILING DATE: 1994-03-04
; PRIOR APPLICATION NUMBER: US 08/159,184
; PRIOR FILING DATE: 1993-11-29
; PRIOR APPLICATION NUMBER: US 08/073,205
; PRIOR FILING DATE: 1993-06-04
; PRIOR APPLICATION NUMBER: US 08/027,146
; PRIOR FILING DATE: 1993-03-05
; NUMBER OF SEQ ID NOS: 2479
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 2357
; LENGTH: 9
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Artificial Peptide

US-10-149-135-2357

Query Match 100.0%; Score 44; DB 12; Length 9;
Best Local Similarity 100.0%; Pred. No. 1.2e+06;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KVAELVHFL 9
| | | | | | | |
Db 1 KVAELVHFL 9

RESULT 6

US-10-149-135-2372
; Sequence 2372, Application US/10149135
; Publication No. US20040053822A1
; GENERAL INFORMATION:
; APPLICANT: Fikes, John
; APPLICANT: Sette, Alessandro

; APPLICANT: Sidney, John
; APPLICANT: Southwood, Scott
; APPLICANT: Chesnut, Robert
; APPLICANT: Celis, Esteban
; APPLICANT: Keogh, Elissa
; TITLE OF INVENTION: Inducing Cellular Immune Responses to
; FILE REFERENCE: 2060.0130001
; CURRENT APPLICATION NUMBER: US/10/149,135
; CURRENT FILING DATE: 2000-12-11
; PRIOR APPLICATION NUMBER: PCT/US00/33545
; PRIOR FILING DATE: 2000-12-11
; PRIOR APPLICATION NUMBER: US 09/458,298
; PRIOR FILING DATE: 1999-12-10
; PRIOR APPLICATION NUMBER: US 09/189,702
; PRIOR FILING DATE: 1998-11-10
; PRIOR APPLICATION NUMBER: US 08/205,713
; PRIOR FILING DATE: 1994-03-04
; PRIOR APPLICATION NUMBER: US 08/159,184
; PRIOR FILING DATE: 1993-11-29
; PRIOR APPLICATION NUMBER: US 08/073,205
; PRIOR FILING DATE: 1993-06-04
; PRIOR APPLICATION NUMBER: US 08/027,146
; PRIOR FILING DATE: 1993-03-05
; NUMBER OF SEQ ID NOS: 2479
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 2372
; LENGTH: 9
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Artificial Peptide
US-10-149-135-2372

Query Match 100.0%; Score 44; DB 12; Length 9;
Best Local Similarity 100.0%; Pred. No. 1.2e+06;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KVAELVHFL 9
| | | | | | | |
Db 1 KVAELVHFL 9

RESULT 7

US-10-116-118-4
; Sequence 4, Application US/10116118
; Publication No. US20030143672A1
; GENERAL INFORMATION:
; APPLICANT: Tangri, Shabnam
; APPLICANT: Sette, Alessandro
; APPLICANT: Ishioka, Glenn
; APPLICANT: Fikes, John D.
; TITLE OF INVENTION: Heterocyclic Analogs and Related Methods
; FILE REFERENCE: 2060.0090003
; CURRENT APPLICATION NUMBER: US/10/116,118
; CURRENT FILING DATE: 2002-08-07
; PRIOR APPLICATION NUMBER: US 60/166,529
; PRIOR FILING DATE: 1999-11-18
; PRIOR APPLICATION NUMBER: US 60/239,008
; PRIOR FILING DATE: 2000-10-06
; NUMBER OF SEQ ID NOS: 53
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 4
; LENGTH: 9
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: MAGE3.112
US-10-116-118-4

Query Match 100.0%; Score 44; DB 14; Length 9;
Best Local Similarity 100.0%; Pred. No. 1.2e+06;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
QY      1 KVAELVHFL 9
      |||||
Db      1 KVAELVHFL 9

RESULT 8
US-10-116-118-46
; Sequence 46, Application US/10116118
; Publication No. US20030143672A1
; GENERAL INFORMATION:
; APPLICANT: Tangri, Shabnam
; APPLICANT: Sette, Alessandro
; APPLICANT: Ishioka, Glenn
; APPLICANT: Fikes, John D.
; TITLE OF INVENTION: Heteroclitic Analogs and Related Methods
; FILE REFERENCE: 2060.0090003
; CURRENT APPLICATION NUMBER: US/10/116,118
; PRIOR FILING DATE: 2002-08-07
; PRIOR APPLICATION NUMBER: US 60/166,529
; PRIOR FILING DATE: 1999-11-18
; PRIOR APPLICATION NUMBER: US 60/239,008
; PRIOR FILING DATE: 2000-10-06
; NUMBER OF SEQ ID NOS: 53
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 46
; LENGTH: 9
; TYPE: PRT
; ORGANISM: Artificial sequence
; FEATURE:
; OTHER INFORMATION: MAGE3.122
US-10-116-118-46

Query Match      100.0%; Score 44; DB 14; Length 9;
Best Local Similarity 100.0%; Pred. No. 1.2e+06;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 KVAELVHFL 9
      |||||
Db      1 KVAELVHFL 9

RESULT 9
US-10-149-135-368
; Sequence 368, Application US/10149135
; Publication No. US20040053822A1
; GENERAL INFORMATION:
; APPLICANT: Fikes, John
; APPLICANT: Sette, Alessandro
; APPLICANT: Sidney, John
; APPLICANT: Southwood, Scott
; APPLICANT: Chesnut, Robert
; APPLICANT: Celis, Eteban
; APPLICANT: Keogh, Elissa
; TITLE OF INVENTION: Inducing Cellular Immune Responses to
; FILE REFERENCE: 2060.0130001
; CURRENT APPLICATION NUMBER: US/10/149,135
; PRIOR FILING DATE: 2000-12-11
; PRIOR APPLICATION NUMBER: PCT/US00/33545
; PRIOR FILING DATE: 1999-12-10
; PRIOR APPLICATION NUMBER: US 09/458,298
; PRIOR FILING DATE: 1998-11-10
; PRIOR APPLICATION NUMBER: US 08/205,713
; PRIOR FILING DATE: 1994-03-04
; PRIOR APPLICATION NUMBER: US 08/159,184
; PRIOR FILING DATE: 1993-11-29
; PRIOR APPLICATION NUMBER: US 08/073,205
; PRIOR FILING DATE: 1993-06-04
; PRIOR APPLICATION NUMBER: US 08/027,146
; NUMBER OF SEQ ID NOS: 2479
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 712
; LENGTH: 10
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Artificial Peptide
US-10-149-135-712

Query Match      100.0%; Score 44; DB 12; Length 10;
Best Local Similarity 100.0%; Pred. No. 0.049;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 KVAELVHFL 9
      |||||
Db      1 KVAELVHFL 9

RESULT 11
US-10-149-135-900
; Sequence 900, Application US/10149135
; Publication No. US20040053822A1
```

```
; GENERAL INFORMATION:
; APPLICANT: Fikes, John
; APPLICANT: Sette, Alessandro
; APPLICANT: Sidney, John
; APPLICANT: Southwood, Scott
; APPLICANT: Chesnut, Robert
; APPLICANT: Celis, Esteban
; APPLICANT: Keogh, Elissa
; TITLE OF INVENTION: Inducing Cellular Immune Responses to
; FILE REFERENCE: 2060.0130001
; CURRENT APPLICATION NUMBER: US/10/149,135
; CURRENT FILING DATE: 2000-12-11
; PRIOR APPLICATION NUMBER: PCT/US00/33545
; PRIOR FILING DATE: 2000-12-11
; PRIOR APPLICATION NUMBER: US 09/458,298
; PRIOR FILING DATE: 1999-12-10
; PRIOR APPLICATION NUMBER: US 09/189,702
; PRIOR FILING DATE: 1998-11-10
; PRIOR APPLICATION NUMBER: US 08/205,713
; PRIOR FILING DATE: 1994-03-04
; PRIOR APPLICATION NUMBER: US 08/159,184
; PRIOR FILING DATE: 1993-11-29
; PRIOR APPLICATION NUMBER: US 08/073,205
; PRIOR FILING DATE: 1993-06-04
; PRIOR APPLICATION NUMBER: US 08/027,146
; PRIOR FILING DATE: 1993-03-05
; NUMBER OF SEQ ID NOS: 2479
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 900
; LENGTH: 10
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Artificial Peptide
US-10-149-135-900

Query Match      100.0%; Score 44; DB 12; Length 10;
Best Local Similarity 100.0%; Pred. No. 0.049;
Matches      9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 KVAELVHFL 9
Db      2 KVAELVHFL 10

RESULT 12
US-10-149-135-2283
; Sequence 2283, Application US/10149135
; Publication No. US20040053822A1
; GENERAL INFORMATION:
; APPLICANT: Fikes, John
; APPLICANT: Sette, Alessandro
; APPLICANT: Sidney, John
; APPLICANT: Southwood, Scott
; APPLICANT: Chesnut, Robert
; APPLICANT: Celis, Esteban
; APPLICANT: Keogh, Elissa
; TITLE OF INVENTION: Inducing Cellular Immune Responses to
; FILE REFERENCE: 2060.0130001
; CURRENT APPLICATION NUMBER: US/10/149,135
; CURRENT FILING DATE: 2000-12-11
; PRIOR APPLICATION NUMBER: PCT/US00/33545
; PRIOR FILING DATE: 2000-12-11
; PRIOR APPLICATION NUMBER: US 09/458,298
; PRIOR FILING DATE: 1999-12-10
; PRIOR APPLICATION NUMBER: US 09/189,702
; PRIOR FILING DATE: 1998-11-10
; PRIOR APPLICATION NUMBER: US 08/205,713
; PRIOR FILING DATE: 1994-03-04
; PRIOR APPLICATION NUMBER: US 08/159,184
; PRIOR FILING DATE: 1993-11-29
; PRIOR APPLICATION NUMBER: US 08/073,205
; PRIOR FILING DATE: 1993-06-04
; PRIOR APPLICATION NUMBER: US 08/027,146
; PRIOR FILING DATE: 1993-03-05
; NUMBER OF SEQ ID NOS: 2479
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 900
; LENGTH: 10
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Artificial Peptide
US-10-149-135-900

Query Match      100.0%; Score 44; DB 12; Length 10;
Best Local Similarity 100.0%; Pred. No. 0.049;
Matches      9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 KVAELVHFL 9
Db      2 KVAELVHFL 10

RESULT 13
US-10-149-135-2358
; Sequence 2358, Application US/10149135
; Publication No. US20040053822A1
; GENERAL INFORMATION:
; APPLICANT: Fikes, John
; APPLICANT: Sette, Alessandro
; APPLICANT: Sidney, John
; APPLICANT: Southwood, Scott
; APPLICANT: Chesnut, Robert
; APPLICANT: Celis, Esteban
; APPLICANT: Keogh, Elissa
; TITLE OF INVENTION: Inducing Cellular Immune Responses to
; FILE REFERENCE: 2060.0130001
; CURRENT APPLICATION NUMBER: US/10/149,135
; CURRENT FILING DATE: 2000-12-11
; PRIOR APPLICATION NUMBER: PCT/US00/33545
; PRIOR FILING DATE: 2000-12-11
; PRIOR APPLICATION NUMBER: US 09/458,298
; PRIOR FILING DATE: 1999-12-10
; PRIOR APPLICATION NUMBER: US 09/189,702
; PRIOR FILING DATE: 1998-11-10
; PRIOR APPLICATION NUMBER: US 08/205,713
; PRIOR FILING DATE: 1994-03-04
; PRIOR APPLICATION NUMBER: US 08/159,184
; PRIOR FILING DATE: 1993-11-29
; PRIOR APPLICATION NUMBER: US 08/073,205
; PRIOR FILING DATE: 1993-06-04
; PRIOR APPLICATION NUMBER: US 08/027,146
; PRIOR FILING DATE: 1993-03-05
; NUMBER OF SEQ ID NOS: 2479
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 2358
; LENGTH: 10
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Artificial Peptide
US-10-149-135-2358

Query Match      100.0%; Score 44; DB 12; Length 10;
Best Local Similarity 100.0%; Pred. No. 0.049;
Matches      9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 KVAELVHFL 9
Db      1 KVAELVHFL 9
```

```
; GENERAL INFORMATION:
; APPLICANT: Fikes, John
; APPLICANT: Sette, Alessandro
; APPLICANT: Sidney, John
; APPLICANT: Southwood, Scott
; APPLICANT: Chesnut, Robert
; APPLICANT: Celis, Esteban
; APPLICANT: Keogh, Elissa
; TITLE OF INVENTION: Inducing Cellular Immune Responses to
; FILE REFERENCE: 2060.0130001
; CURRENT APPLICATION NUMBER: US/10/149,135
; CURRENT FILING DATE: 2000-12-11
; PRIOR APPLICATION NUMBER: PCT/US00/33545
; PRIOR FILING DATE: 2000-12-11
; PRIOR APPLICATION NUMBER: US 09/458,298
; PRIOR FILING DATE: 1999-12-10
; PRIOR APPLICATION NUMBER: US 09/189,702
; PRIOR FILING DATE: 1998-11-10
; PRIOR APPLICATION NUMBER: US 08/205,713
; PRIOR FILING DATE: 1994-03-04
; PRIOR APPLICATION NUMBER: US 08/159,184
; PRIOR FILING DATE: 1993-11-29
; PRIOR APPLICATION NUMBER: US 08/073,205
; PRIOR FILING DATE: 1993-06-04
; PRIOR APPLICATION NUMBER: US 08/027,146
; PRIOR FILING DATE: 1993-03-05
; NUMBER OF SEQ ID NOS: 2479
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 2358
; LENGTH: 10
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Artificial Peptide
US-10-149-135-2358

Query Match      100.0%; Score 44; DB 12; Length 10;
Best Local Similarity 100.0%; Pred. No. 0.049;
Matches      9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 KVAELVHFL 9
Db      1 KVAELVHFL 9
```

RESULT 14
US-10-149-135-2373
; Sequence 2373, Application US/10149135
; Publication No. US20040053822A1
; GENERAL INFORMATION:
; APPLICANT: Fikes, John
; APPLICANT: Sette, Alessandro
; APPLICANT: Sidney, John
; APPLICANT: Southwood, Scott
; APPLICANT: Chesnut, Robert
; APPLICANT: Celis, Esteban
; APPLICANT: Keogh, Elissa
; TITLE OF INVENTION: Inducing Cellular Immune Responses to
; FILE REFERENCE: MAG2/3 Using Peptide and Nucleic Acid Compositions
; CURRENT FILING DATE: 2000-12-11
; PRIOR APPLICATION NUMBER: US/10/149,135
; PRIOR FILING DATE: 2000-12-11
; PRIOR APPLICATION NUMBER: PCT/US00/33545
; PRIOR FILING DATE: 2000-12-11
; PRIOR APPLICATION NUMBER: US 09/458,298
; PRIOR FILING DATE: 1999-12-10
; PRIOR APPLICATION NUMBER: US 09/189,702
; PRIOR FILING DATE: 1998-11-10
; PRIOR APPLICATION NUMBER: US 08/205,713
; PRIOR FILING DATE: 1994-03-04
; PRIOR APPLICATION NUMBER: US 08/159,184
; PRIOR FILING DATE: 1993-11-29
; PRIOR APPLICATION NUMBER: US 08/073,205
; PRIOR FILING DATE: 1993-06-04
; PRIOR APPLICATION NUMBER: US 08/027,146
; PRIOR FILING DATE: 1993-03-05
; NUMBER OF SEQ ID NOS: 2479
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 2373
; LENGTH: 10
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Artificial Peptide
US-10-149-135-2373
Query Match 100.0%; Score 44; DB 12; Length 10;
Best Local Similarity 100.0%; Pred. No. 0.049; DB 12; Length 10;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 KVAELVHFL 9
Db 1 KVAELVHFL 9
RESULT 15
US-10-149-135-369
; Sequence 369, Application US/10149135
; Publication No. US20040053822A1
; GENERAL INFORMATION:
; APPLICANT: Fikes, John
; APPLICANT: Sette, Alessandro
; APPLICANT: Sidney, John
; APPLICANT: Southwood, Scott
; APPLICANT: Chesnut, Robert
; APPLICANT: Celis, Esteban
; APPLICANT: Keogh, Elissa
; TITLE OF INVENTION: Inducing Cellular Immune Responses to
; FILE REFERENCE: MAG2/3 Using Peptide and Nucleic Acid Compositions
; CURRENT FILING DATE: 2000-12-11
; PRIOR APPLICATION NUMBER: PCT/US00/33545
; PRIOR FILING DATE: 2000-12-11
; PRIOR APPLICATION NUMBER: US 09/458,298
; PRIOR FILING DATE: 1999-12-10
; PRIOR APPLICATION NUMBER: US 09/189,702
; PRIOR FILING DATE: 1998-11-10

; PRIOR APPLICATION NUMBER: US 08/205,713
; PRIOR FILING DATE: 1994-03-04
; PRIOR APPLICATION NUMBER: US 08/159,184
; PRIOR FILING DATE: 1993-11-29
; PRIOR APPLICATION NUMBER: US 08/073,205
; PRIOR FILING DATE: 1993-06-04
; PRIOR APPLICATION NUMBER: US 08/027,146
; PRIOR FILING DATE: 1993-03-05
; NUMBER OF SEQ ID NOS: 2479
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 369
; LENGTH: 11
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Artificial Peptide
US-10-149-135-369
Query Match 100.0%; Score 44; DB 12; Length 11;
Best Local Similarity 100.0%; Pred. No. 0.054; DB 12; Length 11;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 KVAELVHFL 9
Db 1 KVAELVHFL 9
RESULT 16
US-10-149-135-713
; Sequence 713, Application US/10149135
; Publication No. US20040053822A1
; GENERAL INFORMATION:
; APPLICANT: Fikes, John
; APPLICANT: Sette, Alessandro
; APPLICANT: Sidney, John
; APPLICANT: Southwood, Scott
; APPLICANT: Chesnut, Robert
; APPLICANT: Celis, Esteban
; APPLICANT: Keogh, Elissa
; TITLE OF INVENTION: Inducing Cellular Immune Responses to
; FILE REFERENCE: MAG2/3 Using Peptide and Nucleic Acid Compositions
; CURRENT FILING DATE: 2000-12-11
; PRIOR APPLICATION NUMBER: PCT/US00/33545
; PRIOR FILING DATE: 2000-12-11
; PRIOR APPLICATION NUMBER: US 09/458,298
; PRIOR FILING DATE: 1999-12-10
; PRIOR APPLICATION NUMBER: US 09/189,702
; PRIOR FILING DATE: 1998-11-10
; PRIOR APPLICATION NUMBER: US 08/205,713
; PRIOR FILING DATE: 1994-03-04
; PRIOR APPLICATION NUMBER: US 08/159,184
; PRIOR FILING DATE: 1993-11-29
; PRIOR APPLICATION NUMBER: US 08/073,205
; PRIOR FILING DATE: 1993-06-04
; PRIOR APPLICATION NUMBER: US 08/027,146
; PRIOR FILING DATE: 1993-03-05
; NUMBER OF SEQ ID NOS: 2479
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 713
; LENGTH: 11
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Artificial Peptide
US-10-149-135-713
Query Match 100.0%; Score 44; DB 12; Length 11;
Best Local Similarity 100.0%; Pred. No. 0.054; DB 12; Length 11;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 KVAELVHFL 9


```
Db          1 KVAELVHFL 9
|||||
PRIORITY APPLICATION NUMBER: US 09/458,298
PRIORITY FILING DATE: 1999-12-10
PRIORITY APPLICATION NUMBER: US 09/189,702
PRIORITY FILING DATE: 1998-11-10
PRIORITY APPLICATION NUMBER: US 08/205,713
PRIORITY FILING DATE: 1994-03-04
PRIORITY APPLICATION NUMBER: US 08/159,184
PRIORITY FILING DATE: 1993-11-29
PRIORITY APPLICATION NUMBER: US 08/073,205
PRIORITY FILING DATE: 1993-06-04
PRIORITY APPLICATION NUMBER: US 08/027,146
PRIORITY FILING DATE: 1993-03-05
NUMBER OF SEQ ID NOS: 2479
SOFTWARE: PatentIn version 3.1
SEQ ID NO 905
LENGTH: 11
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Artificial Peptide
US-10-149-135-905

Query Match          100.0%; Score 44; DB 12; Length 11;
Best Local Similarity 100.0%; Pred. No. 0.054;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy          1 KVAELVHFL 9
|||||
Db          3 KVAELVHFL 11
|||||

RESULT 19
US-10-149-135-2003
Sequence 901, Application US/10149135
Publication No. US20040053822A1
GENERAL INFORMATION:
APPLICANT: Fikes, John
APPLICANT: Sette, Alessandro
APPLICANT: Sidney, John
APPLICANT: Southwood, Scott
APPLICANT: Chesnut, Robert
APPLICANT: Celis, Eteban
APPLICANT: Keogh, Elissa
TITLE OF INVENTION: Inducing Cellular Immune Responses to
FILE REFERENCE: 2060.0130001
CURRENT APPLICATION NUMBER: US/10/149,135
CURRENT FILING DATE: 2000-12-11
PRIORITY APPLICATION NUMBER: PCT/US00/33545
PRIORITY FILING DATE: 2000-12-11
PRIORITY APPLICATION NUMBER: US 09/458,298
PRIORITY FILING DATE: 1999-12-10
PRIORITY APPLICATION NUMBER: US 09/189,702
PRIORITY FILING DATE: 1998-11-10
PRIORITY APPLICATION NUMBER: US 08/205,713
PRIORITY FILING DATE: 1994-03-04
PRIORITY APPLICATION NUMBER: US 08/159,184
PRIORITY FILING DATE: 1993-11-29
PRIORITY APPLICATION NUMBER: US 08/073,205
PRIORITY FILING DATE: 1993-06-04
PRIORITY APPLICATION NUMBER: US 08/027,146
PRIORITY FILING DATE: 1993-03-05
NUMBER OF SEQ ID NOS: 2479
SOFTWARE: PatentIn version 3.1
SEQ ID NO 901
LENGTH: 11
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Artificial Peptide
US-10-149-135-901

Query Match          100.0%; Score 44; DB 12; Length 11;
Best Local Similarity 100.0%; Pred. No. 0.054;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy          1 KVAELVHFL 9
|||||
Db          2 KVAELVHFL 10
|||||

RESULT 18
US-10-149-135-905
Sequence 905, Application US/10149135
Publication No. US20040053822A1
GENERAL INFORMATION:
APPLICANT: Fikes, John
APPLICANT: Sette, Alessandro
APPLICANT: Sidney, John
APPLICANT: Southwood, Scott
APPLICANT: Chesnut, Robert
APPLICANT: Celis, Eteban
APPLICANT: Keogh, Elissa
TITLE OF INVENTION: Inducing Cellular Immune Responses to
FILE REFERENCE: 2060.0130001
CURRENT APPLICATION NUMBER: US/10/149,135
CURRENT FILING DATE: 2000-12-11
PRIORITY APPLICATION NUMBER: PCT/US00/33545
PRIORITY FILING DATE: 2000-12-11
```

Best Local Similarity 100.0%; Pred. No. 0.074; Mismatches 0; Indels 0; Gaps 0;
Matches 9; Conservative 0;

Qy 1 KVAELVHFL 9
| | | | |
Db 7 KVAELVHFL 15

RESULT 20

US-10-170-832-3
; Sequence 3, Application US/10170832
; Publication No. US20030170792A1
; GENERAL INFORMATION:
; APPLICANT: Chaux, Pascal
; APPLICANT: Vantomme, Valrie
; APPLICANT: Stroobant, Vincent
; APPLICANT: Boon-falleur, Thierry
; APPLICANT: van der Bruggen, Pierre
; APPLICANT: Thielemans, Kris
; APPLICANT: Corthals, Jurgen
; TITLE OF INVENTION: MAG-3 PEPTIDES PRESENTED BY HLA CLASS II MOLECULES
; FILE REFERENCE: L0461/7052
; CURRENT APPLICATION NUMBER: US/10/170,832
; CURRENT FILING DATE: 2002-06-12
; PRIOR APPLICATION NUMBER: US/09/166,448
; PRIOR FILING DATE: 1998-10-05
; NUMBER OF SEQ ID NOS: 81
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 3
; LENGTH: 16
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-170-832-3

Query Match 100.0%; Score 44; DB 14; Length 16;
Best Local Similarity 100.0%; Pred. No. 0.079; Mismatches 0; Indels 0; Gaps 0;
Matches 9; Conservative 0;

Qy 1 KVAELVHFL 9
| | | | |
Db 2 KVAELVHFL 10

RESULT 21

US-10-296-734-1296
; Sequence 1296, Application US/10296734
; Publication No. US20040054137A1
; GENERAL INFORMATION:
; APPLICANT: Thompson, Scott A
; APPLICANT: Ramshaw, Ian A
; TITLE OF INVENTION: Synthetic molecules and uses therefor
; FILE REFERENCE: Savine
; CURRENT APPLICATION NUMBER: US/10/296,734
; CURRENT FILING DATE: 2003-08-04
; PRIOR APPLICATION NUMBER: AU PQ761/00
; PRIOR FILING DATE: 2000-05-26
; NUMBER OF SEQ ID NOS: 1507
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 1296
; LENGTH: 30
; TYPE: PRT
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: MAG-3 segment 8
US-10-296-734-1296

Query Match 100.0%; Score 44; DB 12; Length 30;
Best Local Similarity 100.0%; Pred. No. 0.15; Mismatches 0; Indels 0; Gaps 0;
Matches 9; Conservative 0;

Qy 1 KVAELVHFL 9
| | | | |
Db 9 KVAELVHFL 17

RESULT 22

US-09-784-199-4
; Sequence 4, Application US/09784199
; Patent No. US20020164738A1
; GENERAL INFORMATION:
; APPLICANT: MORISHIMA, No. US20020164738A1uhiro
; APPLICANT: SHIBATA, Takehiko
; TITLE OF INVENTION: CELL DEATH INHIBITORY PROTEIN
; FILE REFERENCE: 04853-0057-00000
; CURRENT APPLICATION NUMBER: US/09/784,199
; CURRENT FILING DATE: 2001-06-21
; PRIOR APPLICATION NUMBER: JP 2000-41927
; PRIOR FILING DATE: 2001-02-16
; NUMBER OF SEQ ID NOS: 10
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 4
; LENGTH: 221
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-784-199-4

Query Match 100.0%; Score 44; DB 9; Length 221;
Best Local Similarity 100.0%; Pred. No. 1.2; Mismatches 0; Indels 0; Gaps 0;
Matches 9; Conservative 0;

Qy 1 KVAELVHFL 9
| | | | |
Db 19 KVAELVHFL 27

RESULT 23

US-09-766-889A-55
; Sequence 55, Application US/09766889A
; Patent No. US20020164654A1
; GENERAL INFORMATION:
; APPLICANT: Luiten, Rosalie
; APPLICANT: Boon-Falleur, Thierry
; APPLICANT: van der Bruggen, Pierre
; APPLICANT: Stroobant, Vincent
; APPLICANT: Demotte, Nathalie
; APPLICANT: Schultz, Erwin
; TITLE OF INVENTION: MAG-3 ANTIGENIC PEPTIDES WHICH BIND HLA-B35 AND HLA-B44
; FILE REFERENCE: L0461/7104
; CURRENT APPLICATION NUMBER: US/09/766,889A
; CURRENT FILING DATE: 2001-01-19
; PRIOR APPLICATION NUMBER: US 60/177,242
; PRIOR FILING DATE: 2000-01-20
; PRIOR APPLICATION NUMBER: US 60/243,212
; PRIOR FILING DATE: 2000-10-25
; NUMBER OF SEQ ID NOS: 59
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 55
; LENGTH: 314
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-766-889A-55

Query Match 100.0%; Score 44; DB 9; Length 314;
Best Local Similarity 100.0%; Pred. No. 1.6; Mismatches 0; Indels 0; Gaps 0;
Matches 9; Conservative 0;

Qy 1 KVAELVHFL 9
| | | | |
Db 112 KVAELVHFL 120

RESULT 24

US-09-784-199-2
; Sequence 2, Application US/09784199
; Patent No. US20020164738A1
; GENERAL INFORMATION:

; APPLICANT: MORISHIMA, No. US20020164738A1uhiro
; APPLICANT: SHIBATA, Takehiko
; TITLE OF INVENTION: CELL DEATH INHIBITORY PROTEIN
; FILE REFERENCE: 04853-0057-00000
; CURRENT APPLICATION NUMBER: US/09/784,199
; CURRENT FILING DATE: 2001-06-21
; PRIOR APPLICATION NUMBER: JP 2000-41927
; PRIOR FILING DATE: 2001-02-16
; NUMBER OF SEQ ID NOS: 10
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 2
; LENGTH: 314
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-784-199-2

Query Match 100.0%; Score 44; DB 9; Length 314;
Best Local Similarity 100.0%; Pred. No. 1.6;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KVAELVHFL 9
Db 112 KVAELVHFL 120

RESULT 25
US-09-860-840-2
; Sequence 2, Application US/09860840
; Publication No. US20030049723A1
; GENERAL INFORMATION:
; APPLICANT: Zhang, Yi
; APPLICANT: Chau, Pascal
; APPLICANT: Boon, Thierry
; APPLICANT: van der Bruggen, Pierre
; TITLE OF INVENTION: WAGE-A3 PEPTIDES PRESENTED BY HLA CLASS II MOLECULES
; FILE REFERENCE: L0461/7110 (JRV)
; CURRENT APPLICATION NUMBER: US/09/860,840
; CURRENT FILING DATE: 2001-05-18
; NUMBER OF SEQ ID NOS: 18
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2
; LENGTH: 314
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-860-840-2

Query Match 100.0%; Score 44; DB 10; Length 314;
Best Local Similarity 100.0%; Pred. No. 1.6;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KVAELVHFL 9
Db 112 KVAELVHFL 120

RESULT 26
US-09-849-602-29
; Sequence 29, Application US/09849602
; Publication No. US20030165834A1
; GENERAL INFORMATION:
; APPLICANT: Scanlan, Matthew J.
; APPLICANT: Old, Lloyd J.
; APPLICANT: Stockert, Elisabeth
; APPLICANT: Chen, Yao-Tsang
; TITLE OF INVENTION: Colon Cancer Antigen Panel
; FILE REFERENCE: L0461/7105 (JRV)
; CURRENT APPLICATION NUMBER: US/09/849,602
; CURRENT FILING DATE: 2001-05-04
; NUMBER OF SEQ ID NOS: 30
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 29
; LENGTH: 314
; TYPE: PRT

; ORGANISM: Homo sapiens
US-09-849-602-29

Query Match 100.0%; Score 44; DB 10; Length 314;
Best Local Similarity 100.0%; Pred. No. 1.6;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KVAELVHFL 9
Db 112 KVAELVHFL 120

RESULT 27
US-10-149-135-2440
; Sequence 2440, Application US/10149135
; Publication No. US20040053822A1
; GENERAL INFORMATION:
; APPLICANT: Fikes, John
; APPLICANT: Sette, Alessandro
; APPLICANT: Sidney, John
; APPLICANT: Southwood, Scott
; APPLICANT: Chesnut, Robert
; APPLICANT: Celis, Esteban
; APPLICANT: Keogh, Elissa
; TITLE OF INVENTION: Inducing Cellular Immune Responses to
; FILE REFERENCE: 2060.0130001
; CURRENT APPLICATION NUMBER: US/10/149,135
; CURRENT FILING DATE: 2000-12-11
; PRIOR APPLICATION NUMBER: PCT/US00/33545
; PRIOR FILING DATE: 2000-12-11
; PRIOR APPLICATION NUMBER: US 09/458,298
; PRIOR FILING DATE: 1999-12-10
; PRIOR APPLICATION NUMBER: US 09/189,702
; PRIOR FILING DATE: 1998-11-10
; PRIOR APPLICATION NUMBER: US 08/205,713
; PRIOR FILING DATE: 1994-03-04
; PRIOR APPLICATION NUMBER: US 08/159,184
; PRIOR FILING DATE: 1993-11-29
; PRIOR APPLICATION NUMBER: US 08/073,205
; PRIOR FILING DATE: 1993-06-04
; PRIOR APPLICATION NUMBER: US 08/027,146
; PRIOR FILING DATE: 1993-03-05
; NUMBER OF SEQ ID NOS: 2479
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 2440
; LENGTH: 314
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-149-135-2440

Query Match 100.0%; Score 44; DB 12; Length 314;
Best Local Similarity 100.0%; Pred. No. 1.6;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KVAELVHFL 9
Db 112 KVAELVHFL 120

RESULT 28
US-10-296-734-829
; Sequence 829, Application US/10296734
; Publication No. US20040054137A1
; GENERAL INFORMATION:
; APPLICANT: Thompson, Scott A
; APPLICANT: Ramshaw, Ian A
; TITLE OF INVENTION: Synthetic molecules and uses therefor
; FILE REFERENCE: Savine
; CURRENT APPLICATION NUMBER: US/10/296,734
; CURRENT FILING DATE: 2003-08-04
; PRIOR APPLICATION NUMBER: AU PQ7761/00
; PRIOR FILING DATE: 2000-05-26

```
; NUMBER OF SEQ ID NOS: 1507
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 829
; LENGTH: 314
; TYPE: PRT
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: MAGE-3 consensus polypeptide
US-10-296-734-829

Query Match      100.0%; Score 44; DB 12; Length 314;
Best Local Similarity 100.0%; Pred. No. 1.6;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 KVAELVHFL 9
Db      112 KVAELVHFL 120

RESULT 29
US-10-146-473-53
; Sequence 53, Application US/10146473
; Publication No. US20030108888A1
; GENERAL INFORMATION:
; APPLICANT: Scanlan, Matthew
; APPLICANT: Gout, Ivan
; APPLICANT: Stockert, Elisabeth
; APPLICANT: Gure, Ali
; APPLICANT: Chen, Yao-Tseng
; APPLICANT: Old, Lloyd
; TITLE OF INVENTION: Breast Cancer Antigens
; FILE REFERENCE: L00461/70130(JRV)
; CURRENT APPLICATION NUMBER: US/10/146,473
; CURRENT FILING DATE: 2002-05-15
; PRIOR APPLICATION NUMBER: US 60/291,150
; PRIOR FILING DATE: 2001-05-15
; NUMBER OF SEQ ID NOS: 82
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 53
; LENGTH: 314
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-146-473-53

Query Match      100.0%; Score 44; DB 14; Length 314;
Best Local Similarity 100.0%; Pred. No. 1.6;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 KVAELVHFL 9
Db      112 KVAELVHFL 120

RESULT 30
US-10-177-390-20
; Sequence 20, Application US/10177390
; Publication No. US20030143743A1
; GENERAL INFORMATION:
; APPLICANT: Schuler, Gerold
; APPLICANT: N.V. Antwerp Innovatiecentrum
; TITLE OF INVENTION: Improved Transfection of Eucaryotic Cells with Linear
; FILE REFERENCE: Polynucleotides by Electroporation
; FILE REFERENCE: 021505wo/JH/ml
; CURRENT APPLICATION NUMBER: US/10/177,390
; CURRENT FILING DATE: 2002-06-20
; NUMBER OF SEQ ID NOS: 34
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 20
; LENGTH: 314
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-177-390-20

; NUMBER OF SEQ ID NOS: 1507
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 829
; LENGTH: 314
; TYPE: PRT
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: MAGE-3 consensus polypeptide
US-10-296-734-829

Query Match      100.0%; Score 44; DB 12; Length 314;
Best Local Similarity 100.0%; Pred. No. 1.6;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 KVAELVHFL 9
Db      112 KVAELVHFL 120

RESULT 31
US-10-170-832-2
; Sequence 2, Application US/10170832
; Publication No. US2003017092A1
; GENERAL INFORMATION:
; APPLICANT: Chau, Pascal
; APPLICANT: Vantomme, Valrie
; APPLICANT: Stroobant, Vincent
; APPLICANT: Boon-Falleur, Thierry
; APPLICANT: van der Bruggen, Pierre
; APPLICANT: Thielemans, Kris
; APPLICANT: Corthals, Jurgen
; TITLE OF INVENTION: MAGE-3 PEPTIDES PRESENTED BY HLA CLASS II MOLECULES
; FILE REFERENCE: L0461/7052
; CURRENT APPLICATION NUMBER: US/10/170,832
; CURRENT FILING DATE: 2002-06-12
; PRIOR APPLICATION NUMBER: US/09/166,448
; PRIOR FILING DATE: 1998-10-05
; NUMBER OF SEQ ID NOS: 81
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 2
; LENGTH: 314
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-170-832-2

Query Match      100.0%; Score 44; DB 14; Length 314;
Best Local Similarity 100.0%; Pred. No. 1.6;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 KVAELVHFL 9
Db      112 KVAELVHFL 120

RESULT 32
US-10-117-937-73
; Sequence 73, Application US/10117937
; Publication No. US20030220239A1
; GENERAL INFORMATION:
; APPLICANT: CTL IMMUNO THERAPIES CORP.
; APPLICANT: SIMARD, John, J.L.
; APPLICANT: DIAMOND, David, C.
; APPLICANT: LIU, Liping
; APPLICANT: XIE, Zhidong
; TITLE OF INVENTION: EPITOPE SEQUENCES
; FILE REFERENCE: CTIMM.027A
; CURRENT APPLICATION NUMBER: US/10/117,937
; CURRENT FILING DATE: 2002-04-04
; PRIOR APPLICATION NUMBER: US 60/282,211
; PRIOR FILING DATE: 2001-04-06
; PRIOR APPLICATION NUMBER: US 60/337,017
; PRIOR FILING DATE: 2001-11-07
; PRIOR APPLICATION NUMBER: US 60/363,210
; PRIOR FILING DATE: 2002-03-07
; NUMBER OF SEQ ID NOS: 602
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 73
; LENGTH: 314
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-117-937-73

Query Match      100.0%; Score 44; DB 15; Length 314;
```

Best Local Similarity 100.0%; Pred. No. 1.6; Indels 0; Gaps 0;
Matches 9; Conservative 0; Mismatches 0;

Qy 1 KVAELVHFL 9
Db 112 KVAELVHFL 120

RESULT 33

US-10-444-683-2
; Sequence 2, Application US/10444683
; Publication No. US20040077045A1
; GENERAL INFORMATION:
; APPLICANT: Zhang, Yi
; APPLICANT: Chaux, Pascal
; APPLICANT: Boon-Falleur, Thierry
; APPLICANT: van der Bruggen, Pierre
; TITLE OF INVENTION: MAGE PEPTIDES PRESENTED BY HLA CLASS II MOLECULES
; FILE REFERENCE: L00461.70146.US
; CURRENT APPLICATION NUMBER: US/10/444,683
; CURRENT FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 09/860,840
; PRIOR FILING DATE: 2001-05-18
; NUMBER OF SEQ ID NOS: 63
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 2
; LENGTH: 314
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-444-683-2

Query Match 100.0%; Score 44; DB 16; Length 314;
Best Local Similarity 100.0%; Pred. No. 1.6;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KVAELVHFL 9
Db 112 KVAELVHFL 120

RESULT 34

US-10-093-766-40
; Sequence 40, Application US/10093766
; Publication No. US20030013099A1
; GENERAL INFORMATION:
; APPLICANT: Lasek, Amy W.
; APPLICANT: Jones, David A.
; APPLICANT: Karpf, Adam R.
; TITLE OF INVENTION: GENES REGULATED BY DNA METHYLATION IN COLON TUMORS
; FILE REFERENCE: PA-0047 US
; CURRENT APPLICATION NUMBER: US/10/093,766
; CURRENT FILING DATE: 2002-03-07
; NUMBER OF SEQ ID NOS: 61
; SOFTWARE: PERL Program
; SEQ ID NO 40
; LENGTH: 315
; TYPE: PRT
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: misc_feature
; OTHER INFORMATION: Incyte ID No. US20030013099A1 2502336CD1
US-10-093-766-40

Query Match 100.0%; Score 44; DB 14; Length 315;
Best Local Similarity 100.0%; Pred. No. 1.7;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KVAELVHFL 9
Db 111 KVAELVHFL 119

RESULT 35

US-10-157-031-54

; Sequence 54, Application US/10157031

; Publication No. US2003010890A1

; GENERAL INFORMATION:

; APPLICANT: Baranova, A. V.

; APPLICANT: Yankovsky, N. K.

; APPLICANT: Kozlov, A. P.

; APPLICANT: Lobashev, A. V.

; APPLICANT: Krukovskaya, L. L.

; TITLE OF INVENTION: In silico screening for phenotype-associated expressed sequences

; FILE REFERENCE: 2760-103

; CURRENT APPLICATION NUMBER: US/10/157,031

; CURRENT FILING DATE: 2002-05-30

; NUMBER OF SEQ ID NOS: 415

; SOFTWARE: PatentIn version 3.1

; SEQ ID NO 54

; LENGTH: 315

; TYPE: PRT

; ORGANISM: Homo sapiens

US-10-157-031-54

Query Match 100.0%; Score 44; DB 14; Length 315;

Best Local Similarity 100.0%; Pred. No. 1.7;

Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KVAELVHFL 9

Db 111 KVAELVHFL 119

RESULT 36

US-10-295-027-366

; Sequence 366, Application US/10295027

; Publication No. US20030232350A1

; GENERAL INFORMATION:

; APPLICANT: Afar, Daniel

; APPLICANT: Aziz, Natasha

; APPLICANT: Ginsberg, Wendy M.

; APPLICANT: Gish, Kurt C.

; APPLICANT: Glynn, Richard

; APPLICANT: Hevezi, Peter A.

; APPLICANT: Mack, David H.

; APPLICANT: Murray, Richard

; APPLICANT: Watson, Susan R.

; APPLICANT: Eos Biotechnology, Inc.

; TITLE OF INVENTION: Methods of Diagnosis of Cancer, Compositions and

; TITLE OF INVENTION: Methods of Screening for Modulators of Cancer

; FILE REFERENCE: 018501-012500US

; CURRENT APPLICATION NUMBER: US/10/295,027

; CURRENT FILING DATE: 2002-11-13

; PRIOR APPLICATION NUMBER: US 09/663,733

; PRIOR FILING DATE: 2000-09-15

; PRIOR APPLICATION NUMBER: US 60/350,666

; PRIOR FILING DATE: 2001-11-13

; PRIOR APPLICATION NUMBER: US 60/335,394

; PRIOR FILING DATE: 2001-11-15

; PRIOR APPLICATION NUMBER: US 60/332,464

; PRIOR FILING DATE: 2001-11-21

; PRIOR APPLICATION NUMBER: US 60/334,393

; PRIOR FILING DATE: 2001-11-29

; PRIOR APPLICATION NUMBER: US 60/340,376

; PRIOR FILING DATE: 2001-12-14

; PRIOR APPLICATION NUMBER: US 60/347,211

; PRIOR FILING DATE: 2002-01-08

; PRIOR APPLICATION NUMBER: US 60/347,349

; PRIOR FILING DATE: 2002-01-10

; PRIOR APPLICATION NUMBER: US 60/355,250

; PRIOR FILING DATE: 2002-02-08

; PRIOR APPLICATION NUMBER: US 60/356,714

; PRIOR FILING DATE: 2002-02-13

; Remaining Prior Application data removed - See File Wrapper or PALM.

; NUMBER OF SEQ ID NOS: 1386

; SOFTWARE: PatentIn Ver. 2.1

```
; SEQ ID NO 366
; LENGTH: 315
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-295-027-366

Query Match      100.0%; Score 44; DB 15; Length 315;
Best Local Similarity 100.0%; Pred. No. 1.7;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 KVAELVHFL 9
Db      111 KVAELVHFL 119

RESULT 37
US-10-296-770-2
; Sequence 2, Application US/10296770
; Publication No. US20030104570A1
; GENERAL INFORMATION:
; APPLICANT: Cabezon Silva, Teresa Elisa Virginia
; APPLICANT: Delisse, Anne-Marie Eva Fernande
; TITLE OF INVENTION: Triple Fusion Proteins Comprising
; TITLE OF INVENTION: Ubiquitin Fused Between Thioredoxin and a Polypeptide of
; TITLE OF INVENTION: Interest
; FILE REFERENCE: B45221
; CURRENT APPLICATION NUMBER: US/10/296,770
; CURRENT FILING DATE: 2002-12-13
; PRIOR APPLICATION NUMBER: PCT/EP01/06952
; PRIOR FILING DATE: 2001-06-19
; PRIOR APPLICATION NUMBER: GB 0015619.0
; PRIOR FILING DATE: 2000-06-26
; PRIOR APPLICATION NUMBER: GB 0026484.6
; PRIOR FILING DATE: 2000-10-30
; NUMBER OF SEQ ID NOS: 8
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 2
; LENGTH: 522
; TYPE: PRT
; ORGANISM: Chimaeric (E. coli - human)
US-10-296-770-2

Query Match      100.0%; Score 44; DB 14; Length 522;
Best Local Similarity 100.0%; Pred. No. 2.8;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 KVAELVHFL 9
Db      311 KVAELVHFL 319

RESULT 38
US-10-734-1454
; Sequence 1454, Application US/10296734
; Publication No. US20040054137A1
; GENERAL INFORMATION:
; APPLICANT: Thompson, Scott A
; APPLICANT: Ramshaw, Ian A
; TITLE OF INVENTION: Synthetic molecules and uses therefor
; FILE REFERENCE: Savine
; CURRENT APPLICATION NUMBER: US/10/296,734
; CURRENT FILING DATE: 2003-08-04
; PRIOR APPLICATION NUMBER: AU PQ7761/00
; PRIOR FILING DATE: 2000-05-26
; NUMBER OF SEQ ID NOS: 1507
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 1454
; LENGTH: 3541
; TYPE: PRT
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: Melanoma cancer specific savine
US-10-734-1454
```

```
Query Match      100.0%; Score 44; DB 12; Length 3541;
Best Local Similarity 100.0%; Pred. No. 20;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 KVAELVHFL 9
Db      3400 KVAELVHFL 3408

RESULT 39
US-09-894-018-321
; Sequence 321, Application US/09894018
; Patent No. US20020119127A1
; GENERAL INFORMATION:
; APPLICANT: EPIMUNE, Inc.
; APPLICANT: Sette, Alessandro
; APPLICANT: Chestnut, Robert
; APPLICANT: Livingston, Brian
; APPLICANT: Baker, Denisw
; APPLICANT: Newman, Mark
; APPLICANT: Brown, David
; TITLE OF INVENTION: METHODS AND SYSTEM FOR OPTIMIZING
; TITLE OF INVENTION: MINIGENES AND PEPTIDES THEREBY
; FILE REFERENCE: 39963-20033.00
; CURRENT APPLICATION NUMBER: US/09/894,018
; CURRENT FILING DATE: 2001-06-27
; PRIOR APPLICATION NUMBER: PCT/US00/35568
; PRIOR FILING DATE: 2000-12-28
; PRIOR APPLICATION NUMBER: US 60/173,390
; PRIOR FILING DATE: 1999-12-28
; PRIOR APPLICATION NUMBER: US 60/284,221
; PRIOR FILING DATE: 2001-04-16
; NUMBER OF SEQ ID NOS: 368
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 321
; LENGTH: 9
; TYPE: PRT
; ORGANISM: Transgenic mouse
US-09-894-018-321

Query Match      95.5%; Score 42; DB 9; Length 9;
Best Local Similarity 88.9%; Pred. No. 1.2e+06;
Matches 8; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy      1 KVAELVHFL 9
Db      1 KVAELVHFL 9

RESULT 40
US-10-116-118-5
; Sequence 5, Application US/10116118
; Publication No. US20030143672A1
; GENERAL INFORMATION:
; APPLICANT: Tangri, Shabnam
; APPLICANT: Sette, Alessandro
; APPLICANT: Ishioka, Glenn
; APPLICANT: Fikes, John D.
; TITLE OF INVENTION: Heteroclitic Analogs and Related Methods
; FILE REFERENCE: 2060.0090003
; CURRENT APPLICATION NUMBER: US/10/116,118
; CURRENT FILING DATE: 2002-08-07
; PRIOR APPLICATION NUMBER: US 60/166,529
; PRIOR FILING DATE: 1999-11-18
; PRIOR APPLICATION NUMBER: US 60/239,008
; PRIOR FILING DATE: 2000-10-06
; NUMBER OF SEQ ID NOS: 53
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 5
; LENGTH: 9
; TYPE: PRT
; ORGANISM: Artificial Sequence
```

```
; FEATURE:
; OTHER INFORMATION: MAGE3.112 I5
US-10-116-118-5

Query Match      95.5%; Score 42; DB 14; Length 9;
Best Local Similarity 88.9%; Pred. No. 1.2e+06;
Matches 8; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Oy      1 KVAELVHFL 9
        ||||:||||
Db      1 KVAEIVHFL 9
```

Search completed: July 23, 2004, 12:58:18
Job time : 42 secs

This Page Blank (uspto)

GenCore version 5.1.6
Copyright (c) 1993 - 2004 Compugen Ltd.

OM protein - protein search, using sw model

Run on: July 23, 2004, 12:49:06 ; Search time 16 Seconds
(without alignments)
54.108 Million cell updates/sec

Title: US-09-458-298B-711

Perfect score: 44

Sequence: 1 KVAELVHFL 9

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 283366 seqs, 96191526 residues

Total number of hits satisfying chosen parameters: 283366

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database :

1: pir1:**

2: pir2:**

3: pir3:**

4: pir4:**

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	44	100.0	314	2 JC2361	melanoma antigen M
2	44	100.0	315	2 I38668	melanoma antigen M
3	41	93.2	314	2 I54519	melanoma antigen M
4	40	90.9	133	2 I38663	melanoma antigen M
5	40	90.9	314	2 JC2360	melanoma antigen M
6	40	90.9	968	2 G81743	preprotein translo
7	39	88.6	163	2 D70486	conserved hypothet
8	38	86.4	169	2 H84077	low temperature re
9	37	84.1	314	2 I68889	melanoma antigen M
10	37	84.1	2471	2 T42977	large tegument pro
11	36	81.8	184	2 A82631	hypothetical prote
12	36	81.8	234	2 I38667	melanoma antigen M
13	36	81.8	252	2 D95266	hypothetical prote
14	34	77.3	210	2 A10031	probable two-compo
15	34	77.3	258	2 A95945	probable oxidoredu
16	34	77.3	317	2 I38661	melanoma antigen M
17	34	77.3	461	2 A56239	mannose-6-phosphat
18	34	77.3	524	1 R0KBAP	nif-specific regul
19	34	77.3	2469	2 H36812	hypothetical prote
20	33	75.0	363	2 T19165	hypothetical prote
21	33	75.0	563	2 S49889	probable membrane
22	33	75.0	734	2 T13785	NADH2 dehydrogenas
23	33	75.0	738	2 T14230	NADH2 dehydrogenas
24	33	75.0	738	2 S58612	NADH2 dehydrogenas
25	33	75.0	741	2 T13051	NADH2 dehydrogenas
26	33	75.0	743	2 T12626	NADH2 dehydrogenas
27	33	75.0	743	2 T13073	NADH2 dehydrogenas
28	33	75.0	744	2 T13485	NADH2 dehydrogenas
29	33	75.0	744	2 T13043	NADH2 dehydrogenas

30	33	75.0	804	1 YUMU	sucrose synthase (
31	33	75.0	988	2 T51054	related to alpha-a
32	33	75.0	1557	2 G86419	probable reverse t
33	32	72.7	184	2 T42314	hypothetical prote
34	32	72.7	285	1 D32354	fructose-bisphosph
35	32	72.7	293	2 B90397	membrane conserved
36	32	72.7	357	1 RQECF	DNA replication an
37	32	72.7	357	2 C91208	DNA replication an
38	32	72.7	357	2 E86054	anthranilate phosph
39	32	72.7	362	2 AF1950	hypothetical prote
40	32	72.7	376	2 T40591	thymidine phosphor
41	32	72.7	421	1 S73416	probable thiophene
42	32	72.7	442	2 S73472	probable cytochrom
43	32	72.7	501	2 G86460	adenylosuccinate 1
44	32	72.7	507	2 D64083	probable cytochrom
45	32	72.7	511	2 F86460	

ALIGNMENTS

RESULT 1

JC2361

melanoma antigen MAGE-3 - human

N;Alternate names: MAGE 3 protein

C;Species: Homo sapiens (man)

C;Date: 20-Feb-1995 #sequence_revision 20-Feb-1995 #text_change 18-Feb-2000

C;Accession: JC2361; PH1296; I38438

R;Ding, M.; Beck, R.J.; Keller, C.J.; Fenton, R.G.

Biochem. Biophys. Res. Commun. 202, 549-555, 1994

A;Title: Cloning and analysis of MAGE-1-related genes.

A;Reference number: JC2358; MUID:94311935; PMID:8037761

A;Accession: JC2361

A;Molecule type: mRNA

A;Residues: 1-314 <DIN>

A;Experimental source: melanoma cell line DM150

R;Traversari, C.; van der Bruggen, P.; Luescher, I.F.; Lurquin, C.; Chomez, P.; Van Pel,

J. Exp. Med. 176, 1453-1457, 1992

A;Title: A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic

A;Reference number: PH1294; MUID:93018875; PMID:1402688

A;Accession: PH1296

A;Molecule type: DNA

A;Residues: 168-176 <TRA>

R;Gaugler, B.; Van den Eynde, B.; van der Bruggen, P.; Romero, P.; Gaforio, J.J.; De Plaet

J. Exp. Med. 179, 921-930, 1994

A;Title: Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cy

A;Reference number: I38438; MUID:94157413; PMID:8113684

A;Accession: I38438

A;Status: preliminary; translated from GB/EMBL/DBJ

A;Molecule type: DNA

A;Residues: 1-314 <RES>

A;Cross-references: EMBL:U03735; NID:9468825; PIDN:AAA17446.1; PID:9468826

C;Genetics:

A;Gene: MAGE-3

C;Superfamily: tumor associated protein MAGE

F;168-176/Region: HLA-A1 binding #status predicted

Query Match 100.0%; Score 44; DB 2; Length 314;

Best Local Similarity 100.0%; Pred. No. 0.22;

Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KVAELVHFL 9

|||||

Db 112 KVAELVHFL 120

RESULT 2

I38668

melanoma antigen MAGE-9 - human

C;Species: Homo sapiens (man)

C;Date: 07-Jun-1996 #sequence_revision 07-Jun-1996 #text_change 18-Feb-2000

C;Accession: I38668

R;De Plaen, E.; Arden, K.; Traversari, C.; Gaforio, J.J.; Szikora, J.P.; De Smet, C.; Br

oon, T.
Immunogenetics 40, 360-369, 1994
A;Title: Structure, chromosomal localization, and expression of 12 genes of the MAGE fam
A;Reference number: I38659; MUID:95012457; PMID:7927540
A;Accession: I38668
A;Status: preliminary; translated from GB/EMBL/DBJ
A;Molecule type: DNA
A;Residues: 1-315 <RES>
A;Cross-references: EMBL:U10694; NID:G533527; PIDN:AAA68877.1; PID:G533528
C;Genetics:
A;Gene: GDB:MAGEA9; MAGE9
A;Cross-references: GDB:331125
A;Map position: Xp21.3-Xp21.3
A;Introns: #status absent
C;Superfamily: tumor associated protein MAGE

Query Match 100.0%; Score 44; DB 2; Length 315;
Best Local Similarity 100.0%; Pred. No. 0.22;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KVAELVHFL 9
Db 111 KVAELVHFL 119

RESULT 3
I54519
melanoma antigen MAGE-12 - human
N;Alternate names: MAGE 21 protein
C;Species: Homo sapiens (man)
C;Date: 07-Jun-1996 #sequence_revision 07-Jun-1996 #text_change 18-Feb-2000
C;Accession: I54519; J23362; PH1295
R;De Plaen, C.; Lurquin, C.; van der Bruggen, P.; De Plaen, E.; Brasseur, F.; Boon, T.
Immunogenetics 39, 121-129, 1994
A;Title: Sequence and expression pattern of the human MAGE2 gene.
A;Reference number: I54519; MUID:94102805; PMID:8276455
A;Accession: I54519
A;Status: preliminary; translated from GB/EMBL/DBJ
A;Molecule type: DNA
A;Residues: 1-314 <DBS>
A;Cross-references: GB:I18877; NID:G499345; PIDN:AAA19023.1; PID:G499346
R;Ding, M.; Beck, R.J.; Keller, C.J.; Fenton, R.G.
Biochem. Biophys. Res. Commun. 202, 549-555, 1994
A;Title: Cloning and analysis of MAGE-1-related genes.
A;Reference number: J23358; MUID:94311935; PMID:8037761
A;Accession: J23362
A;Molecule type: mRNA
A;Residues: 1-9,'S',11-186,'D',188-299,'S',301-314 <DIN>
A;Experimental source: melanoma cell line DM150; MAGE-12f
R;Traversari, C.; van der Bruggen, P.; Luescher, I.F.; Lurquin, C.; Chomez, P.; Van Pel,
J. Exp. Med. 176, 1453-1457, 1992
A;Title: A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic
A;Reference number: PH1294; MUID:93018875; PMID:1402688
A;Accession: PH1295
A;Molecule type: DNA
A;Residues: 168-176 <TRA>
A;Experimental source: MAGE-21
C;Genetics:
A;Gene: GDB:MAGEA12; MAGE12; MAGE-12f
A;Cross-references: GDB:331129
A;Map position: Xq28-Xq28
C;Superfamily: tumor associated protein MAGE
F;168-176/region: HLA-A1 binding #status predicted

Query Match 93.2%; Score 41; DB 2; Length 314;
Best Local Similarity 88.9%; Pred. No. 0.92;
Matches 8; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KVAELVHFL 9
Db 112 KVAELVHFL 120

RESULT 4
I38663
melanoma antigen MAGE-5 - human (fragments)
C;Species: Homo sapiens (man)
C;Date: 07-Jun-1996 #sequence_revision 18-Feb-2000 #text_change 18-Feb-2000
C;Accession: I38663; I38664; PH1299; PH1300
R;De Plaen, E.; Arden, K.; Traversari, C.; Gaforio, J.J.; Szikora, J.P.; De Smet, C.; Br
oon, T.
Immunogenetics 40, 360-369, 1994
A;Title: Structure, chromosomal localization, and expression of 12 genes of the MAGE fam
A;Reference number: I38659; MUID:95012457; PMID:7927540
A;Accession: I38663
A;Status: preliminary; translated from GB/EMBL/DBJ
A;Molecule type: DNA
A;Residues: 1-124 <DEP1>
A;Cross-references: EMBL:U10689; NID:G533518; PIDN:AAA68873.1; PID:G533519
A;Experimental source: MAGE-5a antigen
A;Accession: I38664
A;Status: preliminary; translated from GB/EMBL/DBJ
A;Molecule type: DNA
A;Residues: 1-124 <DEP2>
A;Cross-references: EMBL:U10690; NID:G533520; PIDN:AAA68874.1; PID:G533521
A;Experimental source: MAGE-5b antigen
A;Note: these sequences seem to be incomplete with respect to other members of the super
R;Traversari, C.; van der Bruggen, P.; Luescher, I.F.; Lurquin, C.; Chomez, P.; Van Pel,
J. Exp. Med. 176, 1453-1457, 1992
A;Title: A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic
A;Reference number: PH1294; MUID:93018875; PMID:1402688
A;Accession: PH1299
A;Molecule type: DNA
A;Residues: 125-133 <TRAI>
A;Experimental source: MAGE 5 protein
A;Accession: PH1300
A;Molecule type: DNA
A;Residues: 125-133 <TRA2>
A;Experimental source: MAGE 51 protein
C;Genetics:
A;Gene: GDB:MAGEA5; MAGE5
A;Cross-references: GDB:331120
A;Map position: Xq28-Xq28
A;Introns: #status absent
C;Superfamily: tumor associated protein MAGE

Query Match 90.9%; Score 40; DB 2; Length 133;
Best Local Similarity 77.8%; Pred. No. 0.62;
Matches 7; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KVAELVHFL 9
Db 112 KVAELVHFL 120

RESULT 5
J23360
melanoma antigen MAGE-6 - human
N;Alternate names: tumor-associated antigen, MAGE-3b
C;Species: Homo sapiens (man)
C;Date: 20-Feb-1995 #sequence_revision 20-Feb-1995 #text_change 18-Feb-2000
C;Accession: J23360; PH1301; I38665; G01445
R;Ding, M.; Beck, R.J.; Keller, C.J.; Fenton, R.G.
Biochem. Biophys. Res. Commun. 202, 549-555, 1994
A;Title: Cloning and analysis of MAGE-1-related genes.
A;Reference number: J23358; MUID:94311935; PMID:8037761
A;Accession: J23360
A;Molecule type: mRNA
A;Residues: 1-314 <DIN>
A;Experimental source: melanoma cell line DM150
R;Traversari, C.; van der Bruggen, P.; Luescher, I.F.; Lurquin, C.; Chomez, P.; Van Pel,
J. Exp. Med. 176, 1453-1457, 1992
A;Title: A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic
A;Reference number: PH1294; MUID:93018875; PMID:1402688
A;Accession: PH1301
A;Molecule type: DNA

A;Residues: 168-176 <TRA>
R;De Plaen, E.; Arden, K.; Traversari, C.; Gaforio, J.J.; Szikora, J.P.; De Smet, C.; Boon, T.
Immunogenetics 40, 360-369, 1994
A;Title: Structure, chromosomal localization, and expression of 12 genes of the MAGE family
A;Reference number: I38659; MUID:95012457; PMID:7927540
A;Accession: I38665
A;Status: preliminary; translated from GB/EMBL/DBJ
A;Molecule type: DNA
A;Residues: 1-314 <RES>
A;Cross-references: EMBL:U10691; NID:G533522; PIDN:AAAG68875.1; PID:G533522
R;Fenton, R.G.
submitted to the EMBL Data Library, June 1994
A;Reference number: G07126
A;Accession: G01445
A;Status: preliminary; translated from GB/EMBL/DBJ
A;Molecule type: mRNA
A;Residues: 1-314 <FEN>
A;Cross-references: EMBL:U10339; NID:G499121; PIDN:AAAL9006.1; PID:G499122
C;Genetics:
A;Gene: GDB:MAGEA6; MAGE6
A;Cross-references: GDB:331121
A;Map position: Xq28-Xq28
A;Introns: #status absent
C;Superfamily: tumor associated protein MAGE
P;168-176/Region: HLA-A1 binding #status predicted

Query Match 90.9%; Score 40; DB 2; Length 314;
Best Local Similarity 88.9%; Pred. No. 1.5;
Matches 8; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KVAELVHFL 9
|||:|||||
Db 112 KVAELVHFL 120

RESULT 6
G81743
preprotein translocase SecA chain TC0074 [imported] - Chlamydia muridarum (strain Nigg)
C;Species: Chlamydia muridarum, Chlamydia trachomatis MoPn
C;Date: 31-Mar-2000 #sequence_revision 31-Mar-2000 #text_change 17-Nov-2000
C;Accession: G81743
R;Read, T.D.; Brunham, R.C.; Shen, C.; Gill, S.R.; Heidelberg, J.F.; White, O.; Hickey, A.C.; Dodson, R.; Gwinn, M.; Nelson, W.; DeBoy, R.; Kolonay, J.; McClarty, G.; Salzberg, Nucleic Acids Res. 28, 1397-1406, 2000
A;Title: Genome sequences of Chlamydia trachomatis MoPn and Chlamydia pneumoniae AR39.
A;Reference number: A81500; MUID:20150255; PMID:10684935
A;Accession: G81743
A;Status: preliminary
A;Molecule type: DNA
A;Residues: 1-968 <TET>
A;Cross-references: GB:AR002275; GB:AR002160; NID:G7190109; PIDN:AAF38956.1; PID:G719010
A;Experimental source: strain Nigg (MoPn)
C;Genetics:
A;Gene: TC0074
C;Superfamily: preprotein translocase secA

Query Match 90.9%; Score 40; DB 2; Length 968;
Best Local Similarity 100.0%; Pred. No. 4.6;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KVAELVHFL 8
|||||||
Db 255 KVAELVHFL 262

RESULT 7
D70486
conserved hypothetical protein aq_2171 - Aquifex aeolicus
C;Species: Aquifex aeolicus
C;Date: 08-May-1998 #sequence_revision 08-May-1998 #text_change 23-Dec-2002
C;Accession: D70486
R;Deckert, G.; Warren, P.V.; Gaasterland, T.; Young, W.G.; Lenox, A.L.; Graham, D.E.; Ov

V.
Nature 392, 353-358, 1998
A;Title: The complete genome of the hyperthermophilic bacterium Aquifex aeolicus.
A;Reference number: A70300; MUID:98196666; PMID:9537320
A;Accession: D70486
A;Status: preliminary; nucleic acid sequence not shown; translation not shown
A;Molecule type: DNA
A;Residues: 1-163 <AQF>
A;Cross-references: GB:AE000776; NID:G2984355; PIDN:AAAC07894.1; PID:G2984375; GB:AE00065
A;Experimental source: strain VFS
C;Genetics:
A;Gene: aq_2171
C;Superfamily: phosphatase

Query Match 88.6%; Score 39; DB 2; Length 163;
Best Local Similarity 77.8%; Pred. No. 1.2;
Matches 7; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KVAELVHFL 9
|||:|||||
Db 152 EVAELIHFL 160

RESULT 8
H84077
low temperature requirement C protein BH3424 [imported] - Bacillus halodurans (strain C-
C;Species: Bacillus halodurans
C;Date: 01-Dec-2000 #sequence_revision 01-Dec-2000 #text_change 15-Jun-2001
C;Accession: H84077
R;Takami, H.; Nakasone, K.; Takaki, Y.; Maeno, G.; Sasaki, R.; Masui, N.; Fujii, F.; Hirai, Nucleic Acids Res. 28, 4317-4331, 2000
A;Title: Complete genome sequence of the alkaliphilic bacterium Bacillus halodurans and
A;Reference number: A83650; MUID:20512582; PMID:11058132
A;Accession: H84077
A;Status: preliminary
A;Molecule type: DNA
A;Residues: 1-169 <STO>
A;Cross-references: GB:AP001518; GB:BA000004; NID:G10175792; PIDN:BA07143.1; GSPDB:GN001
A;Experimental source: strain C-125
C;Genetics:
A;Gene: BH3424

Query Match 86.4%; Score 38; DB 2; Length 169;
Best Local Similarity 87.5%; Pred. No. 2.1;
Matches 7; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 2 VAEELVHFL 9
|||:|||||
Db 25 IAEELVHFL 32

RESULT 9
I68889
melanoma antigen Mage-2 - human
C;Species: Homo sapiens (man)
C;Date: 07-Jun-1996 #sequence_revision 07-Jun-1996 #text_change 18-Feb-2000
C;Accession: I68889; PH1294
R;De Smet, C.; Lurquin, C.; van der Bruggen, P.; De Plaen, E.; Brasseur, F.; Boon, T. Immunogenetics 39, 121-129, 1994
A;Title: Sequence and expression pattern of the human MAGE2 gene.
A;Reference number: I54519; MUID:94102805; PMID:8276455
A;Accession: I68889
A;Status: preliminary; translated from GB/EMBL/DBJ
A;Molecule type: DNA
A;Residues: 1-314 <RES>
A;Cross-references: GB:L19320; NID:G436180; PIDN:AAAL7729.1; PID:G436181
R;Traversari, C.; van der Bruggen, P.; Luescher, I.F.; Lurquin, C.; Chomez, P.; Van Pel, J. Exp. Med. 176, 1453-1457, 1992
A;Title: A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic
A;Reference number: PH1294; MUID:93018875; PMID:1402688
A;Accession: PH1294
A;Molecule type: DNA
A;Residues: 168-176 <TRA>

C;Genetics:
A;Gene: GDB:MAGEA2; MAGE2
A;Cross-references: GDB:273684
A;Map position: Xq28-Xq28
C;Superfamily: tumor associated protein MAGE

Query Match 84.1%; Score 37; DB 2; Length 314;
Best Local Similarity 77.8%; Pred. No. 6.2;
Matches 7; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

Qy 1 KVAELVHFL 9
|:|||||
Db 112 KQVELVHFL 120

RESULT 10
T42977
large tegument protein - ateline herpesvirus 3 (strain 73)
C;Species: ateline herpesvirus 3
A;Variety: strain 73
C;Date: 21-Jan-2000 #sequence_revision 21-Jan-2000 #text_change 21-Jan-2000
C;Accession: T42977
R;Albrecht, J.C.; Fleckenstein, B.
submitted to the EMBL Data Library, August 1998
A;Description: Primary structure of the herpesvirus ateles genome.
A;Reference number: 222274
A;Accession: T42977
A;Status: preliminary; translated from GB/EMBL/DBJ
A;Molecule type: DNA
A;Residues: 1-2471 <ALB>
A;Cross-references: EMBL:AF083424; PIDN:AAC95588.1
A;Experimental source: strain 73

Query Match 84.1%; Score 37; DB 2; Length 2471;
Best Local Similarity 55.6%; Pred. No. 50;
Matches 5; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KVAELVHFL 9
|:|||||
Db 1520 KISELIHFI 1528

RESULT 11
A82631
hypothetical protein XF1836 [imported] - Xylella fastidiosa (strain 9a5c)
C;Species: Xylella fastidiosa
C;Date: 18-Aug-2000 #sequence_revision 20-Aug-2000 #text_change 20-Aug-2000
C;Accession: A82631
R;anonymous, The Xylella fastidiosa Consortium of the Organization for Nucleotide Sequencing
Nature 406, 151-157, 2000
A;Title: The genome sequence of the plant pathogen Xylella fastidiosa.
A;Reference number: A82515; MUID:20365717; PMID:10910347
A;Note: for a complete list of authors see reference number A59328 below
A;Accession: A82631
A;Status: preliminary
A;Molecule type: DNA
A;Residues: 1-184 <STM>
A;Cross-references: GB:AE004005; GB:AE003849; NID:G9106918; PIDN:AAF84642.1; GSPDB:GN001
A;Experimental source: strain 9a5c
R;Simpson, A.J.G.; Reinach, F.C.; Arruda, P.; Abreu, F.A.; Acencio, M.; Alvarenga, R.; A
Briones, M.R.S.; Bueno, M.R.P.; Camargo, A.A.; Camargo, L.E.A.; Carraro, D.M.; Carrer, H
as-Neto, E.; Docena, C.; El-Dorothy, H.; Facincani, A.P.; Ferreira, A.J.S.
submitted to GenBank, June 2000
A;Authors: Ferreira, V.C.A.; Ferro, J.A.; Fraga, J.S.; Franca, S.C.; Franco, M.C.; Frohm
J.D.; Junqueira, M.L.; Kemper, E.L.; Kitajima, J.P.; Krieger, J.E.; Kuramae, E.E.; Laig
chado, M.A.; Madeira, A.M.B.N.; Madeira, H.M.F.; Marino, C.L.; Marques, M.V.; Martins, E
A;Authors: Martins, E.M.F.; Matsukuma, A.Y.; Menck, C.F.M.; Miracca, E.C.; Miyaki, C.Y.;
F.G.; Nunes, L.R.; Oliveira, M.A.; de Oliveira, M.C.; de Oliveira, R.C.; Palmieri, D.A
Rodrigues, V.; Rosa, A.C.R.; de M.; de Rosa Jr., V.E.; de Sa, R.G.; Santelli, R.V.; Sawasak
A;Authors: da Silva, A.C.R.; da Silva, F.R.; da Silva, A.M.; Silva Jr., W.A.; da Silveir
M.; Tshako, M.H.; Vallada, H.; Van Sluys, M.A.; Verjovski-Almeida, S.; Vettore, A.L.; Z
A;Reference number: A59328
A;Contents: annotation
A;Gene: Sma0074
A;Genome: plasmid

C;Genetics:
A;Gene: XF1836

Query Match 81.8%; Score 36; DB 2; Length 184;
Best Local Similarity 87.5%; Pred. No. 5.8;
Matches 7; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1 KVAELVHF 8
|:|||||
Db 140 KQGLVHF 147

RESULT 12
I38667
melanoma antigen MAGE-8 - human
C;Species: Homo sapiens (man)
C;Date: 07-Jun-1996 #sequence_revision 07-Jun-1996 #text_change 18-Feb-2000
C;Accession: I38667
R;De Plaen, E.; Arden, K.; Traversari, C.; Gaforio, J.J.; Szikora, J.P.; De Smet, C.; Br
oon, T.
Immunogenetics 40, 360-369, 1994
A;Title: Structure, chromosomal localization, and expression of 12 genes of the MAGE fam
A;Reference number: I38659; MUID:95012457; PMID:7927540
A;Accession: I38667
A;Status: preliminary; translated from GB/EMBL/DBJ
A;Molecule type: DNA
A;Residues: 1-234 <RES>
A;Cross-references: EMBL:U10693; NID:G5333525; PIDN:AAA68876.1; PID:G533526
C;Genetics:
A;Gene: GDB:MAGEA8; MAGE8
A;Cross-references: GDB:I331123
A;Map position: Xq28-Xq28
A;Introns: #status absent
C;Superfamily: tumor associated protein MAGE

Query Match 81.8%; Score 36; DB 2; Length 234;
Best Local Similarity 88.9%; Pred. No. 7.5;
Matches 8; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1 KVAELVHFL 9
|:|||||
Db 115 KVAELVRFL 123

RESULT 13
D95266
hypothetical protein Sma0074 [imported] - Sinorhizobium meliloti (strain 1021) magaplasmi
C;Species: Sinorhizobium meliloti
C;Date: 24-Aug-2001 #sequence_revision 24-Aug-2001 #text_change 30-Sep-2001
C;Accession: D95266
R;Barnett, M.J.; Fisher, R.F.; Jones, T.; Komp, C.; Abola, A.P.; Barloy-Hubler, F.; Bowse
.; Kalman, S.; Keating, D.H.; Palm, C.; Peck, M.C.; Surzycki, R.; Wells, D.H.; Yeh, K.C.;
Proc. Natl. Acad. Sci. U.S.A. 98, 9883-9888, 2001
A;Title: Nucleotide sequence and predicted functions of the entire Sinorhizobium meliloti
A;Reference number: A95262; MUID:21396509; PMID:11481432
A;Accession: D95266
A;Status: preliminary
A;Molecule type: DNA
A;Residues: 1-252 <KUR>
A;Cross-references: GB:AE006469; PIDN:AAK64694.1; PID:G14523094; GSPDB:GN00165
A;Experimental source: strain 1021, megaplasmid pSymA
R;Galibert, F.; Finan, T.M.; Long, S.R.; Puhler, A.; Abola, P.; Ampe, P.; Barloy-Hubler,
pela, D.; Chai, P.; Cowie, A.; Davis, R.W.; Dreano, S.; Federspiel, N.A.; Fisher, R.F.;
L.; Hyman, R.W.; Jones, T.
Science 293, 668-672, 2001
A;Authors: Kahn, D.; Kahn, M.L.; Kalman, S.; Keating, D.H.; Kiss, E.; Komp, C.; Lelaure,
neault, P.; Vandenberg, M.; Vorholter, F.J.; Weidner, S.; Wells, D.H.; Wong, K.; Yeh, K.C.
A;Title: The composite genome of the legume symbiont Sinorhizobium meliloti.
A;Reference number: A96039; MUID:21368234; PMID:11474104
A;Contents: annotation
C;Genetics:
A;Gene: Sma0074
A;Genome: plasmid

C;Superfamily: ribitol dehydrogenase; short-chain alcohol dehydrogenase homology

Query Match 81.8%; Score 36; DB 2; Length 252;
Best Local Similarity 87.5%; Pred. No. 8;
Matches 7; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 2 VAELVHFL 9
|||:|||||
Db 226 VADLVHFL 233

RESULT 14

AI0031
probable two-component response regulator YPO0255 [imported] - Yersinia pestis (strain C)
C;Species: Yersinia pestis
C;Date: 02-Nov-2001 #sequence_revision 02-Nov-2001 #text_change 15-Sep-2003
C;Accession: AI0031
R;Parkhill, J.; Wren, B.W.; Thomson, N.R.; Titball, R.W.; Holden, M.T.G.; Prentice, M.B.; deno-Tarraga, A.M.; Chillingworth, T.; Cronin, A.; Davies, R.M.; Davis, P.; Dougan, G.; il, M.; Rutherford, K.; Simmonds, M.; Skelton, J.; Stevens, K.; Whitehead, S.; Barrell, Nature 413, 523-527, 2001
A;Title: Genome sequence of Yersinia pestis, the causative agent of plague.
A;Reference number: AB0001; MUID:21470413; PMID:11586360
A;Accession: AI0031
A;Status: preliminary
A;Molecule type: DNA
A;Residues: 1-210 <KUR>
A;Cross-references: GB:AL590842; PIDN:CAC89116.1; PID:g15978354; GSPDB:GN00175
C;Genetics:
A;Gene: YPO0255
C;Superfamily: response regulator with HTH DNA-binding domain, NarL type; response regul

Query Match 77.3%; Score 34; DB 2; Length 210;
Best Local Similarity 75.0%; Pred. No. 17;
Matches 6; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KVAELVHF 8
|||:|||||
Db 195 KVAELIHW 202

RESULT 15

A95945
probable oxidoreductase, SDR superfamily protein SMB21159 [imported] - Sinorhizobium mel
C;Species: Sinorhizobium meliloti
C;Date: 24-Aug-2001 #sequence_revision 24-Aug-2001 #text_change 30-Sep-2001
C;Accession: A95945
R;Finan, T.M.; Weidner, S.; Wong, K.; Buhrmester, J.; Chain, P.; Vorholter, F.J.; Hernan Proc. Natl. Acad. Sci. U.S.A. 98, 9889-9894, 2001
A;Title: The complete sequence of the 1,683-Kb pSymB megaplasmid from the N2-fixing endo
A;Reference number: A95842; MUID:21396508; PMID:11481431
A;Accession: A95945
A;Status: preliminary
A;Molecule type: DNA
A;Residues: 1-258 <KUR>
A;Cross-references: GB:AL591985; PIDN:CAC49225.1; PID:g15140711; GSPDB:GN00167
A;Experimental source: strain 1021, megaplasmid pSymB
R;Galibert, F.; Finan, T.M.; Long, S.R.; Puhler, A.; Abola, P.; Ampe, F.; Barloy-Hubler, P.; Chain, P.; Cowie, A.; Davis, R.W.; Dreano, S.; Federspiel, N.A.; Fisher, R.F.; L.; Hyman, R.W.; Jones, T.
Science 293, 668-672, 2001
A;Authors: Kahn, D.; Kahn, M.L.; Kalman, S.; Keating, D.H.; Kiss, E.; Komp, C.; Lelaure, hebault, P.; Vandenbol, M.; Vorholter, F.J.; Weidner, S.; Wells, D.H.; Wong, K.; Yeh, K.
A;Title: The composite genome of the legume symbiont Sinorhizobium meliloti.
A;Reference number: A96039; MUID:21368234; PMID:11474104
A;Contents: annotation
C;Genetics:
A;Gene: SMD21159
C;Superfamily: ribitol dehydrogenase; short-chain alcohol dehydrogenase homology

Query Match 77.3%; Score 34; DB 2; Length 258;
Best Local Similarity 87.5%; Pred. No. 21;

Matches 7; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Qy 2 VAELVHFL 9
|||:|||||
Db 215 VAEAVHFL 222

RESULT 16

I38661
melanoma antigen MAGE-4 - human
N;Alternate names: MAGE 41 protein; melanoma antigen MAGE-X2
C;Species: Homo sapiens (man)
C;Date: 07-Jun-1996 #sequence_revision 07-Jun-1996 #text_change 18-Feb-2000
C;Accession: I38661; I38662; PH1297; PH1298; JC2359; G01446
R;De Plaen, E.; Arden, K.; Traversari, C.; Gaforio, J.J.; Szikora, J.P.; De Smet, C.; Bri con, T.
Immunogenetics 40, 360-369, 1994
A;Title: Structure, chromosomal localization, and expression of 12 genes of the MAGE fam
A;Reference number: I38659; MUID:95012457; PMID:7927540
A;Accession: I38661
A;Status: preliminary; translated from GB/EMBL/DBJ
A;Molecule type: DNA
A;Residues: 1-317 <DEP1>
A;Cross-references: EMBL:U10687; NID:G533514; PIDN:AAA68871.1; PID:G533515
A;Experimental source: antigen MAGE-4a
A;Accession: I38662
A;Status: preliminary; translated from GB/EMBL/DBJ
A;Molecule type: DNA
A;Residues: 1-172, 'T', 174-317 <DEP2>
A;Cross-references: EMBL:U10688; NID:G533516; PIDN:AAA68872.1; PID:G533517
A;Experimental source: antigen MAGE-4b
R;Traversari, C.; van der Bruggen, P.; Luescher, I.F.; Lurquin, C.; Chomez, P.; Van Pel, J. Exp. Med. 176, 1453-1457, 1992
A;Title: A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic
A;Reference number: PH1294; MUID:93018875; PMID:1402688
A;Accession: PH1297
A;Molecule type: DNA
A;Residues: 169-177 <TRAI>
A;Experimental source: antigen MAGE-4
A;Accession: PH1298
A;Molecule type: DNA
A;Residues: 169-172, 'T', 174-177 <TRA2>
A;Experimental source: antigen MAGE-41
R;Ding, M.; Beck, R.J.; Keller, C.J.; Fenton, R.G. Biochem. Biophys. Res. Commun. 202, 549-555, 1994
A;Title: Cloning and analysis of MAGE-1-related genes.
A;Reference number: JC2358; MUID:94311935; PMID:8037761
A;Accession: JC2359
A;Molecule type: mRNA
A;Residues: 1-172, 'T', 174-306, 'Q', 308-317 <DIN>
A;Cross-references: EMBL:U10340; NID:g499123; PIDN:AAA19007.1; PID:g499124
A;Experimental source: melanoma cell line DM150
C;Genetics:
A;Gene: GDB:MAGE4; MAGE4; MAGE-X2
A;Cross-references: GDB:331119
A;Map position: Xq28-Xq28
A;Introns: #status absent
C;Superfamily: tumor associated protein MAGE
P;169-177/Region: HLA-A1 binding #status predicted

Query Match 77.3%; Score 34; DB 2; Length 317;
Best Local Similarity 77.8%; Pred. No. 26;
Matches 7; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1 KVAELVHFL 9
|||:|||||
Db 113 KVDELAFHL 121

RESULT 17

A56239
mannose-6-phosphate isomerase (EC 5.3.1.8) - Emericella nidulans
C;Species: Emericella nidulans, Aspergillus nidulans

C;Date: 03-Nov-1995 #sequence_revision 03-Nov-1995 #text_change 24-Sep-1999
C;Accession: A56239; S31241
R;Smith, D.J.; Payton, M.A.
Mol. Cell. Biol. 14, 6030-6038, 1994
A;Title: Hyphal tip extension in *Aspergillus nidulans* requires the *manA* gene, which encodes a 24,206-base-pair DNA fragment carrying the entire *ntrC* and *nifA* genes from *Klebsiella pneumoniae*.
A;Reference number: A56239; MUID:94344113; PMID:8065336
A;Accession: A56239
A;Status: preliminary
A;Molecule type: DNA
A;Residues: 1-461 <SMI>
A;Cross-references: GB:M85239; NID:g168071; PIDN:AAA33319.1; PID:g168072
R;Smith, D.J.; Proudfoot, A.; Friedli, L.; Klig, L.S.; Paravicini, G.; Payton, M.A.
Mol. Cell. Biol. 12, 2924-2930, 1992
A;Title: PMT40, an intron-containing gene required for early steps in yeast mannosylation
A;Reference number: S31240; MUID:92318908; PMID:1377774
A;Accession: S31241
A;Status: nucleic acid sequence not shown; translation not shown
A;Molecule type: DNA
A;Residues: 1-461 <SM2>
A;Cross-references: EMBL:M85239; NID:g168071; PIDN:AAA33319.1; PID:g168072
A;Note: the nucleotide sequence was submitted to the EMBL Data Library, February 1992
C;Genetics:
A;Gene: *manA*
A;Introns: 11/1; 18/1; 48/3; 128/1
C;Superfamily: Yeast mannosyl-6-phosphate isomerase
C;Keywords: intramolecular oxidoreductase; isomerase

Query Match 77.3%; Score 34; DB 2; Length 461;
Best Local Similarity 75.0%; Pred. No. 38;
Matches 6; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Qy 2 VAEIVHFL 9
:|||||
Db 151 LAEIVHFL 158

RESULT 18
RGKGP
nif-specific regulatory protein - *Klebsiella pneumoniae*
C;Species: *Klebsiella pneumoniae*
C;Date: 28-May-1986 #sequence_revision 28-May-1986 #text_change 28-Apr-2003
C;Accession: A91060; A93571; S02513; A03562
R;Drummond, M.; Whitty, P.; Wootton, J.
EMBO J. 5, 441-447, 1986
A;Title: Sequence and domain relationships of *ntrC* and *nifA* from *Klebsiella pneumoniae*.
A;Reference number: A91060; MUID:86220124; PMID:3011408
A;Accession: A91060
A;Status: nucleic acid sequence not shown
A;Molecule type: DNA
A;Residues: 1-524 <DRU>
R;Buikema, W.J.; Szeto, W.W.; Lemley, P.V.; Orme-Johnson, W.H.; Ausubel, F.M.
Nucleic Acids Res. 13, 4539-4555, 1985
A;Title: Nitrogen fixation specific regulatory genes of *Klebsiella pneumoniae* and *Rhizobium meliloti*.
A;Reference number: A93571; MUID:85242120; PMID:2989799
A;Accession: A93571
A;Molecule type: DNA
A;Residues: 1-484 <BUI>
A;Note: this sequence has only 484 residues due to a frameshift caused by a missing G in the *nifA* gene.
R;Arnold, W.; Rump, A.; Klipp, W.; Pfeifer, U.B.; Fuehrer, A.
J. Mol. Biol. 203, 715-738, 1988
A;Title: Nucleotide sequence of a 24,206-base-pair DNA fragment carrying the entire *ntrC* and *nifA* genes from *Klebsiella pneumoniae*.
A;Reference number: S01836; MUID:89094839; PMID:3062178
A;Accession: S02513
A;Molecule type: DNA
A;Residues: 1-524 <ARN>
A;Cross-references: EMBL:X13303; NID:g43820; PIDN:CAA31682.1; PID:g43838
C;Comment: This protein, a transcriptional activator, is required for activation of most *nif* genes.
C;Genetics:
A;Gene: *nifA*
C;Superfamily: Response regulator (sigma54-dependent transcriptional activator), FHA tyrosine phosphorylation
C;Keywords: DNA binding; P-loop; transcription regulation
F;212-433/Domain: RNA polymerase sigma factor interaction domain homology <SFI>
F;240-247/Region: nucleotide-binding motif A (P-loop) #status atypical

F;307-311/Region: nucleotide-binding motif B

Query Match 77.3%; Score 34; DB 1; Length 524;
Best Local Similarity 75.0%; Pred. No. 44;
Matches 6; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

Qy 2 VAEIVHFL 9
:|||||
Db 390 IAEIVHFL 397

RESULT 19
H36812
hypothetical protein ORF64 - *Saimiri* herpesvirus 1 (strain 11)
C;Species: *Saimiri* herpesvirus 1
A;Note: host *Saimiri sciureus* (common squirrel monkey)
C;Date: 16-Oct-1992 #sequence_revision 16-Oct-1992 #text_change 08-Oct-1999
C;Accession: H36812
R;Albrecht, J.
submitted to the EMBL Data Library, January 1992
A;Description: Primary structure of the herpesvirus *Saimiri* genome.
A;Reference number: A36806
A;Accession: H36812
A;Molecule type: DNA
A;Residues: 1-2469 <ALB>
A;Cross-references: GB:X64346; NID:g60320; PIDN:CAA45687.1; PID:g60385
R;Albrecht, J.C.; Nicholas, J.; Biller, D.; Cameron, K.R.; Biesinger, B.; Newman, C.; Witte, W.
J. Virol. 66, 5047-5058, 1992
A;Title: Primary structure of the herpesvirus *Saimiri* genome.
A;Reference number: A37309; MUID:92333688; PMID:1321287
A;Contents: annotation; protein-coding frames
A;Note: neither protein nor nucleotide sequence is given
C;Genetics:
A;Gene: 64

Query Match 77.3%; Score 34; DB 2; Length 2469;
Best Local Similarity 55.6%; Pred. No. 2.1e+02;
Matches 5; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

Qy 1 KVAELVHFL 9
:|||||
Db 1521 RVTELIHFI 1529

RESULT 20
T19165
hypothetical protein C09H10.9 - *Caenorhabditis elegans*
C;Species: *Caenorhabditis elegans*
C;Date: 15-Oct-1999 #sequence_revision 15-Oct-1999 #text_change 15-Oct-1999
C;Accession: T19165
R;Ainscough, R.
submitted to the EMBL Data Library, July 1995
A;Reference number: Z19082
A;Accession: T19165
A;Status: preliminary; translated from GB/EMBL/DDBJ
A;Molecule type: DNA
A;Residues: 1-363 <WIL>
A;Cross-references: EMBL:Z50109; PIDN:CAA90440.1; GSPDB:GN00020; CESP:C09H10.9
A;Experimental source: Clone C09H10
C;Genetics:
A;Gene: CESP:C09H10.9
A;Map position: 2
A;Introns: 30/3; 114/3; 186/2; 232/1; 268/3; 315/1

Query Match 75.0%; Score 33; DB 2; Length 363;
Best Local Similarity 85.7%; Pred. No. 49;
Matches 6; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KVAELVH 7
:|||||
Db 62 KIAELVH 68

RESULT 21

S49889
Probable membrane protein YIL120w - yeast (Saccharomyces cerevisiae)
N;Alternate names: hypothetical protein YI8277.09
C;Species: Saccharomyces cerevisiae
C;Date: 13-Jan-1995 #sequence_revision 20-Feb-1995 #text_change 19-Apr-2002
C;Accession: S49889
R;Hamlyn, N.; Churcher, C.
Submitted to the EMBL Data Library, November 1994
A;Reference number: S49881
A;Accession: S49889
A;Molecule type: DNA
A;Residues: 1-563 <HAM>
A;Cross-references: GB:Z47047; EMBL:Z46833; NID:G603997; PID:G763226; GSPDB:GN00009; MIF

C;Genetics:
A;Gene: SGD:QDR1; MIPS:YIL120W
A;Cross-references: SGD:S0001382
A;Map position: 9L
C;Superfamily: yeast probable membrane protein YIL121W
C;Keywords: transmembrane protein

F;69-85/Domain: transmembrane #status predicted <TM1>
F;109-125/Domain: transmembrane #status predicted <TM2>
F;137-153/Domain: transmembrane #status predicted <TM3>
F;161-177/Domain: transmembrane #status predicted <TM4>
F;197-213/Domain: transmembrane #status predicted <TM5>
F;229-245/Domain: transmembrane #status predicted <TM6>
F;345-361/Domain: transmembrane #status predicted <TM7>
F;424-440/Domain: transmembrane #status predicted <TM8>
F;448-464/Domain: transmembrane #status predicted <TM9>
F;485-501/Domain: transmembrane #status predicted <TM10>
F;513-529/Domain: transmembrane #status predicted <TM11>

Query Match 75.0%; Score 33; DB 2; Length 563;
Best Local Similarity 85.7%; Pred. No. 76;
Matches 6; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KVAELVH 7
| | | | | | |
Db 399 KVAELIH 405

RESULT 22

T13785
NADH2 dehydrogenase (ubiquinone) (EC 1.6.5.3) chain 5 - Chiococca racemosa chloroplast
C;Species: Chloroplast Chiococca racemosa
C;Date: 13-Aug-1999 #sequence_revision 13-Aug-1999 #text_change 03-Jun-2002
C;Accession: T13785

R;Bremer, B.
Submitted to the EMBL Data Library, November 1998
A;Description: More characters or more taxa for a robust phylogeny: A case study from the
A;Reference number: Z17756
A;Accession: T13785
A;Status: preliminary; translated from GB/EMBL/DBJ
A;Molecule type: DNA
A;Residues: 1-734 <BRE>
A;Cross-references: EMBL:AJ130835; PIDN:CAA10211.1
A;Experimental source: specimen voucher: Bremer 2703 (UPS)

C;Genetics:
A;Gene: chloroplast
A;Note: ndhF
C;Superfamily: NADH dehydrogenase (ubiquinone) chain 5
C;Keywords: chloroplast; membrane-associated complex; NAD; oxidoreductase

Query Match 75.0%; Score 33; DB 2; Length 734;
Best Local Similarity 62.5%; Pred. No. 99;
Matches 5; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KVAELVHF 8
| | | | | | |
Db 681 RLAEILHF 688

RESULT 23

T14230

NADH2 dehydrogenase (ubiquinone) (EC 1.6.5.3) chain 5 - Ophiorrhiza mungos chloroplast (f
C;Species: Chloroplast Ophiorrhiza mungos
C;Date: 20-Sep-1999 #sequence_revision 20-Sep-1999 #text_change 03-Jun-2002
C;Accession: T14230
R;Bremer, B.
Submitted to the EMBL Data Library, November 1998
A;Description: More characters or more taxa for a robust phylogeny: A case study from the
A;Reference number: Z17756
A;Accession: T14230
A;Status: preliminary; translated from GB/EMBL/DBJ
A;Molecule type: DNA
A;Residues: 1-738 <BRE>
A;Cross-references: EMBL:AJ130838; PIDN:CAA10214.1
A;Experimental source: specimen voucher: Bremer 3301 (UPS)

C;Genetics:
A;Gene: chloroplast
A;Note: ndhF
C;Superfamily: NADH dehydrogenase (ubiquinone) chain 5
C;Keywords: chloroplast; membrane-associated complex; NAD; oxidoreductase

Query Match 75.0%; Score 33; DB 2; Length 738;
Best Local Similarity 75.0%; Pred. No. 1e+02;
Matches 6; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

Qy 1 KVAELVHF 8
| | | | | | |
Db 685 KSAELIHF 692

RESULT 24

S58612
NADH2 dehydrogenase (ubiquinone) (EC 1.6.5.3) chain 5 - maize chloroplast
C;Species: Chloroplast Zea mays (maize)
C;Date: 29-Nov-1995 #sequence_revision 19-Jan-1996 #text_change 03-Jun-2002
C;Accession: S58612
R;Maier, R.M.; Neckermann, K.; Igloi, G.L.; Koessel, H.
J. Mol. Biol. 251, 614-628, 1995
A;Title: Complete sequence of the maize chloroplast genome: gene content, hotspots of di

A;Reference number: S58531; MUID:95395841; PMID:7666415
A;Accession: S58612
A;Status: nucleic acid sequence not shown; translation not shown
A;Molecule type: DNA
A;Residues: 1-738 <MAI>
A;Cross-references: EMBL:X86563; NID:G902200; PIDN:CAA60346.1; PID:G902281
A;Note: the nucleotide sequence was submitted to the EMBL Data Library, April 1995
C;Genetics:

A;Gene: chloroplast
C;Superfamily: NADH dehydrogenase (ubiquinone) chain 5
C;Keywords: chloroplast; membrane-associated complex; NAD; oxidoreductase

Query Match 75.0%; Score 33; DB 2; Length 738;
Best Local Similarity 75.0%; Pred. No. 1e+02;
Matches 6; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

Qy 1 KVAELVHF 8
| | | | | | |
Db 680 KLAELTHF 687

RESULT 25

T13051
NADH2 dehydrogenase (ubiquinone) (EC 1.6.5.3) chain 5 - chrysanthemum chloroplast
C;Species: Chloroplast Dendranthema x grandiflorum (Chrysanthemum)
C;Date: 13-Aug-1999 #sequence_revision 13-Aug-1999 #text_change 03-Jun-2002
C;Accession: T13051

R;Kim, K.J.; Jansen, R.K.
Proc. Natl. Acad. Sci. U.S.A. 92, 10379-10383, 1995
A;Title: NdhF sequence evolution and the major clades in the sunflower family.
A;Reference number: Z17549; MUID:96036088; PMID:7479788
A;Accession: T13051
A;Status: preliminary; translated from GB/EMBL/DBJ
A;Molecule type: DNA

A;Residues: 1-741 <KIM>
A;Cross-references: EMBL:L39443; NID:9845317; PID:9845318; PIDN:AAB46929.1
C;Genetics:
A;Genome: chloroplast
A;Note: ndhf
C;Superfamily: NADH dehydrogenase (ubiquinone) chain 5
C;Keywords: chloroplast; membrane-associated complex; NAD; oxidoreductase

Query Match 75.0%; Score 33; DB 2; Length 741;
Best Local Similarity 75.0%; Pred. No. 1e+02;
Matches 6; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY 1 KVAELVHF 8
|:|||||
Db 679 KLAELTHF 686

RESULT 26
TI2626
NADH2 dehydrogenase (ubiquinone) (EC 1.6.5.3) chain 5 - Achillea millefolium chloroplast
C;Species: chloroplast Achillea millefolium
C;Date: 23-Jul-1999 #sequence_revision 23-Jul-1999 #text_change 03-Jun-2002
C;Accession: TI2626
R;Kim, K.J.; Jansen, R.K.
Proc. Natl. Acad. Sci. U.S.A. 92, 10379-10383, 1995
A;Title: NdhF sequence evolution and the major clades in the sunflower family.
A;Reference number: Z17549; MUID:96036088; PMID:7479788
A;Accession: TI2626
A;Status: preliminary; translated from GB/EMBL/DBJ
A;Molecule type: DNA
A;Residues: 1-743 <KIM>
A;Cross-references: EMBL:L39442; NID:9845185; PID:9845186; PIDN:AAC37440.1
C;Genetics:
A;Genome: chloroplast
A;Note: ndhf
C;Superfamily: NADH dehydrogenase (ubiquinone) chain 5
C;Keywords: chloroplast; membrane-associated complex; NAD; oxidoreductase

Query Match 75.0%; Score 33; DB 2; Length 743;
Best Local Similarity 75.0%; Pred. No. 1e+02;
Matches 6; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY 1 KVAELVHF 8
|:|||||
Db 679 KLAELTHF 686

RESULT 27
TI3073
NADH2 dehydrogenase (ubiquinone) (EC 1.6.5.3) chain 5 - Eremothamnus marlothianus chloroplast
C;Species: chloroplast Eremothamnus marlothianus
C;Date: 13-Aug-1999 #sequence_revision 13-Aug-1999 #text_change 03-Jun-2002
C;Accession: TI3073
R;Kim, K.J.; Jansen, R.K.
Proc. Natl. Acad. Sci. U.S.A. 92, 10379-10383, 1995
A;Title: NdhF sequence evolution and the major clades in the sunflower family.
A;Reference number: Z17549; MUID:96036088; PMID:7479788
A;Accession: TI3073
A;Status: preliminary; translated from GB/EMBL/DBJ
A;Molecule type: DNA
A;Residues: 1-743 <KIM>
A;Cross-references: EMBL:L39424; NID:9845348; PID:9845349; PIDN:AAC37746.1
C;Genetics:
A;Genome: chloroplast
A;Note: ndhf
C;Superfamily: NADH dehydrogenase (ubiquinone) chain 5
C;Keywords: chloroplast; membrane-associated complex; NAD; oxidoreductase

Query Match 75.0%; Score 33; DB 2; Length 743;
Best Local Similarity 75.0%; Pred. No. 1e+02;
Matches 6; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY 1 KVAELVHF 8
|:|||||

|:|||||
Db 679 KLAELAHF 686

RESULT 28
TI3485
NADH2 dehydrogenase (ubiquinone) (EC 1.6.5.3) chain 5 - Menyanthes trifoliata chloroplast
C;Species: chloroplast Menyanthes trifoliata
C;Date: 13-Aug-1999 #sequence_revision 13-Aug-1999 #text_change 03-Jun-2002
C;Accession: TI3485
R;Kim, K.J.; Jansen, R.K.
Proc. Natl. Acad. Sci. U.S.A. 92, 10379-10383, 1995
A;Title: NdhF sequence evolution and the major clades in the sunflower family.
A;Reference number: Z17549; MUID:96036088; PMID:7479788
A;Accession: TI3485
A;Status: preliminary; translated from GB/EMBL/DBJ
A;Molecule type: DNA
A;Residues: 1-744 <KIM>
A;Cross-references: EMBL:L39388; NID:9845605; PID:9845606; PIDN:AAC37458.1
C;Genetics:
A;Genome: chloroplast
A;Note: ndhf
C;Superfamily: NADH dehydrogenase (ubiquinone) chain 5
C;Keywords: chloroplast; membrane-associated complex; NAD; oxidoreductase

Query Match 75.0%; Score 33; DB 2; Length 744;
Best Local Similarity 75.0%; Pred. No. 1e+02;
Matches 6; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY 1 KVAELVHF 8
|:|||||
Db 682 KLAELTHF 689

RESULT 29
TI3043
NADH2 dehydrogenase (ubiquinone) (EC 1.6.5.3) chain 5 - Dampiera diversifolia chloroplast
C;Species: chloroplast Dampiera diversifolia
C;Date: 13-Aug-1999 #sequence_revision 13-Aug-1999 #text_change 03-Jun-2002
C;Accession: TI3043
R;Kim, K.J.; Jansen, R.K.
Proc. Natl. Acad. Sci. U.S.A. 92, 10379-10383, 1995
A;Title: NdhF sequence evolution and the major clades in the sunflower family.
A;Reference number: Z17549; MUID:96036088; PMID:7479788
A;Accession: TI3043
A;Status: preliminary; translated from GB/EMBL/DBJ
A;Molecule type: DNA
A;Residues: 1-744 <KIM>
A;Cross-references: EMBL:L39386; NID:9845321; PID:9845322; PIDN:AAC37742.1
C;Genetics:
A;Genome: chloroplast
A;Note: ndhf
C;Superfamily: NADH dehydrogenase (ubiquinone) chain 5
C;Keywords: chloroplast; membrane-associated complex; NAD; oxidoreductase

Query Match 75.0%; Score 33; DB 2; Length 744;
Best Local Similarity 75.0%; Pred. No. 1e+02;
Matches 6; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY 1 KVAELVHF 8
|:|||||
Db 682 KLAELTHF 689

RESULT 30
YUMU
sucrose synthase (EC 2.4.1.13) - Arabidopsis thaliana
C;Species: Arabidopsis thaliana (mouse-ear cress)
C;Date: 31-Dec-1992 #sequence_revision 31-Dec-1992 #text_change 11-Jun-1999
C;Accession: S19125
R;Chopra, S.; Del-favero, J.; Dolferus, R.; Jacobs, M.
Plant Mol. Biol. 18, 131-134, 1992
A;Title: Sucrose synthase of Arabidopsis: genomic cloning and sequence characterization.

A;Reference number: S19125; MUID:92119221; PMID:1531031

A;Accession: S19125

A;Status: nucleic acid sequence not shown

A;Molecule type: DNA

A;Residues: 1-804 <CHO>

A;Cross-references: EMBL:X60987; NID:g16525; PIDN:CAA43303.1; PID:g16526

C;Genetics:

A;Introns: 31/2; 72/3; 123/2; 187/3; 227/2; 299/3; 331/3; 389/3; 428/3; 484/2; 559/2; 66

C;Superfamily: sucrose synthase; sucrose/sucrose-phosphate synthase homology

C;Keywords: Glycosyltransferase; hexosyltransferase

F;276-750/Domain: sucrose/sucrose-phosphate synthase homology <SSPS>

Query Match 75.0%; Score 33; DB 1; Length 804;

Best Local Similarity 66.7%; Pred. No. 1.1e+02;

Matches 6; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

Qy 1 KVAELVHFL 9

Db 243 KVSEMVHLL 251

RESULT 31

T51054

related to alpha-adaptin C [imported] - Neurospora crassa

N;Alternate names: protein B12F1.60

C;Species: Neurospora crassa

C;Date: 21-Jul-2000 #sequence_revision 21-Jul-2000 #text_change 21-Jul-2000

C;Accession: T51054

R;Schulte, U.; Aign, V.; Hoheisel, J.; Brandt, P.; Fartmann, B.; Holland, R.; Nyakatura,

submitted to the Protein Sequence Database, July 2000

A;Reference number: 225286

A;Accession: T51054

A;Status: preliminary

A;Molecule type: DNA

A;Residues: 1-988 <SCH>

A;Cross-references: EMBL:AL390091; GSPDB:GN00116; NCSP:B12F1.60

A;Experimental source: BAC clone B12F1; strain OR74A

C;Genetics:

A;Gene: NCSP:B12F1.60

A;Map position: 6

A;Introns: 70/3; 167/2; 934/3

Query Match 75.0%; Score 33; DB 2; Length 988;

Best Local Similarity 75.0%; Pred. No. 1.3e+02;

Matches 6; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Qy 2 VAELVHFL 9

Db 410 VAELHLYL 417

RESULT 32

G86419

Probable reverse transcriptase, 100033-105622 [imported] - Arabidopsis thaliana

C;Species: Arabidopsis thaliana (mouse-ear cress)

C;Date: 02-Mar-2001 #sequence_revision 02-Mar-2001 #text_change 31-Mar-2001

C;Accession: G86419

R;Theologis, A.; Ecker, J.R.; Palm, C.J.; Federspiel, N.A.; Kaul, S.; White, O.; Alonso,

Chin, C.W.; Chung, M.K.; Conn, L.; Conway, A.B.; Conway, T.H.; Dewar, K.;

ansen, N.F.; Hughes, B.; Huizar, L.

Nature 408, 816-820, 2000

A;Authors: Hunter, J.L.; Jenkins, J.; Johnson-Hopson, C.; Khan, S.; Khaykin, B.; Kim, C.

C.A.; Li, J.H.; Li, Y.; Lin, X.; Liu, S.X.; Liu, Z.A.; Luros, J.S.; Maiti, R.; Marziani,

Rizzo, M.; Rooney, T.; Rowley, D.; Sakano, H.

A;Authors: Salzberg, S.L.; Schwartz, J.R.; Shinn, P.; Southwick, A.M.; Sun, H.; Tallon,

ker, M.; Wu, D.; Yu, G.; Fraser, C.M.; Venter, J.C.; Davis, R.W.

A;Title: Sequence and analysis of chromosome 1 of the plant Arabidopsis.

A;Reference number: A86141; MUID:21016719; PMID:11130712

A;Accession: G86419

A;Status: preliminary

A;Molecule type: DNA

A;Residues: 1-1557 <STO>

A;Cross-references: GB:AB005172; NID:gl0092236; PIDN:AAG12652.1; GSPDB:GN00141

C;Genetics:

A;Map position: 1

Query Match 75.0%; Score 33; DB 2; Length 1557;

Best Local Similarity 75.0%; Pred. No. 2.1e+02;

Matches 6; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

Qy 1 KVAELVHF 8

Db 1494 KVSELTTHF 1501

RESULT 33

T42314

hypothetical protein - phage SPP1

C;Species: phage SPP1

C;Date: 03-Dec-1999 #sequence_revision 03-Dec-1999 #text_change 11-May-2000

C;Accession: T42314

R;Alonso, J.C.; Luder, G.; Stiege, A.C.; Chai, S.; Weise, F.; Trautner, T.A.

Gene 204, 201-212, 1997

A;Title: The complete nucleotide sequence and functional organization of Bacillus subtilis

A;Reference number: Z22137; MUID:98094274; PMID:9434185

A;Accession: T42314

A;Status: preliminary; translated from GB/EMBL/DDBJ

A;Molecule type: DNA

A;Residues: 1-184 <ALO>

A;Cross-references: EMBL:X97918; PIDN:CAA66521.1

Query Match 72.7%; Score 32; DB 2; Length 184;

Best Local Similarity 85.7%; Pred. No. 40;

Matches 6; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 2 VAELVHF 8

Db 62 VAELVHF 68

RESULT 34

D32354

fructose-bisphosphate aldolase (EC 4.1.2.13) fbaA - Bacillus subtilis

N;Alternate names: 30K phosphoprotein ofy-tsrf; fructose-1,6-bisphosphate aldolase

C;Species: Bacillus subtilis

C;Date: 03-Mar-1994 #sequence_revision 03-Mar-1994 #text_change 16-Jun-2000

C;Accession: S55426; D32354; E32354; D41835; B9621

R;Glaser, P.; Danchin, A.

submitted to the EMBL Data Library, May 1995

A;Description: Cloning and sequencing of the Bacillus subtilis chromosomal region from 32

A;Reference number: S55414

A;Accession: S55426

A;Molecule type: DNA

A;Residues: 1-285 <GLA>

A;Cross-references: EMBL:Z49782; NID:g853752; PIDN:CAA89873.1; PID:g853765

R;Trach, K.; Chapman, J.W.; Piggot, P.; LeCoq, D.; Hoch, J.A.

J. Bacteriol. 170, 4194-4208, 1988

A;Title: Complete sequence and transcriptional analysis of the spoOF region of the Bacil

A;Reference number: A91883; MUID:88314920; PMID:2457578

A;Accession: D32354

A;Molecule type: DNA

A;Residues: 'MLGKAFARQSGYIRTFD', 1-16, 'RVRCRTI' <TR1>

A;Cross-references: GB:M22039

A;Note: this sequence has been revised

A;Note: prior to the correction of a frameshift error, this portion of the sequence was

A;Accession: E32354

A;Molecule type: DNA

A;Residues: 'M', 77-285 <TR2>

A;Cross-references: GB:M22039

A;Note: this sequence has been revised

A;Note: prior to the correction of a frameshift error, this portion of the sequence was

R;Mitchell, C.; Morris, P.W.; Vary, J.C.

J. Bacteriol. 174, 2474-2477, 1992

A;Title: Identification of proteins phosphorylated by ATP during sporulation of Bacillus

A;Reference number: A41835; MUID:92210489; PMID:1556067

A;Accession: D41835

A:Molecule type: protein
A:Residues: 1-26 <MIT>
A:Note: this sequence was obtained from the amino end
R:Kunst, F.; Ogasawara, N.; Moszer, I.; Albertini, A.M.; Alloni, G.; Azevedo, V.; Berte
C:Bron, S.; Brouillet, S.; Bruschi, C.V.; Caldwell, B.; Capuano, G.; Carter, N.M.; Ch
A.; Ehrlich, S.D.; Emerson, P.T.; Enian, K.D.; Errington, J.; Fabret, C.; Ferrari, E.
Nature 390, 249-256, 1997
A:Authors: Foulger, D.; Fritz, C.; Fujita, M.; Fujita, Y.; Fuma, S.; Galizzi, A.; Galles
A:Authors: Foulger, D.; Foulger, C.R.; Henauf, A.; Hilbert, H.; Holsappel, S.; Hosono, S.; Hulio, M.F.
leach, J.; Harwood, C.R.; Henauf, A.; Hilbert, H.; Holsappel, S.; Hosono, S.; Hulio, M.F.
Koetter, P.; Koningsstein, G.; Krogh, S.; Kumano, M.; Kurita, K.; Lapidus, A.; Lardinois
A:Authors: Lauber, J.; Lazarevic, V.; Lee, S.M.; Levine, A.; Liu, H.; Masuda, S.; Mue
Y, M.; Ogawa, K.; Ogiwara, A.; Oudega, B.; Park, S.H.; Parro, V.; Pohl, T.M.; Portetelle
Rieger, M.; Rivolta, C.; Rocha, E.; Roche, B.; Rose, M.; Sadaie, Y.; Sato, T.; Scanlon,
A:Authors: Schleich, S.; Schroeter, R.; Scoffone, F.; Sekiguchi, J.; Sekowska, A.; Seron
akeuchi, M.; Tamakoshi, A.; Tanaka, T.; Terpstra, P.; Tognoni, A.; Tosato, V.; Uchiyama,
T.; Winters, P.; Wipat, A.; Yamamoto, H.; Yamane, K.; Yasumoto, K.; Yata, K.; Yoshida, K
A:Authors: Yoshikawa, H.F.; Zunstein, E.; Yoshikawa, H.; Danchin, A.
A:Title: The complete genome sequence of the Gram-positive bacterium *Bacillus subtilis*.
A:Reference number: A69580; MUID:98044033; PMID:9384377
A:Accession: B69621
A:Status: nucleic acid sequence not shown; translation not shown
A:Molecule type: DNA
A:Residues: 1-285 <KUN>
A:Cross-references: GB:Z99122; GB:Z99123; GB:AL009126; NID:G2636240; PIDN:CABL5740.1; P
A:Experimental source: strain 168
C:Comment: This sequence is based on translation of residues 3270-3317 and 3319-4128 of
ation. This correction is confirmed by direct protein sequencing in the region of the ex
C:Comment: This gene lies immediately 3' to Spo0F but is not part of the same cistron.
C:Genetics:
A:Gene: fbaA
A:Superfamily: fructose-bisphosphate aldolase II
C:Keywords: aldehyde-lyase; carbon-carbon lyase; phosphoprotein

Query Match 72.7%; Score 32; DB 1; Length 285;
Best Local Similarity 75.0%; Pred. No. 62;
Matches 6; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1 KVAELVHF 8
| | | | |
Db 122 KVELAHF 129

RESULT 35
B90397
membrane conserved hypothetical protein SSO2272 [imported] - *Sulfolobus solfataricus*
C:Species: *Sulfolobus solfataricus*
C:Date: 24-May-2001 #sequence_revision 24-May-2001 #text_change 24-May-2001
C:Accession: B90397
R:She, Q.; Singh, R.K.; Confalonieri, F.; Zivanovic, Y.; Allard, G.; Awayez, M.J.; Chan-
Jong, I.; Jeffries, A.C.; Kozera, C.J.; Medina, N.; Peng, X.; Thi-Ngoc, H.P.; Redder, H
arrett, R.A.; Ragan, M.A.; Sengen, C.W.; Van der Oost, J.
submitted to GenBank, April 2001
A:Description: *Sulfolobus solfataricus* complete genome.
A:Reference number: A99139
A:Accession: B90397
A:Status: preliminary
A:Molecule type: DNA
A:Residues: 1-293 <KUR>
A:Cross-references: GB:AE006641; NID:gl3815571; PIDN:AAK42433.1; GSPDB:GN00155
C:Genetics:
A:Gene: SSO2272

Query Match 72.7%; Score 32; DB 2; Length 293;
Best Local Similarity 75.0%; Pred. No. 63;
Matches 6; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

Qy 2 VAELVHFL 9
| | | | |
Db 286 VVELLHFL 293

RESULT 36
RQECF

DNA replication and repair protein recF [similarity] - *Escherichia coli* (strain K-12)
C:Species: *Escherichia coli*
C:Date: 28-Aug-1985 #sequence_revision 28-Aug-1985 #text_change 01-Mar-2002
C:Accession: A03547; B22168; E65172
R:Blancar, M.A.; Sandler, S.J.; Armenod, M.E.; Ream, L.W.; Clark, A.J.
Proc. Natl. Acad. Sci. U.S.A. 81, 4622-4626, 1984
A:Title: Molecular analysis of the recF gene of *Escherichia coli*.
A:Reference number: A93996; MUID:84272685; PMID:6379647
A:Accession: A03547
A:Molecule type: DNA
A:Residues: 1-357 <BLA>
A:Cross-references: GB:X02179; NID:gl47537; PIDN:AAA24511.1; PID:gl47539
A:Note: the authors translated the codon GAA for residue 172 as Gln
R:Adachi, T.; Mizuchi, K.; Menzel, R.; Gellert, M.
Nucleic Acids Res. 12, 6389-6395, 1984
A:Title: DNA sequence and transcription of the region upstream of the *E. coli* gyrB gene.
A:Reference number: A22168; MUID:84297235; PMID:6089112
A:Accession: B22168
A:Molecule type: DNA
A:Residues: 1-357 <ADA>
A:Cross-references: GB:X04341; GB:X00870; NID:gl41643; PIDN:CAA27870.1; PID:gl41645
R:Blattner, F.R.; Plunkett III, G.; Bloch, C.A.; Perna, N.T.; Burland, V.; Riley, M.; Col
A.; Rose, D.J.; Mau, B.; Shao, Y.
Science 277, 1453-1462, 1997
A:Title: The complete genome sequence of *Escherichia coli* K-12.
A:Reference number: A64720; MUID:97426617; PMID:9278503
A:Accession: E65172
A:Status: preliminary; nucleic acid sequence not shown; translation not shown
A:Molecule type: DNA
A:Residues: 1-357 <BLAT>
A:Cross-references: GB:AE000447; GB:U00096; NID:G2367266; PIDN:AAC76723.1; PID:gl790135;
A:Experimental source: strain K-12, substrain MG1655
C:Comment: The recF gene is involved in DNA metabolism; it is required for DNA replicatio
C:Genetics:
A:Gene: recF
A:Map position: 83 min
C:Superfamily: recF protein
C:Keywords: DNA binding; DNA replication; SOS response

Query Match 72.7%; Score 32; DB 1; Length 357;
Best Local Similarity 66.7%; Pred. No. 77;
Matches 6; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

Qy 1 KVAELVHFL 9
| | | | |
Db 104 KVAELAHLM 112

RESULT 37
C91208
DNA replication and repair protein recF [similarity] - *Escherichia coli* (strain O157:H7;
C:Species: *Escherichia coli*
C:Date: 18-Jul-2001 #sequence_revision 18-Jul-2001 #text_change 02-Nov-2001
C:Accession: C91208
R:Hayashi, T.; Makino, K.; Ohnishi, M.; Kurokawa, K.; Ishii, K.; Yokoyama, K.; Han, C.G.;
gasawara, N.; Yasunaga, T.; Kuhara, S.; Shiba, T.; Hattori, M.; Shinagawa, H.
DNA Res. 8, 11-22, 2001
A:Title: Complete genome sequence of enterohemorrhagic *Escherichia coli* O157:H7 and gen
A:Reference number: A99629; MUID:21156231; PMID:11258796
A:Accession: C91208
A:Status: preliminary
A:Molecule type: DNA
A:Residues: 1-357 <HAY>
A:Cross-references: GB:BA000007; PIDN:BA838058.1; PID:gl33364110; GSPDB:GN00154
A:Experimental source: strain O157:H7, substrain RIMD 0509952
C:Genetics:
A:Gene: ECs4635
C:Superfamily: recF protein

Query Match 72.7%; Score 32; DB 2; Length 357;
Best Local Similarity 66.7%; Pred. No. 77;
Matches 6; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

Qy 1 KVAELVHFL 9
Db 104 KVAELAHLM 112

RESULT 38
E86054
DNA replication and repair protein recF [similarity] - Escherichia coli (strain O157:H7,
C;Species: Escherichia coli
C;Date: 16-Feb-2001 #sequence_revision 16-Feb-2001 #text_change 02-Nov-2001
C;Accession: E86054
R;Perna, N.T.; Plunkett III, G.; Burland, V.; Mau, B.; Glasner, J.D.; Rose, D.J.; Mayhew
iller, L.; Grotbeck, E.J.; Davis, N.W.; Lim, A.; Dimalanta, E.; Potamousis, K.; Apodaca,
Nature 409, 529-533, 2001
A;Title: Genome sequence of enterohemorrhagic Escherichia coli O157:H7.
A;Reference number: A85480; MUID:21074935; PMID:11206551
A;Accession: E86054
A;Status: preliminary
A;Molecule type: DNA
A;Residues: 1-357 <STO>
A;Cross-references: GB:AE005174; MID:gl2518539; PIDN:AGS8897.1; GSPDB:GN00145; UWGP:Z51
A;Experimental source: strain O157:H7, substrain EDL933
C;Genetics:
A;Gene: recF
C;Superfamily: recF protein

Query Match 72.7%; Score 32; DB 2; Length 357;
Best Local Similarity 66.7%; Pred. No. 77;
Matches 6; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

Qy 1 KVAELVHFL 9
Db 104 KVAELAHLM 112

RESULT 39
AF1950
anthranilate phosphoribosyltransferase [imported] - Nostoc sp. (strain PCC 7120)
C;Species: Nostoc sp. PCC 7120
A;Note: Nostoc sp. strain PCC 7120 is a synonym of Anabaena sp. strain PCC 7120
C;Date: 14-Dec-2001 #sequence_revision 14-Dec-2001 #text_change 09-Dec-2002
C;Accession: AF1950
R;Kaneko, T.; Nakamura, Y.; Wolk, C.P.; Kuritz, T.; Sasamoto, S.; Watanabe, A.; Iriguchi
Nakazaki, N.; Shimpo, S.; Sugimoto, M.; Takazawa, M.; Yamada, M.; Yasuda, M.; Tabata, S
DNA Res. 8, 205-213, 2001
A;Title: Complete Genomic Sequence of the Filamentous Nitrogen-fixing Cyanobacterium Ana
A;Reference number: AB1807; MUID:21595285; PMID:11759840
A;Accession: AF1950
A;Status: preliminary
A;Molecule type: DNA
A;Residues: 1-362 <KUR>
A;Cross-references: GB:BA000019; PIDN:BA873110.1; PID:gl7130499; GSPDB:GN00179
A;Experimental source: strain PCC 7120
C;Genetics:
A;Gene: trpD
C;Superfamily: anthranilate phosphoribosyltransferase; trpD homology

Query Match 72.7%; Score 32; DB 2; Length 362;
Best Local Similarity 66.7%; Pred. No. 78;
Matches 6; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KVAELVHFL 9
Db 352 KLAQLVYFL 360

RESULT 40
T40591
hypothetical protein SPBC646.15c - fission yeast (Schizosaccharomyces pombe)
C;Species: Schizosaccharomyces pombe
C;Date: 03-Dec-1999 #sequence_revision 03-Dec-1999 #text_change 04-Mar-2000
C;Accession: T40591
R;Seeger, K.; Harris, D.; Wood, V.; Rajandream, M.A.; Barrell, B.G.

submitted to the EMBL Data Library, January 1999
A;Reference number: Z21938
A;Accession: T40591
A;Status: preliminary; translated from GB/EMBL/DDBJ
A;Molecule type: DNA
A;Residues: 1-376 <SEE>
A;Cross-references: EMBL:AL035216; PIDN:CAA22819.1; GSPDB:GN00067; SPDB:SPBC646.15c
A;Experimental source: strain 972h-; cosmid c646
C;Genetics:
A;Gene: SPDB:SPBC646.15c
A;Map position: 2
A;Introns: 49/1; 126/2; 312/2; 350/1
C;Superfamily: Schizosaccharomyces pombe hypothetical protein SPBC646.15c

Query Match 72.7%; Score 32; DB 2; Length 376;
Best Local Similarity 66.7%; Pred. No. 81;
Matches 6; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KVAELVHFL 9
Db 99 KVELLYFL 107

Search completed: July 23, 2004, 12:53:15
Job time : 17 secs

This Page Blank (uspto)

GenCore version 5.1.6
Copyright (c) 1993 - 2004 Compugen Ltd.

OM protein - protein search, using sw model

Run on: July 23, 2004, 12:42:26 ; Search time 14 Seconds
(without alignments)
33.474 Million cell updates/sec

Title: US-09-458-298b-711

Perfect score: 44

Sequence: 1 KVAELVHFL 9

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 141681 seqs, 52070155 residues

Total number of hits satisfying chosen parameters: 141681

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : SwissProt_42.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	44	100.0	314	1 MAG3 HUMAN	P43357 homo sapien
2	44	100.0	315	1 MAG9 HUMAN	P43362 homo sapien
3	41	93.2	314	1 MAGC HUMAN	P43365 homo sapien
4	40	90.9	124	1 MAG5 HUMAN	P43359 homo sapien
5	40	90.9	314	1 MAG6 HUMAN	P43360 homo sapien
6	40	90.9	968	1 SECA CHLMU	Q9plm5 chlamydia m
7	37	84.1	314	1 MAG2 HUMAN	P43356 homo sapien
8	36	81.8	234	1 MAG8 HUMAN	P43361 homo sapien
9	36	81.8	373	1 MGEL HUMAN	Q9ubf1 homo sapien
10	34	77.3	317	1 MAG4 HUMAN	P43358 homo sapien
11	34	77.3	461	1 MANA EMENI	P29951 emeritella
12	34	77.3	524	1 NIFA KLEBOX	P56266 klebsiella
13	34	77.3	524	1 NIFA KLEBOX	P03027 klebsiella
14	34	77.3	2469	1 TEGU HSUSA	Q01056 herpesvirus
15	33	75.0	563	1 YIMO YEAST	P40475 saccharomyc
16	33	75.0	738	1 NUSC MAIZE	P46620 zea mays (m
17	33	75.0	744	1 NUSC DAMDI	Q32126 dampiera di
18	33	75.0	805	1 SUS2 ARATH	Q00917 arabidopsis
19	32	72.7	285	1 ALF1 BACSU	P33243 bacillus su
20	32	72.7	356	1 RECF ECOLI	P30316 escherichia
21	32	72.7	362	1 TRD2 ANASP	Q8yxq9 anabaena sp
22	32	72.7	421	1 TYPH MYCPN	P75052 mycoplasma
23	32	72.7	442	1 TRME MYCPN	P44797 haemophilus
24	32	72.7	456	1 PUR8 HAEIN	Q00312 candida alb
25	32	72.7	527	1 REFL CANAL	Q62406 mus musculu
26	32	72.7	710	1 TRAI MOUSE	P51617 homo sapien
27	32	72.7	712	1 IRAL HUMAN	Q12929 homo sapien
28	32	72.7	822	1 EPS8 HUMAN	P58104 streptococc
29	31	70.5	163	1 COAD STRPY	Q9rfaf caulobacter
30	31	70.5	230	1 PHOU CAUCR	Q9hav2 homo sapien
31	31	70.5	308	1 MGFI HUMAN	P43355 homo sapien
32	31	70.5	309	1 MAG1 HUMAN	Q8z2n4 salmonella
33	31	70.5	359	1 RECF SAUTI	

RESULT 1

MAG3 HUMAN	31	70.5	356	1	RECF SALTY	P24900 salmonella
ID	MAG3 HUMAN	STANDARD;	PRT;	314 AA.		
AC	P43357;					
DT	01-NOV-1995 (Rel. 32, Created)					
DT	01-NOV-1995 (Rel. 32, Last sequence update)					
DT	10-OCT-2003 (Rel. 42, Last annotation update)					
DE	Melanoma-associated antigen 3 (MAGB-3 antigen) (Antigen M22-D).					
GN	MAGEA3 OR MAGE3.					
OS	Homo sapiens (Human).					
OC	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;					
OC	Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.					
OX	NCBI_TaxID=9606;					
RN	[1]					
RP	SEQUENCE FROM N.A., AND MUTAGENESIS.					
RC	TISSUE=Blood;					
RX	MEDLINE=94157413; PubMed=8113684;					
RA	Gaugier B., van den Eynde B., van der Bruggen P., Romero P.,					
RA	Gaforio J.J., de Plaen E., Lethe B., Brasseur F., Boon T.;					
RT	"Human gene MAGE-3 codes for an antigen recognized on a melanoma by					
RT	autologous cytolytic T lymphocytes.";					
RL	J. Exp. Med. 179:921-930(1994).					
RN	[2]					
RP	SEQUENCE FROM N.A.					
RC	TISSUE=Skin;					
RX	MEDLINE=94311935; PubMed=8037761;					
RA	Ding M., Beck R.J., Keller C.J., Fenton R.G.;					
RT	"Cloning and analysis of MAGE-1-related genes.";					
RL	Biochem. Biophys. Res. Commun. 202:549-555(1994).					
RN	[3]					
RP	SEQUENCE FROM N.A.					
RX	MEDLINE=20314869; PubMed=10854409;					
RA	Mallon A.M., Platzer M., Bates R., Gloeckner G., Botcherby M.,					
RA	Nordstiek G., Strivens M.A., Kioschis P., Dangel A., Cunningham D.,					
RA	Straw R., Weston P., Hunter C., Gilbert M., Fernando S., Goodall K.,					
RA	Kerry G., Gresty J.S., Clark D., Goerdes M., Blechschmidt K.,					
RA	Rump A., Hinzmann B., Mundy C.R., Miller W., Poustka A., Herman G.E.,					
RA	Rhodes M., Denay P., Rosenthal A., Brown S.D.M.;					
RT	"Comparative genome sequence analysis of the Bpa/Str region in mouse					
RT	and man.";					
RL	Genome Res. 10:758-775(2000).					
RN	[4]					
RP	SEQUENCE FROM N.A.					
RC	TISSUE=Bone marrow, Lung, Prostate, and Skin;					
RX	MEDLINE=22398257; PubMed=12477932;					
RA	Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,					
RA	Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,					
RA	Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,					
RA	Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Haieh F.,					
RA	Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,					
RA	Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,					
RA	Brownstein M.J., Udén T.B., Toshiyuki S., Carninci P., Prange C.,					
RA	Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullaly S.J.,					
RA	Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,					
RA	Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,					
RA	Villaalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,					

ALIGNMENTS

```
RA Fahey J., Helton E., Kettelman M., Madan A., Rodrigues S., Sanchez A.,
RA Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,
RA Butlerfield V.S.N., Krzywinski M.I., Skalska U., Smailus D.E.,
RA Schnerch A., Schein J.E., Jones S.J.M., Marra M.A.;
RT "Generation and initial analysis of more than 15,000 full-length
human and mouse cDNA sequences."
RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
CC -!- FUNCTION: Not known, though may play a role in embryonal
development and tumor transformation or aspects of tumor
progression. Antigen recognized on a melanoma by autologous
cytolytic T lymphocytes.
CC -!- TISSUE SPECIFICITY: EXPRESSED IN MANY TUMORS OF SEVERAL TYPES,
SUCH AS MELANOMA, HEAD AND NECK SQUAMOUS CELL CARCINOMA, LUNG
CARCINOMA AND BREAST CARCINOMA, BUT NOT IN NORMAL TISSUES EXCEPT
FOR TESTES AND PLACENTA. NEVER EXPRESSED IN KIDNEY TUMORS,
LEUKEMIAS AND LYMPHOMAS.
CC -!- SIMILARITY: Contains 1 MAGE domain.
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
between the Swiss Institute of Bioinformatics and the EMBL outstation -
the European Bioinformatics Institute. There are no restrictions on its
use by non-profit institutions as long as its content is in no way
modified and this statement is not removed. Usage by and for commercial
entities requires a license agreement (See http://www.isb-sib.ch/announce/
or send an email to license@isb-sib.ch).
CC -----
CC EMBL; U03735; AAA17446.1; -
CC EMBL; U82871; -; NOT_ANNOTATED_CDS.
CC EMBL; BC000340; AAH00340.1; -
CC EMBL; BC005963; AAH05963.1; -
CC EMBL; BC011744; AAH11744.1; -
CC EMBL; BC016803; AAH16803.1; -
CC EMBL; BC017389; AAH17389.1; -
CC PIR; JC2361; JC2361.
CC Genew; HGNC:6801; MAGEA3.
CC MIM; 300174; -
CC InterPro; IPR002190; MAGE.
CC Pfam; PF01454; MAGE; 1.
CC PROSITE; PS50838; MAGE; 1.
CC Antigen; Multigene family; Tumor antigen.
CC DOMAIN 109 308
CC MAGE.
CC FT DOMAIN 40 43
CC FT MUTAGEN 170 170 D->A: ABOLISHES HLA-A1 BINDING.
CC FT MUTAGEN 176 176 Y->A: ABOLISHES HLA-A1 BINDING.
CC SEQUENCE 314 AA; 34747 MW; 3F5EB13D1C9946A1 CRC64;
Query Match 100.0%; Score 44; DB 1; Length 314;
Best Local Similarity 100.0%; Pred. No. 0.09;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 KVAELVHFL 9
Db 112 KVAELVHFL 120
RESULT 2
MAG9 HUMAN
ID MAG9 HUMAN STANDARD; PRT; 315 AA.
AC P43362; Q92910;
DT 01-NOV-1995 (Rel. 32, Created)
DT 01-NOV-1995 (Rel. 32, Last sequence update)
DT 10-OCT-2003 (Rel. 42, Last annotation update)
DE Melanoma-associated antigen 9 (MAGE-9 antigen).
GN MAGEA9 OR MAGE9.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
RP SEQUENCE FROM N.A.
RX MEDLINE=95012457; PubMed=7927540;
```

```
RA de Plaen E., Arden K., Traversari C., Gaforio J.J., Szikora J.-P.,
RA Smet C., Brasseur F., van der Bruggen P., Lethe B., Turquin C.,
RA Brasseur R., Chomez P., de Backer O., Cavenee W., Boon T.;
RT "Structure, chromosomal localization, and expression of 12 genes of
the MAGE family."
RL Immunogenetics 40:360-369(1994).
RN [2]
RP SEQUENCE FROM N.A.
RA Timms K.M., Bondeson M.L., Ansari-Lari M.A., Lagerstedt K.,
RA Nelson D.L., Pettersson U., Gibbs R.A.;
RL Submitted (SEP-1996) to the EMBL/GenBank/DBJ databases.
RN [3]
RP SEQUENCE FROM N.A.
RC TISSUE=Lung;
RX MEDLINE=22388257; PubMed=12477932;
RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
RA Klausner R.D., Collins P.S., Wagner L., Shenmen C.M., Schuler G.D.,
RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,
RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA Stapleton M., Soares M.B., Donald M.F., Casavant T.L., Scheetz T.E.,
RA Brownstein M.J., Usdin T.B., Toshiyuki S., Carninci P., Prange C.,
RA Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullahy S.J.,
RA Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA Villalon D.K., Munzy D.M., Sodergren E.J., Lu X., Gibbs R.A.,
RA Fahey J., Helton E., Kettelman M., Madan A., Rodrigues S., Sanchez A.,
RA Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,
RA Butlerfield V.S.N., Krzywinski M.I., Skalska U., Smailus D.E.,
RA Schnerch A., Schein J.E., Jones S.J.M., Marra M.A.;
RT "Generation and initial analysis of more than 15,000 full-length
human and mouse cDNA sequences."
RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
CC -!- FUNCTION: NOT KNOWN, THOUGH MAY PLAY A ROLE IN EMBRYONAL
DEVELOPMENT AND TUMOR TRANSFORMATION OR ASPECTS OF TUMOR
PROGRESSION.
CC -!- TISSUE SPECIFICITY: EXPRESSED IN MANY TUMORS OF SEVERAL TYPES,
SUCH AS MELANOMA, HEAD AND NECK SQUAMOUS CELL CARCINOMA, LUNG
CARCINOMA AND BREAST CARCINOMA, BUT NOT IN NORMAL TISSUES EXCEPT
FOR TESTES AND PLACENTA.
CC -!- SIMILARITY: Contains 1 MAGE domain.
CC -----
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
between the Swiss Institute of Bioinformatics and the EMBL outstation -
the European Bioinformatics Institute. There are no restrictions on its
use by non-profit institutions as long as its content is in no way
modified and this statement is not removed. Usage by and for commercial
entities requires a license agreement (See http://www.isb-sib.ch/announce/
or send an email to license@isb-sib.ch).
CC -----
CC EMBL; U10694; AAA68877.1; -
CC EMBL; U66083; AAB67888.1; -
CC EMBL; BC002351; AAH02351.1; -
CC PIR; I38668; I38668.
CC Genew; HGNC:6807; MAGEA9.
CC MIM; 300342; -
CC InterPro; IPR002190; MAGE.
CC Pfam; PF01454; MAGE; 1.
CC PROSITE; PS50838; MAGE; 1.
CC Antigen; Multigene family; Tumor antigen.
CC DOMAIN 108 307
CC FT DOMAIN 34 37 MAGE.
CC FT DOMAIN 87 90 POLY-GLU.
CC SEQUENCE 315 AA; 35088 MW; 7FD2ED10D680D928 CRC64;
Query Match 100.0%; Score 44; DB 1; Length 315;
Best Local Similarity 100.0%; Pred. No. 0.091;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 KVAELVHFL 9
|||||
```



```

DR EMBL; U10690; AAA68874.1; -.
DR EMBL; U10689; AAA68873.1; -.
DR PIR; I38663; I38663.
DR Genew; HGNC:6803; MAGEA5.
DR MIM; 300340; -.
DR InterPro; IPR002190; MAGE.
DR Pfam; PF01454; MAGE; 1.
DR PROSITE; PS0838; MAGE; FALSE_NEG.
KW Antigen; Multigene family.
FT DOMAIN 40 43 POLY-SER.
SQ SEQUENCE 124 AA; 13015 MW; 3D8457AFBFD7531E CRC64;

Query Match 90.9%; Score 40; DB 1; Length 124;
Best Local Similarity 77.8%; Pred. No. 0.25;
Matches 7; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KVAELVHFL 9
Db 112 KVADLIHFL 120
||||:|||||

RESULT 5
MAGE6_HUMAN
ID MAGE6_HUMAN STANDARD; PRT; 314 AA.
AC P43360;
DT 01-NOV-1995 (Rel. 32, Created)
DT 01-NOV-1995 (Rel. 32, Last sequence update)
DT 10-OCT-2003 (Rel. 42, Last annotation update)
DE Melanoma-associated antigen 6 (MAGE-6 antigen) (MAGE3B).
GN MAGEA6 OR MAGE6.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
RP SEQUENCE FROM N.A.
RX MEDLINE=95012457; PubMed=7927540;
RA de Plaen E., Arden K., Traversari C., Gaforio J.J., Szikora J.-P.,
RA de Smet C., Brasseur F., van der Bruggen P., Lethe B., Lurquin C.,
RA Brasseur R., Chomez P., de Backer O., Cavenee W., Boon T.;
RT "Structure, chromosomal localization, and expression of 12 genes of
RT the MAGE family.";
RL Immunogenetics 40:360-369(1994).
RN [2]
RP SEQUENCE FROM N.A.
RX TISSUE=Skin;
RC MEDLINE=94311935; PubMed=8037761;
RA Ding M., Beck R.J., Keller C.J., Fenton R.G.;
RT "Cloning and analysis of MAGE-1-related genes.";
RL Biochem. Biophys. Res. Commun. 202:549-555(1994).
RN [3]
RP SEQUENCE FROM N.A.
RX MEDLINE=95369706; PubMed=7642112;
RA Imai Y., Shichijo S., Yamada A., Katayama T., Yano H., Itoh K.;
RT "Sequence analysis of the MAGE gene family encoding human tumor-
RT rejection antigens.";
RL Gene 160:287-290(1995).
RN [4]
RP SEQUENCE FROM N.A.
RC TISSUE=Brain;
RX MEDLINE=22388257; PubMed=12477932;
RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
RA Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Haieh F.,
RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
RA Brownstein M.J., Usdin T.B., Toshiyuki S., Carninci P., Prange C.,
RA Raba S.S., Lequellano N.A., Peters G.J., Abramson R.D., Mullahy S.J.,
RA Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA Villalón D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
RA Fahey J., Heiton E., Ketterman M., Madan A., Rodrigues S., Sanchez A.,

```

```

RA Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,
RA Butterfield Y.S.N., Krzywinski M.I., Skalska U., Smalilus D.E.,
RA Schnerch A., Schein J.E., Jones S.J.M., Marra M.A.;
RT "Generation and initial analysis of more than 15,000 full-length
RT human and mouse cDNA sequences.";
RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
CC -!- FUNCTION: NOT KNOWN, THOUGH MAY PLAY A ROLE IN TUMOR
CC OR ASPECTS OF TUMOR PROGRESSION.
CC -!- TISSUE SPECIFICITY: EXPRESSED IN MANY TUMORS OF SEVERAL TYPES,
CC SUCH AS MELANOMA, HEAD AND NECK SQUAMOUS CELL CARCINOMA, LUNG,
CC CARCINOMA AND BREAST CARCINOMA, BUT NOT IN NORMAL TISSUES EXCEPT
CC FOR TESTES.
CC -!- SIMILARITY: Contains 1 MAGE domain.
CC -----
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC or send an email to license@isb-sib.ch).
CC -----
DR EMBL; U10691; AAA68875.1; -.
DR EMBL; U10339; AAA19006.1; -.
DR EMBL; D32076; BAA06842.1; -.
DR EMBL; BC041599; AAH41599.1; -.
DR PIR; JC2360; JC2360.
DR Genew; HGNC:6804; MAGEA6.
DR MIM; 300176; -.
DR InterPro; IPR002190; MAGE.
DR Pfam; PF01454; MAGE; 1.
DR PROSITE; PS0838; MAGE; 1.
KW Antigen; Multigene family; Tumor antigen.
FT DOMAIN 109 308 MAGE-SER.
FT DOMAIN 40 43 POLY-SER.
SQ SEQUENCE 314 AA; 34891 MW; 29B83C7FA6E50263 CRC64;

Query Match 90.9%; Score 40; DB 1; Length 314;
Best Local Similarity 88.9%; Pred. No. 0.63;
Matches 8; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KVAELVHFL 9
Db 112 KVAKLVHFL 120
||||:|||||

RESULT 6
SECA_CHLMU
ID SECA_CHLMU STANDARD; PRT; 968 AA.
AC Q9PLM5;
DT 16-OCT-2001 (Rel. 40, Created)
DT 16-OCT-2001 (Rel. 40, Last sequence update)
DT 16-OCT-2001 (Rel. 40, Last annotation update)
DE Preprotein translocase secA subunit.
GN SECA OR TC0074.
OS Chlamydia muridarum.
OC Bacteria; Chlamydiae; Chlamydiales; Chlamydiaceae; Chlamydia.
OX NCBI_TaxID=83560;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=MoPn / Nigg;
RX MEDLINE=20150255; PubMed=10684935;
RA Read T.D., Brunham R.C., Shen C., Gill S.R., Heidelberg J.P., Bass S.,
RA White O., Hickey E.K., Peterson J., Utterback T., Berry K., Dodson R.,
RA Linher K., Weidman J., Khouri H., Craven B., Bowman C., Salzman S.L.,
RA Winn M., Nelson W., DeBoy R., Kolonay J., McClarty G., Salzberg S.L.,
RA Eisen J., Fraser C.M.;
RT "Genome sequences of Chlamydia trachomatis MoPn and Chlamydia
RT pneumoniae AR39.";
RL Nucleic Acids Res. 28:1397-1406(2000).
CC -!- FUNCTION: Involved in protein export. Interacts with the secY/secE

```


subunits. SecA has a central role in coupling the hydrolysis of ATP to the transfer of pre-secretory periplasmic and outer membrane proteins across the membrane (By similarity).

-1- SUBUNIT: Part of the prokaryotic protein translocation apparatus which comprise secA, secB, secD, secE, secF, secG and secY (By similarity).

-1- SUBCELLULAR LOCATION: Cytoplasmic side of plasma membrane (By similarity).

-1- SIMILARITY: Belongs to the secA family.

This SWISS-PROT entry is copyright. It is produced through a collaboration between the Swiss Institute of Bioinformatics and the EMBL outstation - the European Bioinformatics Institute. There are no restrictions on its use by non-profit institutions as long as its content is in no way modified and this statement is not removed. Usage by and for commercial entities requires a license agreement (See <http://www.isb-sib.ch/announce/> or send an email to license@isb-sib.ch).

EMBL; AE002275; AAF38956.1; -

PIR; G81743; G81743.

TIGR; TC0074; -

InterPro; IPR001650; Helicase_C.

InterPro; IPR00185; SecA.

Pfam; PF00271; Helicase_C; 1.

Pfam; PF01043; SecA protein; 1.

PRINTS; PR00906; SECA.

TIGRFAMs; TIGR00963; secA; 1.

PROSITE; PS01312; ATP; 1.

Protein transport; Membrane; Translocation; Transport;

Complete proteome.

NP_BIND 114

SEQUENCE 968 AA; 110512 MW; 187B5536F547D3FC CRC64;

Query Match 90.9%; Score 40; DB 1; Length 968;

Best Local Similarity 100.0%; Pred. No. 1.9;

Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KVAELVHP 8

Db 255 KVAELVHP 262

RESULT 7

MAG2 HUMAN

ID MAG2 HUMAN STANDARD; PRT; 314 AA.

AC P43356;

DT 01-NOV-1995 (Rel. 32, Created)

DT 01-NOV-1995 (Rel. 32, Last sequence update)

DT 10-OCT-2003 (Rel. 42, Last annotation update)

DE Melanoma-associated antigen 2 (MAGE-2 antigen).

GN (MAGEA2A OR MAGEA2 OR MAGE2) AND (MAGEA2B OR MAGEA2 OR MAGE2).

OS Homo sapiens (Human).

OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;

OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

OX NCBI_TaxID=9606;

PN (1)

RP SEQUENCE FROM N.A.

RX MEDLINE=94102805; PubMed=8276455;

RA de Smet C., Lurquin C., van der Bruggen P., de Plaen E., Brasseur F., Boon T.;

RT "Sequence and expression pattern of the human MAGE2 gene.";

RL Immunogenetics 39:121-129(1994).

SEQUENCE FROM N.A.

MEDLINE=20314869; PubMed=10854409;

Mallon A.M., Platzer M., Bates R., Gloeckner G., Botcherby M., Nordsiek G., Strivens M.A., Kioschis P., Dangel A., Cunningham D., Straw R., Weston P., Hunter C., Gilbert M., Fernando S., Goodall K., Kerry G., Greystrom J.S., Clark D., Goerdes M., Blechschmidt K., Rump A., Hinzmann B., Mundy C.R., Miller W., Poustka A., Herman G.E., Rhodes M., Denny P., Rosenthal A., Brown S.D.M.;

RT "Comparative genome sequence analysis of the Bpa/Str region in mouse and man.";

Genome Res. 10:758-775(2000).

[3]

MUTAGENESIS.

TISSUE=Blood;

MEDLINE=94157413; PubMed=8113684;

Gaugier B., van den Eynde B., van der Bruggen P., Romero P., Ra Gaforio J.J., de Plaen E., Lethe B., Brasseur F., Boon T.;

RA "Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes.";

RT J. Exp. Med. 179:921-930(1994).

CC -1- FUNCTION: Not known, though may play a role in embryonal development and tumor transformation or aspects of tumor progression. Antigen recognized on a melanoma by autologous cytolytic T lymphocytes.

CC -1- TISSUE SPECIFICITY: EXPRESSED IN MANY TUMORS OF SEVERAL TYPES, SUCH AS MELANOMA, HEAD AND NECK SQUAMOUS CELL CARCINOMA, LUNG CARCINOMA AND BREAST CARCINOMA, BUT NOT IN NORMAL TISSUES EXCEPT FOR TESTES.

CC -1- SIMILARITY: Contains 1 MAGE domain.

This SWISS-PROT entry is copyright. It is produced through a collaboration between the Swiss Institute of Bioinformatics and the EMBL outstation - the European Bioinformatics Institute. There are no restrictions on its use by non-profit institutions as long as its content is in no way modified and this statement is not removed. Usage by and for commercial entities requires a license agreement (See <http://www.isb-sib.ch/announce/> or send an email to license@isb-sib.ch).

EMBL; L18920; AAA17729.1; -

EMBL; U82671; -; NOT_ANNOTATED_CDS.

PIR; I68889; I68889.

Gene; HGNC:6800; MAGEA2.

MIM; 300173; -

InterPro; IPR002190; MAGE.

PROSITE; PS01454; MAGE; 1.

PROSITE; PS00838; MAGE; 1.

KW Antigen; Multigene family; Tumor antigen.

FT DOMAIN 109 308 MAGE.

FT DOMAIN 40 43 POLY-SER.

FT MUTAGEN 170 170 V->D; IMPROVES ABILITY TO BIND TO HLA-A1.

SQ SEQUENCE 314 AA; 35055 MW; 844F16335A2BECE7 CRC64;

Query Match 84.1%; Score 37; DB 1; Length 314;

Best Local Similarity 77.8%; Pred. No. 2.7;

Matches 7; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

Qy 1 KVAELVHFL 9

Db 112 KVAELVHFL 120

RESULT 8

MAG8 HUMAN

ID MAG8 HUMAN STANDARD; PRT; 234 AA.

AC P43361;

DT 01-NOV-1995 (Rel. 32, Created)

DT 01-NOV-1995 (Rel. 32, Last sequence update)

DT 28-FEB-2003 (Rel. 41, Last annotation update)

DE Melanoma-associated antigen 8 (MAGE-8 antigen).

GN MAGEA8 OR MAGE8.

OS Homo sapiens (Human).

OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;

OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

OX NCBI_TaxID=9606;

PN (1)

RP SEQUENCE FROM N.A.

RX MEDLINE=95012457; PubMed=7927540;

RA de Plaen E., Arden K., Traversari C., Gaforio J.J., Szikora J.-P., Ra de Smet C., Brasseur F., van der Bruggen P., Lethe B., Lurquin C., Brasseur R., Chomez P., de Backer O., Cavenee W., Boon T.;

RT "Structure, chromosomal localization, and expression of 12 genes of the MAGE family.";

RL Immunogenetics 40:360-369(1994).

P43358;
01-NOV-1995 (Rel. 32, Created)
01-NOV-1995 (Rel. 32, Last sequence update)
10-OCT-2003 (Rel. 42, Last annotation update)
DE Melanoma-associated antigen 4 (MAGE-4 antigen) (MAGE-X2) (MAGE-41).
MAGEA4 OR MAGE4.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
OK NCBI_TaxID=9606;
[1]
RN SEQUENCE FROM N.A.
RP TISSUE=Blood;
RC MEDLINE=95012457; PubMed=7927540;
RX de Platen E., Arden K., Traversari C., Gaforio J.J., Szikora J.-P.,
RA de Smet C., Brasseur F., van der Bruggen P., Iethé B., Lurquin C.,
RA Brasseur R., Chomez P., de Backer O., Cavenee W., Bion T.;
RT "Structure, chromosomal localization, and expression of 12 genes of
RT the MAGE family";
RL Immunogenetics 40:360-369(1994).
[2]
RN SEQUENCE FROM N.A.
RP TISSUE=Skin;
RC MEDLINE=94311935; PubMed=8037761;
RX Ding M., Beck R.J., Keller C.J., Fenton R.G.;
RA "Cloning and analysis of MAGE-1-related genes";
RT Biochem. Biophys. Res. Commun. 202:549-555(1994).
[3]
RN SEQUENCE FROM N.A.
RP MEDLINE=95369706; PubMed=7642112;
RX Imai Y., Shichijo S., Yamada A., Katayama T., Yano H., Itoh K.;
RA "Sequence analysis of the MAGE gene family encoding human tumor-
RT rejection antigens";
RL Gene 160:287-290(1995).
[4]
RN SEQUENCE FROM N.A.
RP TISSUE=Ductenium;
RC MEDLINE=2238825; PubMed=12477932;
RX Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
RA Klausner R.D., Collins F.S., Wagner L., Shenmen C.F., Schuler G.D.,
RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.M., Bhat N.K.,
RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,
RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
RA Brownstein M.J., Udén T.B., Toshiyuki S., Carninci P., Prange C.,
RA Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullaly S.J.,
RA Bobak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA Villalón D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
RA Fahey J., Helton E., Kettman M., Madan A., Rodriguez S., Sanchez A.,
RA Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,
RA Butterfield Y.S.N., Krzywinski M.I., Skalska U., Smailus D.E.,
RA Schnerch A., Schein J.E., Jones S.J.M., Marra M.A.;
RT "Generation and initial analysis of more than 15,000 full-length
RT human and mouse cDNA sequences";
RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
[1]
RN FUNCTION: NOT KNOWN, THOUGH MAY PLAY A ROLE IN EMBRYONAL
RC DEVELOPMENT AND TUMOR TRANSFORMATION OR ASPECTS OF TUMOR
CC PROGRESSION.
[2]
RN TISSUE SPECIFICITY: EXPRESSED IN MANY TUMORS OF SEVERAL TYPES,
CC SUCH AS MELANOMA, HEAD AND NECK SQUAMOUS CELL CARCINOMA, LUNG
CC CARCINOMA AND BREAST CARCINOMA, BUT NOT IN NORMAL TISSUES EXCEPT
CC FOR TESTES AND PLACENTA.
[3]
RN SIMILARITY: Contains 1 MAGE domain.
[4]
RN This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (see <http://www.isb-sib.ch/announce/>)

or send an email to license@isb-sib.ch.
CC
CC EMBL; U10687; AAA68871.1; -;
DR EMBL; U10688; AAA68872.1; -;
DR EMBL; U10340; AAA19007.1; -;
DR EMBL; D32077; BAA06843.1; -;
DR EMBL; BC017723; AAH17723.1; -;
DR PIR; I38661; I38661.
DR PDB; 1I4F; 25-JUL-01.
DR Genew; HGNC:6802; MAGEA4.
DR MIM; 300175; -;
DR InterPro; IPR002190; MAGE.
DR Pfam; PF01454; MAGE; 1.
DR PROSITE; PS00838; MAGE; 1.
KW Antigen; Multigene family; Polymorphism; Tumor antigen; 3D-structure.
FT DOMAIN 110 309 MAGE.
FT DOMAIN 41 44 POLY-SER.
FT VARIANT 173 173
FT T -> A.
FT /FTID=VAR 004284.
FT CONFLICT 307 307 E -> Q (IN REF. 2).
SQ SEQUENCE 317 AA; 34929 MW; 3CFAC0E2B696257C CRC64;
Query Match 77.3%; Score 34; DB 1; Length 317;
Best Local Similarity 77.8%; Pred. No. 12;
Matches 7; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1 KVAELVHFL 9
DB 113 KVDELAHFL 121
RESULT 11
ID MANA EMENI STANDARD; PRT; 461 AA.
AC P29951;
DT 01-APR-1993 (Rel. 25, Created)
DT 01-APR-1993 (Rel. 25, Last sequence update)
DT 28-FEB-2003 (Rel. 41, Last annotation update)
DE Mannose-6-phosphate isomerase (EC 5.3.1.8) (Phosphomannose isomerase)
DE (PMI) (Phosphohexomutase).
GN MANA.
OS Emericella nidulans (Aspergillus nidulans).
OC Eukaryota; Fungi; Ascomycota; Pezizomycotina; Eurotiomycetes;
OC Eurotiiales; Trichocomaceae; Emericella.
OX NCBI_TaxID=162425;
RN [1]
RP SEQUENCE FROM N.A.
RX MEDLINE=94139717; PubMed=8307007;
RA Smith D.J., Payton M.A.;
RL Unpublished results, cited by:
RL Proudfoot A.E.I., Turcatti G., Wells T.N.C., Payton M.A., Smith D.J.;
RL Eur. J. Biochem. 219:415-423(1994).
CC -1- FUNCTION: Involved in the synthesis of the GDP-mannose and
CC dolichol-phosphate-mannose required for a number of critical
CC nanosyl transfer reactions.
CC -1- CATALYTIC ACTIVITY: D-mannose 6-phosphate = D-fructose 6-
CC phosphate.
CC -1- COFACTOR: Zinc (By similarity).
CC -1- PATHWAY: Glycosylation; early steps of mannosylation.
CC -1- SUBCELLULAR LOCATION: Cytoplasmic (Probable).
CC -1- SIMILARITY: Belongs to the mannose-6-phosphate isomerase family 1.
[5]
RN This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (see <http://www.isb-sib.ch/announce/>)
or send an email to license@isb-sib.ch.
CC
CC EMBL; M85239; AAA33319.1; -;
DR EMBL; A56239; A56239.
DR HSP; P34948; 1PMI.

```
DR InterPro; IPR001250; Man6p_isomerase1.
DR Pfam; PF01238; PMI_type1; 1.
DR PRINTS; PR00714; MAN6PISMRASE.
DR ProDom; PD004391; Man6p_isomerase1; 1.
DR TIGRFAMs; TIGR00218; manA; 1.
DR PROSITE; PS00965; PMI_1; 1.
DR PROSITE; PS00966; PMI_2; 1.
DR KW isomerase; Zinc.
FT METAL 107 107 ZINC (BY SIMILARITY).
FT METAL 109 109 ZINC (BY SIMILARITY).
FT METAL 134 134 ZINC (BY SIMILARITY).
FT METAL 291 291 ZINC (BY SIMILARITY).
FT METAL 291 291 ZINC (BY SIMILARITY).
SQ SEQUENCE 461 AA; 50585 MW; 819F2BBA95D21006 CRC64;

Query Match 77.3%; Score 34; DB 1; Length 461;
Best Local Similarity 75.0%; Pred. No. 17;
Matches 6; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Qy 2 VAEVHFL 9
Db 151 LAEIVHFL 158

RESULT 12
NIFA KLEOX
ID NIFA_KLEOX STANDARD; PRT; 524 AA.
AC P56266;
DT 15-JUL-1998 (Rel. 36, Created)
DT 15-JUL-1998 (Rel. 36, Last sequence update)
DT 28-FEB-2003 (Rel. 41, Last annotation update)
DE Nif-specific regulatory protein.
GN NIFA.
OS Klebsiella oxytoca.
OC Bacteria; Proteobacteria; Gammaproteobacteria; Enterobacteriales;
OC Enterobacteriaceae; Klebsiella.
OX NCBI_TaxID=571;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=NG13;
RX MEDLINE=87115159; PubMed=3027503;
RA Kim Y.-M., Ahn K.-J., Beppu T., Uozumi T.;
RT "Nucleotide sequence of the nifLA operon of Klebsiella oxytoca NG13
and characterization of the gene products.";
RL Mol. Gen. Genet. 205:253-259(1986).
CC -!- FUNCTION: NIFA, A TRANSCRIPTIONAL ACTIVATOR, IS REQUIRED FOR
ACTIVATION OF MOST NIF OPERONS, WHICH ARE DIRECTLY INVOLVED IN
NITROGEN FIXATION. NIFA INTERACTS WITH SIGMA-54 (BY SIMILARITY).
CC -!- SIMILARITY: Contains 1 sigma-54 factor interaction ATP-binding
domain.
CC -----
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
between the Swiss Institute of Bioinformatics and the EMBL outstation -
the European Bioinformatics Institute. There are no restrictions on its
use by non-profit institutions as long as its content is in no way
modified and this statement is not removed. Usage by and for commercial
entities requires a license agreement (See http://www.isb-sib.ch/announce/
or send an email to license@isb-sib.ch).
CC -----
CC EMBL; D00339; BAA00245.1; -.
CC InterPro; IPR003593; AAA_ATPase.
CC InterPro; IPR008931; FIS-like.
CC InterPro; IPR003018; GAF.
CC InterPro; IPR002197; HTH_Fis.
CC InterPro; IPR002078; Sig54_interact.
CC Pfam; PF01590; GAF; 1.
CC Pfam; PF02954; HTH_8; 1.
CC Pfam; PF00158; Sigma54_activat; 1.
CC PRINTS; PR01590; HTHFIS.
CC SMART; SM00382; AAA; 1.
CC SMART; SM00065; GAF; 1.
CC TIGRFAMs; TIGR01199; HTH_fis; 1.
CC PROSITE; PS00675; SIGMA54_INTERACT_1; 1.
CC PROSITE; PS00676; SIGMA54_INTERACT_2; 1.

DR PROSITE; PS00688; SIGMA54_INTERACT_3; 1.
DR PROSITE; PS00445; SIGMA54_INTERACT_4; 1.
DR KW Nitrogen fixation; Transcription regulation; Activator;
KW ATP-binding; DNA-binding.
FT DOMAIN 1 182 A DOMAIN.
FT DOMAIN 212 481 SIGMA-54 FACTOR INTERACTION (POTENTIAL).
FT DOMAIN 482 524 C-TERMINAL DNA-BINDING DOMAIN.
FT NP_BIND 240 247 ATP (POTENTIAL).
FT NP_BIND 303 312 ATP (POTENTIAL).
FT NP_BIND 496 515 H-T-H MOTIF (BY SIMILARITY).
SQ SEQUENCE 524 AA; 58650 MW; E0677A3605E6F9EE CRC64;

Query Match 77.3%; Score 34; DB 1; Length 524;
Best Local Similarity 75.0%; Pred. No. 20;
Matches 6; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

Qy 2 VAEVHFL 9
Db 390 IAEVHFL 397

RESULT 13
NIFA KLEPN
ID NIFA_KLEPN STANDARD; PRT; 524 AA.
AC P03027;
DT 21-JUL-1986 (Rel. 01, Created)
DT 21-JUL-1986 (Rel. 01, Last sequence update)
DT 28-FEB-2003 (Rel. 41, Last annotation update)
DE Nif-specific regulatory protein.
GN NIFA.
OS Klebsiella pneumoniae.
OC Bacteria; Proteobacteria; Gammaproteobacteria; Enterobacteriales;
OC Enterobacteriaceae; Klebsiella.
OX NCBI_TaxID=573;
RN [1]
RP SEQUENCE FROM N.A.
RC MEDLINE=89094839; PubMed=3062178;
RA Arnold W., Rump A., Klipp W., Priefer U.B., Puehler A.;
RT "Nucleotide sequence of a 24,206-base-pair DNA fragment carrying the
entire nitrogen fixation gene cluster of Klebsiella pneumoniae.";
RL J. Mol. Biol. 203:715-738(1988).
RN [2]
RP SEQUENCE FROM N.A.
RC MEDLINE=86220124; PubMed=3011408;
RA Drummond M., Whitty P., Wootton J.;
RT "Sequence and domain relationships of ntrC and nifA from Klebsiella
pneumoniae: homologues to other regulatory proteins.";
RL EMBO J. 5:441-447(1986).
RN [3]
RP SEQUENCE FROM N.A.
RC MEDLINE=85242120; PubMed=2989799;
RA Buikema W.J., Szeto W.W., Lemley P.V., Orme-Johnson W.H.,
Ausubel F.M.;
RT "Nitrogen fixation specific regulatory genes of Klebsiella pneumoniae
and Rhizobium meliloti share homology with the general nitrogen
regulatory gene ntrC of K. pneumoniae.";
RL Nucleic Acids Res. 13:4539-4555(1985).
CC -!- FUNCTION: NIFA, A TRANSCRIPTIONAL ACTIVATOR, IS REQUIRED FOR
ACTIVATION OF MOST NIF OPERONS, WHICH ARE DIRECTLY INVOLVED IN
NITROGEN FIXATION. NIFA INTERACTS WITH SIGMA-54.
CC -!- SIMILARITY: Contains 1 sigma-54 factor interaction ATP-binding
domain.
CC -----
CC CAUTION: REF.3 SEQUENCE DIFFERS FROM THAT SHOWN IN THE C-TERMINUS
AND IS SHORTER (484 AA) DUE TO A FRAMESHIFT.
CC -----
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
between the Swiss Institute of Bioinformatics and the EMBL outstation -
the European Bioinformatics Institute. There are no restrictions on its
use by non-profit institutions as long as its content is in no way
modified and this statement is not removed. Usage by and for commercial
entities requires a license agreement (See http://www.isb-sib.ch/announce/
or send an email to license@isb-sib.ch).
CC -----
```

```

CC between the Swiss Institute of Bioinformatics and the EMBL outstation
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (see http://www.isb-sib.ch/announce/
CC or send an email to license@isb-sib.ch).
CC -----
CC EMBL; X64346; CAA45687.1; -.
CC EMBL; M86409; AAA46140.1; -.
CC InterPro; IPR006928; Herpes teg.N.
CC Pfam; PF04843; Herpes teg.N; 1.
CC SEQUENCE 2469 AA; 280165 MW; D2B4B8DC08644CDB CRC64;
CC -----
Query Match 77.3%; Score 34; DB 1; Length 2469;
Best Local Similarity 55.6%; Pred. No. 92;
Matches 5; Conservative 3; Mismatches 1; Indels 0; Gaps 0;
QY 1 KVAELVHFL 9
DB 1521 RVTELIHFI 1529
: || ||| |||
-----
RESULT 15
YIMO_YEAST STANDARD; PRT; 563 AA.
ID YIMO_YEAST
AC P40475;
DT 01-FEB-1995 (Rel. 31, Created)
DT 01-FEB-1995 (Rel. 31, Last sequence update)
DT 10-OCT-2003 (Rel. 42, Last annotation update)
DE Hypothetical 61.8 kDa protein in KGD1-Sim1 intergenic region.
YIL120W.
GN OS
OS Saccharomyces cerevisiae (Baker's yeast).
OC Eukaryota; Fungi; Ascomycota; Saccharomycotina; Saccharomycetes;
OC Saccharomycetales; Saccharomycetaceae; Saccharomycetes.
OX NCBI_TaxID=4932;
RN [1]
RS SEQUENCE FROM N.A.
RC STRAIN=S288C / AB972;
RX MEDLINE=97313266; PubMed=9169870;
RA Churcher C.M., Bowman S., Badcock K., Bankier A., Brown D.,
RA Chillingworth T., Connor R., Devlin K., Gentles S., Hamlin N.,
RA Harris D.E., Hornsell T., Hunt S., Jagsis K., Jones M., Lye G.,
RA Moulé S., Odell C., Pearson D., Rajadream M.A., Rice P., Rowley N.,
RA Skelton J., Smith V., Walsh S., Whitehead S., Barrell B.G.;
RA "The nucleotide sequence of Saccharomyces cerevisiae chromosome IX.";
RL Nature 387:84-87(1997).
CC -|- SUBCELLULAR LOCATION: Integral membrane protein (Probable).
CC -|- SIMILARITY: BELONGS TO THE MAJOR FACILITATOR FAMILY (ALSO KNOWN
CC AS THE DRUG RESISTANCE TRANSLACASE FAMILY). BELONGS TO THE
CC CAR1/CYHR SUBFAMILY.
CC -----
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (see http://www.isb-sib.ch/announce/
CC or send an email to license@isb-sib.ch).
CC -----
CC EMBL; Z46833; CAA86872.1; -.
CC PIR; S49889; S49889.
CC GeneOnline; 139655; -.
CC SGD; S0001382; YIL120W.
CC GO; GO:0005886; Cytoplasmic membrane; IDA.
CC GO; GO:0006855; P:multidrug transport; IMP.
CC InterPro; IPR007114; MFS.
CC InterPro; IPR005838; Sub transporter.
CC Pfam; PF000083; sugar tr; 1.
CC PROSITE; PS00850; MFS; 1.
CC Hypothetical protein; Transport; Transmembrane.
KW TRANSMEM 76 96 POTENTIAL.
FT TRANSMEM 109 129 POTENTIAL.
FT TRANSMEM 136 156 POTENTIAL.
FT FT

```

```
FT TRANSMEM 166 186 POTENTIAL.
FT TRANSMEM 196 216 POTENTIAL.
FT TRANSMEM 225 245 POTENTIAL.
FT TRANSMEM 297 317 POTENTIAL.
FT TRANSMEM 342 362 POTENTIAL.
FT TRANSMEM 422 442 POTENTIAL.
FT TRANSMEM 446 466 POTENTIAL.
FT TRANSMEM 482 502 POTENTIAL.
FT TRANSMEM 512 532 POTENTIAL.
SQ SEQUENCE 563 AA; 61758 MW; 5FDBA6F9F7C71C72 CRC64;

Query Match 75.0%; Score 33; DB 1; Length 563;
Best Local Similarity 85.7%; Pred. No. 34;
Matches 6; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KVAELVH 7
Db 399 KVAELIH 405

RESULT 16
NUSC_MAIZE STANDARD; PRT; 738 AA.
AC P46620;
DT 01-NOV-1995 (Rel. 32, Created)
DT 01-NOV-1995 (Rel. 32, Last sequence update)
DT 28-FEB-2003 (Rel. 41, Last annotation update)
DE NAD(P)H-quinone oxidoreductase chain 5, chloroplast (EC 1.6.5.-)
DE (NAD(P)H dehydrogenase, chain 5) (NADH-plastoquinone oxidoreductase chain 5).
DE NDHF OR NDH5.
OS Zea mays (Maize).
OG Chloroplast.
OC Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
OC Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae;
OC PACCAD clade; Panicoideae; Andropogoneae; Zea.
OX NCBI_TaxID=4577;
RN [1]
RP SEQUENCE FROM N.A.
RX MEDLINE=95395841; PubMed=7666415;
RA Maier R.M., Neckermann K., Igloi G.L., Koessel H.;
RT "Complete sequence of the maize chloroplast genome: gene content,
RT hotspots of divergence and fine tuning of genetic information by
RT transcript editing.";
RL J. Mol. Biol. 251:614-628(1995).
RN [2]
RP SEQUENCE OF 9-709 FROM N.A.
RC Trisub-Leaf;
RA Clark L.G., Zhang W., Wendel J.F.;
RL Submitted (FEB-1995) to the EMBL/GenBank/DBJ databases.
CC -!- CATALYTIC ACTIVITY: NAD(P)H + plastoquinone = NAD(P) (+) +
CC plastoquinol.
CC
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC or send an email to license@isb-sib.ch).
CC
CC EMBL; X86563; CAA60346.1; -.
CC DR EMBL; U21985; AAA64703.1; -.
CC DR PIR; S58612; S58612.
CC DR Gramene; P46620; -.
CC DR MaizeDB; 107782; -.
CC DR InterPro; IPR003916; NADHub_oxred5.
CC DR InterPro; IPR001750; Oxidored_g1.
CC DR InterPro; IPR002128; Oxidored_g1_C.
CC DR InterPro; IPR001516; Oxidored_g1_N.
CC DR Pfam; PF00361; Oxidored_g1; 1.
CC DR Pfam; PF01010; oxidored_g1_C; 1.
CC DR Pfam; PF00662; oxidored_g1_N; 1.
CC
CC EMBL; X86563; CAA60346.1; -.
CC DR EMBL; U21985; AAA64703.1; -.
CC DR PIR; S58612; S58612.
CC DR Gramene; P46620; -.
CC DR MaizeDB; 107782; -.
CC DR InterPro; IPR003916; NADHub_oxred5.
CC DR InterPro; IPR001750; Oxidored_g1.
CC DR InterPro; IPR002128; Oxidored_g1_C.
CC DR InterPro; IPR001516; Oxidored_g1_N.
CC DR Pfam; PF00361; Oxidored_g1; 1.
CC DR Pfam; PF01010; oxidored_g1_C; 1.
CC DR Pfam; PF00662; oxidored_g1_N; 1.

DR PRINTS; PR01434; NADHDHGNASE5.
KW Oxidoreductase; NAD; NADP; Quinone; Plastoquinone; Chloroplast.
FT CONFLICT 268 268 MISSING (IN REF. 2).
FT CONFLICT 289 289 W -> L (IN REF. 2).
FT CONFLICT 570 570 R -> G (IN REF. 2).
FT CONFLICT 680 680 K -> R (IN REF. 2).
SQ SEQUENCE 738 AA; 82976 MW; F4E3EBD0DD3C91FA CRC64;

Query Match 75.0%; Score 33; DB 1; Length 738;
Best Local Similarity 75.0%; Pred. No. 45;
Matches 6; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

Qy 1 KVAELVHF 8
Db 680 KLAELTHF 687

RESULT 17
NUSC_DAMDI STANDARD; PRT; 744 AA.
AC Q32126;
DT 10-OCT-2003 (Rel. 42, Created)
DT 10-OCT-2003 (Rel. 42, Last sequence update)
DT 10-OCT-2003 (Rel. 42, Last annotation update)
DE NAD(P)H-quinone oxidoreductase chain 5, chloroplast (EC 1.6.5.-)
DE (NAD(P)H dehydrogenase, chain 5) (NADH-plastoquinone oxidoreductase chain 5).
DE NDHF.
GN Dampiera diversifolia.
OS Chloroplast.
OC Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
OC Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots; asterids;
OC campanulids; Asterales; Goodeniaceae; Dampiera.
OX NCBI_TaxID=41565;
RN [1]
RP SEQUENCE FROM N.A.
RX MEDLINE=96036088; PubMed=7479789;
RA Kim K.-J., Jansen R.K.;
RT "ndhF sequence evolution and the major clades in the sunflower
RT family.";
RL Proc. Natl. Acad. Sci. U.S.A. 92:10379-10383(1995).
CC -!- CATALYTIC ACTIVITY: NAD(P)H + plastoquinone = NAD(P) (+) +
CC plastoquinol.
CC
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC or send an email to license@isb-sib.ch).
CC
CC EMBL; L39386; AAC37742.1; -.
CC DR PIR; T13043; T13043.
CC DR InterPro; IPR003916; NADHub_oxred5.
CC DR InterPro; IPR001750; Oxidored_g1.
CC DR InterPro; IPR002128; Oxidored_g1_C.
CC DR InterPro; IPR001516; Oxidored_g1_N.
CC DR Pfam; PF00361; Oxidored_g1; 1.
CC DR Pfam; PF01010; oxidored_g1_C; 1.
CC DR Pfam; PF00662; oxidored_g1_N; 1.
CC
CC EMBL; L39386; AAC37742.1; -.
CC DR PIR; T13043; T13043.
CC DR InterPro; IPR003916; NADHub_oxred5.
CC DR InterPro; IPR001750; Oxidored_g1.
CC DR InterPro; IPR002128; Oxidored_g1_C.
CC DR InterPro; IPR001516; Oxidored_g1_N.
CC DR Pfam; PF00361; Oxidored_g1; 1.
CC DR Pfam; PF01010; oxidored_g1_C; 1.
CC DR Pfam; PF00662; oxidored_g1_N; 1.
CC
CC EMBL; L39386; AAC37742.1; -.
CC DR PIR; T13043; T13043.
CC DR InterPro; IPR003916; NADHub_oxred5.
CC DR InterPro; IPR001750; Oxidored_g1.
CC DR InterPro; IPR002128; Oxidored_g1_C.
CC DR InterPro; IPR001516; Oxidored_g1_N.
CC DR Pfam; PF00361; Oxidored_g1; 1.
CC DR Pfam; PF01010; oxidored_g1_C; 1.
CC DR Pfam; PF00662; oxidored_g1_N; 1.

DR PRINTS; PR01434; NADHDHGNASE5.
KW Oxidoreductase; NAD; NADP; Quinone; Plastoquinone; Chloroplast.
SQ SEQUENCE 744 AA; 84170 MW; 1A92DB816F322A5F CRC64;

Query Match 75.0%; Score 33; DB 1; Length 744;
Best Local Similarity 75.0%; Pred. No. 45;
Matches 6; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

Qy 1 KVAELVHF 8
Db 682 KLAELTHF 689
```

```

RESULT 18
SUS2_ARATH
ID SUS2_ARATH STANDARD; PRT; 805 AA.
AC Q00917; Q9FJ20;
DT 01-APR-1993 (Rel. 25, Created)
DT 28-FEB-2003 (Rel. 41, Last sequence update)
DT 10-OCT-2003 (Rel. 42, Last annotation update)
DE Sucrose synthase (EC 2.4.1.13) (Sucrose-UDP glucosyltransferase).
GN AT5G49190 OR K2IP3.6.
OS Arabidopsis thaliana (Mouse-ear cress).
OC Eukaryota; Viridiplantae; Streptophyta; Tracheophyta;
OC Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots; rosids;
OC eumetazoa; II; Brassicales; Brassicaceae; Arabidopsis.
OX NCBI_TaxID=3702;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=cv. Columbia;
RX MEDLINE=92119221; PubMed=1531031;
RA Chopra S., Del-Favero J., Dolferus R., Jacobs M.;
RT "Sucrose synthase of Arabidopsis: genomic cloning and sequence
RL Plant Mol. Biol. 18:131-134(1992).
RN [2]
RP SEQUENCE FROM N.A.
RC STRAIN=cv. Columbia;
RX MEDLINE=99156233; PubMed=10048488;
RA Asamizu E., Sato S., Kaneko T., Nakamura Y., Kotani H., Miyajima N.,
RA Tabata S.;
RT "Structural analysis of Arabidopsis thaliana chromosome 5. VIII.
RT Sequence features of the regions of 1,081,958 bp covered by seventeen
RT physically assigned P1 and TAC clones.";
RL DNA Res. 5:379-391(1998).
CC -1- FUNCTION: Sucrose-cleaving enzyme that provides UDP-glucose and
CC fructose for various metabolic pathways.
CC -1- CATALYTIC ACTIVITY: UDP-glucose + D-fructose = UDP + sucrose.
CC -1- INDUCTION: By anaerobic stress.
CC -1- SIMILARITY: Belongs to the glycosyltransferase family 1. Plant
CC sucrose synthase subfamily.
CC -1- CAUTION: Ref.1 sequence differs from that shown due to frameshifts
CC in positions 9 and 12.
CC
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC or send an email to license@isb-sib.ch).
CC
CC -----
CC EMBL; X60987; CAA43303.1; ALT FRAME.
CC EMBL; AB016872; BAB10337.1; -.
CC InterPro; IPR001296; Glyco trans 1.
CC InterPro; IPR000368; Sucrose synth.
CC Pfam; PF00534; Glycos_transf_1; 1.
CC Pfam; PF00862; Sucrose_synth; 1.
CC Transferrase; Glycosyltransferase; Multigene family.
CC CONFLICT 35 35 Q -> H (IN REF. 1).
CC CONFLICT 133 133 D -> H (IN REF. 1).
CC CONFLICT 156 157 FL -> LV (IN REF. 1).
CC CONFLICT 281 282 PH -> RY (IN REF. 1).
CC CONFLICT 286 286 G -> A (IN REF. 1).
CC CONFLICT 298 298 G -> A (IN REF. 1).
CC CONFLICT 648 648 A -> V (IN REF. 1).
CC CONFLICT 718 723 ATLVSF -> GSLAL (IN REF. 1).
CC SEQUENCE 805 AA; 92007 MW; 448F92326CCA755E CRC64;
Query Match 75.0%; Score 33; DB 1; Length 805;
Best Local Similarity 66.7%; Pred. No. 49;
Matches 6; Conservative 2; Mismatches 1; Indels 0; Gaps 0;
QY 1 KYAEVLVHFL 9
| | | | |

```

```

Db 243 KVSEMVHLL 251
RESULT 19
ALF1_BACSU STANDARD; PRT; 285 AA.
ID ALF1_BACSU STANDARD; PRT; 285 AA.
AC P13243;
DT 01-JAN-1990 (Rel. 13, Created)
DT 01-JUN-1994 (Rel. 29, Last sequence update)
DT 10-OCT-2003 (Rel. 42, Last annotation update)
DE Probable fructose-bisphosphate aldolase 1 (EC 4.1.2.13).
GN FBAA OR FBA OR FBA1 OR TSR OR BSGU7120.
OS Bacillus subtilis.
OC Bacteria; Firmicutes; Bacillales; Bacillaceae; Bacillus.
OX NCBI_TaxID=1423;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=168 / JH642;
RX MEDLINE=88314920; PubMed=2457578;
RA Trach K., Chapman J.W., Piggot P., Lecoq D., Hoch J.A.;
RT "Complete sequence and transcriptional analysis of the spoOF region
RL of the Bacillus subtilis chromosome.";
RN [2]
RP REVISIONS AND SEQUENCE OF 1-26 FROM N.A.
RC STRAIN=168 / JH642;
RX MEDLINE=92349962; PubMed=1640835;
RA Mitchell C., Morris P.W., Lum L., Spiegelman G., Vary J.C.;
RT "The amino acid sequence of a Bacillus subtilis phosphoprotein that
RL matches an orfY-tsr coding sequence.";
RN [3]
RP SEQUENCE FROM N.A.
RC STRAIN=168;
RX MEDLINE=98015417; PubMed=9353933;
RA Pressac E., Moszer I., Boursier L., Cruz Ramos H.C., De La Fuente V.,
RA Hullo M.-F., Lelong C., Schleich S., Sekowska A., Song B.H.,
RA Villani G., Kunst F., Danchin A., Glaser P.;
RT "The Bacillus subtilis genome from GerBC (311 degrees) to licR (334
RT degrees).";
RL Microbiology 143:3313-3328(1997).
RN [4]
RP SEQUENCE FROM N.A.
RC STRAIN=168;
RX MEDLINE=98044033; PubMed=9384377;
RA Kunst F., Ogasawara N., Moser I., Albertini A.M., Alloni G.,
RA Azevedo V., Betero M.G., Bessieres P., Bolotin A., Borchert S.,
RA Borrias R., Boursier L., Brans A., Braun M., Brignell S.C., Bron S.,
RA Brouillet S., Bruschi C.V., Caldwell B., Capuano V., Carter N.M.,
RA Choi S.K., Codani J.J., Conneron I.F., Cummings N.J., Daniel R.A.,
RA Denizot F., Devine K.M., Dusterhoft A., Ehrlich S.D., Emmerson P.T.,
RA Entian K.D., Errington J., Fabret C., Ferrari E., Foulger D.,
RA Fritz C., Fujita M., Fujita Y., Fuma S., Galizzi A., Galleron N.,
RA Gim S.Y., Glaser P., Goffeau A., Golightly E.J., Grandi G.,
RA Guiseppe G., Guy B.J., Haga K., Haiech J., Harwood C.R., Henaut A.,
RA Hilbert H., Holsappel S., Hosono S., Hullo M.F., Itaya M., Jones L.,
RA Joris B., Karamata D., Kasahara Y., Klaerr-Blanchard M., Klein C.,
RA Kobayashi Y., Koetter P., Koningsstein G., Krogh S., Kumano M.,
RA Kurita K., Lapidus A., Lardinois S., Lauber J., Lazarevic V.,
RA Lee S.M., Levine A., Liu H., Masuda S., Mauel C., Medigue C.,
RA Medina N., Mellado R.P., Mizuno M., Moestl D., Nakai S., Noback M.,
RA Noone D., O'Reilly M., Ogawa K., Ogiwara A., Oudega B., Park S.H.,
RA Parro V., Pohl T.M., Portetelle D., Porwollik S., Prescott A.M.,
RA Pressac E., Pujic P., Purnelle B., Rapoport G., Rey M., Reynolds S.,
RA Rieger M., Rivolta C., Rocha E., Roche B., Rose M., Sadaie Y.,
RA Sato T., Scanlan E., Schleich S., Schroeter R., Scoffone F.,
RA Sekiguchi J., Sekowska A., Seror S.J., Serror P.P., Shin B.S., Soldo B.,
RA Sorokin A., Taccioni E., Takagi T., Takahashi H., Takemaru K.,
RA Takeuchi M., Tamakoshi A., Tanaka T., Terpstra P., Tognoni A.,
RA Tosato V., Uchiyama S., Vandenbol M., Vannier F., Vassarotti A.,
RA Viari A., Wambutt R., Wedler E., Wedler H., Weitzenecker T.,
RA Winters P., Wipat A., Yamamoto H., Yamane K., Yasumoto K., Yata K.,
RA Yoshida K., Yoshikawa H.F., Zumstein E., Yoshikawa H., Danchin A.;

```

RT "The complete genome sequence of the Gram-positive bacterium *Bacillus subtilis*.";
RL Nature 390:249-256 (1997).
RN [5]
RP SEQUENCE OF 1-16, AND PHOSPHORYLATION.
RX MEDLINE=92210489; PubMed=1556067;
RA Mitchell C., Morris P.W., Vary J.C.;
RT "Identification of proteins phosphorylated by ATP during sporulation
of *Bacillus subtilis*.";
RL J. Bacteriol. 174:2474-2477 (1992).
CC -|- CATALYTIC ACTIVITY: D-fructose 1,6-bisphosphate = glycerone
CC phosphate + D-glyceraldenhyde 3-phosphate.
CC -|- COFACTOR: Zinc.
CC -|- PATHWAY: Glycolysis; sixth step.
CC -|- SIMILARITY: Belongs to class II fructose-bisphosphate aldolase
CC family.
CC -----
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>
CC or send an email to license@isb-sib.ch).
CC -----
DR EMBL; M22039; AAA16803.1; -;
DR EMBL; S42590; AAB22716.1; -;
DR EMBL; 249782; CRA89873.1; -;
DR EMBL; 299122; CAB15729.1; -;
DR PIR; S55426; D32354.
DR HSSP; P11604; 1B57.
DR Subtilisin; BG10412; fbaA.
DR InterPro; IPR000771; K_bp_aldolase.
DR Pfam; PF01116; F_bp_aldolase; 1.
DR ProDom; PD002376; K_bp_aldolase; 1.
DR TricRams; TRICR00167; cdbA; 1.
DR PROSITE; PS00602; ALDOALASE CLASS II.1; 1.
DR PROSITE; PS00806; ALDOALASE CLASS II.2; 1.
DR KW Lyase; Glycosylase; Zinc; Phosphorylation; Complete proteome.
FT METAL 83 83 ZINC (BY SIMILARITY).
FT METAL 86 86 ZINC (BY SIMILARITY).
SQ SEQUENCE 285 AA; 30400 MW; 482D3CE048583BCF CRC64;
Query Match 72.7%; Score 32; DB 1; Length 285;
Best Local Similarity 75.0%; Pred. No. 28;
Matches 6; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Qy 1 KVAELVHF 8
Db 122 KVELAHF 129
RESULT 20
REFC_ECOLI STANDARD; PRT; 356 AA.
ID AC P03016;
DT 21-JUL-1986 (Rel. 01, Created)
DT 01-FEB-1991 (Rel. 17, Last sequence update)
DT 28-FEB-2003 (Rel. 41, Last annotation update)
DE DNA replication and repair protein recF.
GN RECF OR UVRF OR B3700 OR C4622 OR Z5191 OR ECS4635.
OS *Escherichia coli*,
OS *Escherichia coli* O6, and
OS *Escherichia coli* O157:H7.
OC Bacteria; Proteobacteria; Gammaproteobacteria; Enterobacteriales;
OC Enterobacteriaceae; *Escherichia*.
OX NCBI_TaxID=562, 217992, 83334;
RN [1]
RP SEQUENCE FROM N.A.
RX MEDLINE=84272685; PubMed=6379647;
RA Blaser M.A., Sandler S.J., Armenod M.-E., Ream L.W., Clark A.J.;
RT "Molecular analysis of the recF gene of *Escherichia coli*.";
Proc. Natl. Acad. Sci. U.S.A. 81:4622-4626 (1984).

RN [2]
RP SEQUENCE FROM N.A.
RC STRAIN=K12;
RX MEDLINE=84297235; PubMed=6089112;
RA Adachi T., Mizuuchi K., Menzel R., Gellert M.;
RT "DNA sequence and transcription of the region upstream of the *E. coli*
gyrB gene.";
RL Nucleic Acids Res. 12:6389-6395 (1984).
RN [3]
RP SEQUENCE FROM N.A.
RC STRAIN=K12 / MG1655;
RX MEDLINE=93315143; PubMed=7686882;
RA Burland V.D., Plunkett G. III, Daniels D.L., Blattner F.R.;
RT "DNA sequence and analysis of 136 kilobases of the *Escherichia coli*
genome: organizational symmetry around the origin of replication.";
RL Genomics 16:551-561 (1993).
RN [4]
RP SEQUENCE FROM N.A.
RC STRAIN=06:H1 / CF7073 / ATCC 700928;
RX MEDLINE=22388234; PubMed=12471157;
RA Welch R.A., Burland V., Plunkett G. III, Redford P., Roesch P.,
Rasko D., Buckles E.L., Liou S.-R., Boutin A., Hackett J., Stroud D.,
Mayhew G.F., Rose D.J., Zhou S., Schwartz D.C., Perna N.T.,
Mobley H.L.T., Donnenberg M.S., Blattner F.R.;
RT "Extensive mosaic structure revealed by the complete genome sequence
of uropathogenic *Escherichia coli*.";
Proc. Natl. Acad. Sci. U.S.A. 99:17020-17024 (2002).
RN [5]
RP SEQUENCE FROM N.A.
RC STRAIN=0157:H7 / EDL933 / ATCC 700927;
RX MEDLINE=21074935; PubMed=11206551;
RA Perna N.T., Plunkett G. III, Burland V., Mau B., Glasner J.D.,
Rose D.J., Mayhew G.F., Evans P.S., Gregor J., Kirkpatrick H.A.,
Posfai G., Hackett J., Klink S., Boutin A., Shao Y., Miller L.,
Grotbeck E.J., Davis N.W., Lim A., Dimalanta E.T., Potamoudis K.,
Apodaca J., Anantharaman T.S., Lin J., Yen G., Schwartz D.C.,
Welch R.A., Blattner F.R.;
RT "Genome sequence of enterohaemorrhagic *Escherichia coli* O157:H7.";
Nature 409:529-533 (2001).
RN [6]
RP SEQUENCE FROM N.A.
RC STRAIN=0157:H7 / RMD 0509952;
RX MEDLINE=21156231; PubMed=11258796;
RA Hayashi T., Makino K., Ohnishi M., Kurokawa K., Ishii K., Yokoyama K.,
Han C.-G., Ohtsubo E., Nakayama K., Murata T., Tanaka M., Tobe T.,
Iida T., Takami H., Honda T., Sakakawa C., Ogasawara N., Yasunaga T.,
Kihara S., Shiba T., Hattori M., Shinagawa H.;
RT "Complete genome sequence of enterohaemorrhagic *Escherichia coli*
O157:H7 and genomic comparison with a laboratory strain K-12.";
DNA Res. 8:11-22 (2001).
RN [7]
RP SEQUENCE OF 1-12, AND DNA-BINDING.
RX MEDLINE=91035238; PubMed=2228960;
RA Griffin T.J. IV, Kolodner R.D.;
RT "Purification and preliminary characterization of the *Escherichia*
coli K-12 recF protein.";
J. Bacteriol. 172:6291-6299 (1990).
RN [8]
RP MUTAGENESIS OF LYS-35.
RX MEDLINE=92178981; PubMed=1542576;
RA Sandler S.J., Chakerian B., Li J.T., Clark A.J.;
RT "Sequence and complementation analysis of recF genes from *Escherichia*
coli, *Salmonella typhimurium*, *Pseudomonas putida* and *Bacillus*
subtilis: evidence for an essential phosphate binding loop.";
Nucleic Acids Res. 20:839-845 (1992).
CC -|- FUNCTION: The recF protein is involved in DNA metabolism; it is
CC required for DNA replication and normal SOS inducibility. RecF
CC binds preferentially to single-stranded, linear DNA. It also seems
CC to bind ATP.
CC -|- SUBCELLULAR LOCATION: Cytoplasmic (potential).
CC -|- SIMILARITY: Belongs to the recF family.
CC -----
CC This SWISS-PROT entry is copyright. It is produced through a collaboration

CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
 CC the European Bioinformatics Institute. There are no restrictions on its
 CC use by non-profit institutions as long as its content is in no way
 CC modified and this statement is not removed. Usage by and for commercial
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>
 CC or send an email to license@isb-sib.ch).
 CC -----
 DR EMBL; K02179; AAA24511.1; -;
 DR EMBL; X04341; CAA27870.1; -;
 DR EMBL; LI0328; CAA62051.1; -;
 DR EMBL; AE000447; AAC76723.1; -;
 DR EMBL; AE016769; AAN83055.1; -;
 DR EMBL; AE005601; AAG58897.1; -;
 DR EMBL; AP002566; BAB38058.1; -;
 DR PIR; A03547; RQECF.
 DR PIR; C91208; C91208.
 DR PIR; E86054; E86054.
 DR EcoGene; EG10828; recF.
 DR HAMAP; MF_00365; -; 1.
 DR InterPro; IPR001238; RecF.
 DR InterPro; IPR003395; SMC_N.
 DR InterPro; IPR002017; Spectrin.
 DR Pfam; PF02463; SMC_N; 1.
 DR TIGRFAMs; TIGR00611; recF; 1.
 DR PROSITE; PS00617; REC_F_1; 1.
 DR PROSITE; PS00618; REC_F_2; 1.
 DR DNA damage; DNA replication; SOS response; DNA repair;
 KW ATP-binding; Complete proteome.
 FT INIT MET 0
 FT NP_BIND 29 36 ATP (POTENTIAL).
 FT MUTAGEN 35 35 K->R; WEAKLY ACTIVE.
 FT SEQUENCE 356 AA; 40382 MW; 1EF15B2BD302776 CRC64;
 SQ
 Query Match 72.7%; Score 32; DB 1; Length 356;
 Best Local Similarity 66.7%; Pred. No. 35;
 Matches 6; Conservative 1; Mismatches 2; Indels 0; Gaps 0;
 QY 1 KVAELVHFL 9
 DB 103 KVAELAHLM 111
 RESULT 21
 TRD2 ANASP
 ID TRD2 ANASP STANDARD; PRT; 362 AA.
 AC Q8YXQ9;
 DT 28-FEB-2003 (Rel. 41, Created)
 DT 28-FEB-2003 (Rel. 41, Last sequence update)
 DT 10-OCT-2003 (Rel. 42, Last annotation update)
 DE Anthranilate phosphoribosyltransferase 2 (EC 2.4.2.18).
 GN TRPD2 OR ALR1153.
 OS Anabaena sp. (strain PCC 7120).
 OC Bacteria; Cyanobacteria; Nostocales; Nostocaceae; Nostoc.
 OX NCBI_TaxID=103690;
 RN [1]
 RP SEQUENCE FROM N.A.
 RX MEDLINE=21595285; PubMed=11759840;
 RA Kaneko T., Nakamura Y., Wolk C.P., Kuritz T., Sasamoto S.,
 RA Watanabe A., Iriguchi M., Ishikawa A., Kawashima K., Kimura T.,
 RA Kishida Y., Kohara M., Matsumoto M., Matsuno A., Muraki A.,
 RA Nakazaki N., Shimpo S., Sugimoto M., Takazawa M., Yamada M.,
 RA Yasuda M., Tabata S.;
 RT "Complete genomic sequence of the filamentous nitrogen-fixing
 RT cyanobacterium Anabaena sp. strain PCC 7120.";
 RL DNA Res. 8:205-213(2001).
 CC -1- CATALYTIC ACTIVITY: Anthranilate + phosphoribosyl-diphosphate =
 CC N-5'-phosphoribosyl-anthranilate + diphosphate.
 CC -1- PATHWAY: Tryptophan biosynthesis; second step.
 CC -1- SIMILARITY: Belongs to the anthranilate phosphoribosyltransferase
 CC family.
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -

CC the European Bioinformatics Institute. There are no restrictions on its
 CC use by non-profit institutions as long as its content is in no way
 CC modified and this statement is not removed. Usage by and for commercial
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>
 CC or send an email to license@isb-sib.ch).
 CC -----
 DR EMBL; AP003584; BAB73110.1; -;
 DR PIR; AP1950; AFI950.
 DR HAMAP; MF_00211; -; 1.
 DR InterPro; IPR005940; Ant_phospho_trans.
 DR InterPro; IPR000312; Glyco_trans_3.
 DR Pfam; PF02885; Glycos_trans_3N; 1.
 DR Pfam; PF00591; Glycos_trans_3; 1.
 DR ProDom; PD001864; Glyco_trans_3; 1.
 DR TIGRFAMs; TIGR01245; trpb; 1.
 DR Tryptophan biosynthesis; Transferase; Glycosyltransferase;
 KW Complete proteome.
 SQ SEQUENCE 362 AA; 37597 MW; C392D1446391AC13 CRC64;
 Query Match 72.7%; Score 32; DB 1; Length 362;
 Best Local Similarity 66.7%; Pred. No. 36;
 Matches 6; Conservative 3; Mismatches 0; Indels 0; Gaps 0;
 QY 1 KVAELVHFL 9
 DB 352 KLAQLVYFL 360
 RESULT 22
 TYPH MYCPN
 ID TYPH MYCPN STANDARD; PRT; 421 AA.
 AC P75052;
 DT 01-NOV-1997 (Rel. 35, Created)
 DT 01-NOV-1997 (Rel. 35, Last sequence update)
 DT 10-OCT-2003 (Rel. 42, Last annotation update)
 DE Thymidine phosphorylase (EC 2.4.2.4) (TDRPase).
 DE DEOA OR MPN064 OR MP090.
 GN Mycoplasma pneumoniae.
 OS Bacteria; Firmicutes; Mollicutes; Mycoplasmataceae; Mycoplasma.
 OX NCBI_TaxID=2104;
 RN [1]
 RP SEQUENCE FROM N.A.
 RC STRAIN=ATCC 29342 / ML29;
 RX MEDLINE=97105885; PubMed=8948633;
 RA Himmelfreich R., Hilbert H., Plagens H., Pirkel E., Li B.-C.,
 RA Herrmann R.;
 RT "Complete sequence analysis of the genome of the bacterium Mycoplasma
 RT pneumoniae";
 RL Nucleic Acids Res. 24:4420-4449(1996).
 CC -1- FUNCTION: THE ENZYMES WHICH CATALYZE THE REVERSIBLE PHOSPHORYLOSIS
 CC OF PYRIMIDINE NUCLEOSIDES ARE INVOLVED IN THE DEGRADATION OF THESE
 CC COMPOUNDS AND IN THEIR UTILIZATION AS CARBON AND ENERGY SOURCES,
 CC OR IN THE RESCUE OF PYRIMIDINE BASES FOR NUCLEOTIDE SYNTHESIS.
 CC -1- CATALYTIC ACTIVITY: Thymidine + phosphate = thymine + 2-deoxy-D-
 CC ribose 1-phosphate.
 CC -1- SUBUNIT: Homodimer (By similarity).
 CC -1- SIMILARITY: Belongs to the thymidine/pyrimidine-nucleoside
 CC phosphorylase family.
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
 CC the European Bioinformatics Institute. There are no restrictions on its
 CC use by non-profit institutions as long as its content is in no way
 CC modified and this statement is not removed. Usage by and for commercial
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>
 CC or send an email to license@isb-sib.ch).
 CC -----
 DR EMBL; AE000011; AAB95738.1; -;
 DR PIR; S73416; S73416.
 DR HGSP; P77836; 1BRW.
 DR InterPro; IPR000312; Glyco_trans_3.
 DR InterPro; IPR000053; Thymid_phosphis.
 DR Pfam; PF02885; Glycos_trans_3N; 1.

```
DR Pfam; PF00591; Glycos_transf_3; 1.
DR PIRSF; PIRSF000478; Thymid_phosphils; 1.
DR ProDom; PD001864; Glyco trans 3; 1.
DR ProDom; PD005916; Thymid_phosphils; 1.
DR PROSITE; PS00647; THYMID_PHOSPHORYLASE; 1.
KW Transferase; Glycosyltransferase; Complete proteome.
SQ SEQUENCE 421 AA; 46628 MW; E29DBF93C6D8549F CRC64;

Query Match 72.7%; Score 32; DB 1; Length 421;
Best Local Similarity 66.7%; Pred. No. 42;
Matches 6; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

Qy 1 KVAVLVHFL 9
Db 251 EVLEWVHFL 259

RESULT 23
TRME MYCPN STANDARD; PRT; 442 AA.
AC P75104;
DT 01-NOV-1997 (Rel. 35, Created)
DT 01-NOV-1997 (Rel. 35, Last sequence update)
DT 28-FEB-2003 (Rel. 41, Last annotation update)
DE Probable tRNA modification GTPase trmE.
GN TRME OR THDF OR MPN008 OR MP146.
OS Mycoplasma pneumoniae.
OC Bacteria; Firmicutes; Mollicutes; Mycoplasmataceae; Mycoplasma.
OX NCBI_TaxID=2104;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=ATCC 29342 / M129;
RA MEDLINE=97105885; PubMed=6948633;
RA Himmelreich R., Hilbert H., Plagens H., Pirkl E., Li B.-C.,
RA Hermann R.;
RT "Complete sequence analysis of the genome of the bacterium Mycoplasma
RT pneumoniae.";
RL Nucleic Acids Res. 24:4420-4449(1996).
CC -1- FUNCTION: Exhibits a very high intrinsic GTPase hydrolysis rate.
CC Involved in the biosynthesis of the hypermodified nucleoside 5-
CC methylaminomethyl-2-thiouridine, which is found in the wobble
CC position of some tRNAs (By similarity).
CC -1- SIMILARITY: Belongs to the era/trmE family of GTP-binding
CC proteins. TrmE subfamily.
CC
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC or send an email to license@isb-sib.ch)
CC
CC EMBL; AE000016; AAB95794.1; -.
CC PIR; S73472; S73472.
CC HAMAP; MF_00379; -.
CC InterPro; IPR005289; GTP-binding_dom.
CC InterPro; IPR006073; GTP1_OBG.
CC InterPro; IPR002917; MWR_HSR1.
CC InterPro; IPR001806; Rast_trnsfrmng.
CC InterPro; IPR005225; Small_GTP.
CC InterPro; IPR004520; TrdF.
CC Pfam; PF01926; MWR_HSR1; 1.
CC PRINTS; PR00326; GTP1_OBG.
CC PRINTS; PR00449; RASTRNSFRMNG.
CC TIGRFAMs; TIGR00650; MG442; 1.
CC TIGRFAMs; TIGR00231; small_GTP; 1.
CC TIGRFAMs; TIGR00450; thdF; 1.
CC TRNA processing; GTP-binding; Complete proteome.
KW NP_BIND 224 231 GTP (POTENTIAL).
FT NP_BIND 271 275 GTP (POTENTIAL).
FT NP_BIND 331 334 GTP (POTENTIAL).
SQ SEQUENCE 442 AA; 49780 MW; FA8849BA0BCB9AD5 CRC64;

Query Match 72.7%; Score 32; DB 1; Length 456;
Best Local Similarity 62.5%; Pred. No. 45;
Matches 5; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

Qy 2 VAEVLVHFL 9
Db 388 IAELEHFL 395

RESULT 24
PUR8_HAEIN STANDARD; PRT; 456 AA.
AC P44787;
DT 01-NOV-1995 (Rel. 32, Created)
DT 01-NOV-1995 (Rel. 32, Last sequence update)
DT 10-OCT-2003 (Rel. 42, Last annotation update)
DE Adenylosuccinate lyase (EC 4.3.2.2) (Adenylosuccinase) (ASL).
GN PUR8 OR HI0639.
OS Haemophilus influenzae.
OC Bacteria; Proteobacteria; Gammaproteobacteria; Pasteurellales;
OC Pasteurellaceae; Haemophilus.
OX NCBI_TaxID=727;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=Rd / KW20 / ATCC 51907;
RX MEDLINE=95350630; PubMed=7542800;
RA Fleischmann R.D., Adams M.D., White O., Clayton R.A., Kirkness E.F.,
RA Kerlavage A.R., Bult C.J., Tomb J.-F., Dougherty B.A., Merrick J.M.,
RA McKenney K., Sutton G., Fitzhugh W., Fields C.A., Gocayne J.D.,
RA Scott J.D., Shirley R., Liu L.-I., Glodek A., Keiley J.M.,
RA Weidman J.F., Phillips C.A., Spriggs T., Hedblom E., Cotton M.D.,
RA Uterback T.R., Hanna M.C., Nguyen D.T., Saudek D.M., Brandon R.C.,
RA Fine L.D., Fritchman J.L., Fuhrmann J.L., Geoghagen N.S.M.,
RA Gnehm C.L., McDonald L.A., Small K.V., Fraser C.M., Smith H.O.,
RA Venter J.C.;
RT "Whole-genome random sequencing and assembly of Haemophilus influenzae
RT Rd.";
RL Science 269:496-512(1995).
CC -1- CATALYTIC ACTIVITY: N(6)-(1,2-dicarboxylethyl)AMP = fumarate + AMP.
CC -1- CATALYTIC ACTIVITY: (S)-2-[5-amino-1-(5-phospho-D-
CC ribosyl)imidazole-4-carboxamidol]succinate = fumarate + 5-amino-1-
CC (5-phospho-D-ribosyl)imidazole-4-carboxamide.
CC -1- PATHWAY: De novo purine biosynthesis; eighth step.
CC -1- SIMILARITY: Belongs to the lyase 1 family. Adenylosuccinate lyase
CC subfamily.
CC
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC or send an email to license@isb-sib.ch)
CC
CC EMBL; U32747; AAC22299.1; -.
CC TIGR; HI0639; -.
CC InterPro; IPR000362; Fumarate lyase.
CC InterPro; IPR008948; L-Aspartase-like.
CC InterPro; IPR004769; Pur lyase.
CC Pfam; PF00206; lyase_1; 1.
CC PRINTS; PR00149; FUMRATLYASE.
CC TIGRFAMs; TIGR00928; purB; 1.
CC PROSITE; PS00163; FUMARATE_LYASES; 1.
CC Purine biosynthesis; Lyase; Complete proteome.
FT ACT_SITE 91 91 ACID (BY SIMILARITY).
FT ACT_SITE 171 171 BASE (BY SIMILARITY).
SQ SEQUENCE 456 AA; 51993 MW; 9C3021D612A3CAC8 CRC64;

Query Match 72.7%; Score 32; DB 1; Length 456;
Best Local Similarity 62.5%; Pred. No. 45;
Matches 5; Conservative 2; Mismatches 1; Indels 0; Gaps 0;
```

```
QY 1 KVAELVHF 8
Db 112 KVSEFIHF 119

RESULT 25
RBF1 CANAL
ID _RBF1 CANAL STANDARD; PRT; 527 AA.
AC Q00312;
DT 01-NOV-1997 (Rel. 35, Created)
DT 01-NOV-1997 (Rel. 35, Last sequence update)
DT 15-JUL-1999 (Rel. 38, Last annotation update)
DE Transcription factor RBF1 (RPG-box-binding factor) (Repressor-
DE activator protein 1).
GN RBF1.
OS Candida albicans (yeast).
OC Eukaryota; Fungi; Ascomycota; Saccharomycotina; Saccharomycetes;
OC Saccharomycetales; mitosporic Saccharomycetales; Candida.
OX NCBI_TaxID=5476;
RN [1]
RN SEQUENCE FROM N.A., AND PARTIAL SEQUENCE.
RC STRAIN=ATCC 10231;
RX MEDLINE=97195789; PubMed=9043119;
RA Iehii N., Yamamoto M., Lahm H.-W., Izumi S., Yoshihara F.,
RA Nakayama H., Arisawa M., Aoki Y.;
RT "A DNA-Binding protein from Candida albicans that binds to the RPG
RT box of Saccharomycetes cerevisiae and the telomeric repeat sequence of
RT C. albicans.";
RL Microbiology 143:417-427(1997).
RN [2]
RN CHARACTERIZATION.
RP MEDLINE=97195789; PubMed=9043120;
RX Iehii N., Yamamoto M., Yoshihara F., Arisawa M., Aoki Y.;
RA "Biochemical and genetic characterization of Rbf1p, a putative
RA transcription factor of Candida albicans.";
RL Microbiology 143:429-435(1997).
CC -!- FUNCTION: Transcriptional activator that binds to the RPG box and
CC to telomeres. May be involved in the regulation of the transition
CC between yeast and filamentous forms at the level of transcription.
CC -!- SUBCELLULAR LOCATION: Nuclear; predominantly.
CC -----
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See http://www.isb-sib.ch/announcement/
CC or send an email to license@isb-sib.ch).
CC -----
DR EMBL; D85862; BAAL2888.1; -
DR Transcription regulation; DNA-binding; Activator; Nuclear protein;
KW Telomere.
FT DNA BIND 160 300 POTENTIAL.
FT DOMAIN 73 80 POLY-ALA.
FT DOMAIN 135 139 POLY-GLN.
FT DOMAIN 326 329 POLY-HIS.
FT DOMAIN 332 353 POLY-GLN.
FT DOMAIN 398 405 POLY-GLN.
FT DOMAIN 445 452 POLY-ALA.
FT DOMAIN 478 481 POLY-GLN.
SQ SEQUENCE 527 AA; 59441 MW; ADD675F937A807D CRC64;

Query Match 72.7%; Score 32; DB 1; Length 527;
Best Local Similarity 85.7%; Pred. No. 52;
Matches 6; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 3 AELVHFL 9
Db 193 AELVHVF 199

RESULT 26
IRAI MOUSE
ID IRAI MOUSE STANDARD; PRT; 710 AA.
AC Q62406;
DT 16-OCT-2001 (Rel. 40, Created)
DT 16-OCT-2001 (Rel. 40, Last sequence update)
DT 15-MAR-2004 (Rel. 43, Last annotation update)
DE Interleukin-1 receptor-associated kinase 1 (EC 2.7.1.-) (IRAK-1)
DE (IRAK) (Pelle-like protein kinase) (MPLK).
GN IRAK1 OR ILIRAK.
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
OX NCBI_TaxID=10090;
RN [1]
RN SEQUENCE FROM N.A.
RP Kopp E.B., Ghosh S.;
RA "Cloning of mouse IRAK.";
RL Submitted (NOV-1998) to the EMBL/GenBank/DBJ databases.
RN [2]
RN SEQUENCE FROM N.A.
RA Harrington M.A.;
RN Submitted (JAN-2001) to the EMBL/GenBank/DBJ databases.
RN [3]
RN SEQUENCE OF 34-710 FROM N.A.
RP TISSUE=Embryo;
RX MEDLINE=96279287; PubMed=8663605;
RA Trofimova M., Sprengle A.B., Green M., Sturgill T.W., Goebel M.G.,
RA Harrington M.A.;
RT "Developmental and tissue-specific expression of mouse pelle-like
RT protein kinase.";
RL J. Biol. Chem. 271:17609-17612(1996).
RN [4]
RN INTERACTION WITH PELI2.
RP MEDLINE=22257640; PubMed=12370331;
RX Yu K.-Y., Kwon H.-J., Norman D.A.M., Vig E., Goebel M.G.,
RA Harrington M.A.;
RT "Cutting edge: mouse pellino-2 modulates IL-1 and lipopolysaccharide
RT signaling.";
RL J. Immunol. 169:4075-4078(2002).
CC -!- FUNCTION: Involved in IL-1 pathway. This kinase associates with
CC the IL-1 receptor IL1-R-1. This association is rapid and IL-1
CC dependent (By similarity).
CC -!- SUBUNIT: Found in a complex containing TRAF6, PELI1 and IRAK4.
CC Interacts with PELI3 (By similarity). Interacts with PELI2.
CC -!- TISSUE SPECIFICITY: Highly expressed in liver, followed by kidney
CC and skeletal muscle.
CC -!- DEVELOPMENTAL STAGE: Expressed from E11 day to E18 day.
CC -!- PTM: Autophosphorylated. An extensive phosphorylation of IRAK
CC occurs after its association with IL1-R-1. This step could be
CC linked to the activation of the kinase (By similarity).
CC -!- SIMILARITY: BELONGS TO THE SER/THR FAMILY OF PROTEIN KINASES.
CC PELLE SUBFAMILY.
CC -----
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See http://www.isb-sib.ch/announcement/
CC or send an email to license@isb-sib.ch).
CC -----
DR EMBL; U56773; AAC52694.2; -
DR EMBL; AF103876; AADI3224.1; ALT_INIT.
DR MGD; MGI:107420; Irak1.
DR GO; GO:0016301; F:kinase activity; IDA.
DR GO; GO:0005515; F:protein binding; IPI.
DR GO; GO:0006468; P:protein amino acid phosphorylation; IDA.
DR GO; GO:0007165; P:signal transduction; IDA.
DR InterPro; IPR000488; Death.
DR InterPro; IPR000719; Ser_thr_kinase.
DR InterPro; IPR008271; Ser_thr_pkin_AS.
DR Pfam; PF00531; death; 1.
DR Pfam; PF00069; pkinase; 1.
DR ProDom; PD000001; Prot_kinase; 1.
```

```
DR PROSITE; PS00107; PROTEIN KINASE ATP; 1.
DR PROSITE; PS00108; PROTEIN KINASE ST; 1.
DR PROSITE; PS50011; PROTEIN KINASE DOM; 1.
KW Transferase; Serine/threonine-protein kinase; ATP-binding.
FT DOMAIN 212 521
FT NP BIND 218 226 ATP (BY SIMILARITY).
FT BINDING 239 239 ATP (BY SIMILARITY).
FT ACT SITE 338 338 BY SIMILARITY.
SQ SEQUENCE 710 AA; 77269 MW; 8A501F002CD3EBD2 CRC64;

Query Match 72.7%; Score 32; DB 1; Length 710;
Best Local Similarity 66.7%; Pred. No. 70;
Matches 6; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 1 KVAELVHFL 9
DB 79 RVADLVHIL 87

RESULT 27
ID _IRAI_HUMAN STANDARD; PRT; 712 AA.
AC PS1617;
DT 01-OCT-1996 (Rel. 34, Created)
DT 01-OCT-1996 (Rel. 34, Last sequence update)
DT 15-MAR-2004 (Rel. 43, Last annotation update)
DE Interleukin-1 receptor-associated kinase 1 (EC 2.7.1.-) (IRAK-1).
GN IRAK1 OR IRAK.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX NCBI_TaxID=9606;
[1]
RN MEDLINE=9618673; PubMed=8599092;
RA Cao Z., Henzel W.J., Gao X.;
RT "IRAK: a kinase associated with the interleukin-1 receptor.";
RL Science 271:1128-1131(1996).
[2]
RN SEQUENCE FROM N.A.
RA Platzter M., Bauer D., Drescher B.;
RL Submitted (MAR-1995) to the EMBL/GenBank/DBJ databases.
[3]
RN SEQUENCE FROM N.A.
RA Reichwald K., Kioschis P., Rosenthal A., Platzter M.;
RL Submitted (OCT-1997) to the EMBL/GenBank/DBJ databases.
[4]
RN INTERACTION WITH PELI1.
RX MEDLINE=22538429; PubMed=12496252;
RA Jiang Z., Johnson H.J., Nie H., Qin J., Bird T.A., Li X.;
RT "Pellino 1 is required for interleukin-1 (IL-1)-mediated signaling
through its interaction with the IL-1 receptor-associated kinase 4
(IRAK4)-IRAK-tumor necrosis factor receptor-associated factor 6
(TRAF6) complex.";
RL J. Biol. Chem. 278:10952-10956(2003).
[5]
RN INTERACTION WITH PELI2.
RX MEDLINE=2274764; PubMed=12860405;
RA Strelow A., Kollweh C., Wesche H.;
RT "Characterization of Pellino2, a substrate of IRAK1 and IRAK4.";
RL FEBS Lett. 547:157-161(2003).
[6]
RN INTERACTION WITH PELI3.
RX MEDLINE=22756745; PubMed=12874243;
RA Jensen L.E., Whitehead A.S.;
RT "Pellino3, a novel member of the Pellino protein family, promotes
activation of c-Jun and Elk-1 and may act as a scaffolding protein.";
RL J. Immunol. 171:1500-1506(2003).
CC -!- FUNCTION: Involved in IL-1 pathway. This kinase associates with
the IL-1 receptor IL1-R-1. This association is rapid and IL-1
dependent.
CC -!- SUBUNIT: Found in a complex containing TRAF6, PELI1 and IRAK4.
CC Interacts with PELI2 and PELI3.

-!- TISSUE SPECIFICITY: Seems to be ubiquitous, although present in
small amounts.
-!- PTM: An extensive phosphorylation of IRAK occurs after its
association with IL1-R-1. This step could be linked to the
activation of the kinase.
-!- SIMILARITY: BELONGS TO THE SER/THR FAMILY OF PROTEIN KINASES.
PELLE SUBFAMILY.
-----
This SWISS-PROT entry is copyrighted. It is produced through a collaboration
between the Swiss Institute of Bioinformatics and the EMBL outstation -
the European Bioinformatics Institute. There are no restrictions on its
use by non-profit institutions as long as its content is in no way
modified and this statement is not removed. Usage by and for commercial
entities requires a license agreement (See http://www.isb-sib.ch/announce/
or send an email to license@isb-sib.ch)
-----
EMBL; L76191; AAC41949.1; -
EMBL; U52112; -; NOT_ANNOTATED_CDS.
DR EMBL; AF030876; AAC08756.1; -
DR PIR; G02512; G02512.
DR Genew; HGNC:6112; IRAK1.
DR MIM; 300283; -
DR GO; GO:0045323; C-interleukin-1 receptor complex; NAS.
DR GO; GO:0004704; F-NF-kappaB-inducing kinase activity; TAS.
DR GO; GO:0005515; F-protein binding; ISS.
DR GO; GO:0006468; P-protein amino acid phosphorylation; TAS.
DR GO; GO:0007165; P-signal transduction; NAS.
DR InterPro; IPR000488; Death.
DR InterPro; IPR000719; Prot kinase.
DR InterPro; IPR008271; Ser_thr_kin_AS.
DR Pfam; PF00531; death; 1.
DR Pfam; PF00069; pkinase; 1.
DR ProDom; PD000001; Prot kinase; 1.
DR PROSITE; PS00107; PROTEIN KINASE ATP; 1.
DR PROSITE; PS00108; PROTEIN KINASE ST; 1.
DR PROSITE; PS50011; PROTEIN KINASE DOM; 1.
KW Transferase; Serine/threonine-protein kinase; ATP-binding.
FT DOMAIN 212 521
FT NP BIND 218 226 ATP (BY SIMILARITY).
FT BINDING 239 239 ATP (BY SIMILARITY).
FT ACT SITE 338 338 BY SIMILARITY.
FT CONFLICT 196 196 F -> S (IN REF. 1).
FT CONFLICT 532 532 S -> L (IN REF. 1).
SQ SEQUENCE 712 AA; 76536 MW; A7ADE75D3A3981D CRC64;

Query Match 72.7%; Score 32; DB 1; Length 712;
Best Local Similarity 66.7%; Pred. No. 70;
Matches 6; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 1 KVAELVHFL 9
DB 79 RVADLVHIL 87

RESULT 28
ID _EPS8_HUMAN STANDARD; PRT; 822 AA.
AC Q12929;
DT 01-NOV-1997 (Rel. 35, Created)
DT 01-NOV-1997 (Rel. 35, Last sequence update)
DT 10-OCT-2003 (Rel. 42, Last annotation update)
DE Epidermal growth factor receptor kinase substrate EPS8.
GN EPS8.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX NCBI_TaxID=9606;
[1]
RN SEQUENCE FROM N.A.
RX MEDLINE=94366758; PubMed=8084614;
RA Wong W.T., Carlomagno F., Druck T., Barletta C., Croce C.M.,
Huebner K., Kraus M.H., di Fiore P.P.;
RT "Evolutionary conservation of the EPS8 gene and its mapping to human
```

```
RT chromosome 12q23-q24."
CC Oncogene 9:3057-3061(1994).
CC -!- FUNCTION: Upon binding to EGF receptor enhances EGF-dependent
CC mitogenic signals. Can bind multiple cellular targets.
CC -!- TISSUE SPECIFICITY: Expressed in all tissues analyzed, including
CC heart, brain, placenta, lung, liver, skeletal muscle, kidney and
CC pancreas. Expressed in all epithelial and fibroblastic lines
CC examined and in some, but not all, hematopoietic cells.
CC -!- PTM: Phosphorylated by several receptor tyrosine kinases.
CC -!- SIMILARITY: Contains 1 PH domain.
CC -!- SIMILARITY: Contains 1 SH3 domain.
CC -----
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (see http://www.isb-sib.ch/announce/
CC or send an email to license@isb-sib.ch).
CC -----
CC EMBL; U12535; AAA62280.1; -.
CC PIR; I38728; I38728.
CC HSP; Q08509; IAOJ.
CC Genew; HGNC:3420; EPS8.
CC MIM; 60206; -.
CC GO; GO:0005070; P:SH3/SH2 adaptor protein activity; TAS.
CC GO; GO:0008283; P:cell proliferation; TAS.
CC GO; GO:0007173; P:EGF receptor signaling pathway; TAS.
CC GO; GO:0007165; P:signal transduction; TAS.
CC InterPro; IPR006020; PTB_P1D.
CC InterPro; IPR001452; SH3.
CC Pfam; PF00018; SH3; 1.
CC ProDom; PD000066; SH3; 1.
CC SMART; SM00462; PTB; 1.
CC SMART; SM00326; SH3; 1.
CC PROSITE; PS50002; SH3; 1.
CC SH3 domain; Phosphorylation.
KW DOMAIN 69 129 PH (FIRST PART).
FT DOMAIN 210 213 POLY-PRO.
FT DOMAIN 322 325 POLY-PRO.
FT DOMAIN 381 414 PH (SECOND PART).
FT DOMAIN 421 440 PRO-RICH.
FT DOMAIN 532 591 SH3.
FT DOMAIN 615 651 PRO-RICH.
FT DOMAIN 659 664 POLY-SER.
SQ SEQUENCE 822 AA; 91081 MW; AC5EB1D28B784B3B CRC64;

Query Match 72.7% Score 32; DB 1; Length 822;
Best Local Similarity 85.7%; Pred. No. 81;
Matches 6; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 3 AELVHFL 9
Db 355 ADLVHFL 361
|:|||||
|:|||||

RESULT 29
COAD STRPY STANDARD; PRT; 163 AA.
AC PS8104;
DT 16-OCT-2001 (Rel. 40, Created)
DT 16-OCT-2001 (Rel. 40, Last sequence update)
DT 15-MAR-2004 (Rel. 43, Last annotation update)
DE Phosphatantethine adenyllyltransferase (EC 2.7.7.3) (Pantetheine-
DE phosphate adenyllyltransferase) (PPAT) (Dephospho-CoA
DE pyrophosphorylase).
GN COAD OR KDTB OR SPI1537 OR SPYM3_1188 OR SPS0674 OR SPYM18_1554.
OS Streptococcus pyogenes,
OS Streptococcus pyogenes (serotype M3), and
OS Streptococcus pyogenes (serotype M18).
OC Bacteria; Firmicutes; Lactobacillales; Streptococcaceae;
OC Streptococcus.
OX NCBI_TaxID=1314, 198466, 186103;
```

```
RN SEQUENCE FROM N.A.
RP STRAIN=SF370 / ATCC 700294 / Serotype M1;
RC MEDLINE=21192684; PubMed=11296296;
RA Ferretti J.J., McShane W.M., Ajdic D.J., Savic D.J., Savic G., Lyon K.,
RA Primeaux C., Sezate S., Suvorov A.N., Kenton S., Lai H.S., Lin S.P.,
RA Qian Y., Jia H.G., Najjar F.Z., Ren Q., Zhu H., Song L., White J.,
RA Yuan X., Clifton S.W., Roe B.A., McLaughlin R.;
RT "Complete genome sequence of an M1 strain of Streptococcus
RT pyogenes."
RL Proc. Natl. Acad. Sci. U.S.A. 98:4658-4663(2001).
RN SEQUENCE FROM N.A.
RP STRAIN=MGAS315 / Serotype M3;
RC MEDLINE=22133808; PubMed=12122206;
RA Beres S.B., Sylva G.L., Barbian K.D., Lei B., Hoff J.S.,
RA Mammarella N.D., Liu M.-Y., Smoot J.C., Porcella S.F., Parkins L.D.,
RA Campbell D.S., Smith T.M., McCormick J.K., Leung D.Y.M.,
RA Schlievert P.M., Musser J.M.;
RT "Genome sequence of a serotype M3 strain of group A Streptococcus:
RT phage-encoded toxins, the high-virulence phenotype, and clone
RT emergence."
RL Proc. Natl. Acad. Sci. U.S.A. 99:10078-10083(2002).
RN SEQUENCE FROM N.A.
RP STRAIN=SSI-1 / Serotype M3;
RC MEDLINE=22683278; PubMed=12799345;
RA Nakagawa I., Kurokawa K., Yamashita A., Nakata M., Tomiyasu Y.,
RA Okahashi N., Kawabata S., Yamazaki K., Shiba T., Yasunaga T.,
RA Hayashi H., Hattori M., Hamada S.;
RT "Genome sequence of an M3 strain of Streptococcus pyogenes reveals a
RT large-scale genomic rearrangement in invasive strains and new insights
RT into phage evolution."
RL Genome Res. 13:1042-1055(2003).
RN SEQUENCE FROM N.A.
RP STRAIN=MGAS8232 / Serotype M18;
RC MEDLINE=21927593; PubMed=11917108;
RA Smoot J.C., Barbian K.D., Van Gompel J.J., Smoot L.M., Chaussee M.S.,
RA Sylva G.L., Sturdevant D.E., Ricklefs S.M., Porcella S.F.,
RA Parkins L.D., Beres S.B., Campbell D.S., Smith T.M., Zhang Q.,
RA Kapur V., Daly J.A., Veasey L.G., Musser J.M.;
RT "Genome sequence and comparative microarray analysis of serotype M18
RT group A Streptococcus strains associated with acute rheumatic fever
RT outbreaks."
RL Proc. Natl. Acad. Sci. U.S.A. 99:4668-4673(2002).
CC -!- FUNCTION: Reversibly transfers an adenyllyl group from ATP to 4'-
CC phosphopantetheine, yielding dephospho-CoA (dPCoA) and
CC pyrophosphate (By similarity).
CC -!- CATALYTIC ACTIVITY: ATP + pantetheine 4'-phosphate = diphosphate +
CC 3'-dephospho-CoA.
CC -!- PATHWAY: Coenzyme A (CoA) biosynthesis; fourth step.
CC -!- SUBUNIT: Homohexamer (By similarity).
CC -!- SUBCELLULAR LOCATION: Cytoplasmic (By similarity).
CC -!- SIMILARITY: Belongs to the bacterial coad family.
CC -----
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (see http://www.isb-sib.ch/announce/
CC or send an email to license@isb-sib.ch).
CC -----
CC EMBL; AS006586; AAK34331.1; -.
CC EMBL; AS014159; AAM79795.1; -.
CC EMBL; AP005143; BAC63769.1; -.
CC EMBL; AS010069; AAL98121.1; -.
CC HSSP; P23875; 1B6T.
CC HAMAP; MF_00151; -.
CC InterPro; IPR004821; Cyt tran rel.
CC InterPro; IPR004820; Cytidyltransf.
CC InterPro; IPR001980; LPS_biosynth.
```

```
DR Pfam; PF01467; CTP_transf_2; 1.
DR PRINTS; PF01020; LPSBIOSINTSS.
DR TIGRFAMs; TIGR01510; coad_prev_kdtB; 1.
DR TIGRFAMs; TIGR00125; cytIran_rei; 1.
DR Transferrase; Nucleotidyltransferase; Coenzyme A biosynthesis;
KW Complete proteome.
SQ SEQUENCE 163 AA; 18629 MW; 310B9D9A990B3158 CRC64;

Query Match 70.5%; Score 31; DB 1; Length 163;
Best Local Similarity 62.5%; Pred. No. 26;
Matches 5; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

Qy 1 KVAVLVHF 8
Db 133 RVRELIHF 140
:|:|:|:|

RESULT 30
PHOU_CAUCR STANDARD; PRT; 230 AA.
AC Q9RF47;
DT 16-OCT-2001 (Rel. 40, Created)
DT 16-OCT-2001 (Rel. 40, Last sequence update)
DT 10-OCT-2003 (Rel. 42, Last annotation update)
DE Phosphate transport system protein phou.
GN PHOU OR CC0293.
OS Caulobacter crescentus.
OC Bacteria; Proteobacteria; Alphaproteobacteria; Caulobacteriales;
OC Caulobacteriaceae; Caulobacter.
OX NCBI_TaxID=155892;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=CB15N / NA1000;
RX MEDLINE=20096675; PubMed=10629178;
RA Gonin M., Quardokus E.M., O'Donnol D., Maddock J.R., Brun Y.V.;
RT "Regulation of stalk elongation by phosphate in Caulobacter
crescentus.";
RL J. Bacteriol. 182:337-347(2000).
[2]
RP SEQUENCE FROM N.A.
RC STRAIN=ATCC 19089 / CB15;
RX MEDLINE=21173698; PubMed=11259647;
RA Nierman W.C., Feldblum T.V., Laub M.T., Paulsen I.T., Nelson K.E.,
Eisen J.A., Heidelberg J.F., Alley M.R.K., Ohta N., Maddock J.R.,
Petrocka I., Nelson W.C., Newton A., Stephens C., Phadke N.D., Ely B.,
DeBoy R.T., Dodson R.J., Durkin A.S., Gwinn M.L., Haft D.H.,
Kolonay J.F., Smit J., Craven M.B., Khouri H., Shetty J., Berry K.,
Uterback T., Tran K., Wolf A., Vamathevan J., Ermolaeva M., White O.,
Saizberg S.L., Venter J.C., Shapiro L., Fraser C.M.;
RT "Complete genome sequence of Caulobacter crescentus.";
RL Proc. Natl. Acad. Sci. U.S.A. 98:4136-4141(2001).
CC -!- FUNCTION: NOT KNOWN; PROBABLY INVOLVED IN PHOSPHATE TRANSPORT
AND/OR METABOLISM (BY SIMILARITY).
CC -!- SUBCELLULAR LOCATION: Cytoplasmic (By similarity).
CC -!- SIMILARITY: Belongs to the phou family.
-----
This SWISS-PROT entry is copyright. It is produced through a collaboration
between the Swiss Institute of Bioinformatics and the EMBL outstation -
the European Bioinformatics Institute. There are no restrictions on its
use by non-profit institutions as long as its content is in no way
modified and this statement is not removed. Usage by and for commercial
entities requires a license agreement (See http://www.isb-sib.ch/announce/
or send an email to license@isb-sib.ch).
-----
EMBL; AF196490; AAF15532.1; -
EMBL; AE005703; AAK22280.1; -
PIR; D87285; D87285.
TIGR; CC0293; -.
InterPro; IPR008170; Phou.
Pfam; PF01895; Phou; 2.
KW Phosphate transport; Complete proteome.
FT CONFLICT 102 102 K -> N (IN REF. 1).
FT CONFLICT 153 153 V -> L (IN REF. 1).
```

```
SQ SEQUENCE 230 AA; 25583 MW; 0998E40680F5F1CB CRC64;

Query Match 70.5%; Score 31; DB 1; Length 230;
Best Local Similarity 57.1%; Pred. No. 37;
Matches 4; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

Qy 2 VAEVLVHF 8
Db 205 IAEIHF 211
:|:|:|:|

RESULT 31
MGFI_HUMAN STANDARD; PRT; 308 AA.
AC Q9HAY2; Q9H215;
DT 28-FEB-2003 (Rel. 41, Created)
DT 28-FEB-2003 (Rel. 41, Last sequence update)
DT 15-MAR-2004 (Rel. 43, Last annotation update)
DE Melanoma-associated antigen F1 (MAGE-F1 antigen).
GN MAGEF1.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
RP SEQUENCE FROM N.A.
RX MEDLINE=21213901; PubMed=11313144;
RA Stone B., Schummer M., Paley P.J., Crawford M., Ford M., Urban N.,
Nelson B.H.;
RT "MAGE-F1, a novel ubiquitously expressed member of the MAGE
superfamily.";
RL Gene 267:173-182(2001).
[2]
RP SEQUENCE FROM N.A.
RC TISSUE=Lung;
RX MEDLINE=22388257; PubMed=12477932;
RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,
Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
Stapleton M.J., Udutin T.B., Toshiyuki S., Carninci P., Prange C.,
Rana S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullany S.J.,
Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
Pahay J., Helton E., Kettelman M., Madan A., Rodriguez S., Sanchez A.,
Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,
Butterfield Y.S.N., Krzywinski M.I., Skalska U., Smailus D.E.,
Schnerch A., Schein J.E., Jones S.J.M., Marra M.A.;
RT "Generation and initial analysis of more than 15,000 full-length
human and mouse cDNA sequences";
RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
[3]
RP SEQUENCE OF 1-284 FROM N.A.
RC TISSUE=Kidney;
RX MEDLINE=21347234; PubMed=11454705;
RA Chomez P., De Backer O., Bertrand M., De Plaen E., Boon T., Lucas S.;
RT "An overview of the MAGE gene family with the identification of all
human members of the family.";
RL Cancer Res. 61:5544-5551(2001).
CC -!- TISSUE SPECIFICITY: Ubiquitous.
CC -!- SIMILARITY: Contains 1 MAGE domain.
-----
This SWISS-PROT entry is copyright. It is produced through a collaboration
between the Swiss Institute of Bioinformatics and the EMBL outstation -
the European Bioinformatics Institute. There are no restrictions on its
use by non-profit institutions as long as its content is in no way
modified and this statement is not removed. Usage by and for commercial
entities requires a license agreement (See http://www.isb-sib.ch/announce/
or send an email to license@isb-sib.ch).
```

```
CC or send an email to license@sib-sib.ch).
CC -----
DR EMBL; AF295378; AAC30208.1; -.
DR EMBL; BC010056; AAH10056.1; -.
DR EMBL; AF320910; AAG38606.1; -.
DR InterPro; IPR002190; MAGE.
DR Pfam; PF01454; MAGE; 1.
DR PROSITE; PS50838; MAGE; 1.
KW Antigen.
FT DOMAIN 76 277 MAGE.
SQ SEQUENCE 308 AA; 35308 MW; 8FB0092653090580 CRC64;

Query Match 70.5%; Score 31; DB 1; Length 308;
Best Local Similarity 87.8%; Pred. No. 50;
Matches 7; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2 VAELVHFL 9
    |||||
DB 80 VAELVQFL 87

RESULT 32
MAG1 HUMAN STANDARD; PRT; 309 AA.
AC P43355; O00346;
DT 01-NOV-1995 (Rel. 32, Created)
DT 01-NOV-1995 (Rel. 32, Last sequence update)
DT 15-MAR-2004 (Rel. 43, Last annotation update)
DE Melanoma-associated antigen 1 (MAGE-1 antigen) (Antigen M23-E).
GN MAGEA1 OR MAGE1 OR MAGE1A.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
RP SEQUENCE FROM N.A.
RX MEDLINE=52086861; PubMed=1840703;
RA van der Bruggen P., Traversari C., Chomez P., Lurquin C., de Plaen E.,
RA van den Eynde B., Knuth A., Boon T.;
RT "A gene encoding an antigen recognized by cytolytic T lymphocytes on
RT a human melanoma."
RL Science 254:1643-1647(1991).
RN [2]
RP SEQUENCE FROM N.A.
RC TISSUE=Skin;
RX MEDLINE=94311935; PubMed=8037761;
RA Ding M., Beck R.J., Keller C.J., Fenton R.G.;
RT "Cloning and analysis of MAGE-1-related genes."
RL Biochem. Biophys. Res. Commun. 202:549-555(1994).
RN [3]
RP SEQUENCE FROM N.A.
RX MEDLINE=20314869; PubMed=10854409;
RA Mallon A.M., Platzer M., Bates R., Gloeckner G., Botcherby M.,
RA Nordsiek G., Strivens M.A., Kloschis P., Dangel A., Cunningham D.,
RA Straw R., Weston P., Hunter C., Gilbert M., Fernando S., Goodall K.,
RA Kerry G., Greystrom J.S., Clark D., Goerdes M., Blechschmidt K.,
RA Rump A., Hinzmann B., Mundy C.R., Miller W., Poustka A., Herman G.E.,
RA Rhodes M., Denny P., Rosenthal A., Brown S.D.M.;
RT "Comparative genome sequence analysis of the Bpa/Str region in mouse
RT and man."
RL Genome Res. 10:758-775(2000).
RN [4]
RP SEQUENCE FROM N.A., AND VARIANT ALA-32.
RA Chen H., Wang L., Mei M., Qin L., Cong X., Xu J., Wei L., Wang Y.,
RA Chen W.;
RT "The polymorphism of MAGE-1 gene in Chinese people."
RN Submitted (SEP-2002) to the EMBL/GenBank/DBJ databases.
RN [5]
RP MUTAGENESIS.
RC TISSUE=Blood;
RX MEDLINE=94157413; PubMed=8113684;
RA Gaugler B., van den Eynde B., van der Bruggen P., Romero P.,
RA Gaforio J.J., de Plaen E., Lethe B., Brasseur F., Boon T.;
```

```
RT "Human gene MAGE-3 codes for an antigen recognized on a melanoma by
RT autologous cytolytic T lymphocytes."
RL J. Exp. Med. 179:921-930(1994).
RN [6]
RP SUBCELLULAR LOCATION.
RX MEDLINE=95012905; PubMed=7927954;
RA Schultze-Thater E., Juretic A., Dellabona P., Luscher U., Siegrist W.,
RA Harder F., Heberer M., Zuber M., Spagnoli G.C.;
RT "MAGE-1 gene product is a cytoplasmic protein."
RL Int. J. Cancer 59:435-439(1994).
CC -1- FUNCTION: Not known, though may play a role in embryonal
CC development and tumor transformation or aspects of tumor
CC progression. Antigen recognized on a melanoma by autologous
CC cytolytic T lymphocytes.
CC -1- SUBCELLULAR LOCATION: Cytoplasmic.
CC -1- TISSUE SPECIFICITY: Expressed in many tumors of several types,
CC such as melanoma, head and neck squamous cell carcinoma, lung
CC carcinoma and breast carcinoma, but not in normal tissues except
CC for testes. Never expressed in kidney tumors, leukemias and
CC lymphomas.
CC -1- SIMILARITY: Contains 1 MAGE domain.
CC -----
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL Outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See http://www.ebi.ac.uk/announcements/
CC or send an email to license@sib-sib.ch).
CC -----
DR EMBL; M77481; AAA03229.1; -.
DR EMBL; U82670; -. NOT_ANNOTATED_CDS.
DR EMBL; AY148486; AAN62752.1; -.
DR Genew; HGNC:6796; MAGEA1.
DR MIM; 300016; -.
DR GO; GO:0005886; C:plasma membrane; TAS.
DR InterPro; IPR002190; MAGE.
DR Pfam; PF01454; MAGE; 1.
DR PROSITE; PS50838; MAGE; 1.
KW Antigen; Multigene family; Polymorphism; Tumor antigen.
FT DOMAIN 102 301
FT DOMAIN 33 36 POLY-SER.
FT VARIANT 32 32 T -> A (probable polymorphism).
FT VARIANT 72 72 R -> Q (in dbSNP:2008144).
FT MUTAGEN 163 163 D->A: ABOLISHES HLA-A1 BINDING.
FT MUTAGEN 169 169 Y->A: ABOLISHES HLA-A1 BINDING.
SQ SEQUENCE 309 AA; 34342 MW; 544EBB1F9F4E9D33 CRC64;

Query Match 70.5%; Score 31; DB 1; Length 309;
Best Local Similarity 77.8%; Pred. No. 50;
Matches 7; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY 1 KVAVLVHFL 9
    |||||
DB 105 KVAVLVQFL 113

RESULT 33
RECF_SALTI
ID RECF_SALTI STANDARD; PRT; 356 AA.
AC Q8Z2N4;
DT 28-FEB-2003 (Rel. 41, Created)
DT 28-FEB-2003 (Rel. 41, Last sequence update)
DT 10-OCT-2003 (Rel. 42, Last annotation update)
DE DNA replication and repair protein recf.
GN RECF OR STY3942 OR T3683.
OS Salmonella typhi.
OC Bacteria; Proteobacteria; Gammaproteobacteria; Enterobacteriales;
OC Enterobacteriaceae; Salmonella.
OX NCBI_TaxID=601;
RN [1]
```



```

CC or send an email to license@sib-sib.ch).
CC -----
DR EMBL; AE001340; AAC68296.1; -.
DR PIR; G71482; G71482.
DR InterPro; IPR001650; Helicase_C.
DR InterPro; IPR00185; SecA.
DR Pfam; PF00271; Helicase_C; 1.
DR Pfam; PF01043; SecA_protein; 1.
DR PRINTS; PR00906; SECA.
DR TIGRFAMs; TIGR00963; secA; 1.
DR PROSITE; PS01312; SECA; 1.
KW Protein transport; ATP-binding; Membrane; Translocation; Transport;
KW Complete proteome.
FT NP_BIND 114 121 ATP (POTENTIAL).
SQ SEQUENCE 969 AA; 110358 MW; 2D551C2269EE86BE CRC64;

Query Match 70.5%; Score 31; DB 1; Length 969;
Best Local Similarity 75.0%; Pred. No. 1.6e+02;
Matches 6; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KVAELVHF 8
Db 255 RVAELVYF 262

```

Search completed: July 23, 2004, 12:52:01
Job time : 15 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2004 Compugen Ltd.

OM protein - protein search, using sw model

Run on: July 23, 2004, 12:48:16 ; Search time 35 Seconds
(without alignments)
81.133 Million cell updates/sec

Title: US-09-458-298b-711

Perfect score: 44

Sequence: 1 KVAELVHFL 9

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 1017041 seqs, 315518202 residues

Total number of hits satisfying chosen parameters: 1017041

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database :

SPTREMBL 25: *
1: sp_archaea: *
2: sp_bacteria: *
3: sp_fungi: *
4: sp_human: *
5: sp_invertebrate: *
6: sp_mammal: *
7: sp_mhc: *
8: sp_organelle: *
9: sp_phase: *
10: sp_plant: *
11: sp_rodent: *
12: sp_virus: *
13: sp_vertebrate: *
14: sp_unclassified: *
15: sp_rvirus: *
16: sp_bacteriap: *
17: sp_archaeap: *

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	44	100.0	315	4 Q7Z5K4	Q7Z5K4 homo sapien
2	44	100.0	316	4 Q8WWH6	Q8WWH6 homo sapien
3	39	88.6	163	16 Q67920	Q67920 aquifex ae
4	38	86.4	163	16 Q81XP4	Q81XP4 bacillus an
5	38	86.4	163	16 Q816B3	Q816B3 bacillus ce
6	38	86.4	169	16 Q9K7E0	Q9K7E0 bacillus ha
7	38	86.4	540	4 Q9NUL7	Q9NUL7 homo sapien
8	37	84.1	314	4 Q96E03	Q96E03 homo sapien
9	37	84.1	683	8 Q95G99	Q95G99 streptocac
10	37	84.1	2471	12 Q9YTK3	Q9YTK3 ateline her
11	36	81.8	163	16 Q8EJMO	Q8EJMO shewanella
12	36	81.8	177	4 Q9BZ80	Q9BZ80 homo sapien
13	36	81.8	184	16 Q9PCE5	Q9PCE5 xylella fas
14	36	81.8	184	16 Q87CN4	Q87CN4 xylella fas
15	36	81.8	252	16 Q93IA8	Q93IA8 rhizobium m
16	36	81.8	279	11 Q9D378	Q9D378 mus musculus

17	36	81.8	279	11 Q9CPR8	Q9CPR8 mus musculus
18	36	81.8	294	11 Q99PB1	Q99PB1 mus musculus
19	36	81.8	318	4 Q9BUN9	Q9BUN9 homo sapien
20	36	81.8	373	4 Q96D45	Q96D45 homo sapien
21	36	81.8	384	8 Q8HWW8	Q8HWW8 aphananthe
22	36	81.8	643	4 Q8TD91	Q8TD91 homo sapien
23	36	81.8	803	4 Q9UNY1	Q9UNY1 homo sapien
24	36	81.8	856	11 Q9R2C5	Q9R2C5 mus musculus
25	36	81.8	859	6 Q9NIE9	Q9NIE9 bos taurus
26	36	81.8	892	4 Q9YGF6	Q9YGF6 homo sapien
27	36	81.8	905	11 Q9WUX5	Q9WUX5 mus musculus
28	36	81.8	911	6 Q9NIF0	Q9NIF0 bos taurus
29	35	79.5	343	4 Q96M61	Q96M61 homo sapien
30	35	79.5	358	16 Q8ZR10	Q8ZR10 salmonella
31	35	79.5	400	11 Q91VT7	Q91VT7 mus musculus
32	35	79.5	715	4 Q9H6K9	Q9H6K9 homo sapien
33	35	79.5	729	11 Q99K30	Q99K30 mus musculus
34	35	79.5	743	4 Q9H6S3	Q9H6S3 homo sapien
35	34	77.3	140	5 Q81788	Q81788 echinococcu
36	34	77.3	210	16 Q8ZJ69	Q8ZJ69 yersinia pe
37	34	77.3	258	16 Q92V84	Q92V84 rhizobium m
38	34	77.3	317	4 Q14798	Q14798 homo sapien
39	34	77.3	660	8 Q9GDV6	Q9GDV6 veratrum vi
40	34	77.3	667	4 Q8NHV8	Q8NHV8 homo sapien
41	34	77.3	760	16 Q9FC45	Q9FC45 streptomyce
42	34	77.3	1174	13 Q7ZV56	Q7ZV56 xenopus lae
43	34	77.3	2477	12 Q80BL6	Q80BL6 salmeline
44	33	75.0	213	4 Q8TE16	Q8TE16 homo sapien
45	33	75.0	276	16 Q88Y59	Q88Y59 lactobacill

ALIGNMENTS

RESULT 1

Q7Z5K4 PRELIMINARY; PRT; 315 AA.
ID Q7Z5K4
AC Q7Z5K4; PRELIMINARY; PRT; 315 AA.
DT 01-OCT-2003 (Tremblrel. 25, Created)
DT 01-OCT-2003 (Tremblrel. 25, Last sequence update)
DT 01-OCT-2003 (Tremblrel. 25, Last annotation update)
DE Melanoma antigen family A 9 (Fragment)
GN MAGEA9.
OS Homo sapiens (Human)
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
RP SEQUENCE FROM N.A.
RC TISSUE=Liver;
RA Zhu J., Feng Z., Guan X.;
RT "MAGE-9 antigen (MAGE9) gene expressed in human hepatocellular
RT carcinoma patients."
RL Submitted (MAY-2003) to the EMBL/GenBank/DBJ databases.
DR EMBL; AY310325; AAF82171.1; -.
FT NON TER 315 315
SQ SEQUENCE 315 AA; 35116 MW; C9488470D409B96F CRC64;

Query Match 100.0%; Score 44; DB 4; Length 315;

Best Local Similarity 100.0%; Pred. No. 0.6; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KVAELVHFL 9

|||||||
111 KVAELVHFL 119

RESULT 2

Q8WWH6 PRELIMINARY; PRT; 316 AA.

ID Q8WWH6

AC Q8WWH6

DT 01-MAR-2002 (Tremblrel. 20, Created)

DT 01-MAR-2002 (Tremblrel. 20, Last sequence update)

```

DT 01-MAR-2003 (TReMBLrel. 23, Last annotation update)
DE Tumor antigen MAGE-N.
OS Homo sapiens (Human).
OC Eukaryota; Eukarya; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
RP SEQUENCE FROM N.A.
RC TISSUE=Hepatoma;
RA Sui Y., Ye J., Wu W.;
RT "Cloning of a new gene of MAGE family in human hepatocellular
RT carcinoma.";
RL Submitted (NOV-2001) to the EMBL/GenBank/DBJ databases.
DR EMBL; AF443295; AAL37897.1; -.
DR InterPro; IPR002190; MAGE.
DR Pfam; PF01454; MAGE; 1.
DR PROSITE; PS0838; MAGE; 1.
SQ SEQUENCE 316 AA; 35409 MW; A463A9A740A089DF CRC64;

Query Match 100.0%; Score 44; DB 4; Length 316;
Best Local Similarity 100.0%; Pred. No. 0.6;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KVAELVHFL 9
Db 112 KVAELVHFL 120

RESULT 3
O67920 PRELIMINARY; PRT; 163 AA.
ID O67920;
AC O67920;
DT 01-AUG-1998 (TReMBLrel. 07, Created)
DT 01-AUG-1998 (TReMBLrel. 07, Last sequence update)
DT 01-JUN-2003 (TReMBLrel. 24, Last annotation update)
DE Hypothetical protein AQ_2171.
GN AQ_2171.
OS Aquifex aeolicus.
OC Bacteria; Aquificae; Aquificales; Aquificaceae; Aquifex.
OX NCBI_TaxID=63363;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=VF5;
RX MEDLINE=98196666; PubMed=9537320;
RA Deckert G., Warren P.V., Gaasterland T., Young W.G., Lenox A.L.,
RA Graham D.E., Overbeek R., Snead M.A., Keller M., Aufay M., Huber R.,
RA Feldman R.A., Short J.M., Olson G.J., Swanson R.V.;
RT "The complete genome of the hyperthermophilic bacterium Aquifex
RT aeolicus.";
RL Nature 392:353-358(1998).
DR EMBL; AE000776; AAC07894.1; -.
DR GO; GO:0016787; F:hydrolase activity; IEA.
DR GO; GO:0008152; P:metabolism; IEA.
DR InterPro; IPR006549; HAD-SF-IIIA.
DR InterPro; IPR008334; Hydrolase.
DR InterPro; IPR008230; Sugar Ptase.
DR Pfam; PF00702; Hydrolase; 1.
DR TIGRFAMs; TIGR01662; HAD-SF-IIIA; 1.
DR PIRSF; PIRSF006118; Sugar Ptase; 1.
DR PIRSF; PIRSF006118; Sugar Ptase; 1.
KW Hypothetical protein; Complete proteome.
SQ SEQUENCE 163 AA; 18356 MW; 7FD36C6D4E1F068E CRC64;

Query Match 88.6%; Score 39; DB 16; Length 163;
Best Local Similarity 77.8%; Pred. No. 3.6;
Matches 7; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KVAELVHFL 9
Db 152 EVAEIHFLL 160

RESULT 4
Q81XP4 PRELIMINARY; PRT; 163 AA.
ID Q81XP4;
AC Q81XP4;
DT 01-JUN-2003 (TReMBLrel. 24, Created)
DT 01-JUN-2003 (TReMBLrel. 24, Last sequence update)
DT 01-OCT-2003 (TReMBLrel. 25, Last annotation update)
DE Hypothetical protein.
GN BA5189.
OS Bacillus anthracis (strain Ames).
OC Bacteria; Firmicutes; Bacilliales; Bacillaceae; Bacillus.
OX NCBI_TaxID=198094;
RN [1]
RP SEQUENCE FROM N.A.
RX MEDLINE=22608414; PubMed=12721629;
RA Read T.D., Peterson S.N., Tourasse N., Baillie L.W., Paulsen I.T.,
RA Nelson K.E., Tettelin H., Fouts D.E., Eisen J.A., Gill S.R.,
RA Holtzapple E.K., Okstad O.A., Helgason E., Ristone J., Wu M.,
RA Kolonay J.F., Beanan M.J., Dodson R.J., Brinkac L.M., Gwinn M.,
RA DeBoy R.T., Madpu R., Daugherty S.C., Durkin A.S., Haft D.H.,
RA Nelson W.C., Peterson J.D., Pop M., Khouri H.M., Radune D.,
RA Benton J.L., Mahamoud Y., Jiang L., Hance I.R., Weidman J.P.,
RA Berry K.J., Plaut R.D., Wolf A.M., Watkins K.L., Nierman W.C.,
RA Hazen A., Cline R., Redmond C., Thwaite J.E., White O., Salzberg S.L.,
RA Thomson B., Friedlander A.M., Koehler T.M., Hanna P.C., Kolsto A.-B.,
RA Fraser C.M.;
RT "The genome sequence of Bacillus anthracis Ames and comparison to
RT closely related bacteria.";
RL Nature 423:81-86(2003).
DR EMBL; AE017040; AAP28858.1; -.
DR TIGR; BA5189; -.
DR InterPro; IPR002752; DUF64.
DR Pfam; PF01892; DUF64; 1.
KW Hypothetical protein; Complete proteome.
SQ SEQUENCE 163 AA; 18228 MW; 7B8F8515AD3C7CFF CRC64;

Query Match 86.4%; Score 38; DB 16; Length 163;
Best Local Similarity 87.5%; Pred. No. 5.9;
Matches 7; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 2 VAEIVHFL 9
Db 25 IAEIVHFL 32

RESULT 5
Q816B3 PRELIMINARY; PRT; 163 AA.
ID Q816B3;
AC Q816B3;
DT 01-JUN-2003 (TReMBLrel. 24, Created)
DT 01-JUN-2003 (TReMBLrel. 24, Last sequence update)
DT 01-OCT-2003 (TReMBLrel. 25, Last annotation update)
DE Low temperature requirement C protein.
GN BC4955.
OS Bacillus cereus (strain ATCC 14579 / DSM 31).
OC Bacteria; Firmicutes; Bacilliales; Bacillaceae; Bacillus.
OX NCBI_TaxID=226900;
RN [1]
RP SEQUENCE FROM N.A.
RX MEDLINE=22608415; PubMed=12721630;
RA Ivanova N., Sorokin A., Anderson I., Galleron N., Candelon B.,
RA Kparal V., Bhattacharyya A., Reznik G., Mikhailova N., Lapidus A.,
RA Chu L., Mazur M., Goltsman E., Larsen N., D'Souza M., Walunas T.,
RA Grechkin Y., Pusch G., Haselkorn R., Fonstein M., Ehrlich S.D.,
RA Overbeek R., Kyrpides N.;
RT "Genome sequence of Bacillus cereus and comparative analysis with
RT Bacillus anthracis.";
RL Nature 423:87-91(2003).
DR EMBL; AE017014; AAP11827.1; -.
DR InterPro; IPR002752; DUF64.
DR Pfam; PF01892; DUF64; 1.
KW Complete proteome.
SQ SEQUENCE 163 AA; 18270 MW; ACOA38BE16057D4C CRC64;

Query Match 86.4%; Score 38; DB 16; Length 163;

```

```
Best Local Similarity 87.5%; Pred. No. 5.9;
Matches 7; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 2 VAEVLVHFL 9
Db 25 IAEVLVHFL 32

RESULT 6
Q9K7E0 PRELIMINARY; PRT; 169 AA.
AC Q9K7E0;
DT 01-OCT-2000 (TrEMBLrel. 15, Created)
DT 01-OCT-2000 (TrEMBLrel. 15, Last sequence update)
DT 01-JUN-2003 (TrEMBLrel. 24, Last annotation update)
DE Low temperature requirement C protein.
GN BH3424.
OS Bacillus halodurans.
OC Bacteria; Firmicutes; Bacillales; Bacillaceae; Bacillus.
OX NCBI_TaxID=86665;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=C-125 / JCM 9153;
RX MEDLINE=20512582; PubMed=11058132;
RA Takami H., Nakasone K., Takaki Y., Maeno G., Sasaki R., Masui N.,
Fuji F., Hirama C., Nakamura Y., Ogasawara N., Kuhara S.,
RA Horikoshi K.;
RT "Complete genome sequence of the alkaliphilic bacterium Bacillus
halodurans and genomic sequence comparison with Bacillus subtilis.";
RL Nucleic Acids Res. 28:4317-4331 (2000).
DR EMBL; AP001518; BAB07143.1; -.
DR PIR; H84077; H84077.
DR InterPro; IPR002752; DUF64.
DR Pfam; PF01892; DUF64; 1.
KW Complete proteome.
SQ SEQUENCE 169 AA; 18954 MW; 09C631B5162FA591 CRC64;

Query Match 86.4%; Score 38; DB 16; Length 169;
Best Local Similarity 87.5%; Pred. No. 6.1;
Matches 7; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 2 VAEVLVHFL 9
Db 25 IAEVLVHFL 32

RESULT 7
Q9NUL7 PRELIMINARY; PRT; 540 AA.
AC Q9NUL7;
DT 01-OCT-2000 (TrEMBLrel. 15, Created)
DT 01-OCT-2000 (TrEMBLrel. 15, Last sequence update)
DT 01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
DE Hypothetical protein FLJ11282 (Putative DEAD-box helicase MDDX28)
DE (DEAD/H (Asp-Glu-Ala-Asp/His) box polypeptide 28).
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
RP SEQUENCE FROM N.A.
RC TISSUE=Placenta;
RA Isogai T., Ota T., Hayashi K., Sugiyama T., Otsuki T., Suzuki Y.,
RA Nishikawa T., Nagai K., Sugano S., Shiratori A., Sudo H.,
RA Nagatsuma M., Hosoi T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA Takahashi M., Chiba Y., Ishida S., Murakawa K., Ono Y., Takiguchi S.,
RA Watanabe S., Kimura K., Murakami K., Ishii S., Kawai Y., Saito K.,
RA Yamamoto J., Wakamatsu A., Nakamura Y., Negahari K., Masuho Y.,
RA Ninomiya K., Iwayanagi T.;
RT "NEDO human cDNA sequencing project.";
RL Submitted (FEB-2000) to the EMBL/GenBank/DBJ databases.
RN [2]
RP SEQUENCE FROM N.A.
```

```
RA Valgardottir R., Brøde G., Eide L.G., Frøngen E., Prydz H.;
RT "Cloning and characterization of MDDX28, a putative DEAD-box helicase
with mitochondrial and nuclear localization.";
RL Submitted (DEC-2000) to the EMBL/GenBank/DBJ databases.
RN [3]
RP SEQUENCE FROM N.A.
RC TISSUE=Brain;
RA Strausberg R.;
RL Submitted (FEB-2002) to the EMBL/GenBank/DBJ databases.
DR EMBL; AK002144; BAA92106.1; -.
DR EMBL; AF329821; AAG59833.1; -.
DR EMBL; BC024273; AAH24273.1; -.
DR Genew; HGNC:17330; DDX28.
DR GO; GO:0005524; F-ATP binding; IEA.
DR GO; GO:0008026; F-ATP dependent helicase activity; IEA.
DR GO; GO:0016787; F-hydrolase activity; IEA.
DR GO; GO:0003676; F-nucleic acid binding; IEA.
DR InterPro; IPR001410; DEAD.
DR InterPro; IPR001650; Helicase_C.
DR Pfam; PF00270; DEAD; 1.
DR Pfam; PF00271; helicase_C; 1.
DR SMART; SM00487; DEXDC; 1.
DR SMART; SM00490; HELIC; 1.
KW Hypothetical protein; ATP-binding; Helicase; Hydrolase.
SQ SEQUENCE 540 AA; 59551 MW; 19E8DA08203893B5 CRC64;

Query Match 86.4%; Score 38; DB 4; Length 540;
Best Local Similarity 88.9%; Pred. No. 19;
Matches 8; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1 KVAELVHFL 9
Db 377 KVAELVHFL 385

RESULT 8
Q96E03 PRELIMINARY; PRT; 314 AA.
AC Q96E03;
DT 01-DEC-2001 (TrEMBLrel. 19, Created)
DT 01-DEC-2001 (TrEMBLrel. 19, Last sequence update)
DT 01-MAR-2003 (TrEMBLrel. 23, Last annotation update)
DE Similar to melanoma antigen, family A, 2.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
RP SEQUENCE FROM N.A.
RC TISSUE=Adrenal gland;
RA Strausberg R.;
RL Submitted (AUG-2001) to the EMBL/GenBank/DBJ databases.
DR EMBL; BC013098; AAH13098.1; -.
DR InterPro; IPR002190; MAGE.
DR Pfam; PF01454; MAGE; 1.
DR PROSITE; PS00838; MAGE; 1.
SQ SEQUENCE 314 AA; 35024 MW; A94F16247D1BFBC0 CRC64;

Query Match 84.1%; Score 37; DB 4; Length 314;
Best Local Similarity 77.8%; Pred. No. 18;
Matches 7; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

Qy 1 KVAELVHFL 9
Db 112 KVAELVHFL 120

RESULT 9
Q95G99 PRELIMINARY; PRT; 683 AA.
AC Q95G99;
DT 01-DEC-2001 (TrEMBLrel. 19, Created)
DT 01-DEC-2001 (TrEMBLrel. 19, Last sequence update)
```

```

DT 01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
DE NADH dehydrogenase F (Fragment).
GN NDHF.
OS Streptococcus ramosa.
OC Chloroplast.
CC Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
CC Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae;
CC PACAD clade; Panicoideae; Paniceae; Streptocystis.
OX NCBI_TaxID=158166;
RN [1]
RN SEQUENCE FROM N.A.
RA Giussani L.M., Cota-Sanchez J.H., Zuloaga F.O., Kellogg E.A.;
RT "A molecular phylogeny of the grass subfamily Panicoideae (Poaceae)
RT shows multiple origins of C4 photosynthesis.";
RL Am. J. Bot. 0:0-0(2001).
DR EMBL; AY029686; AAK50525.1; -.
DR GO; GO:0009507; C:chloroplast; IEA.
DR GO; GO:0016020; C:membrane; IEA.
DR GO; GO:0009523; C:photosystem II; IEA.
DR GO; GO:0008137; F:NADH dehydrogenase (ubiquinone) activity; IEA.
DR GO; GO:0016491; F:oxidoreductase activity; IEA.
DR GO; GO:0005215; F:transporter activity; IEA.
DR GO; GO:0006118; P:electron transport; IEA.
DR GO; GO:0006120; P:mitochondrial electron transport, NADH to u. . .; IEA.
DR GO; GO:0006810; P:transport; IEA.
DR InterPro; IPR003916; NADH_oxred5.
DR InterPro; IPR001750; Oxidored_q1.
DR InterPro; IPR002128; Oxidored_q1_C.
DR InterPro; IPR001516; Oxidored_q1_N.
DR InterPro; IPR005829; Sug transporter.
DR Pfam; PF00361; oxidored_q1; 1.
DR Pfam; PF01010; oxidored_q1_C; 1.
DR Pfam; PF00662; oxidored_q1_N; 1.
DR PRINTS; PR01434; NADH_OXRED5.
DR PROSITE; PS00217; SUGAR TRANSPORT 2; 1.
KW NAD; Oxidoreductase; Plastoquinone; Chloroplast.
FT NON_TER 1
FT NON_TER 683
SQ SEQUENCE 683 AA; 76675 MW; C49617F716205F5A CRC64;

Query Match 84.1%; Score 37; DB 8; Length 683;
Best Local Similarity 77.8%; Pred. No. 39;
Matches 7; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

Qy 1 KVAELVHFL 9
Db 663 KLAELTHFL 671

RESULT 10
ID Q9YTK3 PRELIMINARY; PRT; 2471 AA.
AC Q9YTK3;
DT 01-MAY-1999 (TrEMBLrel. 10, Created)
DT 01-MAY-1999 (TrEMBLrel. 10, Last sequence update)
DT 01-JUN-2003 (TrEMBLrel. 24, Last annotation update)
DE Large tegument protein.
OS Ateline herpesvirus 3.
CC Viruses; dsDNA viruses, no RNA stage; Herpesviridae;
CC Gammaherpesvirinae; Rhadinovirus.
OX NCBI_TaxID=85616;
RN [1]
RN SEQUENCE FROM N.A.
RA STRAIN=73;
RC MEDLINE=20091363; PubMed=10623770;
RA Albrecht J.C.;
RT "Primary structure of the Herpesvirus Ateles genome.";
RL J. Virol. 74:1033-1037(2000).
RN [2]
RN SEQUENCE FROM N.A.
RA STRAIN=73;
RC Albrecht J.-C., Fleckenstein B.;
RA Submitted (AUG-1998) to the EMBL/GenBank/DBJ databases.

DR EMBL; AF083424; AAC95588.1; -.
DR PIR; T42977; T42977.
DR InterPro; IPR006928; Herpes teg_N.
DR Pfam; PF04843; Herpes teg_N; 1.
SQ SEQUENCE 2471 AA; 280025 MW; ACC1575FEE225B1D CRC64;

Query Match 84.1%; Score 37; DB 12; Length 2471;
Best Local Similarity 55.6%; Pred. No. 1.4e+02;
Matches 5; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KVAELVHFL 9
Db 1520 KISELHFI 1528

RESULT 11
ID Q8EJMO PRELIMINARY; PRT; 163 AA.
AC Q8EJMO;
DT 01-MAR-2003 (TrEMBLrel. 23, Created)
DT 01-MAR-2003 (TrEMBLrel. 23, Last sequence update)
DT 01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
DE Transcriptional regulator, MerR family.
GN SO0443.
OS Shewanella oneidensis.
OC Bacteria; Proteobacteria; Gammaproteobacteria; Alteromonadales;
OC Alteromonadaceae; Shewanella.
OX NCBI_TaxID=70863;
RN [1]
RN SEQUENCE FROM N.A.
RC STRAIN=MR-1;
RX MEDLINE=22297686; PubMed=12368813;
RA Heidelberg J.F., Paulsen I.T., Nelson K.E., Gaidos E.J., Nelson W.C.,
RA Read T.D., Eisen J.A., Seshadri R., Ward N., Methe B., Clayton R.A.,
RA Meyer T., Tsapin A., Scott J., Beanan M., Brinkac L., Daugherty S.,
RA Daoy R.T., Dodson R.J., Durkin A.S., Haft D.H., Kolonay J.F.,
RA Madupu R., Peterson J.D., Umayam L.A., White O., Wolf A.M.,
RA Vamathevan J., Weidman J., Impraim M., Lee K., Berry K., Lee C.,
RA Mueller J., Khouri H., Gill J., Utterback T.R., McDonald L.A.,
RA Feldblyum T.V., Smith H.O., Venter J.C., Neelson K.H., Fraser C.M.;
RT "Genome sequence of the dissimilatory metal ion-reducing bacterium
RT Shewanella oneidensis.";
RL Nat. Biotechnol. 20:1118-1123(2002).
DR EMBL; AE015493; AAN53525.1; -.
DR TIGR; SO0443; -.
DR GO; GO:0005622; C:intracellular; IEA.
DR GO; GO:0003700; F:transcription factor activity; IEA.
DR GO; GO:0006355; P:regulation of transcription, DNA-dependent; IEA.
DR InterPro; IPR000551; HTH_MerR.
DR Pfam; PF00376; merR; 1.
DR PRINTS; PR00040; HTHMERR.
DR SMART; SM00422; HTH_MERR; 1.
DR PROSITE; PS00552; HTH_MERR_FAMILY; 1.
KW Complete proteome.
SQ SEQUENCE 163 AA; 17834 MW; 6DE0A3D55C2F2976 CRC64;

Query Match 81.8%; Score 36; DB 16; Length 163;
Best Local Similarity 75.0%; Pred. No. 16;
Matches 6; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KVAELVHFL 8
Db 96 KIAELLHF 103

RESULT 12
ID Q9BZ80 PRELIMINARY; PRT; 177 AA.
AC Q9BZ80;
DT 01-JUN-2001 (TrEMBLrel. 17, Created)
DT 01-JUN-2001 (TrEMBLrel. 17, Last sequence update)
DT 01-MAR-2003 (TrEMBLrel. 23, Last annotation update)
DE MAGE family testis and tumor-specific protein (Fragment).

```


GN MAGEC3
 OS Homo sapiens (Human)
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
 OX NCBI_TaxID=9606;
 RN (1)
 RP SEQUENCE FROM N.A.
 RC TISSUE=Blood;
 RX MEDLINE=20321428; PubMed=10861452;
 RA Lucas S., De Plaen E., Boon T.;
 RL Submitted (JAN-2001) to the EMBL/GenBank/DBJ databases.
 DR EMBL; AF333706; AAK00358.1; -;
 DR InterPro; IPR002190; MAGE.
 DR Pfam; PF01454; MAGE; 1.
 DR PROSITE; PS50838; MAGE; 1.
 FT NON TER 1 177
 FT TER 177 177
 SQ SEQUENCE 177 AA; 19702 MW; FA141309E327C4A0 CRC64;

 Query Match 81.8%; Score 36; DB 4; Length 177;
 Best Local Similarity 88.9%; Pred. No. 17;
 Matches 8; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

 QY 1 KVAELVHFL 9
 DB 98 KVAELVQFL 106

 RESULT 13
 Q9PCES PRELIMINARY; PRT; 184 AA.
 ID Q9PCES
 AC Q9PCES;
 DT 01-OCT-2000 (TrEMBLrel. 15, Created)
 DT 01-OCT-2000 (TrEMBLrel. 15, Last sequence update)
 DT 01-JUN-2003 (TrEMBLrel. 24, Last annotation update)
 DE Hypothetical protein Xf1836.
 GN Xf1836.
 OS Xylella fastidiosa.
 OC Bacteria; Proteobacteria; Gammaproteobacteria; Xanthomonadales;
 OC Xanthomonadaceae; Xylella.
 OX NCBI_TaxID=2371;
 RN (1)
 RP SEQUENCE FROM N.A.
 RC STRAIN=9a5C;
 RX MEDLINE=20365717; PubMed=10910347;
 RA Simpson A.J.G., Reinach F.C., Arruda P., Abreu F.A., Acencio M.,
 RA Alvarenga R., Alves L.M.C., Araya J.E., Baia G.S., Baptista C.S.,
 RA Barros M.H., Bonaccorsi E.D., Bordin S., Bove J.M., Briones M.R.S.,
 RA Bueno M.R.P., Camargo A.A., Camargo L.E.A., Carraro D.M., Carrer H.,
 RA Colauto N.B., Colombo C., Costa F.F., Costa M.C.R., Costa-Neto C.M.,
 RA Coutinho L.L., Cristofani M., Dias-Neto E., Docena C., El-Dorry H.,
 RA Facincani A.P., Ferreira A.J.S., Ferreira V.C.A., Ferro J.A.,
 RA Fraga J.S., Franca S.C., Franco M.C., Frohne M., Furlan L.R.,
 RA Garnier M., Goldman G.H., Goldman M.H.S., Gomes S.L., Gruber A.,
 RA Ho P.L., Hoheisel J.D., Junqueira M.L., Kemper E.L., Kitajima J.P.,
 RA Krieger J.E., Kuramae E.E., Laigret F., Lambais M.R., Leite L.C.C.,
 RA Lemos E.G.M., Lemos M.V.F., Lopes S.A., Lopes C.R., Machado J.A.,
 RA Machado M.A., Madeira A.M.B.N., Madeira H.M.F., Marino C.L.,
 RA Marques M.V., Martins E.A.L., Martins E.M.F., Matsukuma A.Y.,
 RA Menck C.F.M., Miracca E.C., Miyaki C.Y., Monteiro-Vitorello C.B.,
 RA Moon D.H., Nagai M.A., Nascimento A.L.T.O., Netto L.B.S.,
 RA Nhani A. Jr., Nobrega F.G., Nunes L.R., Oliveira M.A.,
 RA de Oliveira M.C., de Oliveira R.C., Palmieri D.A., Paris A.,
 RA Peixoto B.R., Pereira G.A.G., Pereira H.A. Jr., Pesquero J.B.,
 RA Quaggio R.B., Roberto P.G., Rodrigues V., de Rosa A.J.M.,
 RA de Rosa V.E. Jr., de Sa R.G., Santelli R.V., Sawasaki H.E.,

RA da Silva A.C.R., da Silva A.M., da Silva F.R., Silva W.A. Jr.,
 RA da Silveira J.F., Silvestri M.L.Z., Siqueira W.J., de Souza A.A.,
 RA de Souza A.P., Terenzi M.F., Truffi D., Tsai S.M., Tsuchioka M.H.,
 RA Vallada H., Van Sluys M.A., Verjovski-Almeida S., Vettore A.L.,
 RA Zago M.A., Zatz M., Meidanis J., Setubal J.C.;
 RT "The genome sequence of the plant pathogen Xylella fastidiosa.";
 RL Nature 406:151-159(2000).
 DR EMBL; AE004005; AAF84642.1; -;
 DR PIR; A82631; A82631.
 KW Hypothetical protein; Complete proteome.
 SQ SEQUENCE 184 AA; 19461 MW; 5D1D446EB2F73A03 CRC64;

 Query Match 81.8%; Score 36; DB 16; Length 184;
 Best Local Similarity 87.5%; Pred. No. 17;
 Matches 7; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

 QY 1 KVAELVHF 8
 DB 140 KVGELVHF 147

 RESULT 14
 Q87CN4 PRELIMINARY; PRT; 184 AA.
 ID Q87CN4
 AC Q87CN4;
 DT 01-JUN-2003 (TrEMBLrel. 24, Created)
 DT 01-JUN-2003 (TrEMBLrel. 24, Last sequence update)
 DT 01-JUN-2003 (TrEMBLrel. 24, Last annotation update)
 DE Conserved hypothetical protein.
 GN PD1031.
 OS Xylella fastidiosa (strain Temeculal / ATCC 700964).
 OC Bacteria; Proteobacteria; Gammaproteobacteria; Xanthomonadales;
 OC Xanthomonadaceae; Xylella.
 OX NCBI_TaxID=183190;
 RN (1)
 RP SEQUENCE FROM N.A.
 RX MEDLINE=22421331; PubMed=12533478;
 RA Van Sluys M.A., de Oliveira M.C., Monteiro-Vitorello C.B., Moon D.H.,
 RA Miyaki C.Y., Furlan L.R., Camargo L.E.A., da Silva A.C.R., da Silva F.R.,
 RA Takita M.A., Lemos E.G.M., Machado M.A., Ferro M.I.T., da Silva F.R.,
 RA Goldman M.H.S., Goldman G.H., Lemos M.V.F., El-Dorry H., Tsai S.M.,
 RA Carrer H., Carraro D.M., de Oliveira R.C., Nunes L.R., Siqueira W.J.,
 RA Coutinho L.L., Kimura E.T., Ferro E.S., Harakava R., Kuramae E.E.,
 RA Marino C.L., Gigliotti E., Abreu I.L., Alves L.M.C., do Amaral A.M.,
 RA Baia G.S., Blanco S.R., Brito M.S., Cannavan F.S., Celestino A.V.,
 RA da Cunha A.F., Fenille R.C., Ferro J.A., Formighieri E.P., Kishi L.T.,
 RA Leoni S.G., Oliveira A.R., Rosa V.E. Jr., Sasaki F.T., Sena J.A.D.,
 RA de Souza A.A., Truffi D., Tsukumo F., Yanai G.M., Zaros L.G.,
 RA Civerolo E.L., Simpson A.J.G., Almeida N.F. Jr., Setubal J.C.,
 RA Kitajima J.P.;
 RT "Comparative analyses of the complete genome sequences of Pierce's
 RT disease and citrus variegated chlorosis strains of Xylella
 RT fastidiosa.";
 RL J. Bacteriol. 185:1018-1026(2003).
 DR EMBL; AE012557; AAO28891.1; -;
 KW Hypothetical protein; Complete proteome.
 SQ SEQUENCE 184 AA; 19509 MW; E642A9226D75F15A CRC64;

 Query Match 81.8%; Score 36; DB 16; Length 184;
 Best Local Similarity 87.5%; Pred. No. 17;
 Matches 7; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

 QY 1 KVAELVHF 8
 DB 140 KVGELVHF 147

 RESULT 15
 Q931A8 PRELIMINARY; PRT; 252 AA.
 ID Q931A8
 AC Q931A8;
 DT 01-DEC-2001 (TrEMBLrel. 19, Created)
 DT 01-DEC-2001 (TrEMBLrel. 19, Last sequence update)

```
DT 01-JUN-2003 (TrEMBLrel. 24, Last annotation update)
DE SMA0074 protein.
GN RA0036 OR SMA0074.
OS Rhizobium meliloti (Sinorhizobium meliloti).
OG Plasmid pSymA (megaplasmid 1).
OC Bacteria; Proteobacteria; Alphaproteobacteria; Rhizobiales;
OC Rhizobiaceae; Sinorhizobium/Ensifer group; Sinorhizobium.
OX NCBI_TaxID=382;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=1021;
RX MEDLINE=21396509; PubMed=11481432;
RA Barnett M.J., Fisher R.F., Jones T., Komp C., Abola A.P.,
RA Barloy-Hubler F., Bowser L., Capela D., Galibert F., Gouzy J.,
RA Gurjal M., Hong A., Huizar L., Hyman R.W., Kahn D., Kahn M.L.,
RA Kalman S., Keating D.H., Palm C., Peck M.C., Surzycki R., Wells D.H.,
RA Yen K.-C., Davis R.W., Federspiel N.A., Long S.R.;
RT "Nucleotide sequence and predicted functions of the entire
RT Sinorhizobium meliloti pSymA megaplasmid."
RL Proc. Natl. Acad. Sci. U.S.A. 98:9883-9888 (2001).
DR EMBL: AE007198; AAK64694.1; -.
DR PIR: D95266; D95266.
DR GO: GO:0046821; C:extrachromosomal DNA; IEA.
DR GO: GO:0016491; F:oxidoreductase activity; IEA.
DR GO: GO:0008152; P:metabolism; IEA.
DR InterPro: IPR002198; ADH_short.
DR Pfam: PF00106; adh_short; 1.
DR PRINTS: PR00080; SDFAMILY.
DR PROSITE: PS00061; ADH_SHORT; 1. Complete proteome.
KW Plasmid; Hypothetical protein.
SQ SEQUENCE 252 AA; 26808 MW; 7D406C067435E9 CRC64;

Query Match 81.8%; Score 36; DB 16; Length 252;
Best Local Similarity 87.5%; Pred. No. 24;
Matches 7; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 2 VAEVLVHFL 9
Db 226 VADLVVHFL 233

RESULT 16
ID Q9D378 PRELIMINARY; PRT; 279 AA.
AC Q9D378;
DT 01-JUN-2001 (TrEMBLrel. 17, Created)
DT 01-JUN-2001 (TrEMBLrel. 17, Last sequence update)
DT 01-MAR-2003 (TrEMBLrel. 23, Last annotation update)
DE 5730494G16Rik protein.
GN 5730494G16Rik.
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
OX NCBI_TaxID=10090;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=C57BL/6J; TISSUE=Medulla oblongata;
RX MEDLINE=21085660; PubMed=11217851;
RA Kawai J., Shinagawa A., Shibata K., Yoshino M., Itoh M., Ishii Y.,
RA Arakawa T., Hara A., Fukunishi Y., Konno H., Adachi J., Fukuda S.,
RA Aizawa K., Izawa M., Nishi K., Kiyosawa H., Kondo S., Yamanaka I.,
RA Saito T., Okazaki Y., Gojobori T., Bono H., Kasukawa T., Saito R.,
RA Kadota K., Matsuda H.A., Ashburner M., Batalov S., Casavant T.,
RA Fleischmann W., Gaasterland T., Gissi C., King B., Kochiwa H.,
RA Kuehl P., Lewis S., Matsuo Y., Nikaide I., Pesole G., Quackenbush J.,
RA Schriml L.M., Staublei F., Suzuki R., Tomita M., Wagner L., Washio T.,
RA Sakai K., Okido T., Furuno M., Aono H., Baldarelli R., Barsh G.,
RA Blake J., Boffelli D., Bojunga N., Carninci P., de Bonaldo M.F.,
RA Brownstein M.J., Bult C., Fletcher C., Fujita M., Gariboldi M.,
RA Gustincich S., Hill D., Hofmann M., Hume D.A., Kamiya M., Lee N.H.,
RA Lyons P., Marchionni L., Mashima J., Mazzarelli J., Mombaerts P.,
RA Nordone P., Ring B., Ringwald M., Rodriguez I., Sakamoto N.,
RA Sasaki H., Sato K., Schoenbach C., Seya T., Shibata Y., Storch K.-F.,
RA Suzuki H., Toyooka K., Wang K.H., Weitz C., Whittaker C., Wilming L.,
RA Wynshaw-Boris A., Yoshida K., Hasegawa Y., Kawaji H., Kohseki S.,
RA Hayashizaki Y.;
RP SEQUENCE FROM N.A.
RC STRAIN=C57BL/6J; TISSUE=Medulla oblongata;
RX MEDLINE=21085660; PubMed=11217851;
RA Kawai J., Shinagawa A., Shibata K., Yoshino M., Itoh M., Ishii Y.,
RA Arakawa T., Hara A., Fukunishi Y., Konno H., Adachi J., Fukuda S.,
RA Aizawa K., Izawa M., Nishi K., Kiyosawa H., Kondo S., Yamanaka I.,
RA Saito T., Okazaki Y., Gojobori T., Bono H., Kasukawa T., Saito R.,
RA Kadota K., Matsuda H.A., Ashburner M., Batalov S., Casavant T.,
RA Fleischmann W., Gaasterland T., Gissi C., King B., Kochiwa H.,
RA Kuehl P., Lewis S., Matsuo Y., Nikaide I., Pesole G., Quackenbush J.,
RA Schriml L.M., Staublei F., Suzuki R., Tomita M., Wagner L., Washio T.,
RA Sakai K., Okido T., Furuno M., Aono H., Baldarelli R., Barsh G.,
RA Blake J., Boffelli D., Bojunga N., Carninci P., de Bonaldo M.F.,
RA Brownstein M.J., Bult C., Fletcher C., Fujita M., Gariboldi M.,
RA Gustincich S., Hill D., Hofmann M., Hume D.A., Kamiya M., Lee N.H.,
RA Lyons P., Marchionni L., Mashima J., Mazzarelli J., Mombaerts P.,
RA Nordone P., Ring B., Ringwald M., Rodriguez I., Sakamoto N.,
RA Sasaki H., Sato K., Schoenbach C., Seya T., Shibata Y., Storch K.-F.,
RA Suzuki H., Toyooka K., Wang K.H., Weitz C., Whittaker C., Wilming L.,
RA Wynshaw-Boris A., Yoshida K., Hasegawa Y., Kawaji H., Kohseki S.,
RA Hayashizaki Y.;
RP SEQUENCE FROM N.A.
RC STRAIN=C57BL/6J; TISSUE=Embryo, and Embryonic stem cells;
RX MEDLINE=21085660; PubMed=11217851;
RA Kawai J., Shinagawa A., Shibata K., Yoshino M., Itoh M., Ishii Y.,
RA Arakawa T., Hara A., Fukunishi Y., Konno H., Adachi J., Fukuda S.,
RA Aizawa K., Izawa M., Nishi K., Kiyosawa H., Kondo S., Yamanaka I.,
RA Saito T., Okazaki Y., Gojobori T., Bono H., Kasukawa T., Saito R.,
RA Kadota K., Matsuda H.A., Ashburner M., Batalov S., Casavant T.,
RA Fleischmann W., Gaasterland T., Gissi C., King B., Kochiwa H.,
RA Kuehl P., Lewis S., Matsuo Y., Nikaide I., Pesole G., Quackenbush J.,
RA Schriml L.M., Staublei F., Suzuki R., Tomita M., Wagner L., Washio T.,
RA Sakai K., Okido T., Furuno M., Aono H., Baldarelli R., Barsh G.,
RA Blake J., Boffelli D., Bojunga N., Carninci P., de Bonaldo M.F.,
RA Brownstein M.J., Bult C., Fletcher C., Fujita M., Gariboldi M.,
RA Gustincich S., Hill D., Hofmann M., Hume D.A., Kamiya M., Lee N.H.,
RA Lyons P., Marchionni L., Mashima J., Mazzarelli J., Mombaerts P.,
RA Nordone P., Ring B., Ringwald M., Rodriguez I., Sakamoto N.,
RA Sasaki H., Sato K., Schoenbach C., Seya T., Shibata Y., Storch K.-F.,
RA Suzuki H., Toyooka K., Wang K.H., Weitz C., Whittaker C., Wilming L.,
RA Wynshaw-Boris A., Yoshida K., Hasegawa Y., Kawaji H., Kohseki S.,
RA Hayashizaki Y.;
RP SEQUENCE FROM N.A.
RC STRAIN=C57BL/6J; TISSUE=Mammary gland;
RX Strausberg R.;
RL Submitted (JUL-2002) to the EMBL/GenBank/DBJ databases.
RN [4]
RP SEQUENCE FROM N.A.
RC STRAIN=C57BL/6J; TISSUE=Head, and Spinal cord;
RX MEDLINE=22354683; PubMed=12466851;
RA The FANTOM Consortium,
```

```
RA Suzuki H., Toyooka K., Wang K.H., Weitz C., Whittaker C., Wilming L.,
RA Wynshaw-Boris A., Yoshida K., Hasegawa Y., Kawaji H., Kohseki S.,
RA Hayashizaki Y.;
RP "Functional annotation of a full-length mouse cDNA collection.";
RL Nature 409:685-690 (2001).
DR EMBL: AK018250; BAB31133.1; -.
DR MGD; MGI:1913897; 5730494G16Rik.
DR InterPro: IPR002190; MAGE.
DR Pfam: PF01454; MAGE; 1.
DR PROSITE: PS50838; MAGE; 1.
SQ SEQUENCE 279 AA; 31474 MW; 5E243590A99F15F0 CRC64;

Query Match 81.8%; Score 36; DB 11; Length 279;
Best Local Similarity 88.9%; Pred. No. 26;
Matches 8; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1 KVAELVHFL 9
Db 62 KVAELVQFL 70

RESULT 17
Q9CPR8 PRELIMINARY; PRT; 279 AA.
ID Q9CPR8;
AC Q9CPR8;
DT 01-JUN-2001 (TrEMBLrel. 17, Created)
DT 01-JUN-2001 (TrEMBLrel. 17, Last sequence update)
DT 01-MAR-2003 (TrEMBLrel. 23, Last annotation update)
DE 5730494G16Rik protein (MAGE-g1) (RIKEN CDNA 5730494G16 gene).
GN 5730494G16Rik.
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
OX NCBI_TaxID=10090;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=C57BL/6J; TISSUE=Embryo, and Embryonic stem cells;
RX MEDLINE=21085660; PubMed=11217851;
RA Kawai J., Shinagawa A., Shibata K., Yoshino M., Itoh M., Ishii Y.,
RA Arakawa T., Hara A., Fukunishi Y., Konno H., Adachi J., Fukuda S.,
RA Aizawa K., Izawa M., Nishi K., Kiyosawa H., Kondo S., Yamanaka I.,
RA Saito T., Okazaki Y., Gojobori T., Bono H., Kasukawa T., Saito R.,
RA Kadota K., Matsuda H.A., Ashburner M., Batalov S., Casavant T.,
RA Fleischmann W., Gaasterland T., Gissi C., King B., Kochiwa H.,
RA Kuehl P., Lewis S., Matsuo Y., Nikaide I., Pesole G., Quackenbush J.,
RA Schriml L.M., Staublei F., Suzuki R., Tomita M., Wagner L., Washio T.,
RA Sakai K., Okido T., Furuno M., Aono H., Baldarelli R., Barsh G.,
RA Blake J., Boffelli D., Bojunga N., Carninci P., de Bonaldo M.F.,
RA Brownstein M.J., Bult C., Fletcher C., Fujita M., Gariboldi M.,
RA Gustincich S., Hill D., Hofmann M., Hume D.A., Kamiya M., Lee N.H.,
RA Lyons P., Marchionni L., Mashima J., Mazzarelli J., Mombaerts P.,
RA Nordone P., Ring B., Ringwald M., Rodriguez I., Sakamoto N.,
RA Sasaki H., Sato K., Schoenbach C., Seya T., Shibata Y., Storch K.-F.,
RA Suzuki H., Toyooka K., Wang K.H., Weitz C., Whittaker C., Wilming L.,
RA Wynshaw-Boris A., Yoshida K., Hasegawa Y., Kawaji H., Kohseki S.,
RA Hayashizaki Y.;
RP SEQUENCE FROM N.A.
RC STRAIN=C57BL/6J; TISSUE=Mammary gland;
RX Strausberg R.;
RL Submitted (JUL-2002) to the EMBL/GenBank/DBJ databases.
RN [4]
RP SEQUENCE FROM N.A.
RC STRAIN=C57BL/6J; TISSUE=Head, and Spinal cord;
RX MEDLINE=22354683; PubMed=12466851;
RA The FANTOM Consortium,
```

the RIKEN Genome Exploration Research Group Phase I & II Team;
 "Analysis of the mouse transcriptome based on functional annotation of
 60,770 full-length cDNAs.";
 Nature 420:563-573 (2002).
 R1 EMBL; AK017727; BAB30899.1; -
 R2 EMBL; AK010294; BAB26830.1; -
 R3 EMBL; AF319979; AAK01207.1; -
 R4 EMBL; BC034892; AAH34892.1; -
 R5 EMBL; AK049759; BAC33907.1; -
 R6 EMBL; AK076471; BAC36358.1; -
 R7 MGD; MGI:1913897; 5730494G16R1K.
 R8 InterPro; IPR002190; MAGE.
 R9 Pfam; PF01454; MAGE; 1.
 R10 PROSITE; PS0838; MAGE; 1.
 R11 SEQUENCE 279 AA; 31460 MW; F22435919BDG3160 CRC64;
 R12
 R13
 R14
 R15
 R16
 R17
 R18
 R19
 R20
 R21
 R22
 R23
 R24
 R25
 R26
 R27
 R28
 R29
 R30
 R31
 R32
 R33
 R34
 R35
 R36
 R37
 R38
 R39
 R40
 R41
 R42
 R43
 R44
 R45
 R46
 R47
 R48
 R49
 R50
 R51
 R52
 R53
 R54
 R55
 R56
 R57
 R58
 R59
 R60
 R61
 R62
 R63
 R64
 R65
 R66
 R67
 R68
 R69
 R70
 R71
 R72
 R73
 R74
 R75
 R76
 R77
 R78
 R79
 R80
 R81
 R82
 R83
 R84
 R85
 R86
 R87
 R88
 R89
 R90
 R91
 R92
 R93
 R94
 R95
 R96
 R97
 R98
 R99
 R100
 R101
 R102
 R103
 R104
 R105
 R106
 R107
 R108
 R109
 R110
 R111
 R112
 R113
 R114
 R115
 R116
 R117
 R118
 R119
 R120
 R121
 R122
 R123
 R124
 R125
 R126
 R127
 R128
 R129
 R130
 R131
 R132
 R133
 R134
 R135
 R136
 R137
 R138
 R139
 R140
 R141
 R142
 R143
 R144
 R145
 R146
 R147
 R148
 R149
 R150
 R151
 R152
 R153
 R154
 R155
 R156
 R157
 R158
 R159
 R160
 R161
 R162
 R163
 R164
 R165
 R166
 R167
 R168
 R169
 R170
 R171
 R172
 R173
 R174
 R175
 R176
 R177
 R178
 R179
 R180
 R181
 R182
 R183
 R184
 R185
 R186
 R187
 R188
 R189
 R190
 R191
 R192
 R193
 R194
 R195
 R196
 R197
 R198
 R199
 R200
 R201
 R202
 R203
 R204
 R205
 R206
 R207
 R208
 R209
 R210
 R211
 R212
 R213
 R214
 R215
 R216
 R217
 R218
 R219
 R220
 R221
 R222
 R223
 R224
 R225
 R226
 R227
 R228
 R229
 R230
 R231
 R232
 R233
 R234
 R235
 R236
 R237
 R238
 R239
 R240
 R241
 R242
 R243
 R244
 R245
 R246
 R247
 R248
 R249
 R250
 R251
 R252
 R253
 R254
 R255
 R256
 R257
 R258
 R259
 R260
 R261
 R262
 R263
 R264
 R265
 R266
 R267
 R268
 R269
 R270
 R271
 R272
 R273
 R274
 R275
 R276
 R277
 R278
 R279
 R280
 R281
 R282
 R283
 R284
 R285
 R286
 R287
 R288
 R289
 R290
 R291
 R292
 R293
 R294
 R295
 R296
 R297
 R298
 R299
 R300
 R301
 R302
 R303
 R304
 R305
 R306
 R307
 R308
 R309
 R310
 R311
 R312
 R313
 R314
 R315
 R316
 R317
 R318
 R319
 R320
 R321
 R322
 R323
 R324
 R325
 R326
 R327
 R328
 R329
 R330
 R331
 R332
 R333
 R334
 R335
 R336
 R337
 R338
 R339
 R340
 R341
 R342
 R343
 R344
 R345
 R346
 R347
 R348
 R349
 R350
 R351
 R352
 R353
 R354
 R355
 R356
 R357
 R358
 R359
 R360
 R361
 R362
 R363
 R364
 R365
 R366
 R367
 R368
 R369
 R370
 R371
 R372
 R373
 R374
 R375
 R376
 R377
 R378
 R379
 R380
 R381
 R382
 R383
 R384
 R385
 R386
 R387
 R388
 R389
 R390
 R391
 R392
 R393
 R394
 R395
 R396
 R397
 R398
 R399
 R400
 R401
 R402
 R403
 R404
 R405
 R406
 R407
 R408
 R409
 R410
 R411
 R412
 R413
 R414
 R415
 R416
 R417
 R418
 R419
 R420
 R421
 R422
 R423
 R424
 R425
 R426
 R427
 R428
 R429
 R430
 R431
 R432
 R433
 R434
 R435
 R436
 R437
 R438
 R439
 R440
 R441
 R442
 R443
 R444
 R445
 R446
 R447
 R448
 R449
 R450
 R451
 R452
 R453
 R454
 R455
 R456
 R457
 R458
 R459
 R460
 R461
 R462
 R463
 R464
 R465
 R466
 R467
 R468
 R469
 R470
 R471
 R472
 R473
 R474
 R475
 R476
 R477
 R478
 R479
 R480
 R481
 R482
 R483
 R484
 R485
 R486
 R487
 R488
 R489
 R490
 R491
 R492
 R493
 R494
 R495
 R496
 R497
 R498
 R499
 R500
 R501
 R502
 R503
 R504
 R505
 R506
 R507
 R508
 R509
 R510
 R511
 R512
 R513
 R514
 R515
 R516
 R517
 R518
 R519
 R520
 R521
 R522
 R523
 R524
 R525
 R526
 R527
 R528
 R529
 R530
 R531
 R532
 R533
 R534
 R535
 R536
 R537
 R538
 R539
 R540
 R541
 R542
 R543
 R544
 R545
 R546
 R547
 R548
 R549
 R550
 R551
 R552
 R553
 R554
 R555
 R556
 R557
 R558
 R559
 R560
 R561
 R562
 R563
 R564
 R565
 R566
 R567
 R568
 R569
 R570
 R571
 R572
 R573
 R574
 R575
 R576
 R577
 R578
 R579
 R580
 R581
 R582
 R583
 R584
 R585
 R586
 R587
 R588
 R589
 R590
 R591
 R592
 R593
 R594
 R595
 R596
 R597
 R598
 R599
 R600
 R601
 R602
 R603
 R604
 R605
 R606
 R607
 R608
 R609
 R610
 R611
 R612
 R613
 R614
 R615
 R616
 R617
 R618
 R619
 R620
 R621
 R622
 R623
 R624
 R625
 R626
 R627
 R628
 R629
 R630
 R631
 R632
 R633
 R634
 R635
 R636
 R637
 R638
 R639
 R640
 R641
 R642
 R643
 R644
 R645
 R646
 R647
 R648
 R649
 R650
 R651
 R652
 R653
 R654
 R655
 R656
 R657
 R658
 R659
 R660
 R661
 R662
 R663
 R664
 R665
 R666
 R667
 R668
 R669
 R670
 R671
 R672
 R673
 R674
 R675
 R676
 R677
 R678
 R679
 R680
 R681
 R682
 R683
 R684
 R685
 R686
 R687
 R688
 R689
 R690
 R691
 R692
 R693
 R694
 R695
 R696
 R697
 R698
 R699
 R700
 R701
 R702
 R703
 R704
 R705
 R706
 R707
 R708
 R709
 R710
 R711
 R712
 R713
 R714
 R715
 R716
 R717
 R718
 R719
 R720
 R721
 R722
 R723
 R724
 R725
 R726
 R727
 R728
 R729
 R730
 R731
 R732
 R733
 R734
 R735
 R736
 R737
 R738
 R739
 R740
 R741
 R742
 R743
 R744
 R745
 R746
 R747
 R748
 R749
 R750
 R751
 R752
 R753
 R754
 R755
 R756
 R757
 R758
 R759
 R760
 R761
 R762
 R763
 R764
 R765
 R766
 R767
 R768
 R769
 R770
 R771
 R772
 R773
 R774
 R775
 R776
 R777
 R778
 R779
 R780
 R781
 R782
 R783
 R784
 R785
 R786
 R787
 R788
 R789
 R790
 R791
 R792
 R793
 R794
 R795
 R796
 R797
 R798
 R799
 R800
 R801
 R802
 R803
 R804
 R805
 R806
 R807
 R808
 R809
 R810
 R811
 R812
 R813
 R814
 R815
 R816
 R817
 R818
 R819
 R820
 R821
 R822
 R823
 R824
 R825
 R826
 R827
 R828
 R829
 R830
 R831
 R832
 R833
 R834
 R835
 R836
 R837
 R838
 R839
 R840
 R841
 R842
 R843
 R844
 R845
 R846
 R847
 R848
 R849
 R850
 R851
 R852
 R853
 R854
 R855
 R856
 R857
 R858
 R859
 R860
 R861
 R862
 R863
 R864
 R865
 R866
 R867
 R868
 R869
 R870
 R871
 R872
 R873
 R874
 R875
 R876
 R877
 R878
 R879
 R880
 R881
 R882
 R883
 R884
 R885
 R886
 R887
 R888
 R889
 R890
 R891
 R892
 R893
 R894
 R895
 R896
 R897
 R898
 R899
 R900
 R901
 R902
 R903
 R904
 R905
 R906
 R907
 R908
 R909
 R910
 R911
 R912
 R913
 R914
 R915
 R916
 R917
 R918
 R919
 R920
 R921
 R922
 R923
 R924
 R925
 R926
 R927
 R928
 R929
 R930
 R931
 R932
 R933
 R934
 R935
 R936
 R937
 R938
 R939
 R940
 R941
 R942
 R943
 R944
 R945
 R946
 R947
 R948
 R949
 R950
 R951
 R952
 R953
 R954
 R955
 R956
 R957
 R958
 R959
 R960
 R961
 R962
 R963
 R964
 R965
 R966
 R967
 R968
 R969
 R970
 R971
 R972
 R973
 R974
 R975
 R976
 R977
 R978
 R979
 R980
 R981
 R982
 R983
 R984
 R985
 R986
 R987
 R988
 R989
 R990
 R991
 R992
 R993
 R994
 R995
 R996
 R997
 R998
 R999
 R1000
 R1001
 R1002
 R1003
 R1004
 R1005
 R1006
 R1007
 R1008
 R1009
 R1010
 R1011
 R1012
 R1013
 R1014
 R1015
 R1016
 R1017
 R1018
 R1019
 R1020
 R1021
 R1022
 R1023
 R1024
 R1025
 R1026
 R1027
 R1028
 R1029
 R1030
 R1031
 R1032
 R1033
 R1034
 R1035
 R1036
 R1037
 R1038
 R1039
 R1040
 R1041
 R1042
 R1043
 R1044
 R1045
 R1046
 R1047
 R1048
 R1049
 R1050
 R1051
 R1052
 R1053
 R1054
 R1055
 R1056
 R1057
 R1058
 R1059
 R1060
 R1061
 R1062
 R1063
 R1064
 R1065
 R1066
 R1067
 R1068
 R1069
 R1070
 R1071
 R1072
 R1073
 R1074
 R1075
 R1076
 R1077
 R1078
 R1079
 R1080
 R1081
 R1082
 R1083
 R1084
 R1085
 R1086
 R1087
 R1088
 R1089
 R1090
 R1091
 R1092
 R1093
 R1094
 R1095
 R1096
 R1097
 R1098
 R1099
 R1100
 R1101
 R1102
 R1103
 R1104
 R1105
 R1106
 R1107
 R1108
 R1109
 R1110
 R1111
 R1112
 R1113
 R1114
 R1115
 R1116
 R1117
 R1118
 R1119
 R1120
 R1121
 R1122
 R1123
 R1124
 R1125
 R1126
 R1127
 R1128
 R1129
 R1130
 R1131
 R1132
 R1133
 R1134
 R1135
 R1136
 R1137
 R1138
 R1139
 R1140
 R1141
 R1142
 R1143
 R1144
 R1145
 R1146
 R1147
 R1148
 R1149
 R1150
 R1151
 R1152
 R1153
 R1154
 R1155
 R1156
 R1157
 R1158
 R1159
 R1160
 R1161
 R1162
 R1163
 R1164
 R1165
 R1166
 R1167
 R1168
 R1169
 R1170
 R1171
 R1172
 R1173
 R1174
 R1175
 R1176
 R1177
 R1178
 R1179
 R1180
 R1181
 R1182
 R1183
 R1184
 R1185
 R1186
 R1187
 R1188
 R1189
 R1190
 R1191
 R1192
 R1193
 R1194
 R1195
 R1196
 R1197
 R1198
 R1199
 R1200
 R1201
 R1202
 R1203
 R1204
 R1205
 R1206
 R1207
 R1208
 R1209
 R1210
 R1211
 R1212
 R1213
 R1214
 R1215
 R1216
 R1217
 R1218
 R1219
 R1220
 R1221
 R1222
 R1223
 R1224
 R1225
 R1226
 R1227
 R1228
 R1229
 R1230
 R1231
 R1232
 R1233
 R1234
 R1235
 R1236
 R1237
 R1238
 R1239
 R1240
 R1241
 R1242
 R1243
 R1244
 R1245
 R1246
 R1247
 R1248
 R1249
 R1250
 R1251
 R1252
 R1253
 R1254
 R1255
 R1256
 R1257
 R1258
 R1259
 R1260
 R1261
 R1262
 R1263
 R1264
 R1265
 R1266
 R1267
 R1268
 R1269
 R1270
 R1271
 R1272
 R1273
 R1274
 R1275
 R1276
 R1277
 R1278
 R1279
 R1280
 R1281
 R1282
 R1283
 R1284
 R1285
 R1286
 R1287
 R1288
 R1289
 R1290
 R1291
 R1292
 R1293
 R1294
 R1295
 R1296
 R1297
 R1298
 R1299
 R1300
 R1301
 R1302
 R1303
 R1304
 R1305
 R1306
 R1307
 R1308
 R1309
 R1310
 R1311
 R1312
 R1313
 R1314
 R1315
 R1316
 R1317
 R1318
 R1319
 R1320
 R1321
 R1322
 R1323
 R1324
 R1325
 R1326
 R1327
 R1328
 R1329
 R1330
 R1331
 R1332
 R1333
 R1334
 R1335
 R1336
 R1337
 R1338
 R1339
 R1340
 R1341
 R1342
 R1343
 R1344
 R1345
 R1346
 R1347
 R1348
 R1349
 R1350
 R1351
 R1352
 R1353
 R1354
 R1355
 R1356
 R1357
 R1358
 R1359
 R1360
 R1361
 R1362
 R1363
 R1364
 R1365
 R1366
 R1367
 R1368
 R1369
 R1370
 R1371
 R1372
 R1373
 R1374
 R1375
 R1376
 R1377
 R1378
 R1379
 R1380
 R1381
 R1382
 R1383
 R1384
 R1385
 R1386
 R1387
 R1388
 R1389
 R1390
 R1391
 R1392
 R1393
 R1394
 R1395
 R1396
 R1397
 R1398
 R1399
 R1400
 R1401
 R1402
 R1403
 R1404
 R1405
 R1406
 R1407
 R1408
 R1409
 R1410
 R1411
 R1412
 R1413
 R1414
 R1415
 R1416
 R1417
 R1418
 R1419
 R1420
 R1421
 R1422
 R1423
 R1424
 R1425
 R1426
 R1427
 R1428
 R1429
 R1430
 R1431
 R1432
 R1433
 R1434
 R1435
 R1436
 R1437
 R1438
 R1439
 R1440
 R1441
 R1442
 R1443
 R1444
 R1445

```
OC eurosids I; Rosales; Ulmaceae; Aphananthe.
OX NCBI_TaxID=63051;
RN [1]
RP SEQUENCE FROM N.A.
RA Sytsma K.J., Morawetz J., Pires J.C., Nepokroff M., Conti E.,
RA Zjhra M., Hall J.C., Chase M.W.;
RT "Urticalean rosids: circumscription, rosid ancestry, and phylogenetics
RT based on rbcL, trnL-F, and ndhF sequences.";
RL Am. J. Bot. 89:1531-1546(2002).
DR EMBL: AF500366; AAG63302.1; -.
DR GO: GO:0009507; C:chloroplast; IEA.
DR GO: GO:0008137; F:NADH dehydrogenase (ubiquinone) activity; IEA.
DR GO: GO:0006120; P:mitochondrial electron transport, NADH to u. . .; IEA.
DR InterPro: IPR003916; NADHb oxred5.
DR InterPro: IPR01750; Oxidored q1.
DR InterPro: IPR002128; Oxidored q1_C.
DR Pfam: PF00361; oxidored_q1; 1.
DR Pfam: PF01010; oxidored_q1_C; 1.
DR PRINTS: PR01434; NADHGHNGASE5.
KW Chloroplast.
FT NON TER 1 384
FT NON TER 384 384
SQ SEQUENCE 384 AA; 43581 MW; 8789DB112193AA60 CRC64;

Query Match 81.8%; Score 36; DB 8; Length 384;
Best Local Similarity 75.0%; Pred. No. 36;
Matches 6; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KVAELVHF 8
Db 365 KLAELIHF 372

RESULT 22
Q8TD91 ID Q8TD91 PRELIMINARY; PRT; 643 AA.
AC Q8TD91;
DT 01-JUN-2002 (TrEMBLrel. 21, Created)
DT 01-JUN-2002 (TrEMBLrel. 21, Last sequence update)
DT 01-MAR-2003 (TrEMBLrel. 23, Last annotation update)
DE Hepatocellular carcinoma-associated protein HCA2.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
RP SEQUENCE FROM N.A.
RA Dong X., Chen W.;
RT "Identification of genes in the chromosome X that are differentially
RT expressed in hepatocellular carcinoma.";
RL Submitted (MAR-2002) to the EMBL/GenBank/DBJ databases.
DR EMBL: AF490508; AAM08355.1; -.
DR InterPro: IPR002190; MAGE.
DR Pfam: PF01454; MAGE; 2.
DR PROSITE: PS00838; MAGE; 2.
SQ SEQUENCE 643 AA; 71908 MW; 4BE342288B3FB8A6 CRC64;

Query Match 81.8%; Score 36; DB 4; Length 643;
Best Local Similarity 88.9%; Pred. No. 59;
Matches 8; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1 KVAELVHF 9
Db 459 KVAELVQFL 467

RESULT 23
Q9UNY1 ID Q9UNY1 PRELIMINARY; PRT; 803 AA.
AC Q9UNY1;
DT 01-MAY-2000 (TrEMBLrel. 13, Created)
DT 01-MAY-2000 (TrEMBLrel. 13, Last sequence update)
DT 01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
```

```
DE JAW1-related protein MRV11B short isoform.
GN MRV11.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
RP SEQUENCE FROM N.A.
RX MEDLINE=99253648; PubMed=10321731;
RA Shaughnessy J.D. Jr., Largaespada D.A., Tian E., Fletcher C.F.,
RA Cho B.C., Vyas P., Jenkins N.A., Copeland N.G.;
RT "Mrv11, a common MRV integration site in BXH2 myeloid leukemias,
RT encodes a protein with homology to a lymphoid-restricted membrane
RT protein Jawi.";
RL Oncogene 18:2069-2084(1999).
DR EMBL: AF081250; AAD25923.1; -.
DR InterPro: IPR008677; MRV11.
DR Pfam: PF05781; MRV11; 1.
SQ SEQUENCE 803 AA; 88078 MW; F1E19AC014EF3A30 CRC64;

Query Match 81.8%; Score 36; DB 4; Length 803;
Best Local Similarity 77.8%; Pred. No. 74;
Matches 7; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

Qy 1 KVAELVHFL 9
Db 724 KLEELVHFL 732

RESULT 24
Q9R2C5 ID Q9R2C5 PRELIMINARY; PRT; 856 AA.
AC Q9R2C5;
DT 01-MAY-2000 (TrEMBLrel. 13, Created)
DT 01-MAY-2000 (TrEMBLrel. 13, Last sequence update)
DT 01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
DE MRV11 protein.
GN MRV11.
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
OX NCBI_TaxID=10090;
RN [1]
RP SEQUENCE FROM N.A.
RX MEDLINE=99253648; PubMed=10321731;
RA Shaughnessy J.D. Jr., Largaespada D.A., Tian E., Fletcher C.F.,
RA Cho B.C., Vyas P., Jenkins N.A., Copeland N.G.;
RT "Mrv11, a common MRV integration site in BXH2 myeloid leukemias,
RT encodes a protein with homology to a lymphoid-restricted membrane
RT protein Jawi.";
RL Oncogene 18:2069-2084(1999).
DR EMBL: U63407; AAD22568.1; -.
DR MGD: MGI:1338023; MRV11.
DR InterPro: IPR008677; MRV11.
DR Pfam: PF05781; MRV11; 1.
SQ SEQUENCE 856 AA; 93264 MW; D6BCBFD701DB9A43 CRC64;

Query Match 81.8%; Score 36; DB 11; Length 856;
Best Local Similarity 77.8%; Pred. No. 78;
Matches 7; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

Qy 1 KVAELVHFL 9
Db 777 KLEELVHFL 785

RESULT 25
Q9N1E9 ID Q9N1E9 PRELIMINARY; PRT; 859 AA.
AC Q9N1E9;
DT 01-OCT-2000 (TrEMBLrel. 15, Created)
DT 01-OCT-2000 (TrEMBLrel. 15, Last sequence update)
DT 01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
```

DE IP3 receptor associated cGMP kinase substrate B.
GN IRAG.
OS Bos taurus (Bovine).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Cetartiodactyla; Ruminantia; Pecora; Bovidae;
OC Bovidae; Bovinae; Bos.
OX NCBI_TaxID=9913;
RN [1]
RP SEQUENCE FROM N.A.
RX MEDLINE=20186769; PubMed=10724174;
RA Schlossmann J., Ammendola A., Ashman K., Zong X., Huber A.,
RA Neubauer G., Wang G.X., Allescher H.D., Korth M., Wilm M., Hofmann F.,
RA Ruth P.;
RT "Regulation of intracellular calcium by a signalling complex of IRAG,
RT IP3 receptor and cGMP kinase Ibeta.";
RL Nature 404:197-201(2000).
DR ENBL; AF195527; AAF61203.1; -.
DR GO; GO:0016301; F:kinase activity; IEA.
DR GO; GO:0004872; F:receptor activity; IEA.
DR InterPro; IPR008677; MRV11.
DR Pfam; PF05781; MRV11; 1.
KW Kinase; Receptor.
SQ SEQUENCE 859 AA; 93136 MW; CFD33CF2EAFB99B2 CRC64;
Query Match 81.8%; Score 36; DB 6; Length 859;
Best Local Similarity 77.8%; Pred. No. 79;
Matches 7; Conservative 1; Mismatches 1; Indels 0; Gaps 0;
Qy 1 KVAELVHFL 9
Db 780 KLELVHFL 788
|: |||||
RESULT 26
Q9Y6F6 PRELIMINARY; PRT; 892 AA.
AC Q9Y6F6;
DT 01-NOV-1999 (TrEMBLrel. 12, Created)
DT 01-NOV-1999 (TrEMBLrel. 12, Last sequence update)
DT 01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
DE JAW1-related protein MRV11A long isoform.
GN MRV11.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
RP SEQUENCE FROM N.A.
RX MEDLINE=9253648; PubMed=10321731;
RA Shaughnessy J.D. Jr., Largaespada D.A., Tian E., Fletcher C.F.,
RA Cho B.C., Vyas P., Jenkins N.A., Copeland N.G.;
RT "Mrv11, a common MRV integration site in BXH2 myeloid leukemias,
RT encodes a protein with homology to a lymphoid-restricted membrane
RT protein Jaw1.";
RL Oncogene 18:2069-2084(1999).
DR ENBL; AF081249; AAD25922.1; -.
DR Genew; HGNC:7237; MRV11.
DR GO; GO:0005789; C:endoplasmic reticulum membrane; TAS.
DR InterPro; IPR008677; MRV11.
DR Pfam; PF05781; MRV11; 1.
SQ SEQUENCE 892 AA; 96981 MW; B67FAFBADCC1D9A6 CRC64;
Query Match 81.8%; Score 36; DB 4; Length 892;
Best Local Similarity 77.8%; Pred. No. 82;
Matches 7; Conservative 1; Mismatches 1; Indels 0; Gaps 0;
Qy 1 KVAELVHFL 9
Db 813 KLELVHFL 821
|: |||||
RESULT 27
Q9WUX5 PRELIMINARY; PRT; 905 AA.
AC Q9WUX5;
DT 01-NOV-1999 (TrEMBLrel. 12, Created)
DT 01-NOV-1999 (TrEMBLrel. 12, Last sequence update)
DT 01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
DE MRV11A protein.
GN MRV11.
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
OX NCBI_TaxID=10090;
RN [1]
RP SEQUENCE FROM N.A.
RX MEDLINE=99253648; PubMed=10321731;
RA Shaughnessy J.D. Jr., Largaespada D.A., Tian E., Fletcher C.F.,
RA Cho B.C., Vyas P., Jenkins N.A., Copeland N.G.;
RT "Mrv11, a common MRV integration site in BXH2 myeloid leukemias,
RT encodes a protein with homology to a lymphoid-restricted membrane
RT protein Jaw1.";
RL Oncogene 18:2069-2084(1999).
DR ENBL; U63408; AAD22569.1; -.
DR MGD; MGI:1338023; Mrv11.
DR InterPro; IPR008677; MRV11.
DR Pfam; PF05781; MRV11; 1.
SQ SEQUENCE 905 AA; 98104 MW; E458EBF59224AE77 CRC64;
Query Match 81.8%; Score 36; DB 11; Length 905;
Best Local Similarity 77.8%; Pred. No. 83;
Matches 7; Conservative 1; Mismatches 1; Indels 0; Gaps 0;
Qy 1 KVAELVHFL 9
Db 826 KLELVHFL 834
|: |||||
RESULT 28
Q9N1F0 PRELIMINARY; PRT; 911 AA.
AC Q9N1F0;
DT 01-OCT-2000 (TrEMBLrel. 15, Created)
DT 01-OCT-2000 (TrEMBLrel. 15, Last sequence update)
DT 01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
DE IP3 receptor associated cGMP kinase substrate A.
GN IRAGA.
OS Bos taurus (Bovine).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Cetartiodactyla; Ruminantia; Pecora; Bovidae;
OC Bovidae; Bovinae; Bos.
OX NCBI_TaxID=9913;
RN [1]
RP SEQUENCE FROM N.A.
RX MEDLINE=20186769; PubMed=10724174;
RA Schlossmann J., Ammendola A., Ashman K., Zong X., Huber A.,
RA Neubauer G., Wang G.X., Allescher H.D., Korth M., Wilm M., Hofmann F.,
RA Ruth P.;
RT "Regulation of intracellular calcium by a signalling complex of IRAG,
RT IP3 receptor and cGMP kinase Ibeta.";
RL Nature 404:197-201(2000).
DR ENBL; AF195526; AAF61202.1; -.
DR GO; GO:0016301; F:kinase activity; IEA.
DR GO; GO:0004872; F:receptor activity; IEA.
DR InterPro; IPR008677; MRV11.
DR Pfam; PF05781; MRV11; 1.
KW Kinase; Receptor.
SQ SEQUENCE 911 AA; 98375 MW; D743EFA5A28FF62D CRC64;
Query Match 81.8%; Score 36; DB 6; Length 911;
Best Local Similarity 77.8%; Pred. No. 83;
Matches 7; Conservative 1; Mismatches 1; Indels 0; Gaps 0;
Qy 1 KVAELVHFL 9
Db 832 KLELVHFL 840
|: |||||

```
RESULT 29
Q96M61
ID Q96M61 PRELIMINARY; PRT; 343 AA.
AC Q96M61;
DT 01-DEC-2001 (TrEMBLrel. 19, Created)
DT 01-DEC-2001 (TrEMBLrel. 19, Last sequence update)
DT 01-MAR-2003 (TrEMBLrel. 23, Last annotation update)
DE Hypothetical protein FLJ32799.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
RP SEQUENCE FROM N.A.
RC TISSUE=Testis;
RA Ishibashi T., Kanehori K., Yosida M., Watanabe S., Ishida S., Ono Y.,
RA Hotata T., Hiraoka S., Murakawa K., Takiguchi S., Kusano J.,
RA Watanabe M., Fujimori K., Tanai H., Ishida M., Yamashita H., Chiba Y.,
RA Sugiyama T., Irie R., Otsuki T., Sato H., Wakamatsu A., Ishii S.,
RA Yamamoto J., Isono Y., Kawai-Hio Y., Saito K., Nishikawa T.,
RA Kimura K., Matsuo K., Nakamura Y., Sekine M., Kikuchi H., Kanda K.,
RA Wgatauma M., Takahashi-Fujii A., Oshima A., Sugiyama A., Kawakami B.,
RA Suzuki Y., Sugano S., Nagahari K., Masuho Y., Nagai K., Isogai T.;
RA "NEDO human cDNA sequencing project.";
RT Submitted (OCT-2001) to the EMBL/GenBank/DBJ databases.
RL [2]
RN [2]
RP SEQUENCE FROM N.A.
RC TISSUE=Testis;
RA Strauberg R.;
RL Submitted (MAY-2002) to the EMBL/GenBank/DBJ databases.
DR EMBL; AK057361; BAB71450.1; -.
DR EMBL; BC029525; AAH29525.1; -.
DR InterPro; IPR002190; MAGE.
DR Pfam; PF01454; MAGE; 1.
DR PROSITE; PS0838; MAGE; 1.
KW Hypothetical protein.
SQ SEQUENCE 343 AA; 38522 MW; C1E9286D8545EC87 CRC64;

Query Match 79.5%; Score 35; DB 4; Length 343;
Best Local Similarity 77.8%; Pred. No. 52;
Matches 7; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1 KVAELVHFL 9
DB 110 KVSIVHFL 118
|||
|||||

RESULT 30
Q8ZR10
ID Q8ZR10 PRELIMINARY; PRT; 358 AA.
AC Q8ZR10;
DT 01-MAR-2002 (TrEMBLrel. 20, Created)
DT 01-MAR-2002 (TrEMBLrel. 20, Last sequence update)
DT 01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
DE Citrate lyase synthetase (Citrate (pro-3S)-lyase ligase
DE (EC 6.2.1.22)).
DE CITC OR STM0624.
GN Citronella typhimurium.
OS Salmonella typhimurium.
OC Bacteria; Proteobacteria; Gammaproteobacteria; Enterobacteriales;
OC Enterobacteriaceae; Salmonella.
OX NCBI_TaxID=602;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=LT2 / SGSC1412 / ATCC 700720;
RX MEDLINE=21534948; PubMed=11677609;
RA McClelland M., Sanderson K.E., Spieth J., Clifton S.W., Latreille P.,
RA Courtney L., Porwollik S., Ali J., Dante M., Du F., Hou S., Layman D.,
RA Leonard S., Nguyen C., Scott K., Holmes A., Grewal N., Mulvaney E.,
RA Ryan E., Sun H., Flores L., Miller W., Stoneking T., Nhan M.,
RA Waterston R., Wilson R.K.;
RA "Complete genome sequence of Salmonella enterica serovar Typhimurium
```

```
RT LT2.";
RL Nature 413:852-856 (2001).
DR EMBL; AE008724; AAL19575.1; -.
DR GO; GO:0016874; F:ligase activity; IEA.
DR GO; GO:0016829; F:lyase activity; IEA.
DR GO; GO:0008080; F:N-acetyltransferase activity; IEA.
DR GO; GO:0008771; F:citrate (pro-3S)-lyase ligase activity; IEA.
DR InterPro; IPR005216; Cit_ly_ligase.
DR InterPro; IPR004821; Cyt_tran_rel.
DR InterPro; IPR000182; GCN5acetyl_trans.
DR Pfam; PF00593; Acetyltransf; 1.
DR TIGRFAMS; TIGR00124; cit_ly_ligase; 1.
DR TIGRFAMS; TIGR00125; cyt_tran_rel; 1.
KW Lyase; Ligase; Complete proteome.
SQ SEQUENCE 358 AA; 40443 MW; 823CCFD7C90CDD56 CRC64;

Query Match 79.5%; Score 35; DB 16; Length 358;
Best Local Similarity 66.7%; Pred. No. 54;
Matches 6; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 1 KVAELVHFL 9
DB 17 KMAEIAHFL 25
|||
|||||

RESULT 31
Q91VT7
ID Q91VT7 PRELIMINARY; PRT; 400 AA.
AC Q91VT7;
DT 01-DEC-2001 (TrEMBLrel. 19, Created)
DT 01-DEC-2001 (TrEMBLrel. 19, Last sequence update)
DT 01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
DE Hypothetical protein.
GN EPS8L2 OR AI042819.
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
OX NCBI_TaxID=10090;
RN [1]
RP SEQUENCE FROM N.A.
RC TISSUE=Breast tumor;
RA Strauberg R.;
RL Submitted (JUN-2001) to the EMBL/GenBank/DBJ databases.
DR EMBL; BC009098; AAH09098.1; -.
DR MGD; MGI:2138828; Eps8L2.
DR InterPro; IPR006020; PTB_PID.
DR PROSITE; PS01179; PID; 1.
KW Hypothetical protein.
SQ SEQUENCE 400 AA; 44839 MW; E50B9205E139ECEF CRC64;

Query Match 79.5%; Score 35; DB 11; Length 400;
Best Local Similarity 100.0%; Pred. No. 61;
Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3 AELVHFL 9
DB 344 AELVHFL 350
|||||

RESULT 32
Q9H6K9
ID Q9H6K9 PRELIMINARY; PRT; 715 AA.
AC Q9H6K9;
DT 01-MAR-2001 (TrEMBLrel. 16, Created)
DT 01-MAR-2001 (TrEMBLrel. 16, Last sequence update)
DT 01-JUN-2003 (TrEMBLrel. 24, Last annotation update)
DE Hypothetical protein FLJ22171 (Epidermal growth factor receptor
DE pathway substrate 8 related protein 2).
GN EPS8R2.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX NCBI_TaxID=9606;
```



```

DR SMART; SM00054; EFH; 4.
DR PROSITE; PS00018; EF HAND; 4.
SQ SEQUENCE 140 AA; 15595 MW; 908648B6652B361E CRC64;

Query Match 77.3%; Score 34; DB 5; Length 140;
Best Local Similarity 77.8%; Pred. No. 35;
Matches 7; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

Qy 1 KVAELVHFL 9
Db 91 EVELKHFL 99

RESULT 36
Q8ZJ69 PRELIMINARY; PRT; 210 AA.
AC Q8ZJ69;
DT 01-MAR-2002 (TrEMBLrel. 20, Created)
DT 01-MAR-2002 (TrEMBLrel. 20, Last sequence update)
DT 01-JUN-2003 (TrEMBLrel. 24, Last annotation update)
DE Putative two-component response regulator (Response
DE regulator/transcription activator).
GN YPO0235 OR Y0512.
OS Yersinia pestis.
OC Bacteria; Proteobacteria; Gammaproteobacteria; Enterobacteriales;
OC Enterobacteriaceae; Yersinia.
OX NCBI_TaxID=632;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=CO-92 / Biovar Orientalis;
RA Parkhill J., Wren B.W., Thomson N.R., Titball R.W., Holden M.T.G.,
RA Prentice M.B., Sebahia M., James K.D., Churcher C., Mungall K.L.,
RA Baker S., Basham D., Bentley S.D., Brooks K., Cerdeno-Tarraga A.M.,
RA Chillingworth T., Cronin A., Davies R.M., Davis P., Dougan G.,
RA Fellwell T., Hamlin N., Holroyd S., Jagels K., Karlyshev A.V.,
RA Leather S., Moule S., Oyston P.C.F., Quail M., Rutherford K.,
RA Simmonds M., Skelton J., Stevens K., Whitehead S., Barrell B.G.;
RT "Genome sequence of Yersinia pestis, the causative agent of plague.";
RL Nature 413:523-527(2001).
RN [2]
RP SEQUENCE FROM N.A.
RC STRAIN=KIM5 / Biovar Mediaevalis;
RA Deng W., Burland V., Plunkett G. III, Boutin A., Mayhew G.F., Liss P.,
RA Perna N.T., Rose D.J., Mau B., Zhou S., Schwartz D.C.,
RA Fetherston J.D., Lindler L.E., Brubaker R.R., Plano G.V., Blattner F.R.,
RA Straley S.C., McDonough K.A., Nilles M.D., Matson J.S., Perry R.D.;
RT "Genome sequence of Yersinia pestis KIM.";
RL J. Bacteriol. 184:4601-4611(2002).
DR EMBL; AJ414141; CAC89116.1; -.
DR EMBL; AE013653; AAM84101.1; -.
DR PIR; A10031; A10031.
DR GO; GO:0005622; C:intracellular; IEA.
DR GO; GO:0003700; F:transcription factor activity; IEA.
DR GO; GO:0000156; P:two-component response regulator activity; IEA.
DR GO; GO:0000160; P:two-component signal transduction system (p. . .); IEA.
DR InterPro; IPR000792; HTH_LuxR.
DR InterPro; IPR001789; Response_reg.
DR Pfam; PF00196; GerE; 1.
DR Pfam; PF00072; response_reg; 1.
DR PRINTS; PR00038; HTHLUXR.
DR ProDom; PD000307; HTH_LuxR; 1.
DR ProDom; PD000039; Response_reg; 1.
DR PROSITE; PS00622; HTH_LUXR_FAMILY; 1.
DR PROSITE; PS00110; RESPONSE_REGULATORY; 1.
KW Hypothetical protein; Complete proteome.
SQ SEQUENCE 210 AA; 23575 MW; 051170240F203DBE CRC64;

Query Match 77.3%; Score 34; DB 16; Length 210;
Best Local Similarity 75.0%; Pred. No. 53;
Matches 6; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

```

```

Qy 1 KVAELVHF 8
Db 195 KVAELIHW 202

RESULT 37
Q92V84 PRELIMINARY; PRT; 258 AA.
AC Q92V84;
DT 01-DEC-2001 (TrEMBLrel. 19, Created)
DT 01-DEC-2001 (TrEMBLrel. 19, Last sequence update)
DT 01-JUN-2003 (TrEMBLrel. 24, Last annotation update)
DE Putative oxidoreductase, SDR superfamily protein.
GN RH0825 OR SMD21159.
OS Rhizobium meliloti (Sinorhizobium meliloti).
OC Bacteria; Proteobacteria; Alphaproteobacteria; Rhizobiales;
OC Rhizobiaceae; Sinorhizobium/Ensifer group; Sinorhizobium.
OX NCBI_TaxID=382;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=1021;
RX MEDLINE=21396508; PubMed=11481431;
RA Finan T.M., Weidner S., Wong K., Buhrmester J., Chain P.,
RA Vorhoeelter F.J., Hernandez-Lucas I., Becker A., Cowie A., Goury J.,
RA Golding B., Puehler A.;
RT "The complete sequence of the 1.683-kb pSymb megaplasmid from the N2-
RT fixing endosymbiont Sinorhizobium meliloti";
RL Proc. Natl. Acad. Sci. U.S.A. 98:9889-9894(2001).
DR EMBL; AL603645; CAC49225.1; -.
DR PIR; A95945; A95945.
DR GO; GO:0046821; C:extrachromosomal DNA; IEA.
DR GO; GO:0016491; F:oxidoreductase activity; IEA.
DR GO; GO:0008152; P:metabolism; IEA.
DR InterPro; IPR002198; ADH_short.
DR Pfam; PF00106; adh_short; 1.
DR PRINTS; PR00080; SDRFAMILY.
DR PROSITE; PS00061; ADH_SHORT; 1.
KW Plasmid; Hypothetical protein; Complete proteome.
SQ SEQUENCE 258 AA; 27066 MW; 2A9824BE86044A4E CRC64;

Query Match 77.3%; Score 34; DB 16; Length 258;
Best Local Similarity 87.5%; Pred. No. 64;
Matches 7; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2 VAELVHFL 9
Db 215 VAELVHFL 222

RESULT 38
Q14798 PRELIMINARY; PRT; 317 AA.
AC Q14798;
DT 01-NOV-1996 (TrEMBLrel. 01, Created)
DT 01-NOV-1996 (TrEMBLrel. 01, Last sequence update)
DT 01-MAR-2003 (TrEMBLrel. 23, Last annotation update)
DE MAGE-4 protein.
GN MELANOMA ANTIGEN-4.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
RP SEQUENCE FROM N.A.
RX MEDLINE=95369706; PubMed=7642112;
RA Imai Y., Shichijo S., Yamada A., Katayama T., Yano H., Itoh K.;
RT "Sequence analysis of the MAGE gene family encoding human tumor-
RT rejection antigens.";
RL Gene 160:287-290(1995).
DR EMBL; D32075; BAA06841.1; -.
DR InterPro; IPR002190; MAGE.

```


DR Pfam; PF01454; MAGE; 1.
 DR PROSITE; PS50838; MAGE; 1.
 SQ SEQUENCE 317 AA; 35044 MW; 989477253FE307C4 CRC64;

Query Match 77.3%; Score 34; DB 4; Length 317;
 Best Local Similarity 77.8%; Pred. No. 79;
 Matches 7; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1 KVAELVHFL 9
 |||||
 Db 113 KVDELAHFL 121

RESULT 39
 Q9GDV6 PRELIMINARY; PRT; 660 AA.

ID Q9GDV6
 AC Q9GDV6;
 DT 01-MAR-2001 (TReMBLrel. 16, Created)
 DT 01-MAR-2001 (TReMBLrel. 16, Last sequence update)
 DT 01-OCT-2003 (TReMBLrel. 25, Last annotation update)
 DE NADH dehydrogenase subunit F (fragment).
 GN NDHF.
 OS Veratrum viride.
 OC Chloroplast.
 OC Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
 OC Spermatophyta; Magnoliophyta; Liliopsida; Liliales; Melanthiaceae;
 OC Veratrum.
 OC NCBI_TaxID=72650;
 RN [1]
 RP SEQUENCE FROM N.A.
 RA Patterson T.B., Givnish T.J.;
 RT "Phylogeny, concerted convergence, and phylogenetic niche conservatism
 in the core Liliales: insights from rbcl and ndhf sequence data."
 RL Submitted (JUN-2000) to the EMBL/GenBank/DBJ databases.
 DR EMBL; AF276024; AAG25140.1; -;
 DR GO; GO:0009507; C:chloroplast; IEA.
 DR GO; GO:0009523; C:photosystem II; IEA.
 DR GO; GO:0008137; F:NADH dehydrogenase (ubiquinone) activity; IEA.
 DR GO; GO:0016491; F:oxidoreductase activity; IEA.
 DR GO; GO:0006118; P:electron transport; IEA.
 DR GO; GO:0006120; P:mitochondrial electron transport, NADH to u. . .; IEA.
 DR InterPro; IPR003916; NADHoxred5.
 DR InterPro; IPR001750; Oxidored_q1.
 DR InterPro; IPR002128; Oxidored_q1_C.
 DR InterPro; IPR001516; Oxidored_q1_N.
 DR Pfam; PF00361; oxidored_q1; 1.
 DR Pfam; PF01010; oxidored_q1_C; 1.
 DR Pfam; PF00662; oxidored_q1_N; 1.
 DR PRINTS; PR01434; NADHoxGNASE5.
 KW NAD; Oxidoreductase; Plastocquinone; Chloroplast.
 FT NON_TER 1
 FT NON_TER 660
 SQ SEQUENCE 660 AA; 74328 MW; 5AD2A256F0F18375 CRC64;

Query Match 77.3%; Score 34; DB 8; Length 660;
 Best Local Similarity 55.6%; Pred. No. 1.6e+02;
 Matches 5; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KVAELVHFL 9
 :|||:
 Db 646 RLAEIVHFI 654

RESULT 40
 Q8NHV8 PRELIMINARY; PRT; 667 AA.

ID Q8NHV8
 AC Q8NHV8;
 DT 01-OCT-2002 (TReMBLrel. 22, Created)
 DT 01-OCT-2002 (TReMBLrel. 22, Last sequence update)
 DT 01-OCT-2003 (TReMBLrel. 25, Last annotation update)
 DE Protein phosphatase 2 (formerly 2A), regulatory subunit A (PR 65),
 DE beta isoform.
 OS Homo sapiens (Human).

OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
 OX NCBI_TaxID=9606;
 RN [1]
 RP SEQUENCE FROM N.A.
 RA Straussberg R.;
 RL Submitted (APR-2002) to the EMBL/GenBank/DBJ databases.
 DR EMBL; BC027596; AAH27596.1; -;
 DR InterPro; IPR008938; ARM.
 DR InterPro; IPR000357; HEAT.
 DR Pfam; PF02985; HEAT; 12.
 DR PROSITE; PS50077; HEAT_REPEAT; 12.
 SQ SEQUENCE 667 AA; 73584 MW; 726EA8A8FB0DEB23 CRC64;

Query Match 77.3%; Score 34; DB 4; Length 667;
 Best Local Similarity 85.7%; Pred. No. 1.6e+02;
 Matches 6; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 2 VAELVHP 8
 :|||:
 Db 656 IAEIVHP 662

Search completed: July 23, 2004, 12:52:48
 Job time : 36 secs

This Page Blank (uspto)